US20210324063A1 - Antibodies and conjugates thereof - Google Patents
Antibodies and conjugates thereof Download PDFInfo
- Publication number
- US20210324063A1 US20210324063A1 US17/301,599 US202117301599A US2021324063A1 US 20210324063 A1 US20210324063 A1 US 20210324063A1 US 202117301599 A US202117301599 A US 202117301599A US 2021324063 A1 US2021324063 A1 US 2021324063A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- vegf
- polymer
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 321
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 202
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 198
- 238000000034 method Methods 0.000 claims abstract description 114
- 229940127121 immunoconjugate Drugs 0.000 claims abstract description 62
- 235000018102 proteins Nutrition 0.000 claims description 195
- 230000027455 binding Effects 0.000 claims description 74
- 238000006243 chemical reaction Methods 0.000 claims description 66
- 239000003999 initiator Substances 0.000 claims description 57
- 239000000178 monomer Substances 0.000 claims description 55
- 235000001014 amino acid Nutrition 0.000 claims description 49
- 229940027941 immunoglobulin g Drugs 0.000 claims description 49
- 230000035772 mutation Effects 0.000 claims description 48
- 235000018417 cysteine Nutrition 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 44
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 40
- 229950004354 phosphorylcholine Drugs 0.000 claims description 40
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 39
- 239000003446 ligand Substances 0.000 claims description 36
- 239000003638 chemical reducing agent Substances 0.000 claims description 34
- 230000002829 reductive effect Effects 0.000 claims description 32
- 239000012636 effector Substances 0.000 claims description 28
- 150000003573 thiols Chemical class 0.000 claims description 25
- 239000003054 catalyst Substances 0.000 claims description 24
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 108020004511 Recombinant DNA Proteins 0.000 claims description 20
- 238000005516 engineering process Methods 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 229910052751 metal Inorganic materials 0.000 claims description 18
- 239000002184 metal Substances 0.000 claims description 18
- 230000003647 oxidation Effects 0.000 claims description 18
- 238000007254 oxidation reaction Methods 0.000 claims description 18
- 229910052723 transition metal Inorganic materials 0.000 claims description 18
- 150000003624 transition metals Chemical class 0.000 claims description 18
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 15
- 238000006116 polymerization reaction Methods 0.000 claims description 14
- 230000001268 conjugating effect Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 7
- 150000001945 cysteines Chemical class 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- 238000011065 in-situ storage Methods 0.000 claims description 6
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 4
- 230000006920 protein precipitation Effects 0.000 claims description 4
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 230000012743 protein tagging Effects 0.000 claims description 3
- 230000021615 conjugation Effects 0.000 abstract description 36
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 21
- -1 amino, aminocarbonyl Chemical group 0.000 description 133
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 83
- 239000000243 solution Substances 0.000 description 80
- 239000000203 mixture Substances 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 239000002158 endotoxin Substances 0.000 description 48
- 229940024606 amino acid Drugs 0.000 description 47
- 230000001225 therapeutic effect Effects 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 46
- 125000000217 alkyl group Chemical group 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 42
- 239000011780 sodium chloride Substances 0.000 description 39
- 229960002433 cysteine Drugs 0.000 description 37
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 33
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 33
- 239000007983 Tris buffer Substances 0.000 description 33
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 33
- 125000003545 alkoxy group Chemical group 0.000 description 33
- 125000003118 aryl group Chemical group 0.000 description 33
- 238000002347 injection Methods 0.000 description 33
- 239000007924 injection Substances 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- 229960000397 bevacizumab Drugs 0.000 description 29
- 238000011282 treatment Methods 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 28
- 125000004429 atom Chemical group 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 108091008605 VEGF receptors Proteins 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 229960003876 ranibizumab Drugs 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 230000000977 initiatory effect Effects 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 125000001072 heteroaryl group Chemical group 0.000 description 20
- 230000003993 interaction Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 238000001042 affinity chromatography Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 229940120638 avastin Drugs 0.000 description 17
- 238000001542 size-exclusion chromatography Methods 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 15
- 229920001222 biopolymer Polymers 0.000 description 15
- 150000002367 halogens Chemical group 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 14
- 206010064930 age-related macular degeneration Diseases 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 14
- 208000002780 macular degeneration Diseases 0.000 description 14
- 238000000569 multi-angle light scattering Methods 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 13
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 13
- 0 [1*]C(=C)C(=O)OC(C)OP(=O)([O-])OC[N+]([2*])([3*])[4*] Chemical compound [1*]C(=C)C(=O)OC(C)OP(=O)([O-])OC[N+]([2*])([3*])[4*] 0.000 description 13
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000010949 copper Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical group [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 239000011550 stock solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
- 125000002947 alkylene group Chemical group 0.000 description 11
- 125000000732 arylene group Chemical group 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229940076783 lucentis Drugs 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 108010081667 aflibercept Proteins 0.000 description 10
- 239000012539 chromatography resin Substances 0.000 description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- 201000011190 diabetic macular edema Diseases 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 208000022873 Ocular disease Diseases 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 108010004073 cysteinylcysteine Proteins 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 150000004820 halides Chemical class 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 239000003456 ion exchange resin Substances 0.000 description 9
- 229920003303 ion-exchange polymer Polymers 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 8
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 8
- 125000004450 alkenylene group Chemical group 0.000 description 8
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000004419 alkynylene group Chemical group 0.000 description 8
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 8
- 125000005110 aryl thio group Chemical group 0.000 description 8
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 description 8
- 125000002993 cycloalkylene group Chemical group 0.000 description 8
- 125000001188 haloalkyl group Chemical group 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 102000058223 human VEGFA Human genes 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- VMGSQCIDWAUGLQ-UHFFFAOYSA-N n',n'-bis[2-(dimethylamino)ethyl]-n,n-dimethylethane-1,2-diamine Chemical compound CN(C)CCN(CCN(C)C)CCN(C)C VMGSQCIDWAUGLQ-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 7
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000003957 anion exchange resin Substances 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 235000009697 arginine Nutrition 0.000 description 7
- 229960003121 arginine Drugs 0.000 description 7
- 229960005261 aspartic acid Drugs 0.000 description 7
- 206010014801 endophthalmitis Diseases 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 6
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 6
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 208000017442 Retinal disease Diseases 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- 201000007917 background diabetic retinopathy Diseases 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 201000005667 central retinal vein occlusion Diseases 0.000 description 6
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 6
- 239000011615 dehydroascorbic acid Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 6
- 229940011051 isopropyl acetate Drugs 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012038 nucleophile Substances 0.000 description 6
- 150000002894 organic compounds Chemical group 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000004644 retinal vein occlusion Diseases 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 5
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 5
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010073807 IgG Receptors Proteins 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 229960002833 aflibercept Drugs 0.000 description 5
- 125000004103 aminoalkyl group Chemical group 0.000 description 5
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 125000004181 carboxyalkyl group Chemical group 0.000 description 5
- 238000005277 cation exchange chromatography Methods 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 229940051306 eylea Drugs 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000011046 pyrogen test Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WDFKCTHHZTUGMR-UHFFFAOYSA-N CC(C)OP(=O)([O-])OCC[N+](C)(C)C Chemical compound CC(C)OP(=O)([O-])OCC[N+](C)(C)C WDFKCTHHZTUGMR-UHFFFAOYSA-N 0.000 description 4
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 4
- 102000009490 IgG Receptors Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 208000007135 Retinal Neovascularization Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 4
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 4
- 229920001515 polyalkylene glycol Polymers 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- PXDSLLKFEAXYKW-UHFFFAOYSA-N C=C(C)C(=O)OCCOP(=O)(O)OCCN(C)(C)C Chemical compound C=C(C)C(=O)OCCOP(=O)(O)OCCN(C)(C)C PXDSLLKFEAXYKW-UHFFFAOYSA-N 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 238000011050 LAL assay Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000009857 Microaneurysm Diseases 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 206010069093 Non-infectious endophthalmitis Diseases 0.000 description 3
- JKHVDAUOODACDU-UHFFFAOYSA-N O=C(CCN1C(=O)C=CC1=O)ON1C(=O)CCC1=O Chemical compound O=C(CCN1C(=O)C=CC1=O)ON1C(=O)CCC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 206010066366 Toxic anterior segment syndrome Diseases 0.000 description 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 150000001356 alkyl thiols Chemical class 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002484 inorganic compounds Chemical group 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000010526 radical polymerization reaction Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- VGUWFGWZSVLROP-UHFFFAOYSA-N 1-pyridin-2-yl-n,n-bis(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 VGUWFGWZSVLROP-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XXSPGBOGLXKMDU-UHFFFAOYSA-M 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C([O-])=O XXSPGBOGLXKMDU-UHFFFAOYSA-M 0.000 description 2
- WERYVPSBTOUFTC-UHFFFAOYSA-N 2-ethylhexyl 3-[2-[bis[2-[bis[3-(2-ethylhexoxy)-3-oxopropyl]amino]ethyl]amino]ethyl-[3-(2-ethylhexoxy)-3-oxopropyl]amino]propanoate Chemical compound CCCCC(CC)COC(=O)CCN(CCC(=O)OCC(CC)CCCC)CCN(CCN(CCC(=O)OCC(CC)CCCC)CCC(=O)OCC(CC)CCCC)CCN(CCC(=O)OCC(CC)CCCC)CCC(=O)OCC(CC)CCCC WERYVPSBTOUFTC-UHFFFAOYSA-N 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- BLDQUHPMDSICNF-UHFFFAOYSA-N 4-nonan-5-yl-2-(4-nonan-5-ylpyridin-2-yl)pyridine Chemical compound CCCCC(CCCC)C1=CC=NC(C=2N=CC=C(C=2)C(CCCC)CCCC)=C1 BLDQUHPMDSICNF-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KKNLITQIIZFTBE-UHFFFAOYSA-N C.CCNC(=O)C(C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C.CCNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C.CCOC(=O)C(C)(C)C Chemical compound C.CCNC(=O)C(C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C.CCNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C.CCOC(=O)C(C)(C)C KKNLITQIIZFTBE-UHFFFAOYSA-N 0.000 description 2
- ZSZRUEAFVQITHH-UHFFFAOYSA-O C=C(C)C(=O)OCCOP(=O)(O)OCC[N+](C)(C)C Chemical compound C=C(C)C(=O)OCCOP(=O)(O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-O 0.000 description 2
- YKNWWKJRSXGBFL-UHFFFAOYSA-N CC(C)(C)C(=O)OCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C)(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C)COCCNC(=O)CCOCCN)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C Chemical compound CC(C)(C)C(=O)OCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C)(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C)COCCNC(=O)CCOCCN)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C YKNWWKJRSXGBFL-UHFFFAOYSA-N 0.000 description 2
- VXYGCKNHIUQSPI-UHFFFAOYSA-N CC(C)CC(C)(C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)C(C)C Chemical compound CC(C)CC(C)(C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)C(C)C VXYGCKNHIUQSPI-UHFFFAOYSA-N 0.000 description 2
- LESHXKMAKICTNK-UHFFFAOYSA-N CCNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C Chemical compound CCNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)C)(COC(=O)C(C)(C)C)COC(=O)C(C)(C)C LESHXKMAKICTNK-UHFFFAOYSA-N 0.000 description 2
- SDUPUZGABMCIRT-UHFFFAOYSA-N CPCCOC(=O)C(C)(C)CC(C)(C)C(=O)CCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(CNC(=O)CCNC(=O)COCC(CCC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)C(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COCCNC(=O)CCOCCNC(=O)CCN1C(=O)CC(SC)C1=O)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)C(=O)C(C)(C)CC(C)(C)C(=O)OCCPC Chemical compound CPCCOC(=O)C(C)(C)CC(C)(C)C(=O)CCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(CNC(=O)CCNC(=O)COCC(CCC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)C(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COCCNC(=O)CCOCCNC(=O)CCN1C(=O)CC(SC)C1=O)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)C(=O)C(C)(C)CC(C)(C)C(=O)OCCPC SDUPUZGABMCIRT-UHFFFAOYSA-N 0.000 description 2
- KOGCAAWHEIAJMY-UHFFFAOYSA-N CPCCOC(=O)C(C)(C)CC(C)(C)C(=O)OCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCC#P)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCC#P)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COCCOCCOCCOCCNC(=O)CCOCCOCCOCCOCCNC(=O)CCN1C(=O)CC(SC)C1=O)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC Chemical compound CPCCOC(=O)C(C)(C)CC(C)(C)C(=O)OCC(COCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCC#P)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCC#P)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C)(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COCCOCCOCCOCCNC(=O)CCOCCOCCOCCOCCNC(=O)CCN1C(=O)CC(SC)C1=O)(COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC)COC(=O)C(C)(C)CC(C)(C)C(=O)OCCPC KOGCAAWHEIAJMY-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- HKRYOHNBGZLDSH-UHFFFAOYSA-N butyl 3-[2-[bis[2-[bis(3-butoxy-3-oxopropyl)amino]ethyl]amino]ethyl-(3-butoxy-3-oxopropyl)amino]propanoate Chemical compound CCCCOC(=O)CCN(CCC(=O)OCCCC)CCN(CCN(CCC(=O)OCCCC)CCC(=O)OCCCC)CCN(CCC(=O)OCCCC)CCC(=O)OCCCC HKRYOHNBGZLDSH-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 208000001309 degenerative myopia Diseases 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013400 design of experiment Methods 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000006334 disulfide bridging Effects 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- UMVIOFIPJIQCAD-UHFFFAOYSA-N dodecyl 3-[2-[bis[2-[bis(3-dodecoxy-3-oxopropyl)amino]ethyl]amino]ethyl-(3-dodecoxy-3-oxopropyl)amino]propanoate Chemical compound CCCCCCCCCCCCOC(=O)CCN(CCC(=O)OCCCCCCCCCCCC)CCN(CCN(CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC)CCN(CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC UMVIOFIPJIQCAD-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011013 endotoxin removal Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000002430 laser surgery Methods 0.000 description 2
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- DWFKOMDBEKIATP-UHFFFAOYSA-N n'-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CCN(C)CCN(C)C DWFKOMDBEKIATP-UHFFFAOYSA-N 0.000 description 2
- LGISBDHECCBNHK-UHFFFAOYSA-N n,n-bis(pyridin-2-ylmethyl)octadecan-1-amine Chemical compound C=1C=CC=NC=1CN(CCCCCCCCCCCCCCCCCC)CC1=CC=CC=N1 LGISBDHECCBNHK-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 238000012705 nitroxide-mediated radical polymerization Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 229920005646 polycarboxylate Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- LNKSLLXPNOTUHF-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;dodecyl sulfate Chemical compound [Na+].OCC(N)(CO)CO.CCCCCCCCCCCCOS([O-])(=O)=O LNKSLLXPNOTUHF-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- INIKTCFEWCCJMM-WCCKRBBISA-N (2s)-2-(trifluoromethyl)morpholine;hydrochloride Chemical compound Cl.FC(F)(F)[C@@H]1CNCCO1 INIKTCFEWCCJMM-WCCKRBBISA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- XXSPGBOGLXKMDU-UHFFFAOYSA-N 2-bromo-2-methylpropanoic acid Chemical group CC(C)(Br)C(O)=O XXSPGBOGLXKMDU-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical group OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FJMFJMWTRLAKMH-UHFFFAOYSA-N C.CC.CN(C)(C)CCOP(=O)(O)OCCO.O Chemical compound C.CC.CN(C)(C)CCOP(=O)(O)OCCO.O FJMFJMWTRLAKMH-UHFFFAOYSA-N 0.000 description 1
- JFPHANNKVWEGNG-UHFFFAOYSA-N C=CC(=O)NCCOP(=O)([O-])OCC[N+](C)(C)C.CCCCCPC Chemical compound C=CC(=O)NCCOP(=O)([O-])OCC[N+](C)(C)C.CCCCCPC JFPHANNKVWEGNG-UHFFFAOYSA-N 0.000 description 1
- QJLHJLYDAZGLQR-UHFFFAOYSA-N C=CC(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C Chemical compound C=CC(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C QJLHJLYDAZGLQR-UHFFFAOYSA-N 0.000 description 1
- LANMFRYSBBOVBW-UHFFFAOYSA-N CC(C)(Br)C(=O)OCC(COCC(=O)NCCC(=O)O)(COC(=O)C(C)(C)Br)COC(=O)C(C)(C)Br Chemical compound CC(C)(Br)C(=O)OCC(COCC(=O)NCCC(=O)O)(COC(=O)C(C)(C)Br)COC(=O)C(C)(C)Br LANMFRYSBBOVBW-UHFFFAOYSA-N 0.000 description 1
- HTOJPJVEEVLYRE-UHFFFAOYSA-N CC(C)(Br)C(=O)OCC(COCC(=O)NCCOCCOCCN)(COC(=O)C(C)(C)Br)COC(=O)C(C)(C)Br.O=C(O)C(F)(F)F Chemical compound CC(C)(Br)C(=O)OCC(COCC(=O)NCCOCCOCCN)(COC(=O)C(C)(C)Br)COC(=O)C(C)(C)Br.O=C(O)C(F)(F)F HTOJPJVEEVLYRE-UHFFFAOYSA-N 0.000 description 1
- YZGXSXCAKILYRH-UHFFFAOYSA-N CC(C)CC(C)(C(=O)OCCOP(=O)(O)OCCN(C)(C)C)C(C)C Chemical compound CC(C)CC(C)(C(=O)OCCOP(=O)(O)OCCN(C)(C)C)C(C)C YZGXSXCAKILYRH-UHFFFAOYSA-N 0.000 description 1
- JITUAZXQHBEGQK-UHFFFAOYSA-N CC(C)SC1CC(=O)[N]C1=O Chemical compound CC(C)SC1CC(=O)[N]C1=O JITUAZXQHBEGQK-UHFFFAOYSA-N 0.000 description 1
- UVRWUNGZTFLKLO-UHFFFAOYSA-N CCCOCCC(=O)CCCOC Chemical compound CCCOCCC(=O)CCCOC UVRWUNGZTFLKLO-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001433703 Escherichia coli O111:B4 Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical class [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108700005371 Moraxella catarrhalis UspA Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- SIZXBOOHOMQGEN-UHFFFAOYSA-N O=C1C=CC(=O)[N]1 Chemical compound O=C1C=CC(=O)[N]1 SIZXBOOHOMQGEN-UHFFFAOYSA-N 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- LNQWKPQOJUQNKZ-UHFFFAOYSA-N [CH2]CCOCCC(=O)CCCO[CH2] Chemical compound [CH2]CCOCCC(=O)CCCO[CH2] LNQWKPQOJUQNKZ-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- GRADOOOISCPIDG-UHFFFAOYSA-N buta-1,3-diyne Chemical group [C]#CC#C GRADOOOISCPIDG-UHFFFAOYSA-N 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000005352 carboxycycloalkyl group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 125000000481 dehydro ascorbic acid group Chemical group 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 229960002907 follitropin beta Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical class [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005062 perfluorophenyl group Chemical group FC1=C(C(=C(C(=C1F)F)F)F)* 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 150000003623 transition metal compounds Chemical class 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to antibodies and conjugates thereof and methods of using and manufacturing said antibodies, conjugates thereof, and other protein conjugates.
- Diabetic retinopathy is a leading cause of blindness in people between the ages of about 20 to 64 years of age. Engelgau M, Geiss L, Saaddine J, Boyle J, et al. 2004. The Evolving Diabetes Burden in the United States. Ann of Int Med. 140 (11): 945-951. In the United States, diabetic retinopathy accounts for some 12% of new cases of blindness. Typically, in cases of diabetic retinopathy, retinal blood vessels will swell and leak fluid into the rear of the eye. Hyperglycemia induces intramural and thickening of the basement membrane, resulting in leaky or permeable blood vessels.
- diabetic retinopathy changes in blood glucose level cause changes to retinal blood vessels. All people with diabetes mellitus are at risk. The longer a person has diabetes, the higher their risk of developing some ocular problem. Between 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy. Causes and Risk Factors. Diabetic Retinopathy. United States National Library of Medicine. 15 Sep. 2009.
- Diabetic retinopathy is first exhibited in the development of microaneurysms in the retina.
- Microaneurysms occur when there is a swelling of capillaries (very small blood vessels) that feed the retina. The presence of relatively small numbers of microaneurysms will not usually cause problems with vision. However, if the retinopathy develops to later stages, there are significant chances of vision loss.
- Such early stage retinopathy are referred to as background diabetic retinopathy or non-proliferative diabetic retinopathy (NPDR). While NPDR patients are generally asymptomatic, early detection of retinopathy is crucial because if the disease proceeds to later stages, significant vision loss is very likely.
- neovascularization occurs in the back of the eye (proliferative diabetic retinopathy).
- the neovasculature is leaky and the vessels can burst, followed by bleeding and resulting in blurred or obscured vision. Due to lack of oxygen in the eye, still further neovascularization occurs.
- Blood vessels grow along the retina and in the vitreous humor. As these vessels burst, there is further bleeding and the retina can be badly damaged or destroyed.
- the accumulation of fluid in the macula due to leaking blood vessels is called diabetic macular edema. Many patients with diabetic retinopathy will develop diabetic macular edema.
- AVASTIN® bevacizumab
- LUCENTIS® ranibizumab
- Eylea® aflibercept
- laser surgery is generally effective in treating diabetic retinopathy
- retinal damage induced by the laser is a frequent side effect.
- Steroid preparations such as triamcinolone acetonide have been administered via intravitreal injection to treat diabetic retinopathy.
- the steroid solutions must be frequently administered.
- intravitreal treatment with steroids has been associated with cataracts, steroid-induced glaucoma and endophthalmitis.
- VEGF-directed therapies are effective not just for diabetic retinopathy, but also for Age-Related Macular Degeneration (AMD), such as neovascular (wet) AMD.
- AMD Age-Related Macular Degeneration
- the anti-VEGF-A antibody comprises a light chain and a heavy chain and the heavy chain comprises an Fc region.
- the anti-VEGF-A antibody is an immunoglobulin G (IgG).
- the cysteine is in the Fc region of the heavy chain.
- the anti-VEGF-A heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T, and the anti-VEGF-A light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14), and Kabat position 4 is L.
- the anti-VEGF-A heavy chain isotype is human IgG1.
- the heavy chain constant domain of the anti-VEGF-A antibody IgG1 has one or more mutations relative to an IgG1 constant domain to modulate effector function.
- the mutations are optionally to one or more of the following amino acid positions (EU numbering): E233X, L234X, L235X, G236X, G237X, A327X, A330X, and P331X wherein X is any natural or unnatural amino acid.
- the mutations are selected from the group consisting of (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- the mutations are (EU numbering) L234A, L235A, and G237A.
- the effector function is decreased.
- CDC, ADCC, and/or ADCP is decreased at least 10, 20, 30, 40, 50, 60, 70, or more percent.
- CDC is mediated by Fc binding to C1q
- ADCC and ADCP are mediated by Fc binding to various Fc gamma receptors and each of these binding interactions is decreased at least 10, 20, 30, 40, 50, 60, 70, or more percent.
- the cysteine residue is optionally in the anti-VEGF-A heavy chain and is optionally Q347C (EU numbering) or L443C (EU numbering).
- the anti-VEGF-A heavy chain is SEQ ID NO. 1 and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- the cysteine is L443C (EU numbering).
- the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- polymer comprises the following repeating units:
- n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- the polymer optionally has three or more arms, or is synthesized with an initiator comprising 3 or more polymer initiation sites.
- the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms, or is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites.
- the polymer has 2, 3, 6, or 9 arms, or is synthesized with an initiator comprising 2, 3, 6 or 9 polymer initiation sites.
- the polymer has 9 arms, or is synthesized with an initiator comprising 9 polymer initiation sites.
- the polymer has a molecular weight between about 300,000 and about 1,750,000 Da, as measured by size exclusion chromatography—multi angle light scattering (hereinafter “SEC-MALS”).
- SEC-MALS size exclusion chromatography—multi angle light scattering
- the polymer has a molecular weight between about 500,000 and about 1,000,000 Da.
- the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- the antibody conjugate is purified and the polymer is polydisperse.
- the polymer has a polydispersity value (PDI) of less than 1.2.
- PDI Polydispersity Index
- any of the conjugate solutions provided herein can have a PolyDispersity Index (PDI) that is equal to or less than 1.8, for example, less than or equal to: 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.
- an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C449 in SEQ ID NO. 1 to the polymer.
- the polymer has 9 arms; and the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C443 (EU numbering) to the polymer.
- the polymer has 9 arms; and the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- the antibody conjugate has the following structure:
- each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
- the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C449 in SEQ ID NO: 1, which bond is depicted on one of the heavy chains;
- PC is
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 3000.
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 500.
- X OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxys
- the antibody conjugate has the following structure:
- each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L; the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443 (EU numbering), which bond is depicted on one of the heavy chains; PC is
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 3000.
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 500.
- X OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxys
- an antibody conjugate as described above in a liquid solution is provided.
- the liquid solution has a pharmaceutically acceptable carrier.
- an anti-VEGF-A antibody which comprises a heavy chain and a light chain, wherein is provided.
- the heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T and the light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14), and Kabat position 4 is L.
- the heavy chain isotype is IgG1, wherein the IgG1 constant domain comprises one or more of the following mutations to modulate effector function (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- the antibody has (EU numbering) L234A, L235A, and G237A.
- the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1
- sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- a method for treatment or prophylaxis of an ocular disease comprises administering an antibody conjugate as described above, or the pharmaceutical composition as described above.
- the ocular disease is selected from the group consisting of diabetic retinopathy, choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, and hypertensive retinopathy.
- the disease is diabetic retinopathy.
- a method of making an antibody conjugate comprising an anti-VEGF-A antibody conjugated to a phosphorylcholine containing polymer comprises the step of: conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer; wherein the anti-VEGF-A antibody comprises a cysteine residue added via recombinant DNA technology and wherein the cysteine is outside a variable region of the antibody; wherein the phosphorylcholine containing polymer comprises a sulfhydryl specific reacting group selected from the group consisting of a maleimide, a vinylsulfone, an orthopyridyl-disulfide, and an iodoacetamide; and wherein the sulfhydryl specific reacting group on the phosphorylcholine containing polymer reacts with the cysteine residue on the anti-VEGF-A antibody to make the antibody conjugate.
- the anti-VEGF-A antibody is an immunoglobulin G (IgG) and the cysteine is in the Fc region of the antibody.
- the anti-VEGF-A antibody comprises a light chain and a heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO.
- the anti-VEGF-A antibody light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14), and Kabat position 4 is L.
- the anti-VEGF-A antibody heavy chain isotype is IgG1.
- the IgG1 constant domain has one or more mutations relative to an IgG1 constant domain to modulate effector function.
- the mutations are to one or more of the following amino acid positions (EU numbering): E233X, L234X, L235X, G236X, G237X, G236X, D270X, K322X, A327X, P329X, A330X, A330X, P331X, and P331X, wherein X is any natural or non-natural amino acid.
- the mutations are selected from the group consisting of (EU numbering) E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- the mutations are (EU numbering) L234A, L235A, and G237A.
- the cysteine residue added by recombinant DNA technology is selected from the group consisting of Q347C (EU numbering) and L443C (EU numbering).
- the cysteine residue added by recombinant DNA technology is L443C (EU numbering).
- the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1 and sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- polymer comprises the following repeating units:
- n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- the polymer has three or more arms.
- the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms.
- the polymer has 2, 3, 6, or 9 arms.
- the polymer has 9 arms.
- the polymer has a molecular weight between about 300,000 and 1,750,000 Da.
- the polymer has a molecular weight between about 500,000 and 1,000,000 Da.
- the polymer has a molecular weight of between about 600,000 to 800,000 Da.
- the method has a further step comprising the step of contacting the anti-VEGF-A antibody with a thiol reductant under conditions that produce a reduced cysteine sulfhydryl group to produce a reduced anti-VEGF-A antibody in which all cysteine residues are reduced.
- the thiol reductant is selected from the group consisting of Tris[2-carboxyethyl]phosphine hydrochloride (TCEP), dithiothreitol (DTT), dithioerythritol (DTE), sodium borohydride (NaBH 4 ), sodium cyanoborohydride (NaCNBH 3 ), ⁇ -mercaptoethanol (BME), cysteine hydrochloride, and cysteine.
- the thiol reductant is TCEP.
- the thiol reductant is between 1 and 100 fold molar excess relative to the concentration of the anti-VEGF-A antibody.
- the thiol reductant is between 20 to 50 fold molar excess relative to the concentration of the anti-VEGF-A antibody.
- the method further comprising the steps of removing the thiol reductant from the reduced anti-VEGF-A antibody, and treating the reduced anti-VEGF-A antibody with an oxidizing agent.
- the oxidizing agent is air, aqueous CuSO 4 , or dehydroascorbic acid (DHAA).
- the method further comprises the step of purifying the antibody conjugate.
- the antibody conjugate is purified using a technique selected from the group consisting of ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, affinity chromatography, and combinations thereof.
- the purified antibody conjugate retains at least 20% biological activity relative to an unconjugated anti-VEGF-A antibody.
- the purified antibody conjugate retains at least 50% biological activity relative to an unconjugated anti-VEGF-A antibody.
- the purified antibody conjugate retains at least 90% biological activity relative to an unconjugated anti-VEGF-A antibody.
- the purified antibody conjugate has an increased half-life relative to an unconjugated anti-VEGF-A antibody.
- the purified antibody conjugate has at least a 1.5 fold increase in half-life relative to an unconjugated anti-VEGF-A antibody.
- the method further comprises the step of polymerizing a free radically polymerizable phosphorylcholine containing monomer in a polymerization medium to provide the phosphorylcholine containing polymer, the medium comprising: the radically polymerizable phosphorylcholine containing monomer; a transition metal catalyst M t (q ⁇ 1)+ wherein M t is a transition metal, q is the maximum oxidation state of the metal and q ⁇ 1 is the oxidation state of the metal, wherein the metal can act as a catalyst, wherein the transition metal catalyst is supplied as a salt of the form M t (q ⁇ 1)+ X′ (q ⁇ 1) , wherein X′ is a counterion or group, or wherein the transition metal catalyst is supplied in situ by providing the inactive metal salt at its highest oxidation state M t q+ X′ q together with a reducing agent that is capable of reducing the transition metal from the oxidized inactive state to the reduced active state; a ligand; and an
- the radically polymerizable phosphorylcholine containing monomer is
- R1 is H or C 1-6 alkyl
- R2, R3, R4 are each methyl
- X and Y are each 2.
- Mt is selected from the group consisting of Cu, Fe, Ru, Cr, Mo, W, Mn, Rh, Re, Co, V, Zn, Au, and Ag.
- the metal catalyst is supplied as a salt of the form M t (q ⁇ 1)+ X′ (q ⁇ 1) .
- M t (q ⁇ 1)+ is selected from the group consisting of Cu 1+ , Fe 2+ , Ru 2+ , Cr 2+ , Mo 2+ , W 2+ , Mn 3+ , Rh 3+ , Re 2+ , Co + , V 2+ , Zn + , Au + , and Ag + and X′ is selected from the group consisting of halogen, C 1-6 alkoxy, (SO 4 ) 1/2 , (PO 4 ) 1/3 , (R7PO 4 ) 1/2 , (R7 2 PO 4 ), triflate, hexaluorophosphate, methanesulfonate, arylsulfonate, CN and R7CO 2 , where R7 is H or a straight or branched C 1-6 alkyl group which may be substituted from 1 to 5 times with a halogen.
- M t (q ⁇ 1)+ is Cu 1+ and X′ is Br.
- M t (q ⁇ 1)+ is
- the reducing agent is an inorganic compound.
- the inorganic compound is selected from the group consisting of a sulfur compound of a low oxidation level, sodium hydrogen sulfite, sodium sulfite, an inorganic salt comprising a metal ion, a metal, hydrazine hydrate, and derivatives of such compounds.
- the reducing agent is a metal.
- the reducing agent is Cu 0 .
- the reducing agent is an organic compound.
- the organic compound is selected from the group consisting of alkylthiols, mercaptoethanol, or carbonyl compounds that can be easily enolized, ascorbic acid, acetyl acetonate, camphorsulfonic acid, hydroxy acetone, reducing sugars, monosaccharides, glucose, aldehydes, and derivatives of such organic compounds.
- the ligand is selected from the group consisting of 2,2′-bipyridine, 4,4′-Di-5-nonyl-2,2′-bipyridine, 4,4-dinonyl-2,2′-dipyridyl, 4,4′,4′′-tris(5-nonyl)-2,2′:6′,2′′-terpyridine, N,N,N′,N′,N′′-Pentamethyldiethylenetriamine, 1,1,4,7,10,10-Hexamethyltriethylenetetramine, Tris(2-dimethylaminoethyl)amine, N,N-bis(2-pyridylmethyl)octadecylamine, N,N,N′,N′-tetra[(2-pyridal)methyl]ethylenediamine, tris[(2-pyridyl)methyl]amine, tris(2-aminoethyl)amine, tris(2-bis(3-butoxy-3-oxopropyl
- the initiator has the structure:
- R1 is a nucleophilic reactive group
- R2 comprises a linker
- R3 comprises a polymer synthesis initiator moiety having the structure
- R4 and R5 are the same or different and are selected from the group consisting of alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido, and any combination thereof;
- Z is a halogen or CN; and s is an integer between 1 and 20.
- R1 is selected from the group consisting of NH 2 —, OH—, and SH—.
- R1 is NH 2 —.
- R2 is alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido, and any combination thereof.
- R2 is
- X and Y are the same or different and are integers from 1-20.
- X and Y are each 4.
- R3 further comprises
- R6, R7 and R8 are the same or different and are selected from the group consisting of
- Z is NCS, F, Cl, Br or I.
- Z is Br.
- R6, R7 and R8 are each
- the initiator has the structure
- a and B are the same or different and are integers from 2 to 12 and Z is any halide, such as Br.
- a and B are each 4.
- the method further comprising the step of reacting the polymer with a maleimide reagent to provide a polymer having a terminal maleimide.
- the maleimide compound is
- the options provided herein avoid one or more issues with other methods or forms of therapy. For example, they can reduce the frequency of administration to less than once a month intravitreal injection, as such intravitreal injections can be painful and require a clinical setting. Furthermore, diabetic retinopathy patients whose vision is relatively unimpaired could be resistant to monthly intravitreal injections and thus may go untreated under other forms of therapy. There is thus a need for diabetic retinopathy treatments with less frequent dosing. In this context, a treatment for diabetic retinopathy could be used early in the disease to prevent progression of the disease and associated vision threatening events.
- the antibody conjugate comprises (1) an anti-VEGF-A antibody and (2) a phosphorylcholine containing polymer.
- the polymer is covalently bonded to the antibody at a cysteine outside a variable region of the antibody and said cysteine has been added via recombinant DNA technology.
- the anti-VEGF-A antibody heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the anti-VEGF-A light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- the polymer conjugated to the antibody has a molecular weight between about 300,000 and about 1,750,000 Da as measured by size exclusion chromatography—multi angle light scattering (hereinafter “SEC-MALS”).
- the anti-VEGF-A antibody comprises a heavy chain and a light chain.
- the heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11) and the light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14), and the heavy chain isotype is IgG1.
- the IgG1 constant domain comprises one or more of the following mutations to reduce effector function (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- any of the methods can employ an anti-VEGF-A antibody that comprises a light chain and a heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the anti-VEGF-A antibody light chain comprises CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- the anti-VEGF-A antibody heavy chain comprises CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ
- the antibody comprises a heavy chain amino acid variable region that comprises SEQ ID NO 1 and a light chain amino acid variable region that comprises SEQ ID NO. 2.
- the antibody is a human IgG1
- the heavy chain constant domain comprises one or more mutations that reduce an immune-mediated effector function.
- the antibody is further conjugated to a polymer to form a bioconjugate, and wherein the bioconjugate has a molecular weight between about 450,000 and 1,900,000 Daltons.
- the PolyDispersity Index (PDI) is equal to or less than 1.5.
- the antibody that binds to VEGF-A comprises a CDR H 1 that is the CDR H 1 in SEQ ID NO: 1; a CDR H 2 that is the CDR H 2 in SEQ ID NO: 1; a CDR H 3 that is the CDR H 3 in SEQ ID NO: 1; a CDR L 1 that is the CDR L 1 in SEQ ID NO: 2; a CDR L 2 that is the CDR L 2 in SEQ ID NO: 2; a CDR L 3 that is the CDR L 3 in SEQ ID NO: 2; at least one of the following mutations: L234A, L235A, and G237A (EU numbering); and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering).
- the antibody comprises all three of the following mutations (EU numbering) L234A, L235A, and G237A, and wherein the antibody comprises L443C (EU numbering).
- a process for preparing a conjugated protein comprises reducing one or more cysteines in a protein to form a decapped protein in a solution, reoxidizing the decapped protein to restore at least one disulfide linkage in the reduced protein while ensuring that an engineered cysteine residue in the protein remains in a free thiol form to thereby form a reoxidized decapped protein in the solution, and adding at least one excipient to the solution, wherein the excipient reduces a polymer induced protein precipitation.
- the process further includes adding a polymer to the solution, and conjugating the polymer to the reoxidized decapped protein at the engineered cysteine residue to form a conjugated protein.
- the protein is an antibody, an antibody protein fusion or a binding fragment thereof.
- the excipient is an acid or a base.
- the excipient is selected from the group consisting of at least one of: a detergent, a sugar, and a charged amino acid.
- reaction of a polymer with the reduced protein occurs under aqueous conditions between pH 6.0 to pH 8.5.
- an amount of the reduced protein is less than an amount of the polymer.
- the polymer is conjugated to the protein at 2-37 degrees Celsius.
- the process further comprises the process of contacting a solution comprising the conjugated protein to an ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium.
- the ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium separates the conjugated protein from the free polymer and from the reoxidized decapped protein.
- the polymer comprises a zwitterion.
- the polymer comprises a phosphorylcholine.
- the polymer comprises a PEG linker bridging a center of a polymer branching point to the maleimide functional group.
- an anti-VEGF antibody conjugate is provided that is capable of blocking at least 90% of an interaction between a VEGF ligand and a VEGF-receptor.
- an anti-VEGF antibody conjugate that blocks at least 95% of an interaction between a VEGF ligand and a VEGF-receptor.
- an anti-VEGF antibody that blocks at least 90% of an interaction between a VEGF ligand and a VEGF-receptor.
- FIG. 1 shows Compound L.
- FIG. 2 shows Compound K.
- FIG. 3 shows the synthesis of OG1802 from R3707.
- FIG. 4 shows OG1786.
- FIG. 5 shows the synthesis of OG1546 from OG1550.
- FIG. 6 shows the synthesis of OG1784 from OG1546 and OG1563.
- FIG. 7 shows the synthesis of OG1405 from OG1784.
- FIG. 8 shows the synthesis of OG1785 from OG1405.
- FIG. 9 shows the synthesis of OG1786 from OG1785.
- FIG. 10 shows OG1802.
- FIG. 11 shows Compound E.
- FIG. 12 depicts some embodiments of anti-VEGF-A heavy chain with certain effector function mutations and L443C (EU numbering, which is position 449 in SEQ ID NO. 1).
- FIG. 13 depicts some embodiments of an anti-VEGF-A light chain (SEQ ID NO. 2).
- FIG. 14 depicts some embodiments of a Bevaizumab heavy chain (SEQ ID NO. 3).
- FIG. 15 depicts some embodiments of a Bevaizumab light chain (SEQ ID NO. 4).
- FIG. 16 depicts some embodiments of a Ranibizumab heavy chain (SEQ ID NO. 5).
- FIG. 17 depicts some embodiments of a Ranibizumab light chain (SEQ ID NO. 6).
- FIG. 18 depicts some embodiments of a method for preparing an antibody conjugate.
- FIG. 19 depicts Ion Exchanger analysis (A280 absorbance) of reactions A through G.
- FIG. 20 depicts the effect of various anti-VEGF molecules on binding of biotin-VEGF to plate bound VEGFR ECD-Fc protein, and their IC50 values.
- FIG. 21 depicts the OG1950 binding affinity to VEGF measured by BIAcore single cycle kinetics.
- FIG. 22 depicts binding of the OG1950 to Fc gamma receptor I.
- FIG. 23 depicts binding of the OG1950 to Fc gamma receptor IIIa.
- FIG. 24 depicts binding of QG 1950 to human complement protein C1q.
- FIG. 25 depicts the results of a proliferation assay (including IC50 values).
- FIG. 26 depicts the results of single cycle kinetics of VEGF binding to anti-VEGF agents.
- FIG. 27 depicts some embodiments of nucleic acid sequences encoding heavy and light chain variable regions.
- FIG. 28 depicts the screening results after incubation of various samples (of various excipients) in polymer solution (OG1802) for 20 hours at 2-8 degrees Centigrade.
- anti-VEGF-A antibodies are provided herein.
- these antibodies can be conjugated to a half-life extending moiety.
- the conjugate can be used for the treatment of certain conditions, such as diabetic retinopathy and/or age-related macular degeneration.
- conjugate compositions of antibodies of any type of antibody. In some embodiments, these methods allow for lower aggregate formation or higher efficiency of formation of the desired antibody conjugate.
- a “neovascular disorder” is a disorder or disease state characterized by altered, dysregulated or unregulated angiogenesis.
- neovascular disorders include neoplastic transformation (e.g. cancer) and ocular neovascular disorders including diabetic retinopathy and age-related macular degeneration.
- an “ocular neovascular” disorder is a disorder characterized by altered, dysregulated or unregulated angiogenesis in the eye of a patient.
- Such disorders include optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreal neovascularization, glaucoma, pannus, pterygium, macular edema, diabetic retinopathy, diabetic macular edema, vascular retinopathy, retinal degeneration, uveitis, inflammatory diseases of the retina, and proliferative vitreoretinopathy.
- antibody includes intact antibodies and binding fragments thereof.
- a binding fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of binding fragments include Fv, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. scFv antibodies are described in Houston J S. 1991. Methods in Enzymol. 203:46-96.
- antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.
- Specific binding of an antibody to its target antigen(s) means an affinity of at least 10 6 , 10 7 , 10 8 , 10 9 , or 10 10 M ⁇ 1 . Specific binding is detectably higher in magnitude and distinguishable from non-specific binding occurring to at least one unrelated target. Specific binding can be the result of formation of bonds between particular functional groups or particular spatial fit (e.g., lock and key type) whereas nonspecific binding is usually the result of van der Waals forces. Specific binding does not however necessarily imply that an antibody or fusion protein binds one and only one target.
- a basic antibody structural unit is a tetramer of subunits.
- Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa).
- the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. This variable region is initially expressed linked to a cleavable signal peptide.
- the variable region without the signal peptide is sometimes referred to as a mature variable region.
- a light chain mature variable region means a light chain variable region without the light chain signal peptide.
- variable region does not mean that a signal sequence is necessarily present; and in fact signal sequences are cleaved once the antibodies or fusion proteins have been expressed and secreted.
- a pair of heavy and light chain variable regions defines a binding region of an antibody. The carboxy-terminal portion of the light and heavy chains respectively defines light and heavy chain constant regions. The heavy chain constant region is primarily responsible for effector function. In IgG antibodies, the heavy chain constant region is divided into CH1, hinge, CH2, and CH3 regions. The CH1 region binds to the light chain constant region by disulfide and noncovalent bonding.
- the hinge region provides flexibility between the binding and effector regions of an antibody and also provides sites for intermolecular disulfide bonding between the two heavy chain constant regions in a tetramer subunit.
- the CH2 and CH3 regions are the primary site of effector functions and FcR binding.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
- the variable and constant regions are joined by a “J” segment of about 12 or more amino acids, with the heavy chain also including a “D” segment of about 10 or more amino acids.
- bispecific antibodies can be made in which the two binding sites are different (see, e.g., Songsivilai S, Lachmann P C. 1990. Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol. 79:315-321; Kostelny S A, Cole M S, Tso J Y. 1992. Formation of bispecific antibody by the use of leucine zippers. J Immunol. 148: 1547-1553).
- variable regions all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
- the CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope.
- both light and heavy chains comprise the domains FRI, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
- the variable heavy CDRs can be referred to as CDR H 1, CDR H 2 and CDR H 3; the variable light chain CDRs can be referred to as CDR L 1, CDR L 2 and CDR L 3.
- epitope refers to a site on an antigen to which an antibody or extracellular trap segment binds.
- An epitope on a protein can be formed from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of one or more proteins. Epitopes formed from contiguous amino acids (also known as linear epitopes) are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding (also known as conformational epitopes) are typically lost on treatment with denaturing solvents.
- An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.
- Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996).
- Antibodies that recognize the same or overlapping epitopes can be identified in a simple immunoassay showing the ability of one antibody to compete with the binding of another antibody to a target antigen.
- the epitope of an antibody can also be defined by X-ray crystallography of the antibody (or Fab fragment) bound to its antigen to identify contact residues.
- two antibodies have the same epitope if all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.
- Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.
- Competition between antibodies is determined by an assay in which an antibody under test inhibits specific binding of a reference antibody to a common antigen (see, e.g., Junghans et al., Cancer Res. 50: 1495, 1990).
- a test antibody competes with a reference antibody if an excess of a test antibody (e.g., at least 2 ⁇ , 5 ⁇ , 10 ⁇ , 20 ⁇ or 100 ⁇ ) inhibits binding of the reference antibody by at least 50%.
- the test antibody inhibits binding of the reference antibody by 75%, 90%, or 99% as measured in a competitive binding assay.
- Antibodies identified by competition assay include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.
- patient includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
- amino acids are grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gin, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.
- Percentage sequence identities are determined with antibody sequences maximally aligned by the Kabat numbering convention for a variable region or EU numbering for a constant region. After alignment, if a subject antibody region (e.g., the entire mature variable region of a heavy or light chain) is being compared with the same region of a reference antibody, the percentage sequence identity between the subject and reference antibody regions is the number of positions occupied by the same amino acid in both the subject and reference antibody region divided by the total number of aligned positions of the two regions, with gaps not counted, multiplied by 100 to convert to percentage.
- a subject antibody region e.g., the entire mature variable region of a heavy or light chain
- Sequence identities of other sequences can be determined by aligning sequences using algorithms, such as BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis., using default gap parameters, or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence similarity over a comparison window). Percentage of sequence identity is calculated by comparing two optimally aligned sequences over a window of comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- algorithms such as BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis., using default gap parameters, or by inspection, and the best alignment (i.e.
- compositions or methods “comprising” one or more recited elements may include other elements not specifically recited.
- a composition that comprises antibody may contain the antibody alone or in combination with other ingredients.
- ADCC antibody-dependent cellular cytotoxicity
- target cells i.e., cells with bound antibody
- immune cells possessing lytic activity also referred to as effector cells.
- effector cells include natural killer cells, monocytes/macrophages and neutrophils.
- ADCC is triggered by interactions between the Fc region of an antibody bound to a cell and Fcy receptors, particularly Fc ⁇ RI and Fc ⁇ RIII, on immune effector cells such as neutrophils, macrophages and natural killer cells.
- the target cell is eliminated by phagocytosis or lysis, depending on the type of mediating effector cell. Death of the antibody-coated target cell occurs as a result of effector cell activity.
- opsonization also known as “antibody-dependent cellular phagocytosis”, or ADCP, refers to the process by which antibody-coated cells are internalized, either in whole or in part, by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells) that bind to an immunoglobulin Fc region.
- phagocytic immune cells e.g., macrophages, neutrophils and dendritic cells
- complement-dependent cytotoxicity refers to a mechanism for inducing cell death in which an Fc effector domain(s) of a target-bound antibody activates a series of enzymatic reactions culminating in the formation of holes in the target cell membrane.
- antigen-antibody complexes such as those on antibody-coated target cells bind and activate complement component C1q which in turn activates the complement cascade leading to target cell death.
- Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes.
- complement receptors e.g., CR3
- a humanized antibody is a genetically engineered antibody in which the CDRs from a non-human “donor” antibody are grafted into human “acceptor” antibody sequences (see, e.g., Queen, U.S. Pat. Nos. 5,530,101 and 5,585,089; Winter, U.S. Pat. No. 5,225,539, Carter, U.S. Pat. No. 6,407,213, Adair, U.S. Pat. No. 5,859,205 6,881,557, Foote, U.S. Pat. No. 6,881,557).
- the acceptor antibody sequences can be, for example, a mature human antibody sequence, a composite of such sequences, a consensus sequence of human antibody sequences, or a germline region sequence.
- a humanized antibody is an antibody having some or all CDRs entirely or substantially from a donor antibody and variable region framework sequences and constant regions, if present, entirely or substantially from human antibody sequences.
- a humanized heavy chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody heavy chain, and a heavy chain variable region framework sequence and heavy chain constant region, if present, substantially from human heavy chain variable region framework and constant region sequences.
- a humanized light chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody light chain, and a light chain variable region framework sequence and light chain constant region, if present, substantially from human light chain variable region framework and constant region sequences.
- a humanized antibody comprises a humanized heavy chain and a humanized light chain.
- a CDR in a humanized antibody is substantially from a corresponding CDR in a non-human antibody when at least 85%, 90%, 95% or 100% of corresponding residues (as defined by Kabat) are identical between the respective CDRs.
- the variable region framework sequences of an antibody chain or the constant region of an antibody chain are substantially from a human variable region framework sequence or human constant region respectively when at least 85, 90, 95 or 100% of corresponding residues defined by Kabat are identical.
- humanized antibodies often incorporate all six CDRs (which can be as defined by Kabat) from a mouse antibody, they can also be made with less than all CDRs (e.g., at least 3, 4, or 5 CDRs from a mouse antibody) (e.g., De Pascalis R, Iwahashi M, Tamura M, et al. 2002. Grafting “Abbreviated” Complementary-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody. J Immunol. 169:3076-3084; Vajdos F F, Adams C W, Breece T N, Presta L G, de Vos A M, Sidhu, S S. 2002.
- a chimeric antibody is an antibody in which the mature variable regions of light and heavy chains of a non-human antibody (e.g., a mouse) are combined with human light and heavy chain constant regions. Such antibodies substantially or entirely retain the binding specificity of the mouse antibody, and are about two-thirds human sequence.
- a veneered antibody is a type of humanized antibody that retains some and usually all of the CDRs and some of the non-human variable region framework residues of a non-human antibody but replaces other variable region framework residues that may contribute to B- or T-cell epitopes, for example exposed residues (Padlan E A. 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol. 28:489-98) with residues from the corresponding positions of a human antibody sequence. The result is an antibody in which the CDRs are entirely or substantially from a non-human antibody and the variable region frameworks of the non-human antibody are made more human-like by the substitutions.
- a human antibody can be isolated from a human, or otherwise result from expression of human immunoglobulin genes (e.g., in a transgenic mouse, in vitro or by phage display).
- Methods for producing human antibodies include the trioma method of ⁇ stberg L, Pursch E. 1983. Human ⁇ (mouse ⁇ human) hybridomas stably producing human antibodies. Hybridoma 2:361-367; ⁇ stberg, U.S. Pat. No. 4,634,664; and Engleman et al., U.S. Pat. No. 4,634,666, use of transgenic mice including human immunoglobulin genes (see, e.g., Lonberg et al., WO93/12227 (1993); U.S. Pat. Nos.
- Polymer refers to a series of monomer groups linked together.
- a polymer is composed of multiple units of a single monomer (a homopolymer) or different monomers (a heteropolymer).
- High MW polymers are prepared from monomers that include, but are not limited to, acrylates, methacrylates, acrylamides, methacrylamides, styrenes, vinyl-pyridine, vinyl-pyrrolidone and vinyl esters such as vinyl acetate. Additional monomers are useful in high MW polymers. When two different monomers are used, the two monomers are called “comonomers,” meaning that the different monomers are copolymerized to form a single polymer.
- the polymer can be linear or branched.
- each polymer chain is referred to as a “polymer arm.”
- the end of the polymer arm linked to the initiator moiety is the proximal end, and the growing-chain end of the polymer arm is the distal end.
- the polymer arm end group can be the radical scavenger, or another group.
- “Initiator” refers to a compound capable of initiating a polymerization using monomers or comonomers.
- the polymerization can be a conventional free radical polymerization or a controlled/“living” radical polymerization, such as Atom Transfer Radical Polymerization (ATRP), Reversible Addition-Fragmentation-Termination (RAFT) polymerization or nitroxide mediated polymerization (NMP).
- ATRP Atom Transfer Radical Polymerization
- RAFT Reversible Addition-Fragmentation-Termination
- NMP nitroxide mediated polymerization
- the polymerization can be a “pseudo” controlled polymerization, such as degenerative transfer.
- the initiator When the initiator is suitable for ATRP, it contains a labile bond which can be homolytically cleaved to form an initiator fragment, I, being a radical capable of initiating a radical polymerization, and a radical scavenger, I′, which reacts with the radical of the growing polymer chain to reversibly terminate the polymerization.
- the radical scavenger I′ is typically a halogen, but can also be an organic moiety, such as a nitrile.
- the initiator contains one of more 2-bromoisobutyrate groups as sites for polymerization via ATRP.
- a “chemical linker” refers to a chemical moiety that links two groups together, such as a half-life extending moiety and a protein.
- the linker can be cleavable or non-cleavable.
- Cleavable linkers can be hydrolyzable, enzymatically cleavable, pH sensitive, photolabile, or disulfide linkers, among others.
- Other linkers include homobifunctional and heterobifunctional linkers.
- a “linking group” is a functional group capable of forming a covalent linkage consisting of one or more bonds to a bioactive agent. Non-limiting examples include those illustrated in Table 1 of WO2013059137 (incorporated by reference).
- reactive group refers to a group that is capable of reacting with another chemical group to form a covalent bond, i.e. is covalently reactive under suitable reaction conditions, and generally represents a point of attachment for another substance.
- the reactive group is a moiety, such as maleimide or succinimidyl ester, is capable of chemically reacting with a functional group on a different moiety to form a covalent linkage.
- Reactive groups generally include nucleophiles, electrophiles and photoactivatable groups.
- Phosphorylcholine also denoted as “PC,” refers to the following:
- the phosphorylcholine is a zwitterionic group and includes salts (such as inner salts), and protonated and deprotonated forms thereof.
- Phosphorylcholine containing polymer is a polymer that contains phosphorylcholine.
- Zwitterion containing polymer refers to a polymer that contains a zwitterion.
- Poly(acryloyloxyethyl phosphorylcholine) containing polymer refers to a polymer containing 2-(acryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEA-PC shown below in Example 6) as monomer.
- Poly(methacryloyloxyethyl phosphorylcholine) containing polymer refers to a polymer containing 2-(methacryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEMA-PC or MPC) as monomer (see below):
- Molecular weight in the context of the polymer can be expressed as either a number average molecular weight, or a weight average molecular weight or a peak molecular weight. Unless otherwise indicated, all references to molecular weight herein refer to the peak molecular weight. These molecular weight determinations, number average (Mn), weight average (Mw) and peak (Mp), can be measured using size exclusion chromatography or other liquid chromatography techniques.
- molecular weight values can also be used, such as the use of end-group analysis or the measurement of colligative properties (e.g., freezing-point depression, boiling-point elevation, or osmotic pressure) to determine number average molecular weight, or the use of light scattering techniques, ultracentrifugation or viscometry to determine weight average molecular weight.
- the molecular weight is measured by SEC-MALS (size exclusion chromatography—multi angle light scattering).
- the polymeric reagents are typically polydisperse (i.e., number average molecular weight and weight average molecular weight of the polymers are not equal), and can possess low polydispersity values of, for example, less than about 1.5, as judged, for example, by the PDI value derived from the SEC-MALS measurement.
- the polydispersities (PDI) are in the range of about 1.4 to about 1.2. In some embodiments the PDI is less than about 1.15, 1.10, 1.05, or 1.03.
- a or “an” entity refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound.
- a compound refers to one or more compounds or at least one compound.
- the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.
- Protecting group refers to the presence of a group (i.e., the protecting group) that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions.
- Protecting groups vary depending upon the type of chemically reactive group being protected as well as the reaction conditions to be employed and the presence of additional reactive or protecting groups in the molecule, if any. Suitable protecting groups include those such as found in the treatise by Greene et al., “Protective Groups In Organic Synthesis,” 3 rd Edition, John Wiley and Sons, Inc., New York, 1999.
- Alkyl refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated.
- C 1 -C 6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc.
- Other alkyl groups include, but are not limited to heptyl, octyl, nonyl, decyl, etc.
- Alkyl can include any number of carbons, such as 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6 and 5-6.
- the alkyl group is typically monovalent, but can be divalent, such as when the alkyl group links two moieties together.
- lower referred to above and hereinafter in connection with organic radicals or compounds respectively defines a compound or radical which can be branched or unbranched with up to and including 7 or up to and including 4 and (as unbranched) one or two carbon atoms.
- Alkylene refers to an alkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene.
- a straight chain alkylene can be the bivalent radical of —(CH 2 ) n , where n is 1, 2, 3, 4, 5 or 6.
- Alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.
- Substituents for the alkyl and heteroalkyl radicals can be a variety of groups selected from: —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NH—C(NH 2 ) ⁇ NH, —NR′C(NH 2 ) ⁇ NH, —NH—NH 2 ) ⁇ NH, —NH′C(NH 2 ) ⁇ NH, —NH—NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —NH 2 —
- R′, R′′ and R′′′ each independently refer to hydrogen, unsubstituted (C 1 -C 8 )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C 1 -C 4 )alkyl groups.
- R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- —NR′R′′ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
- alkyl is include groups such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
- the substituted alkyl and heteroalkyl groups have from 1 to 4 substituents.
- the substituted alkyl and heteroalkyl groups have 1, 2 or 3 substituents. Exceptions are those perhalo alkyl groups (e.g., pentafluoroethyl and the like).
- Substituents for the alkyl and heteroalkyl radicals can be one or more of a variety of groups selected from, but not limited to: —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —O C(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′,
- R′, R′′, R′′′ and R′′′′ each independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
- each of the R groups is independently selected as are each R′, R′′, R′′′ and R′′′′ groups when more than one of these groups is present.
- R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- —NR′R′′ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
- alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
- Alkoxy refers to alkyl group having an oxygen atom that either connects the alkoxy group to the point of attachment or is linked to two carbons of the alkoxy group.
- Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc.
- the alkoxy groups can be further substituted with a variety of substituents described within. For example, the alkoxy groups can be substituted with halogens to form a “halo-alkoxy” group.
- Carboxyalkyl means an alkyl group (as defined herein) substituted with a carboxy group.
- carboxycycloalkyl means a cycloalkyl group (as defined herein) substituted with a carboxy group.
- alkoxyalkyl means an alkyl group (as defined herein) substituted with an alkoxy group.
- carboxy employed herein refers to carboxylic acids and their esters.
- Haloalkyl refers to alkyl as defined above where some or all of the hydrogen atoms are substituted with halogen atoms.
- Halogen represents chloro or fluoro, but may also be bromo or iodo.
- haloalkyl includes trifluoromethyl, fluoromethyl, 1,2,3,4,5-pentafluoro-phenyl, etc.
- perfluoro defines a compound or radical which has all available hydrogens that are replaced with fluorine.
- perfluorophenyl refers to 1,2,3,4,5-pentafluorophenyl
- perfluoromethyl refers to 1,1,1-trifluoromethyl
- perfluoromethoxy refers to 1,1,1-trifluoromethoxy
- Fluoro-substituted alkyl refers to an alkyl group where one, some, or all hydrogen atoms have been replaced by fluorine.
- Cytoke is a member of a group of protein signaling molecules that may participate in cell-cell communication in immune and inflammatory responses. Cytokines are typically small, water-soluble glycoproteins that have a mass of about 8-35 kDa.
- Cycloalkyl refers to a cyclic hydrocarbon group that contains from about 3 to 12, from 3 to 10, or from 3 to 7 endocyclic carbon atoms. Cycloalkyl groups include fused, bridged and spiro ring structures.
- Endocyclic refers to an atom or group of atoms which comprise part of a cyclic ring structure.
- Exocyclic refers to an atom or group of atoms which are attached but do not define the cyclic ring structure.
- Cyclic alkyl ether refers to a 4 or 5 member cyclic alkyl group having 3 or 4 endocyclic carbon atoms and 1 endocyclic oxygen or sulfur atom (e.g., oxetane, thietane, tetrahydrofuran, tetrahydrothiophene); or a 6 to 7 member cyclic alkyl group having 1 or 2 endocyclic oxygen or sulfur atoms (e.g., tetrahydropyran, 1,3-dioxane, 1,4-dioxane, tetrahydrothiopyran, 1,3-dithiane, 1,4-dithiane, 1,4-oxathiane).
- alkenyl refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one double bond.
- alkenyl groups include, but are not limited to, vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl.
- Alkenyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons.
- the alkenyl group is typically monovalent, but can be divalent, such as when the alkenyl group links two moieties together.
- Alkenylene refers to an alkenyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkenylene can be linked to the same atom or different atoms of the alkenylene.
- Alkenylene groups include, but are not limited to, ethenylene, propenylene, isopropenylene, butenylene, isobutenylene, sec-butenylene, pentenylene and hexenylene.
- Alkynyl refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one triple bond.
- alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentenyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatrienyl.
- Alkynyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons.
- the alkynyl group is typically monovalent, but can be divalent, such as when the alkynyl group links two moieties together.
- Alkynylene refers to an alkynyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkynylene can be linked to the same atom or different atoms of the alkynylene.
- Alkynylene groups include, but are not limited to, ethynylene, propynylene, butynylene, sec-butynylene, pentenylene and hexynylene.
- Cycloalkyl refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated.
- Monocyclic rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl.
- Bicyclic and polycyclic rings include, for example, norbornane, decahydronaphthalene and adamantane.
- C 3-8 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and norbornane.
- Cycloalkylene refers to a cycloalkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the cycloalkylene can be linked to the same atom or different atoms of the cycloalkylene.
- Cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cyclooctylene.
- Heterocycloalkyl refers to a ring system having from 3 ring members to about 20 ring members and from 1 to about 5 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can also be oxidized, such as, but not limited to, —S(O)— and —S(O) 2 —.
- heterocycle includes, but is not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, quinuclidinyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl.
- Heterocycloalkylene refers to a heterocycloalkyl group, as defined above, linking at least two other groups.
- the two moieties linked to the heterocycloalkylene can be linked to the same atom or different atoms of the heterocycloalkylene.
- Aryl refers to a monocyclic or fused bicyclic, tricyclic or greater, aromatic ring assembly containing 6 to 16 ring carbon atoms.
- aryl may be phenyl, benzyl or naphthyl.
- Arylene means a divalent radical derived from an aryl group.
- Aryl groups can be mono-, di- or tri-substituted by one, two or three radicals selected from alkyl, alkoxy, aryl, hydroxy, halogen, cyano, amino, amino-alkyl, trifluoromethyl, alkylenedioxy and oxy-C 2 -C 3 -alkylene; all of which are optionally further substituted, for instance as hereinbefore defined; or 1- or 2-naphthyl; or 1- or 2-phenanthrenyl.
- Alkylenedioxy is a divalent substitute attached to two adjacent carbon atoms of phenyl, e.g. methylenedioxy or ethylenedioxy.
- Oxy-C 2 -C 3 -alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. oxyethylene or oxypropylene.
- phenyl e.g. oxyethylene or oxypropylene.
- An example for oxy-C 2 -C 3 -alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
- the aryl is naphthyl, phenyl or phenyl mono- or disubstituted by alkoxy, phenyl, halogen, alkyl or trifluoromethyl, especially phenyl or phenyl-mono- or disubstituted by alkoxy, halogen or trifluoromethyl, and in particular phenyl.
- substituted phenyl groups as R are, e.g. 4-chlorophen-1-yl, 3,4-dichlorophen-1-yl, 4-methoxyphen-1-yl, 4-methylphen-1-yl, 4-aminomethylphen-1-yl, 4-methoxyethylaminomethylphen-1-yl, 4-hydroxyethylaminomethylphen-1-yl, 4-hydroxyethyl-(methyl)-aminomethylphen-1-yl, 3-aminomethylphen-1-yl, 4-N-acetylaminomethylphen-1-yl, 4-aminophen-1-yl, 3-aminophen-1-yl, 2-aminophen-1-yl, 4-phenyl-phen-1-yl, 4-(imidazol-1-yl)-phenyl, 4-(imidazol-1-ylmethyl)-phen-1-yl, 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1-
- Arylene refers to an aryl group, as defined above, linking at least two other groups. The two moieties linked to the arylene are linked to different atoms of the arylene. Arylene groups include, but are not limited to, phenylene.
- Arylene-oxy refers to an arylene group, as defined above, where one of the moieties linked to the arylene is linked through an oxygen atom. Arylene-oxy groups include, but are not limited to, phenylene-oxy.
- substituents for the aryl and heteroaryl groups are varied and are selected from: -halogen, —OR′, —OC(O)R′, —NR′R′′, —SR′, —R′, —CN, —NO 2 , —CO 2 R′, —CONR′R′′, —C(O)R′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′′C(O) 2 R′, —NR′—C(O)NR′′R′′′, —NH—C(NH 2 ) ⁇ NH, —NR′C(NH 2 ) ⁇ NH, —NH—C(NH 2 ) ⁇ NR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, —N 3 , —CH(Ph) 2 , perfluoro(C 1 -C 4 )alkoxy, and perfluoro(C 1 -
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)—(CH 2 ) q —U—, wherein T and U are independently —NH—, —O—, —CH 2 — or a single bond, and q is an integer of from 0 to 2.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r —B—, wherein A and B are independently —CH 2 —, —O—, —NH—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′— or a single bond, and r is an integer of from 1 to 3.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CH 2 ) r —X—(CH 2 ) r —, where s and t are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
- the substituent R′ in —NR′— and —S(O) 2 NR′— is selected from hydrogen or unsubstituted (C 1 -C 6 )alkyl.
- Heteroaryl refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, where from 1 to 4 of the ring atoms are a heteroatom each N, O or S.
- heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any other radicals substituted, especially mono- or di-substituted, by e.g. alkyl, nitro or halogen.
- Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl.
- Thienyl represents 2- or 3-thienyl.
- quinolinyl represents 2-, 3- or 4-quinolinyl.
- isoquinolinyl represents 1-, 3- or 4-isoquinolinyl.
- benzopyranyl, benzothiopyranyl can represent 3-benzopyranyl or 3-benzothiopyranyl, respectively.
- thiazolyl can represent 2- or 4-thiazolyl.
- triazolyl can be 1-, 2- or 5-(1,2,4-triazolyl).
- tetrazolyl can be 5-tetrazolyl.
- heteroaryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl, oxazolyl, indazolyl, or any of the radicals substituted, especially mono- or di-substituted.
- heteroalkyl refers to an alkyl group having from 1 to 3 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can also be oxidized, such as, but not limited to, —S(O)— and —S(O) 2 —.
- heteroalkyl can include ethers, thioethers, alkyl-amines and alkyl-thiols.
- heteroalkylene refers to a heteroalkyl group, as defined above, linking at least two other groups.
- the two moieties linked to the heteroalkylene can be linked to the same atom or different atoms of the heteroalkylene.
- Electrophile refers to an ion or atom or collection of atoms, which may be ionic, having an electrophilic center, i.e., a center that is electron seeking, capable of reacting with a nucleophile.
- An electrophile or electrophilic reagent is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
- Nucleophile refers to an ion or atom or collection of atoms, which may be ionic, having a nucleophilic center, i.e., a center that is seeking an electrophilic center or capable of reacting with an electrophile.
- a nucleophile or nucleophilic reagent is a reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons.
- a “nucleophilic group” refers to a nucleophile after it has reacted with a reactive group. Non limiting examples include amino, hydroxyl, alkoxy, haloalkoxy and the like.
- Maleimido refers to a pyrrole-2,5-dione-1-yl group having the structure:
- “naturally occurring amino acids” found in proteins and polypeptides are L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and or L-valine.
- “Non-naturally occurring amino acids” found in proteins are any amino acid other than those recited as naturally occurring amino acids.
- Non-naturally occurring amino acids include, without limitation, the D isomers of the naturally occurring amino acids, and mixtures of D and L isomers of the naturally occurring amino acids.
- Other amino acids such as N-alpha-methyl amino acids (e.g. sarcosine), 4-hydroxyproline, desmosine, isodesmosine, 5-hydroxylysine, epsilon-N-methyllysine, 3-methylhistidine, although found in naturally occurring proteins, are considered to be non-naturally occurring amino acids found in proteins for the purpose of this disclosure as they are generally introduced by means other than ribosomal translation of mRNA.
- Linear in reference to the geometry, architecture or overall structure of a polymer, refers to polymer having a single polymer arm.
- Branched in reference to the geometry, architecture or overall structure of a polymer, refers to a polymer having 2 or more polymer “arms” extending from a core structure contained within an initiator.
- the initiator may be employed in an atom transfer radical polymerization (ATRP) reaction.
- a branched polymer may possess 2 polymer chains (arms), 3 polymer arms, 4 polymer arms, 5 polymer arms, 6 polymer arms, 7 polymer arms, 8 polymer arms, 9 polymer arms or more.
- Each polymer arm extends from a polymer initiation site.
- Each polymer initiation site is capable of being a site for the growth of a polymer chain by the addition of monomers.
- the site of polymer initiation on an initiator is typically an organic halide undergoing a reversible redox process catalyzed by a transition metal compound such as cuprous halide.
- the halide is a bromine.
- “Pharmaceutically acceptable excipient” refers to an excipient that can be included in compositions and that causes no significant adverse toxicological effect on the patient and is approved or approvable by the FDA for therapeutic use, particularly in humans.
- Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose and the like.
- Therapeutic proteins are administered in an effective regime meaning a dosage, route of administration and frequency of administration that delays the onset, reduces the severity, inhibits further deterioration, and/or ameliorates at least one sign or symptom of a disorder. If a patient is already suffering from a disorder, the regime can be referred to as a therapeutically effective regime. If the patient is at elevated risk of the disorder relative to the general population but is not yet experiencing symptoms, the regime can be referred to as a prophylactically effective regime. In some instances, therapeutic or prophylactic efficacy can be observed in an individual patient relative to historical controls or past experience in the same patient. In other instances, therapeutic or prophylactic efficacy can be demonstrated in a preclinical or clinical trial in a population of treated patients relative to a control population of untreated patients.
- the “biological half-life” of a substance is a pharmacokinetic parameter which specifies the time required for one half of the substance to be removed from a tissue or an organism following introduction of the substance.
- OG1786 is a 9-arm initiator used for polymer synthesis with the structure shown in FIG. 30 , which depicts that salt form of OG1786 with trifluoroacetic acid. OG1786 may be used as other salts are used or as the free base.
- OG1801 is an approximately (+/ ⁇ 15%) 750 kDa polymer (either by Mn or Mp) made using OG1786 as an intiator for ATRP synthesis using the monomer HEMA-PC.
- OG1802 is OG1801 with a maleimide functionality added and is shown in FIG. 36 wherein each of n 1 , n 2 , n 3 , n 4 , n 5 , n 6 , n 7 , n 8 and n 9 is an integer (positive) (from 0 up to about 3000) such that the total molecular weight of the polymer is (Mw) 750,000 t 15% daltons.
- Multi-angle light scattering is a technique of analyzing macromolecules where the laser light impinges on the molecule, the oscillating electric field of the light induces an oscillating dipole within it. This oscillating dipole will re-radiate light and can be measured using a MALS detector such as Wyatt miniDawn TREOS.
- the intensity of the radiated light depends on the magnitude of the dipole induced in the macromolecule which in turn is proportional to the polarizability of the macromolecule, the larger the induced dipole, and hence, the greater the intensity of the scattered light. Therefore, in order to analyze the scattering from a solution of such macromolecules, one should know their polarizability relative to the surrounding medium (e.g., the solvent).
- Two molar weight parameters that MALS determination employ are number average molecular weight (Mn) and weight average molecular weight (Mw) where the polydispersity index (PDI) equals Mw divided by Mn.
- SEC also allows another average molecular weight determination of the peak molecular weight Mp which is defined as the molecular weight of the highest peak at the SEC.
- the PDI is used as a measure of the broadness of a molecular weight distribution of a polymer and bioconjugate which is derived from conjugation of a discrete protein (e.g. OG1950) to a polydisperse biopolymer (e.g., OG1802).
- a discrete protein e.g. OG1950
- a polydisperse biopolymer e.g., OG1802
- Size exclusion chromatography is a chromatography technique in which molecules in solution are separated by their size. Typically an aqueous solution is applied to transport the sample through the column which is packed with resins of various pore sizes. The resin is expected to be inert to the analyte when passing through the column and the analytes separate from each other based on their unique size and the pore size characteristics of the selected column.
- Coupling the SEC with MALS or SEC/MALS provides accurate distribution of molar mass and size (root mean square radius) as opposed to relying on a set of SEC calibration standards.
- This type of arrangement has many advantages over traditional column calibration methods. Since the light scattering and concentration are measured for each eluting fraction, the molar mass and size can be determined independently of the elution position. This is particularly relevant for species with non-globular shaped macromolecules such as the biopolymers (OG1802) or bioconjugates (OG1953); such species typically do not elute in a manner that might be described by a set of column calibration standards.
- a SEC/MALS analysis includes a Waters HPLC system with Alliance 2695 solvent delivery module and Waters 2996 Photodiole Array Detector equipped with a Shodex SEC-HPLC column (7.8 ⁇ 300 mm). This is connected online with a Wyatt miniDawn TREOS and Wyatt Optilab T-rEX differential refractometer.
- the Empower software from Waters can be used to control the Waters HPLC system and the ASTRA V 6.1.7.16 software from Wyatt can be used to acquire the MALS data from the Wyatt miniDawn TREOS, dn/dc data from the T-rEX detector and the mass recovery data using the A280 absorbance signal from the Waters 2996 Photodiole Array detector.
- SEC can be carried out at 1 ml/min in 1 ⁇ PBS pH 7.4, upon sample injection, the MALS and RI signals can be analyzed by the ASTRA software for determination of absolute molar mass (Mp, Mw, Mn) and polydisperse index (PDI).
- the calculation also involves the input dn/dc values for polymer and protein as 0.142 and 0.183, respectively.
- the dn/dc is calculated based on the weighted MW of the polymer and the protein to be about 0.148 using the formula below:
- MWpolymer for OG1802 is 800 kDa and the MWprotein for OG1950 is 146 kDa.
- anti-VEGF antibodies and conjugates thereof are provided herein.
- the antibodies themselves are different from other anti-VEGF agents and provide superior results over other anti-VEGF agents.
- the anti-VEGF antibody conjugate displays a surprising superiority over other antibodies and/or the expectation of the activity other antibody conjugates.
- the conjugate can be superior to the antibody alone.
- the interaction of a ligand and its specific receptor is often driven through the stereospecific interaction of the ligand and the receptor, as directed by the interactions of the hydrophilic amino acids on the ligand with the hydrophilic amino acids on the receptor, and water molecules are front and center in those interactions.
- this hydrophilic stereospecificity is further enhanced by de-emphasizing and/or suppressing non-specific hydrophobic interactions that might generally be mediated/created by hydrophobic-to-hydrophobic amino acids.
- an anti-VEGF antibody conjugate is provided that is capable of blocking at least 90% of an interaction between a VEGF ligand (“VEGFL”) and a VEGF-receptor (“VEGFR”). For example, it can block at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all of the interaction between VEGFR and VEGFL. In some embodiments, the noted blocking occurs at saturating concentrations. In some embodiments, an anti-VEGF antibody conjugate is provided that blocks at least 95% of an interaction between a VEGF ligand and a VEGF-receptor. As an example of such superiority of blocking, see FIG.
- the antibodies or conjugates thereof inhibit at least 70, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% of the activity and/or interaction between VEGFR and VEGFL.
- the IC50 value can be 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100 nM or less than any one or more of the preceding values.
- the KD can be 2*10 ⁇ circumflex over ( ) ⁇ -13, 1*10 ⁇ circumflex over ( ) ⁇ -13, 1*10 ⁇ circumflex over ( ) ⁇ -12, 1*10 ⁇ circumflex over ( ) ⁇ -11, 1*10- ⁇ circumflex over ( ) ⁇ 10M or less than any one of the preceding values.
- the IC50 value can be 1, 5, 10, 20, 30, 40, 50, 60, 70 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, or less than any one of the preceding values.
- an anti-VEGF antibody that blocks at least 90% of an interaction between a VEGF ligand and a VEGF-receptor. For example, it can block at least 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all of the interaction between VEGFR and VEGFL.
- superiority of blocking see FIG. 20 , regarding the ability of OG1950 (and antibody provided herein) to block to a higher degree than Lucentis® (ranibizumab) or Avastin® (bevacizumab).
- antibodies such as Lucentis® (ranibizumab) or Avastin® (bevacizumab) can be conjugated to one or more of the polymers as described herein, by one or more of the processes described herein.
- any antibody, or fragment thereof can be conjugated to one or more of the polymers as described herein, by one or more of the processes described herein.
- the antibody comprises a heavy chain amino acid variable region that comprises SEQ ID NO 1 and a light chain amino acid variable region that comprises SEQ ID NO. 2.
- the antibody is conjugated to one or more of the polymers provided herein.
- the conjugated antibody is at least 90% identical to SEQ ID NO: 1 and/or 2.
- the antibody contains the 6 CDRs within SEQ ID NO:1 and SEQ ID NO: 2, as well as a point mutation of L443C (EU numbering, or 449C in SEQ ID NO: 1).
- the conjugated antibody is at least 90% identical to SEQ ID NO: 1 and/or 2 and includes the following mutations: L234A, L235A, and G237A (EU numbering), and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering).
- an antibody that binds to VEGF-A comprises: a CDR H 1 that is the CDR H 1 in SEQ ID NO: 1, a CDR H 2 that is the CDR H 2 in SEQ ID NO: 1, a CDR H 3 that is the CDR H 3 in SEQ ID NO: 1, a CDR L 1 that is the CDR L 1 in SEQ ID NO: 2, a CDR L 2 that is the CDR L 2 in SEQ ID NO: 2, a CDR L 3 that is the CDR L 3 in SEQ ID NO: 2, at least one of the following mutations: L234A, L235A, and G237A (EU numbering), and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering).
- any of the antibodies provided herein can be conjugated to any of the polymers provided herein and/or any antibody provided herein can have a cysteine added such that it allows for site specific conjugation to a polymer.
- VEGF vascular endothelial growth factor
- vascular endothelial growth factor is a human vascular endothelial growth factor that affects angiogenesis or an angiogenic process.
- VEGF means any member of the class of growth factors that (i) bind to a VEGF receptor such as VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), or VEGFR-3 (FLT-4); (ii) activates a tyrosine kinase activity associated with the VEGF receptor; and (iii) thereby affects angiogenesis or an angiogenic process.
- VEGF-A also known as VPE
- VPE vanadium phosphate
- VEGF-A vascular endothelial growth factor
- VEGF-A is the most well studied and is the target of anti-angiogenic therapy. Ferrara et al, (2003) Nat. Med. 9:669-676.
- VEGF-A exists as a number of different isotypes which are generated both by alternative splicing and proteolysis: VEGF-A 206 , VEGF-A 189 , VEGF-A 165 , and VEGF-A 121 .
- the isoforms differ in their ability to bind heparin and non-signaling binding proteins called neuropilins.
- the isoforms are all biologically active as dimers.
- VEGF-A VEGF-A
- -B P49766
- -C P49767
- -D receptor tyrosine kinases
- RTKs receptor tyrosine kinases
- the VEGF family receptors belong to class V RTKs and each carry seven Ig-like domains in the extracellular domain (ECD).
- VEGF binds to three types of RTKs: VEGFR-1 (Flt-1) (P17948), VEGFR-2 (KDR, Flk-1) (P935968) and VEGFR-3 (Flt-4) (P35916).
- VEGF vascular endothelial growth factor
- VEGF-A, -B, -C, -D, and PGF in any of the natural isoforms or natural variants or induced variants having at least 90, 95, 98 or 99% or 100% sequence identity to a natural form.
- such VEGFs are human VEGFs.
- VEGFR means any of VEGR-1, R-2 or R-3, including any natural isoform or natural variant, or an induced variant having at least 90, 95, 98 or 99% or 100% sequence identity to a natural sequences.
- VEGF antagonist therapies have been approved for the treatment of certain cancers and wet AMD.
- Bevacizumab (AVASTIN, Genentech/Roche) is a humanized mouse monoclonal antibody that binds to and neutralizes human VEGF, in particular to all isoforms of VEGF-A and to bioactive proteolytic fragments of VEGF-A. See, e.g., Ferrara N, Hillan K J, Gerber H P, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3(5):391-400. Bevacizumab has been approved for the treatment of certain cancers.
- the protein sequence of the heavy and light chains of bevacizumab (DrugBank DB00112) are set forth in SEQ ID NO. 3 (heavy) and SEQ ID NO. 4 (light).
- Bevacizumab variable light chain CDRs are CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13) and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- Bevacizumab variable heavy chain CDRs are CDR H 1: GYTFTNYGMN, CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPHYYGSSHWYFDV.
- CDRs are defined by Kabat except CDR H 1 uses the composite Kabat/Chothia definition.
- a cysteine can be added to the Bevacizumab sequence and the antibody (and/or a variant that includes the 6 CDRs of Bevacizumab) can be conjugated to any one or more of the polymers provided herein.
- ranibizumab is an antibody fragment or Fab.
- Ranibizumab was produced by affinity maturation of the variable heavy and light chains of bevacizumab.
- the sequence of the heavy and light chains of ranibizumab (as published by Novartis) is set forth in SEQ ID NO. 5 and 6 respectively.
- a cysteine can be added to the ranibizumab sequence and the antibody (and/or a variant that includes the 6 CDRs of ranibizumab) can be conjugated to any one or more of the polymers provided herein.
- the Ranibizumab CDRS are the same as Bevacizumab except where an improvement was added after affinity maturation:
- Ranibizumab variable light chain CDRs are CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13) and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- Ranibizumab variable heavy chain CDRs are CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11).
- an antibody conjugate having an anti-VEGF-A antibody bonded at a cysteine outside a variable region of the antibody to a phosphorylcholine containing polymer, wherein the cysteine has been added via recombinant DNA technology.
- the polymer is bonded to a single cysteine.
- “added by recombinant DNA technology” means that the cysteine residue replaces a non-cysteine amino acid that occurs in the same position in a known or existing antibody or in a consensus antibody sequence.
- the leucine is replaced via recombinant DNA technology with a cysteine (L443C, EU numbering, or 449C in SEQ ID NO: 1).
- the native IgG1 sequence at EU position 347 is Q (glutamine) and the Q is replaced with cysteine via recombinant DNA technology to yield Q347C.
- the anti-VEGF-A antibody comprises a light chain and a heavy chain where the heavy chain has an Fc region.
- the cysteine is in the Fc region and the anti-VEGF-A antibody is an immunoglobulin G (IgG).
- the anti-VEGF-A heavy chain has CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO.
- the anti-VEGF-A light chain has CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14), and Kabat position 4 is L.
- the anti-VEGF-A heavy chain isotype is IgG1.
- the IgG1 constant domain has one or more mutations relative to an IgG1 constant domain (e.g. constant region of SEQ ID NO. 3) to modulate effector function.
- the effector function mutations are one or more of the following: (EU numbering) E233X, L234X, L235X, G236X, G237X, A327X, A330X, and P331X wherein X is any natural or unnatural amino acid.
- the mutations are selected from the group consisting of (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- antibody conjugate has the following mutations (EU numbering): L234A, L235A, and G237A.
- the cysteine residue is in the anti-VEGF-A heavy chain and is Q347C (EU numbering) or L443C (EU numbering). In some embodiments, the cysteine residue is L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1 and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- polymer comprises the following repeating units:
- n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- the polymer has three or more arms, or is synthesized with an initiator comprising 3 or more polymer initiation sites. In some embodiments, the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms, or is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 polymer initiation sites. More preferably, the polymer has 3, 6, or 9 arms, or is synthesized with an initiator comprising 3, 6, or 9 polymer initiation sites. In some embodiments, the polymer has 9 arms, or is synthesized with an initiator comprising 9 polymer initiation sites.
- the polymer that is added has a molecular weight between about 300,000 and about 1,750,000 Da (SEC-MALs). In some embodiments, the polymer has a molecular weight between about 500,000 and about 1,000,000 Da. In some embodiments, the polymer has a molecular weight of between about 600,000 to about 900,000 Da. In some embodiments, the polymer has a molecular weight of between about 750,000 to about 850,000 Da. In some embodiments, the polymer has a molecular weight of between about 800,000 to about 850,000 Da. In some embodiments, the polymer has a molecular weight of between about 750,000 to about 800,000 Da.
- any of the antibodies described herein can be further conjugated to a polymer to form a bioconjugate.
- the molecular weight of the bioconjugate (in total, SEC-MALs) can be between about 350,000 and 2,000,000 Daltons, for example, between about 450,000 and 1,900,000 Daltons, between about 550,000 and 1,800,000 Daltons, between about 650,000 and 1,700,000 Daltons, between about 750,000 and 1,600,000 Daltons, between about 850,000 and 1,500,000 Daltons, between about 900,000 and 1,400,000 Daltons, between about 950,000 and 1,300,000 Daltons, between about 900,000 and 1,000,000 Daltons, between about 1,000,000 and 1,300,000 Daltons, between about 850,000 and 1,300,000 Daltons, between about 850,000 and 1,000,000 Daltons, and between about 1,000,000 and 1,200,000 Daltons.
- the antibody conjugate is purified.
- the polymer is aspect of the antibody conjugate is polydisperse, i.e. the polymer PDI is not 1.0.
- the PDI is less than 1.5.
- the PDI is less than 1.4.
- the PDI is less than 1.3.
- the PDI is less than 1.2.
- the PDI is less than 1.1.
- the antibody conjugate has an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C449 in SEQ ID NO. 1 to the polymer.
- the polymer has 9 arms and has a molecular weight of between about 600,000 to about 1,000,000 Da.
- the antibody conjugate has an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C443 (EU numbering, or 449C in SEQ ID NO: 1) to the polymer.
- the polymer has 9 arms and has a molecular weight of between about 600,000 to about 1,000,000 Da.
- the antibody conjugate has the following structure:
- each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L; the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C449 of SEQ ID NO: 1, which bond is depicted on one of the heavy chains; PC is,
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500.
- X OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R 7 , carbony
- the antibody conjugate has the following structure:
- each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
- the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443 (EU numbering, or 449C in SEQ ID NO: 1), which bond is depicted on one of the heavy chains;
- PC is,
- n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500.
- X OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C 1 -C 24 alkyl, unsaturated C 2 -C 24 alkenyl or C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R 7 , carbony
- the antibody conjugate is present in a liquid formulation. In some embodiments, the antibody conjugate is combined with a pharmaceutically acceptable carrier.
- an anti-VEGF-A antibody is presented.
- the anti-VEGF-A antibody heavy chain has at least the following CDR sequences: CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11).
- the anti-VEGF-A heavy chain has those CDRs and in addition has threonine (T) at position 221 (via sequential counting as in SEQ ID NO. 3).
- the anti-VEGF-A light chain has at least the following CDRs: CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13) and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- the anti-VEGF-A antibody has those CDRs and in addition has leucine (L) at Kabat position 4.
- the isotype of the anti-VEGF-A antibody heavy chain is IgG1 and has a CH 1 , hinge, CH 2 and CH 3 domains.
- the light chain isotype is kappa.
- the IgG1 domain of the anti-VEGF-A antibody has one or more mutations to modulate effector function, such as ADCC, ADCP, and CDC.
- the IgG1 mutations reduce effector function.
- the amino acids to use for effector function mutations include (EU numbering) E233X, L234X, L235X, G236X, G237X, G236X, D270X, K322X, A327X, P329X, A330X, A330X, P331X, and P331X, in which X is any natural or non-natural amino acid.
- the mutations include one or more of the following: E233P, L234V, L234A, L235A, G237A, A327G, A330S and P331S (EU numbering).
- the anti-VEGF-A heavy chain has the following mutations (EU numbering): L234A, L235A and G237A.
- the number of effector function mutations relative to a natural human IgG1 sequence is no more than 10.
- the number of effector function mutations reparative to a natural human IgG1 sequence is no more than 5, 4, 3, 2 or 1.
- the antibody has decreased Fc gamma binding and/or complement C1q binding, such that the antibody's ability to result in an effector function is decreased. This can be especially advantageous for ophthalmic indications/disorders.
- the anti-VEGF-A antibody comprises one or more of the following amino acid mutations: L234A, L235A, G237A (EU numbering), and L443C (EU numbering, or 449C in SEQ ID NO: 1).
- the anti-VEGF-A antibody is or is part of a human immunoglobulin G (IgG1).
- the VEGF-A antibody comprises a heavy chain constant domain that comprises one or more mutations that reduce an immune-mediated effector function.
- an anti-VEGF-A antibody comprises a heavy chain that comprises a CDR H 1 comprising the sequence GYDFTHYGMN (SEQ ID NO: 9), a CDR H 2 comprising the sequence WINTYTGEPTYAADFKR (SEQ ID NO: 10), a CDR H 3 comprising the sequence YPYYYGTSHWYFDV (SEQ ID NO: 11), a CDR L 1 comprising the sequence SASQDISNYLN (SEQ ID NO: 12), a CDR L 2 comprising the sequence FTSSLHS (SEQ ID NO: 13), and a CDR L 3 comprising the sequence QQYSTVPWT (SEQ ID NO: 14).
- the IgG domain can be IgG2, IgG3 or IgG4 or a composite in which a constant regions is formed from more than one of these isotypes (e.g., CH1 region from IgG2 or IgG4, hinge, CH2 and CH3 regions from IgG1).
- Such domains can contain mutations to reduce and/or modulate effector function at one or more of the EU position mentioned for IgG1.
- Human IgG2 and IgG4 have reduced effector functions relative to human IgG1 and IgG3.
- the anti-VEGF-A heavy chain has a cysteine residue added as a mutation by recombinant DNA technology which can be used to conjugate a half-life extending moiety.
- the mutation is (EU numbering) Q347C (EU numbering) and/or L443C (EU numbering, or 449C in SEQ ID NO: 1).
- the mutation is L443C (EU numbering, or 449C in SEQ ID NO: 1).
- the stoichiometry of antibody to polymer is 1:1; in other words, a conjugate has one molecule of antibody conjugated to one molecule of polymer.
- half-life of the anti-VEGF-A antibodies can be extended by attachment of a “half-life (“half life”) extending moieties” or “half-life (“half life”) extending groups”.
- Half-life extending moieties include peptides and proteins which can be expressed in frame with the biological drug of issue (or conjugated chemically depending on the situation) and various polymers which can be attached or conjugated to one or more amino acid side chain or end functionalities such as —SH, —OH, —COOH, —CONH2, —NH2, or one or more N- and/or O-glycan structures.
- Half-life extending moieties generally act to increase the in vivo circulatory half-life of biologic drugs.
- peptide/protein half-life extending moieties examples include Fc fusion (Capon D J, Chamow S M, Mordenti J, et al. Designing CD4 immunoadhesions for AIDS therapy. Nature. 1989. 337:525-31), human serum albumin (HAS) fusion (Yeh P, Landais D, Lemaitre M, et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA. 1992. 89:1904-08), carboxy terminal peptide (CTP) fusion (Fares F A, Suganuma N. Nishimori K, et al.
- polymer half-life extending moieties examples include polyethylene glycol (PEG), branched PEG, PolyPEG® (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxylethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrate, polysaccharides, pullulane, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl-dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG), polyoxazoline, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylate, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic acid anyhydride, polystyrene-co-maleic acid anhydride, poly(1-hydroxyme
- a half-life extending moiety can be conjugated to an antibody via free amino groups of the protein using N-hydroxysuccinimide (NHS) esters.
- NHS N-hydroxysuccinimide
- Reagents targeting conjugation to amine groups can randomly react to E-amine group of lysines, ⁇ -amine group of N-terminal amino acids, and S-amine group of histidines.
- the anti-VEGF-A antibodies disclosed herein have many amine groups available for polymer conjugation. Conjugation of polymers to free amino groups, thus, might negatively impact the ability of the antibody proteins to bind to VEGF.
- a half-life extending moiety is coupled to one or more free SH groups using any appropriate thiol-reactive chemistry including, without limitation, maleimide chemistry, or the coupling of polymer hydrazides or polymer amines to carbohydrate moieties of the antibody after prior oxidation.
- maleimide coupling is used
- coupling occurs at cysteines naturally present or introduced via genetic engineering.
- polymers are covalently attached to cysteine residues introduced into anti-VEGF-A antibodies by site directed mutagenesis.
- the cysteine residues are employed in the Fc portion of the antibody.
- the sites to introduce cysteine residues into an Fc region are provided in WO 2013/093809, U.S. Pat. No. 7,521,541, WO 2008/020827, U.S. Pat. Nos. 8,008,453, 8,455,622 and US2012/0213705, incorporated herein by reference for all purposes.
- the cysteine mutations are Q347C (EU numbering) and L443C referring to the human IgG heavy chain by EU numbering.
- conjugates of antibody and high MW polymers serving as half-life extenders are provided.
- a conjugate comprises an antibody that is coupled to a zwitterionic polymer wherein the polymer is formed from one or more monomer units and wherein at least one monomer unit has a zwitterionic group is provided.
- the zwitterionic group is phosphorylcholine.
- one of the monomer units is HEMA-PC.
- a polymer is synthesized from a single monomer which is HEMA-PC.
- some antibody conjugates have 2, 3, or more polymer arms wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 polymer arms wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 3, 6 or 9 arms. In some embodiments, the conjugate has 9 arms.
- polymer-antibody conjugates have a polymer portion with a molecular weight of between 100,000 and 1,500,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 500,000 and 1,000,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 to 800,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 and 850,000 Da and has 9 arms. When a molecular weight is given for an antibody conjugated to a polymer, the molecular weight will be the addition of the molecular weight of the protein, including any carbohydrate moieties associated therewith, and the molecular weight of the polymer.
- an anti-VEGF-A antibody has a HEMA-PC polymer which has a molecular weight measured by Mw of between about 100 kDa and 1650 kDa is provided. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 500 kDa and 1000 kDa. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 600 kDa to about 900 kDa. In some embodiments, the polymer molecular weight as measured by Mw is 750 kDa plus or minus 15%.
- the polymer is made from an initiator suitable for ATRP having one or more polymer initiation sites.
- the polymer initiation site has a 2-bromoisobutyrate site.
- the initiator has 3 or more polymer initiation sites.
- the initiator has 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites.
- the initiator has 3, 6 or 9 polymer initiation sites.
- the initiator has 9 polymer initiation sites.
- the initiator is OG1786.
- the anti-VEGF-A antibodies can be produced by recombinant expression including (i) the production of recombinant DNA by genetic engineering, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by, for example and without limitation, transfection, electroporation or microinjection, (iii) cultivating the transformed cells, (iv) expressing antibody, e.g. constitutively or on induction, and (v) isolating the antibody, e.g. from the culture medium or by harvesting the transformed cells, in order to (vi) obtain purified antibody.
- recombinant expression including (i) the production of recombinant DNA by genetic engineering, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by, for example and without limitation, transfection, electroporation or microinjection, (iii) cultivating the transformed cells, (iv) expressing antibody, e.g. constitutively or on induction, and (v
- the anti-VEGF-A antibodies can be produced by expression in a suitable prokaryotic or eukaryotic host system characterized by producing a pharmacologically acceptable antibody molecule.
- eukaryotic cells are mammalian cells, such as CHO, COS, HEK 293, BHK, SK-Hip, and HepG2.
- suitable expression systems are prokaryotic (e.g., E. coli with pET/BL21 expression system), yeast ( Saccharomyces cerevisiae and/or Pichia pastoris systems), and insect cells.
- vectors can be used for the preparation of the antibodies disclosed herein and are selected from eukaryotic and prokaryotic expression vectors.
- vectors for prokaryotic expression include plasmids such as, and without limitation, preset, pet, and pad, wherein the promoters used in prokaryotic expression vectors include one or more of, and without limitation, lac, trc, trp, recA, or araBAD.
- vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as, and without limitation, pAO, pPIC, pYES, or pMET, using promoters such as, and without limitation, AOX1, GAP, GAL1, or AUG1; (ii) for expression in insect cells, vectors such as and without limitation, pMT, pAc5, pIB, pMIB, or pBAC, using promoters such as and without limitation PH, p10, MT, Ac5, OpIE2, gp64, or polh, and (iii) for expression in mammalian cells, vectors such as, and without limitation, pSVL, pCMV, pRc/RSV, pcDNA3, or pBPV, and vectors derived from, in one aspect, viral systems such as and without limitation vaccinia virus, adeno-associated viruses, herpes viruses, or retroviruses, using promoters such as and without limitation
- a method is presented of preparing a therapeutic protein-half life extending moiety conjugate having the step of conjugating a therapeutic protein which has a cysteine residue added via recombinant DNA technology to a half-life extending moiety having a sulfhydryl specific reacting group selected from the group consisting of maleimide, vinylsulfones, orthopyridyl-disulfides, and iodoacetamides to provide the therapeutic protein-half life extending moiety conjugate.
- a method of preparing the OG1953 antibody conjugate from OG1950 comprises reducing the OG1950 protein with a 50 ⁇ molar excess of the TCEP reducing agent ( FIG. 18 ). After reduction, the antibody is oxidized to produce a decapped OG1950 antibody where the inter- and intra-light and heavy chain disulfide bonds naturally occurring in the antibody are formed, but the engineered Cysteine on the heavy chain position L443C (EU numbering, or 449C in SEQ ID NO: 1) remains to be decapped ( FIG. 18 ). The OG1950 is then conjugated by adding an excipient and adding 5-10 ⁇ molar excess of a maleimide biopolymer.
- FIG. 18 The biopolymer links to the OG1950 antibody through a covalent thiolether linkage ( FIG. 18 ). After conjugation, the OG19503 antibody conjugate is purified with both unconjugated antibody and polymer removed ( FIG. 18 ).
- a process for preparing a conjugated protein (which need not be an antibody or an anti-VEGF antibody) is provided.
- the process includes reducing one or more cysteines in a protein to form a decapped protein in a solution. After reducing the one or more cysteines the decapped protein is reoxidized to restore at least one disulfide linkage in the reduced protein while ensuring that an engineered cysteine residue in the protein remains in a free thiol form to form a reoxidized decapped protein in the solution. At least one excipient is then added to the solution. The excipient reduces a polymer induced protein precipitation. After the excipient is added, a polymer is added to the solution, which is conjugated to the reoxidized decapped protein at the engineered cysteine residue to form a conjugated protein.
- the molar excess of the reducing agent can be altered to any amount that functions.
- 10, 20, 30, 40, 50, 60, 70, 80, 90 ⁇ molar excess of the reducing agent (which need not be TCEP in all embodiments) can be employed.
- any antibody (therapeutic or otherwise) can be employed.
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ⁇ molar excess of a maleimide biopolymer can be employed.
- the amount of the reduced protein is less than the amount of the polymer.
- the amount of the reduced protein is 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1% of the amount of the polymer. In some embodiments, 10-15 times as much polymer is used as protein. In some embodiments the amount of the reduced antibody is greater than the amount of the polymer. In some embodiments the amount of the polymer is greater than the amount of the reduced antibody.
- the purification step is optional.
- the method of making an antibody conjugate comprises conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer. In some embodiments the method comprises the steps of conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer.
- the anti-VEGF-A antibody comprises an amino residue added via recombinant DNA technology. In some embodiments, the added amino acid residue is a cysteine residue. In some embodiments, the cysteine residue is added outside a variable region of the antibody. The cysteine residue can be added to either the heavy chain or light chain of the antibody.
- the polymer comprises or consists of a phosphorylcholine containing polymer.
- the phosphorylcholine containing polymer comprises a sulfhydryl specific reacting group selected from the group consisting of a maleimide, a vinylsulfone, an orthopyridyl-disulfide, and an iodoacetamide.
- the sulfhydryl specific reacting group on the phosphorylcholine containing polymer reacts with the cysteine residue on the anti-VEGF-A antibody to make the antibody conjugate.
- the protein to be conjugated can be an antibody, an antibody protein fusion, or a binding fragment thereof.
- the protein is not an antibody but is an enzyme, a ligand, a receptor, or other protein or mutants or variants thereof.
- the native protein contains at least one disulfide bond and at least one non-native cysteine.
- the excipient can be an acid or a base. In some embodiments, the excipient is a detergent, a sugar, or a charged amino acid. In some embodiments, the excipient assists in keeping the protein in solution during the conjugation to the polymer. In some embodiments, the excipient is added to the solution containing the protein, prior to the addition of the polymer to the solution that contains the protein.
- the reaction occurs under aqueous conditions between about pH 5 to about pH 9. In some embodiments, the reaction occurs between 6.0 and 8.5, between 6.5 and 8.0 or between 7.0 and 7.5.
- the polymer is conjugated to the protein at 2-37 degrees Celsius. In some embodiments, the conjugation occurs at 0-40 degrees Celsius, 5-35 degrees Celsius, 10-30 degrees Celsius, and 15-25 degrees Celsius.
- the conjugated proteins described herein can be contacted to an ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium for purification (to remove the conjugated from the unconjugated).
- the ion exchange medium, hydrophobic interaction chromatography, and/or affinity chromatography medium separates the conjugated protein from the free polymer and from the reoxidized decapped protein.
- the processes described herein and outlined in FIG. 18 involves an excipient that is capable of facilitating and/or maintaining a solubility system.
- the process allows the solution to maintain the solubility of the two components meant to interact. This can include the solubility of the protein and the polymer and then the end conjugate as well.
- the issue can be that while the protein it is soluble, when the biopolymer is added, the solubility of the solution (e.g., protein) drops and it crashes/precipitates out of solution. Of course, when the protein crashes out, it is not available to conjugate efficiently with the biopolymer.
- an excipient can be employed to maintain the solubility of the protein in the presence of the biopolymer so the two can couple to form the protein conjugate (or as depicted in FIG. 18 , an antibody conjugate). This also allows for the solubility of the conjugate to be maintained.
- the polymers disclosed herein can comprise one or more of the following: a zwitterion, a phosphorylcholine, or a PEG linker bridging a center of a polymer branching point to the maleimide functional group.
- any of the polymers provided herein can be added to a protein via the methods provided herein.
- any of the proteins provided herein can be conjugated to any of the polymers provided herein via one or more of the methods provided herein.
- the process(es) provided herein allow(s) for larger scale processing to make and purify protein and/or antibody conjugates.
- the volume employed is at least 1 liter, for example 1, 10, 100, 1,000, 5,000, 10,000, liters or more.
- the amount of the antibody conjugate produced and/or purified can be 0.1, 1, 10, 100, 1000, or more grams.
- the therapeutic protein may be any of the anti-VEGF-A antibodies described herein having a cysteine residue added via recombinant DNA technology.
- the anti-VEGF antibody heavy chain has the following CDRs: CDR H 1: GYDFTHYGMN (SEQ ID NO: 9), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 11).
- the heavy chain can also have threonine (T) at position 221 (via sequential counting as in SEQ ID NO. 3).
- the anti-VEGF light chain has the following CDRs: CDR L 1: SASQDISNYLN (SEQ ID NO: 12), CDR L 2: FTSSLHS (SEQ ID NO: 13), and CDR L 3: QQYSTVPWT (SEQ ID NO: 14).
- the anti-VEGF-A light chain can also have leucine (L) at Kabat position 4.
- the anti-VEGF-A antibody is IgG1.
- the heavy chain has one or more mutations to modulate effector function.
- the mutations are to one or more of the following amino acid positions (EU numbering): E233, L234, L235, G236, G237, A327, A330, and P331.
- the mutations are selected from the group consisting of: E233P, L234V, L234A, L235A, G237A, A327G, A330S and P331S (EU numbering).
- the mutations are (EU numbering) L234A, L235A and G237A.
- the cysteine residue added to the therapeutic protein via recombinant DNA technology should not be involved in Cys-Cys disulfide bond pairing.
- therapeutic proteins may be dimeric. So for example, an intact anti-VEGF-A antibody has two light chains and two heavy chains. If a Cys residue is introduced into the heavy chain for instance, the intact antibody will have two such introduced cysteines at identical positions and the possibility exists that these cysteine residues will form intra-chain disulfide bonds. If the introduced cysteine residues form Cys-Cys disulfide bonds or have a propensity to do so, that introduced Cys residue will not be useful for conjugation. It is know in the art how to avoid positions in the heavy and light chains that will give rise to intra-chain disulfide pairing. See, e.g., U.S. Patent Application No. 2015/0158952.
- the cysteine residue introduced via recombinant DNA technology is selected from the group consisting of (EU numbering) Q347C and L443C.
- the cysteine residue is L443C (EU numbering, or 449C in SEQ ID NO: 1).
- the heavy chain the antibody has the amino acid sequence set forth in SEQ ID NO. 1 and the light chain has the amino acid sequence of SEQ ID NO. 2.
- the sulfhydral specific reacting group is maleimide.
- the half-life extending moiety is selected from the group consisting of polyethylene glycol (PEG), branched PEG, PolyPEG® (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxylethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrate, polysaccharides, pullulane, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl-dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG), polyoxazoline, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylate, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic acid anyhydride, polystyrene-co-maleic acid anhydr
- the half-life extending moiety is a zwitterionic polymer.
- the zwitterion is phosphorylcholine, i.e. a phosphorylcholine containing polymer.
- the polymer is composed of MPC units.
- the MPC polymer has three or more arms. In some embodiments, the MPC polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms. In some embodiments, the MPC polymer has 3, 6, or 9 arms. In some embodiments, the MPC polymer has 9 arms. In some embodiments, the polymer is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more polymer initiation sites
- the MPC polymer has a molecular weight between about 300,000 and 1,750,000 Da. In some embodiments, the MPC polymer has a molecular weight between about 500,000 and 1,000,000 Da or between about 600,000 to 900,000 Da.
- the method of preparing a therapeutic protein-half life extending moiety conjugate has an additional step of contacting the therapeutic protein with a thiol reductant under conditions that produce a reduced cysteine sulfhydryl group.
- the cysteine residue added via recombinant DNA technology are unpaired, i.e. are not involved in Cys-Cys intra chain disulfide bonds or are not substantially involved in such bonding.
- Cys residues which are not involved in such Cys-Cys disulfide bonding and are free for conjugation are known to react with free cysteine in the culture media to form disulfide adducts. See, e.g., WO 2009/052249.
- a cysteine so derivatized will not be available for conjugation.
- the protein after purification is treated with a reducing agent, e.g., dithiothreitol.
- a reducing agent e.g., dithiothreitol.
- such treatment with a reducing agent will reduce all of the cysteine residues in the therapeutic protein, including native cysteines many of which are involved in inter and intra chain Cys-Cys disulfides bonds.
- the native Cys-Cys disulfides are generally crucial to protein stability and activity and they should be reformed. In some embodiments, all native (e.g., inter and intra) Cys-Cys disulfides are reformed.
- the therapeutic protein is exposed to oxidizing conditions and/or oxidizing agents for a prescribed period of time, e.g., overnight. In some embodiments, ambient air exposure overnight can be used to achieve reformation of the native disulfide bonds.
- an oxidizing agent is employed to restore the native disulfides.
- the oxidizing agent is selected from the group consisting of aqueous CuSO 4 and dehydroascorbic acid (DHAA).
- the oxidizing agent is DHAA.
- the range of DHAA used is in the range of 5-30 equivalents. In some embodiments, the range is 10-20 equivalents. In some embodiments, the range is 15 equivalents.
- the thiol reductant is selected from the group consisting of: Tris[2-carboxyethyl]phosphine hydrochloride (TCEP), dithiothreitol (DTT), dithioerythritol (DTE), sodium borohydride (NaBH 4 ), sodium cyanoborohydride (NaCNBH 3 ), ⁇ -mercaptoethanol (BME), cysteine hydrochloride and cysteine.
- the thiol reductant is TCEP.
- the thiol reductant concentration is between 1 and 100 fold molar excess relative to the therapeutic protein concentration. In some embodiments, the thiol reductant concentration is between 20 to 50 fold molar excess relative to the therapeutic protein concentration. In some embodiments, the thiol reductant is removed following incubation with the therapeutic protein prior to oxidation of the therapeutic protein.
- the method for conjugating a therapeutic protein to a half-life extending moiety has a further step of purifying the therapeutic protein conjugate after conjugation.
- the therapeutic protein conjugate is purified using a technique selected from the group consisting of ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, and affinity chromatography or combinations thereof.
- the therapeutic protein conjugate retains at least 20% biological activity relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 50% biological activity relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 90% biological activity relative to native therapeutic protein.
- the therapeutic protein conjugate has an increased half-life relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate has at least a 1.5 fold increase in half-life relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate has at least a 5 fold increase in half-life relative to unconjugated therapeutic protein.
- the zwitterionic polymer of the method of conjugating a therapeutic protein to a half-life extending moiety is a radically polymerizable monomer having a zwitterionic group and the method has a further step of polymerizing the free radically polymerizable zwitterionic monomer in a polymerization medium to provide a polymer, the medium comprising: the radically polymerizable zwitterionic monomer; a transition metal catalyst M t (q ⁇ 1)+ wherein M t is a transition metal, q is a higher oxidation state of the metal and q ⁇ 1 is a lower oxidation state of the metal, wherein the metal catalyst is supplied as a salt of the form M t (q ⁇ 1)+ X′ q ⁇ 1) wherein X′ is a counterion or group or the transition metal catalyst is supplied in situ by providing the inactive metal salt at its higher oxidation state M t q+ X′ q together with a reducing agent that is capable of
- the transition metal should have at least two readily accessible oxidation states separated by one electron, a higher oxidation state and a lower oxidation state.
- ATRP a reversible redox reaction results in the transition metal catalyst cycling between the higher oxidation state and the lower oxidation state while the polymer chains cycle between having propagating chain ends and dormant chain ends. See, e.g., U.S. Pat. No. 7,893,173.
- the radically polymerizable zwitterionic monomer is selected from the group consisting of
- R1 is H or C 1-6 alkyl
- ZW is a zwitterion
- n is an integer from 1-6.
- the radically polymerizable monomer is
- R1 is H or C 1-6 alkyl
- R2, R3, R4 are the same or different and are H or C 1-4 alkyl
- X and Y are the same or different and are integers from 1-6.
- R1, R2, R3 and R4 are each methyl and X and Y are each 2.
- the radically polymerizable monomer is
- R1 is H or C 1-6 alkyl
- R2 and R3 are the same or different and are H or C 1-4 alkyl
- R4 is PO 4 —, SO 3 — or CO 2 —
- X and Y are the same or different and are integers from 1-6.
- R1, R2 and R3 are methyl
- R4 is P04- and X and Y are each 2.
- the monomer is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R1 is H or C 1-6 alkyl
- R2, R3 and R4 are the same or different and are H or C 1-4 alkyl
- R5 is PO 4 —, SO 3 — or CO 2 —
- X and Y are the same or different and are integers from 1-6.
- R1, R2, R3 and R4 are methyl
- R5 is P04- and X and Y are 2.
- the transition metal M t is selected from the group consisting of Cu, Fe, Ru, Cr, Mo, W, Mn, Rh, Re, Co, V, Zn, Au, and Ag.
- the metal catalyst is supplied as a salt of the form M t (q ⁇ 1)+ X′ (q ⁇ 1) .
- M t (q ⁇ 1)+ is selected from the group consisting of Cu 1+ , Fe 2+ , Ru 2+ , Cr 2+ , Mo 2+ , W 2+ , Mn 3+ , Rh 3+ , Re 2+ , Co + , V 2+ , Zn + , Au + , and Ag + and X′ is selected from the group consisting of halogen, C 1-6 alkoxy, (SO 4 ) 1/2 , (PO 4 ) 1/3 , (R7PO 4 ) 1/2 , (R7 2 PO 4 ), triflate, hexaluorophosphate, methanesulfonate, arylsulfonate, CN and R7CO 2 , where R7 is H or a straight or branched C 1-6 alkyl group which may be substituted from 1 to 5 times with a halogen.
- M t (q ⁇ 1)+ is Cu 1+ and X′ is Br.
- M t (q-1)+ is supplied in situ.
- M t q+ X q is CuBr 2 .
- the reducing agent is an inorganic compound.
- the reducing agent is selected from the group consisting of a sulfur compound of a low oxidation level, sodium hydrogen sulfite, an inorganic salt comprising a metal ion, a metal, hydrazine hydrate and derivatives of such compounds.
- the reducing agent is a metal.
- the reducing agent is Cu 0 .
- the reducing agent is an organic compound.
- the organic compound is selected from the group consisting of alkylthiols, mercaptoethanol, or carbonyl compounds that can be easily enolized, ascorbic acid, acetyl acetonate, camphorsulfonic acid, hydroxy acetone, reducing sugars, monosaccharides, glucose, aldehydes, and derivatives of such organic compounds.
- the ligand is selected from the group consisting of 2,2′-bipyridine, 4,4′-Di-5-nonyl-2,2′-bipyridine, 4,4-dinonyl-2,2′-dipyridyl, 4,4′,4′′-tris(5-nonyl)-2,2′:6′,2′′-terpyridine, N,N,N′,N′,N′′-Pentamethyldiethylenetriamine, 1,1,4,7,10,10-Hexamethyltriethylenetetramine, Tris(2-dimethylaminoethyl)amine, N,N-bis(2-pyridylmethyl)octadecylamine, N,N,N′,N′-tetra[(2-pyridal)methyl]ethylenediamine, tris[(2-pyridyl)methyl]amine, tris(2-aminoethyl)amine, tris(2-bis(3-butoxy-3-oxoprop
- R1 is a nucleophilic reactive group
- R2 comprises a linker
- R3 comprises a polymer synthesis initiator moiety having the structure
- R4 and R5 are the same or different and are selected from the group consisting of alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido or any combination thereof;
- Z is a halogen or CN; and s is an integer between 1 and 20.
- Z is Br and R4 and R5 are each methyl.
- R1 is selected from the group consisting of NH 2 —, OH—, and SH—.
- R2 is alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido or any combination thereof.
- R2 is
- X and Y are the same or different and are integers from 1-20. In some embodiments, X and Y are each 4.
- R3 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R6, R7 and R8 are the same or different and are selected from the group consisting of
- Z is NCS, F, Cl, Br or I.
- Z is Br and R6, R7 and R8 are each
- the initiator has the structure:
- a and B are the same or different and are integers from 2 to 12 and Z is any halide, for example Br. In some embodiments, A and B are each 4.
- the method further has the step of reacting the polymer with a maleimide reagent to provide a polymer having a terminal maleimide.
- the maleimide compound is
- a method for the treatment or prophylaxis of an ocular disease having the step of administering a therapeutic protein selected from the group consisting of an anti-VEGF-A antibody (and conjugates thereof).
- a therapeutic protein selected from the group consisting of an anti-VEGF-A antibody (and conjugates thereof).
- any one or more of the antibodies or antibody conjugates provided herein can be used as treatment and/or prophylaxis for an ocular disease.
- the method includes administering to the subject any one or more of the antibodies or antibody conjugates provided herein.
- a method for treatment or prophylaxis of an ocular disease comprises administering an effective dose of any of the an antibody and/or antibody conjugates described herein to a subject in need thereof.
- the disease can be age-related macular degeneration (AMD) or diabetic macular edema (DME).
- the disease can be wet AMD.
- the ocular disease is selected from one or more of the group consisting of diabetic retinopathy, choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, and hypertensive retinopathy.
- the ocular disease is diabetic retinopathy.
- the antibody or antibody conjugate is administered no more frequently than once a month. In some embodiments, the antibody or conjugate thereof is administered two times per month or weekly. In some embodiments, the antibody or conjugate thereof is administered once every two months, once every three months, once every four months, once every five months, once every six months, once every seven months, once every eight months, once every nine months, once every ten months, once every eleven months, or once every twelve months.
- one or more of the compositions provided herein can allow for a reduction in the consequences of high treatment burdens from the use of intravitreal injection of anti-VEGF agents for the treatment of the wet (proliferative) form of age related macular degeneration (AMD).
- AMD age related macular degeneration
- Real world outcomes for patients with wet AMD lag behind the clinical outcomes demonstrated in the phase 3 clinical studies such as the MARINA and ANCHOR studies with Lucentis® (ranibizumab) and the VIEW 1 and VIEW 2 studies with Eylea® (aflibercept).
- An anti-VEGF therapeutic with a longer ocular residence time such that it can be administered less frequently and therefore with a more patient-tolerable profile can bring real world outcomes closer to phase 3 clinical outcomes for more patients.
- compounds, including antibody conjugates and anti-VEGF-A antibodies described herein are used to treat patients who have background or nonproliferative diabetic retinopathy but have little or no vision impairment.
- such patients are dosed less than once a month via intravitreal injection.
- such patients are dosed six times a year.
- such pateints are dosed no more than four times a year.
- the patients are dose no more than three times a year.
- the patients are dosed no more than twice a year.
- the patients are dosed no more than once a year.
- the subject receives the antibody or antibody conjugate via intravitreal injection.
- the therapeutic proteins e.g., both antibodies and antibody conjugates
- the therapeutic proteins can be employed by expression of such polypeptides in vivo in a patient, i.e., gene therapy.
- nucleic acid (optionally contained in a vector) into the patient's cells
- in vivo and ex vivo the nucleic acid is injected directly into the patient, usually at the sites where the therapeutic protein is required, i.e., where biological activity of the therapeutic protein is needed.
- ex vivo treatment the patient's cells are removed, the nucleic acid is introduced into these isolated cells, and the modified cells are administered to the patient either directly or, for example, encapsulated within porous membranes that are implanted into the patient (see, e.g, U.S. Pat. Nos. 4,892,538 and 5,283,187).
- techniques available for introducing nucleic acids into viable cells There are a variety of techniques available for introducing nucleic acids into viable cells.
- the techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or transferred in vivo in the cells of the intended host.
- Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, transduction, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc.
- Transduction involves the association of a replication-defective, recombinant viral (including retroviral) particle with a cellular receptor, followed by introduction of the nucleic acids contained by the particle into the cell.
- a commonly used vector for ex vivo delivery of the gene is a retrovirus.
- the in vivo nucleic acid transfer techniques include transfection with viral or non-viral vectors (such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV)) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol; see, e.g., Tonkinison et al., Cancer Investigation, 14(1): 54-65 (1996)).
- the vectors for use in gene therapy are viruses, which include adenoviruses, AAV, lentiviruses, or retroviruses.
- a viral vector such as a retroviral vector includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger.
- a viral vector such as a retroviral vector includes a nucleic acid molecule that, when transcribed in the presence of a gene encoding the therapeutic protein, is operably linked thereto and acts as a translation initiation sequence.
- Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used (if these are not already present in the viral vector).
- such vector typically includes a signal sequence for secretion of the PRO polypeptide from a host cell in which it is placed.
- the signal sequence for this purpose is a mammalian signal sequence.
- the signal is the native signal sequence for the therapeutic protein.
- the vector construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence.
- such vectors will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof.
- Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.
- the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell-surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
- an agent that targets the target cells such as an antibody specific for a cell-surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
- proteins that bind to a cell-surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g., capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins that undergo internalization in cycling, and proteins that target intracellular localization and enhance intracellular half-life.
- the technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol.
- a method for treatment or prophylaxis of an ocular disease in a mammal in which a nucleic acid molecule that encodes a therapeutic protein selected from the group consisting of an anti-VEGF-A antibody is administered.
- the nucleic acid is set forth in FIG. 27 .
- the heavy chain is that set forth in SEQ ID NO. 1 and the light chain is that set forth in SEQ ID NO. 2.
- the nucleic acid molecule is administered via ex vivo gene therapy.
- Therapeutic proteins can be incorporated into a pharmaceutical composition with a pharmaceutically acceptable excipient.
- Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules, as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions).
- Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
- excipients which may be used include for example water, polyols and sugars.
- suspensions oils e.g. vegetable oils
- suspensions oils may be used to provide oil-in-water or water in oil suspensions.
- compositions can be adapted for nasal administration wherein the excipient is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurized aerosols, nebulizers or insufflators.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example.
- compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carried, for example water for injections, immediately prior to use.
- sterile liquid carried, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- Pharmaceutical compositions can be substantially isotonic, implying an osmolality of about 250-400 mOsm/kg water.
- the pharmaceutical compositions may contain preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts (substances may themselves be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents or antioxidants. They may also contain therapeutically active agents in addition to the substance.
- the pharmaceutical compositions may be employed in combination with one or more pharmaceutically acceptable excipients. Such excipients may include, but are not limited to, saline, buffered saline (such as phosphate buffered saline), dextrose, liposomes, water, glycerol, ethanol and combinations thereof.
- the antibodies and pharmaceutical compositions containing them may be administered in an effective regime for treating or prophylaxis of a patient's disease including, for instance, administration by oral, intravitreal, intravenous, subcutaneous, intramuscular, intraosseous, intranasal, topical, intraperitoneal, and intralesional administration.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration or routes among others.
- the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion
- the agent is isotonic or substantially isotonic.
- the dosage of the active agent is from 0.01 mg/kg body weight, typically around 1 mg/kg.
- the physician can determine the actual dosage most suitable for an individual which depends on factors including the age, weight, sex and response of the individual, the disease or disorder being treated and the age and condition of the individual being treated.
- the above dosages are exemplary of the average case. There can, of course, be instances where higher or lower dosages are merited.
- the dosage can be 0.5 to 20 mg/eye, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 mg.
- the pharmaceutical composition may be administered once every one to thirty days. In one embodiment, the pharmaceutical composition may be administered twice every thirty days. In one embodiment, the pharmaceutical composition may be administered once a week.
- the antibodies and pharmaceutical compositions can be employed alone or in conjunction with other compounds, such as therapeutic compounds or molecules, e.g. anti-inflammatory drugs, analgesics or antibiotics. Such administration with other compounds may be simultaneous, separate or sequential.
- the components may be prepared in the form of a kit which may comprise instructions as appropriate.
- the antibodies and pharmaceutical compositions disclosed herein can be used for treatment or prophylaxis of disease, particularly the ocular diseases or conditions described herein.
- the conjugates are typically formulated for and administered by ocular, intraocular, and/or intravitreal injection, and/or juxtascleral injection, and/or subretinal injection and/or subtenon injection, and/or superchoroidal injection and/or subconjunctival and/or topical administration in the form of eye drops and/or ointment.
- Such antibodies and compositions can be delivered by a variety of methods, e.g. intravitreally as a device and/or a depot that allows for slow release of the compound into the vitreous, including those described in references such as Intraocular Drug Delivery, Jaffe, Ashton, and Pearson, editors, Taylor & Francis (March 2006).
- a device may be in the form of a minipump and/or a matrix and/or a passive diffusion system and/or encapsulated cells that release the compound for a prolonged period of time (Intraocular Drug Delivery, Jaffe, Ashton, and Pearson, editors, Taylor & Francis (March 2006).
- Formulations for ocular, intraocular or intravitreal administration can be prepared by methods and using ingredients known in the art.
- a main requirement for efficient treatment is proper penetration through the eye. Unlike diseases of the front of the eye, where drugs can be delivered topically, retinal diseases require a more site-specific approach. Eye drops and ointments rarely penetrate the back of the eye, and the blood-ocular barrier hinders penetration of systemically administered drugs into ocular tissue. Accordingly, usually the method of choice for drug delivery to treat retinal disease, such as AMD and CNV, is direct intravitreal injection. Intravitrial injections are usually repeated at intervals which depend on the patient's condition, and the properties and half-life of the drug delivered.
- Therapeutic antibodies and related conjugates generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- a sterile access port for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- Such compositions may also be supplied in the form of pre-filled syringes.
- a “stable” formulation is one in which the protein or protein conjugated to a polymer of other half-life extending moiety therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage.
- stable is also meant a formulation which exhibits little or no signs of instability, including aggregation and/or deamidation.
- the formulations provided may remain stable for at least two year, when stored as indicated at a temperature of 5-8° C.
- Stability can be measured at a selected temperature for a selected time period.
- the storage of the formulations is stable for at least 6 months, 12 months, 12-18 months, or for 2 or more years.
- a protein such as an antibody or fragment thereof, “retains its physical stability” in a pharmaceutical formulation if it shows no signs of aggregation, precipitation, deamidation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography.
- a protein “retains its chemical stability” in a pharmaceutical formulation if the chemical stability at a given time is such that the protein is considered to still retain its biological activity.
- Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein.
- Chemical alteration may involve size modification (e.g., clipping), which can be evaluated using size exclusion chromatography, SDS-PAGE and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS), for examples.
- Other types of chemical alteration include charge alteration (e.g., occurring as a result of deamidation), which can be evaluated by ion-exchange chromatography, for example.
- An antibody “retains its biological activity” in a pharmaceutical formulation, if the biological activity of the antibody at a given time is within about 10% (within the errors of the assay) of the biological activity exhibited at the time the pharmaceutical formulation was prepared as determined in an antigen binding assay, for example.
- a protein-polymer conjugate “retains its chemical stability” the chemical bond between the protein and the polymer is maintained intact, e.g., it is not hydrolyzed or otherwise disrupted.
- the protein part of the conjugate retains its chemical stability as described above.
- isotonic is meant that the formulation of interest has essentially the same osmotic pressure as human blood or the vitreous for intravitreal injections. Isotonic formulations will generally have an osmotic pressure from about 250 to 400 mOsm. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
- buffer refers to a buffered solution that resists changes in pH by the action of its acid-base conjugate components.
- the buffer has a pH from about 3.0 to about 8.0; for example from about 4.5 to 8; or about pH 6 to about 7.5; or about 6.0 to about 7.0, or about 6.5-7.0, or about pH 7.0 to about 7.5; or about 7.1 to about 7.4.
- a pH of any point in between the above ranges is also contemplated.
- PBS phosphate buffered saline
- Tris based buffers Tris based buffers
- histidine based buffers are used.
- the PBS buffer is made up of at least Na 2 HPO 4 , KH 2 PO 4 and NaCl adjusted so as to provide the appropriate pH.
- the buffer may contain other pharmaceutical excipients such as KCl and other salts, detergents and/or preservatives so as to provide a stable storage solution.
- a “preservative” is a compound which can be included in the formulation to essentially reduce bacterial action therein, thus facilitating the production of a multi-use formulation, for example.
- potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride.
- preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
- Endotoxin is lipopolysaccharide (LPS) derived from the cell membrane of Gram-negative bacteria. Endotoxin is composed of a hydrophilic polysaccharide moiety covalently linked to a hydrophobic lipid moiety (lipid A). Raetz C R, Ulevitch R J, Wright S D, Sibley C H, Ding A, Nathan C F. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5(12):2652-2660.
- Lipid A is responsible for most of the biological activities of endotoxin, i.e., its toxicity. Endotoxins are shed in large amount upon bacterial cell death as well as during growth and division. They are highly heat-stable and are not destroyed under regular sterilizing conditions. Extreme treatments with heat or pH, e.g., 180-250° C. and over 0.1 M of acid or base must be used (Petsch D, Anspach F. 2000. Endotoxin removal from protein solutions. J Biotechnol. 76: 97-119). Such conditions of course would be highly detrimental to biological drugs.
- endotoxin In the biotech and pharmaceutical industries, it is possible to find endotoxin during both production processes and in final products. As bacteria can grow in nutrient poor media, including water, saline and buffers, endotoxins are prevalent unless precautions are taken. Endotoxin injection into an animal or human causes a wide variety of pathophysiological effects, including endotoxin shock, tissue injury and even death. Ogikubo Y, Ogikubo Y, Norimatsu M, Noda K, Takahashi J, Inotsume M, Tsuchiya M, Tamura Y. 2004. Evaluation of the bacterial endotoxin test for quantifications of endotoxin contamination of porcine vaccines. Biologics 32:88-93.
- EU is a measurement of the biological activity of an endotoxin.
- 100 pg of the standard endotoxin EC-5 and 120 pg of endotoxin from Escherichia coli O111:B4 have activity of 1 EU (Hirayama C, Sakata M. 2002. Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chrom B 781:419-432). Meeting this threshold level has always been a challenge in biological research and pharmaceutical industry (Berthold W, Walter J. 1994. Protein Purification: Aspects of Processes for Pharmaceutical Products. Biologicals 22:135-150; Petsch D, Anspach F B. 2000. Endotoxin removal from protein solutions. J Biotech 76:97-119).
- Intravitreal injection of drug penicillin
- penicillin was first performed in 1945 by Rycroft. Rycroft B W. 1945. Penicillin and the control of deep intra-ocular infection.
- the vitreous is a chamber where high level of drug can be introduced and maintained for relatively long periods of time. The concentration of drug that can be achieved via intravitreal injection far exceeds what can be generated by topical administration or by systemic administration (e.g. intravenous).
- Endophthalmitis falls into two classes: infectious and sterile. Infectious endophthalmitis is generally cause by bacteria, fungi or parasites. The symptoms of infectious endophthalmitis include severe pain, loss of vision, and redness of the conjunctiva and the underlying episclera. Infectious endophthalmitis requires urgent diagnosis and treatment. Possible treatments include intravitreal injection of antibiotics and pars plana vitrectomy in some cases. Enucleation may be called for to remove a blind and painful eye. See, e.g., Christy N E, Sommer A. 1979. Antibiotic prophylaxis of postoperative endophthalmitis. Ann Ophthalmol 11 (8): 1261-1265.
- Sterile endophthalmitis in contrast does not involve an infectious agent and can be defined as the acute intraocular inflammation of the vitreous cavity that resolves without the need of intravitreal antibiotics and/or vitreoretinal surgery. If a vitreous microbiological study has been done, it needs to be negative culture proven to sustain a diagnosis of sterile endophthalmitis. Marticorena J, Romano V, Gomez-Ulla F. 2012 “Sterile Endophthalmitis after Intravitreal Injections” Med Inflam. 928123.
- Bevacizumab (Avastin) is approved by the Food and Drug Administration for the treatment of glioblastoma and of metastatic colorectal cancer, advanced nonsquamous non-small-cell lung cancer and metastatic kidney cancer. Bevacizumab is also widely used off label as a treatment for wet AMD. Bevacizumab comes from the manufacturer as a 100 mg/4 ml. This solution cannot be directly used for intravitreal injection and should be compounded by a pharmacist. Clusters of sterile endophthalmitis have been observed and are theorized to be cause by inadvertent contamination of bevacizumab by endotoxin by the compounding pharmacist.
- a solution having an antibody or antibody-conjugate having an endotoxin level that does not exceed 5.0 EU/ml.
- the endotoxin level does not exceed 1.0 EU/ml.
- the endotoxin level does not exceed 0.5 EU/ml.
- the endotoxin level does not exceed 0.2 EU/ml.
- the endotoxin level does not exceed 2, 1, 0.5, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02 or 0.01 EU/ml.
- LAL Limulus Amoebodyte Lysate
- LAL gel-clot assay One of the simplest LAL assays is the LAL gel-clot assay. Essentially, the LAL clotting assay is combined with a serial dilution of the sample in question. Formation of the gel is proportional to the amount of endotoxin in the sample. Serial dilutions are prepared from the sample and each dilution assayed for its ability to form LAL gel. At some point a negative reaction is contained. The amount of endotoxin in the original sample can be estimated from the dilution assay.
- LAL tests have also been developed, including the turbidimetric LAL assay (Ong K G, Lelan J M, Zeng K F, Barrett G, Aourob M, Grimes C A. 2006. A rapid highly-sensitive endotoxin detection system. Biosensors and Bioelectronics 21:2270-2274) and the chromogenic LAL assay (Haishima Y, Hasegawa C, Yagami T, Tsuchiya T, Matsuda R, Hayashi Y. 2003. Estimation of uncertainty in kinetic-colorimetric assay of bacterial endotoxins. J Pharm Biomed Analysis. 32:495-503). The turbidimetric and chromogenic assays are much more sensitive and quantitative than the simple gel-clot dilution assay.
- a method of reducing the amount of endotoxin in a composition having an antibody disclosed herein having the steps of contacting the composition with an affinity chromatography resin that binds to the antibody; eluting the antibody from the affinity chromatography resin to form an affinity chromatography eluent having the antagonist; contacting the affinity chromatography eluent with an ion-exchange resin that binds the antibody; and eluting the antibody from the ion-exchange resin, wherein the antibody eluted from the ion-exchange resin is substantially free from endotoxin.
- the above method for reducing the amount of endotoxin, or other method or process recited herein, can be performed in the order described in the steps above or it can optionally be performed by varying the order of the steps or even repeating one or more of the steps.
- the method of reducing the amount of endotoxin in a composition is performed in the order of the described steps.
- the affinity chromatography resin contacting, washing and eluting steps are repeated in the same order more than one time before contacting the affinity chromatography eluent with the ion exchange resin.
- the method can also include a filtering step using, for example, a 0.1 micron, 0.22 micron, or 0.44 micron filter, that can be performed on either one or more of the eluents removed after each resin binding step.
- the steps of contacting the composition with affinity chromatography resin, washing and eluting the antibody from the affinity chromatography resin can be repeated more than one time before contacting the first eluent with an ion-exchange resin.
- the affinity chromatography resin comprises a recombinant Protein A
- rProteinA (“rProteinA”) resin.
- a suitable recombinant Protein A resin is rProteinA Sepharose FF® resin (Amersham, Piscataway, N.J.).
- a suitable affinity chromatography resin would comprise a protein G chromatography resin.
- a suitable affinity chromatography resin comprises a mixed Protein A/Protein G resin.
- a suitable affinity chromatography resin comprises a hydrophobic charge induction resin that comprises a 4-mercaptoethylpyridine ligand such as a MEP HypeiCel® resin (BioSepra, Cergy, Saint Christophe, France).
- the ion exchange resin comprises an anion-exchange resin.
- ion exchangers may be based on various materials with respect to the matrix as well as to the attached charged groups.
- the following matrices may be used, in which the materials mentioned may be more or less cross-linked: MacroCap Q (GE Healthcare Biosciences, Piscataway, N.J.), agarose based (such as Sepharose CL-6B®, Sepharose Fast Flow® and Sepharose High Performance®), cellulose based (such as DEAE Sephacel®), dextran based (such as Sephadex®), silica based and synthetic polymer based.
- MacroCap Q GE Healthcare Biosciences, Piscataway, N.J.
- agarose based such as Sepharose CL-6B®, Sepharose Fast Flow® and Sepharose High Performance®
- cellulose based such as DEAE Sephacel®
- dextran based such as Sephadex®
- the charged groups which are covalently attached to the matrix, may, for example, be diethylaminoethyl, quaternary aminoethyl, and/or quaternary ammonium.
- the anion-exchange resin comprises a quaternary amine group.
- An exemplarily anion-exchange resin that has a quaternary amine group for binding the anti-M-CSF antibody is a Q Sepharose® resin (Amersham, Piscataway, N.J.).
- the composition may in the alternative be subjected to a cation exchange resin.
- any endotoxin in the composition should have a differential binding to the ion-exchange resin than the protein in question to allow purification of the protein from the endotoxin.
- endotoxin is negatively charged and will generally bind to an anion exchange resin. If both the protein and the endotoxin bind to the anion exchange resin, purification of one from the other may be effectuated by using a salt gradient to elute the two into different fractions.
- the relative binding of the protein to a particular resin may also be effected by changing the pH of the buffer relative to the pI of the protein.
- cation-exchange chromatography is the sole ion-exchange chromatography employed.
- the composition may be further subjected to a second ion-exchange step, for example, by contacting the compositions with a cation exchange resin and followed by a wash step, then elution from the ion-exchange resin.
- the cation exchange resin comprises a sulfonic group for binding.
- Exemplary cation exchange resins are SP Sepharose® resin FF (Amersham, Piscataway, N.J.) Poros XS (CEX) (Life Technology, Grand Island, N.Y.).
- a half-life extending moiety is conjugated to the protein.
- the conjugate is then formulated into a final drug formulation which is injected into the patients.
- the conjugate is again purified on an ion-exchange resin which can be a cation-exchange resin.
- the protein is formulated. In all cases, normal laboratory procedures should be employed to prevent the introduction of endotoxin contaminants into the protein sample or into the protein-polymer conjugate.
- a first route for the synthesis of OG1802 is as follows. First, TFA/amine salt initiator (Compound L) having the structure shown in FIG. 1 was synthesized as follows.
- Compound K having the structure shown in FIG. 2 was synthesized as follows. Into a 200 mL round bottom flask under nitrogen was placed Compound J (OG1563) (1.9 g, 2.67 mmol, 3.3 equiv)
- Compound L ( FIG. 1 ) was synthesized as follows: into a 100 mL round bottom under nitrogen was added Compound K (2.0 g, 0.8 mmol), dichloromethane (10 mL) followed by trifluoroacetic acid (5 mL). The reaction was stirred at room temperature for 30 minutes. The reaction was concentrated under a vacuum. The reaction was diluted using dichloromethane (10 mL) and concentrated under a vacuum.
- Initiator is typically prepared as a stock solution in DMF of about 100 mg/mL.
- the initiator and the ligand (2,2′-bipyridyl) were introduced into a Schlenk tube.
- the resultant solution was cooled to ⁇ 78° C. using a dry ice/acetone mixture, and was degassed under vacuum for 10 min.
- the tube was refilled under Argon and the catalyst (CuBr unless otherwise indicated), kept under Argon, was introduced into the Schlenck tube (the Molar ratio of atom bromine on the initiator/catalyst (CuBr)/ligand was kept at 1/1/2).
- the solution became dark brown immediately.
- a solution of HEMA-PC was prepared by mixing a defined quantity of monomer, prepared in a glovebox kept under nitrogen, with 200 proof degassed ethanol. The monomer solution was added drop wise into the Schlenk tube (via cannula) (and homogenized by light stirring). The temperature was maintained at ⁇ 78° C. A thorough vacuum was applied to the reaction mixture for at least 10 to 15 min. until bubbling from the solution ceased. The tube was then refilled with Argon and warmed to room temperature. The solution was stirred, and as the polymerization proceeded, the solution became viscous.
- the maleimide Mal-PEG4-PFP ester was snapped on (as set forth in FIG. 29 ) to the 750 kDa polymer referred to above to provide OG1802.
- Polymer R3707 750 kDa polymer made using L as initiator, 515 mg
- ethanol 4.0 mL
- the filtrate is removed for analysis while the retentate is diluted and mixed with water ( ⁇ 10 mL/tube).
- the centrifuge procedure repeated 5 more times, after which the retentate is removed and placed into a vial.
- the Amicon membrane tubes were rinsed with water (2 ⁇ ⁇ 2 mL each tube) and this combined with the retentate.
- the retentate solution was filtered through a syringe filter (Acrodisc Supor, PN 4612), frozen and placed on a lyophilizer. This resulted in 485 mgs as a white powder.
- OG1786 is the nine-arm initiator for polymer synthesis used as a precursor in the synthesis of OG1802. Each arm is terminated with a 2-bromoisobutyrate which is capable of initiating polymerization under ATRP.
- OG1786 is a salt of trifluoro acetic acid (TFA) as shown in FIG. 30 .
- OG1786 is prepared as follows. First, OG1550 is reacted with TFA (trifluoro acetic acid) to produce OG1546 as depicted in FIG. 31 .
- the mixture was partitioned.
- the MTBE layer was washed with water (30 ml).
- Combine aqueous layers then the aqueous extracted with MTBE (150 ml).
- This second MTBE phase was washed with water (30 ml).
- the combined aqueous layers were washed with a third portion of MTBE (100 ml).
- the third MBTE phase was washed with water (25 ml).
- the aqueous layers were again combined ( ⁇ 250 ml, pH ⁇ 4, by pH paper).
- the product was collected by lyophilization. 11.5 g white solid was obtained. This material is extremely hygroscopic, so best handled under nitrogen. The product was confirmed by LCMS.
- the prepared OG1546 was then reacted with OG1563 to yield OG1784 (as depicted in FIG. 32 ).
- OG1546 hygroscopic, 9.0 g
- N,N-dimethylformamide 110 ml
- the mixture was stirred at room temperature until all OG1546 dissolved (about 15 minutes), then OG1563 (29.9 g) was added, and the mixture stirred a further 3 minutes until the OG1563 had also been dissolved.
- the organic phase was washed with water/saturated sodium chloride (100 ml/25 ml), and the aqueous phase was AQ3 (pH-3). The organic phase was finally washed with saturated sodium chloride (100 ml), and the aqueous phase was AQ4. None of the AQ fractions contained any significant product (data not provided).
- the organic phase confirmed the product via LCMS.
- the product was dried over sodium sulfate (80 g), filtered and rinsed with isopropyl acetate (75 ml), and concentrated on a rotary evaporator to a tan oil (33.2 g). The crude was stored overnight under nitrogen.
- the filtrate was loaded onto a RediSep Rf Gold C18 column (275 g, SN 69-2203-339, Lot #24126-611Y) equilibrated with 50% acetonitrile/water.
- the material was eluted at 100 ml/min using the following gradient (solvent A: water, solvent B: acetonitrile). All the relevant fractions were checked by HPLC. The fractions adjudged to be pure enough were pooled (from all three runs) and concentrated (bath temperature kept at about 20° C.) on rotovap, then partitioned between dichloromethane (100 ml) and water (5 ml)/saturated sodium chloride (25 ml).
- OG1405 was prepared from OG1784 as depicted in FIG. 33 .
- OG1784 (20.9 g)
- dichloromethane 50 ml
- trifluoroacetic acid 20 ml
- the mixture was stirred at room temperature and HPLC analysis showed complete deprotection in 23 minutes.
- the mixture was concentrated on a rotary evaporator, redissolved in dichloromethane (25 ml) and re-concentrated, then redissolved in acetonitrile (25 ml) and re-concentrated.
- the product was confirmed by LCMS.
- the material from above (OG1405, 34.5 g, assume 21.0 g as quantitative yield) was used as a crude oil in the next step. No purification is needed.
- OG1405 was reacted with OG1402 to prepare OG1785 as set forth in FIG. 34 .
- OG1402 5.5 g
- acetonitrile 70 ml
- N,N-diisopropylethylamine 26.3 ml
- T3P solution 7.9 ml
- the solution was stirred at room temperature for 30 minutes, then cooled in an ice water bath and a solution of OG1405 (crude oil from above, 34.5 g) in acetonitrile (70 ml) added.
- the mixture was warmed to room temperature. After 20 minutes the reaction was cooled in an ice water bath and quenched with water (5 ml). The mixture was then concentrated under vacuum using a rotary evaporator to half volume. Samples were taken for LCMS.
- the oil was dissolved in acetonitrile/water (3:1, 15 ml/5 ml), filtered through an HPLC filter disk (Cole-Parmer PTFE membrane 0.2 ⁇ m, product number 02915-20) and split into three equal portions, each of which were individually purified as follows.
- Polymer OG1801 is made first from the initiator OG1786.
- OG1801 has an amine functionality, which is more stable (than maleimide) during polymer synthesis.
- a modified version of ATRP is used wherein the copper species (Cu(I)) is generated in situ by adding metallic copper to Cu (II).
- Starting materials and reagents needed in the reaction are calculated based on batch input of the monomer (HEMA-PC) OG47, as well as the targeted molecular weight (MW).
- the linker is 3-maleimidopropionic acid, NHS ester.
- OG1802 (see FIG. 36 ) is then purified as follows: Milipore cross flow cassettes are used for polymer purification in aqueous system. Started with concentrating the polymer solution to 250 mL ( ⁇ 200 mg/mL). Added the fresh WFI from reservoir, and adjusted the flow rate of the fresh WFI feed to the same as the permeate ( ⁇ 2 mL/min). The UFIDF was set up at 2-8° C. overnight. Typically 2.5 L of WFI was used (10 ⁇ volume ratio to the polymer solution). A sample of retente was collected for purity test. The targeted purity was >98%. Filtered the polymer solution by 0.2 ⁇ M 1 L filter bottle. The polymer solution could be stored at 2-8° C. for up to 3 month before conjugation.
- HEA-PC (2-(acryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate), which is an acrylate as opposed to the methacrylate HEMA-PC described above, has the following structure:
- HEA-PC was polymerized to the initiator shown in Example 1 as compound L.
- Example 1 the maleimide Mal-PEG4-PFP (see Example 1 above) ester was snapped on to the HEA-PC polymer as shown in Example 1.
- the resulting maleimide functionalized HEA-PC polymer can then be conjugated to sulfhydryl groups as discussed herein for HEMA-PC polymers.
- An acrylamide PC polymer was also made using the monomer 2-(acrylamyl)ethyl-2-(trimethylammonium)ethyl phosphate (Am-PC), having the following structure:
- the Am-PC was used for polymerization employing a 3 arm initiator (a TFA salt) having the structure:
- a stock solution of ligand at 200 mg/mL was prepared by dissolving 9 mg of Me6TREN in 45 uL of dry DMF. Add 19.7 uL of the stock solution to a reaction vessel. Prepare a stock solution of initiator at 200 mg/mL by dissolving 6.5 mg of material in 32.5 uL of DMF. Add 11 uL of the initiator stock solution to the ligand from above. Degas for 5 mn. Add 1 mg of CuBr. Prepared a stock solution of CuBr 2 at 200 mg/mL by dissolving 4 mg CuBr 2 in 20 ⁇ L of DMF.
- Am-PC polymer may be dialyzed.
- the molecular weight of the above polymer was determined by SEC/MALS: Mn is 215 kDa, Mp: 250 kDa, PDI is 1.17. Conversion was estimated by 1H NMR to be 94%.
- a maleimide functionality can be added to the Am-PC polymer as discussed above for HEMA-PC and HEA-PC. Maleimide functionalized Am-PC polymer can be conjugated to a protein as described above.
- an Ellman's assay was used to determine the amount of functional maleimide (i.e. conjugatable) in a sample.
- a standard curve was established with cysteine. Since the maleimide reacts with thiol, this assay actually measured the thiol (cysteine) left. The inhibition was calculated as the (original thiol-thiol left after maleimide polymer addition)/(original thiol) and is expressed as a percentage.
- a standard curve was prepared using the cysteine from 62.5 ⁇ M to 2 ⁇ M.
- Polymer stock solutions were prepared by dissolving the powder in 1 ⁇ PBS pH7.4 (reaction buffer) and mixing thoroughly.
- An equal molar of polymer and cysteine solutions were mixed and allowed to react at 27° C. for 30 minutes.
- the 150 ⁇ M of DTNB solution was added into the cysteine standards and polymer/cysteine reactions and the color was developed at 27° C. for 5 minutes.
- OD at 412 nm was read on the Spectramax plate reader and percent inhibition was calculated with the Softmax Pro software and the cysteine standard curve.
- the OG1950 heavy and light chains may be cloned into expression plasmids and transfected into CHO cells. Cells can be grown up in appropriate media and harvested. OG1950 may be purified using techniques described above.
- the OG1950 cysteine at position 443 (L443C (EU numbering)) residue is typically “capped” or oxidized by chemicals in the cell culture media and is not available for conjugation.
- purified OG1950 may be subjected to a decapping (i.e. reducing) procedure to remove the cap and enable the free (i.e. those not involved in Cys-Cys disulfide bonds) cysteine residue to be conjugated to the maleimide functionality of a polymer.
- Decapping may be done by mixing purified OG1950 protein with a 30 ⁇ molar excess for 1 hour at 25° C. of the reducing agent TCEP (3,3′,3′′-Phosphanetriyltripropanoic acid).
- the reduction reaction with TCEP may be monitored by SDS-PAGE.
- the OG1950 protein maybe washed by UFdF using a Pellion XL Ultrafiltration Cassette with 20 mM Tris pH7.5, 150 mM NaCl, 0.5 mM TCEP buffer to remove the cap.
- the TCEP reagent may then be removed in the same UFdF setup with 20 mM Tris pH7.5, 150 mM NaCl.
- Reduced OG1950 may then be allowed to refold using air (ambient oxygen) which again is followed by SDS-PAGE as an assay
- the OG1950 heavy and light chains may be cloned into expression plasmids and transfected into CHO cells. Cells can be grown up in appropriate media and harvested. OG1950 may be purified using techniques described above.
- the OG1950 cysteine at position 443 (L443C (EU numbering)) residue is typically “capped” or oxidized by chemicals in the cell culture media and is not available for conjugation.
- purified OG1950 may be subjected to a decapping (i.e. reducing) procedure to remove the cap and enable the free (i.e. those not involved in Cys-Cys disulfide bonds) cysteine residue to be conjugated to the maleimide functionality of a polymer.
- Decapping may be done by mixing purified OG1950 protein with a 30 ⁇ molar excess for 1 hour at 25° C. of the reducing agent TCEP (3,3′,3′′-Phosphanetriyltripropanoic acid).
- the reduction reaction with TCEP may be monitored by SDS-PAGE.
- the OG1950 protein can be washed by Ultrafiltration/Diafiltration (UF/DF) system using a Pellicon XL Ultrafiltration Cassette with 30 kDa MWCO membrane from Millipore with 20 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM TCEP buffer to remove the cap and the excess TCEP.
- UF/DF Ultrafiltration/Diafiltration
- the residual TCEP reagent may then be removed in the same UF/DF setup with 20 mM Tris pH7.5, 150 mM NaCl. Reduced OG1950 can then be allowed to reoxidize using dHAA at ambient temperature for 1 hour followed by UF/DF for removal of dHAA to form decapped OG1950. The decapping status is monitored by SDS-PAGE assay.
- Decapped OG1950 may be conjugated to polymer OG1802. An excess of OG1802 is used (10-20 fold molar excess). Conjugation can be monitored by SDS-PAGE and driven to near completion. OG1950 conjugate may be purified via cation exchanger chromatography and buffer exchanged into the formulation buffer by UF/DF. Polymer-OG1950 conjugate may be purified chromatographically as described above.
- recombinant human VEGF-165 (R&D Systems) was applied at various concentrations with a pulse of 60 s at a flow rate of 30 ⁇ l/min and a final dissociation time of 1000 s.
- the experiment was carried out at 25° C.
- the surface was regenerated with 10 mM glycine pH 1.7 for 1 min at a flow rate of 50 ⁇ L/min.
- Binding kinetics analysis was performed using the Biacore T200 evaluation software with responses globally fit to a 1:1 interaction. Results are summarized in Table 10.1 and FIG. 21 .
- OG1950 protein expression and protein preparation OG1950 protein was expressed in mammalian GSCHOK1 expression system followed by purification using a Protein A affinity column. The purity of the Protein A column purified OG1950 was over 90% based on size exclusion chromatography and SDS-PAGE. The engineered specific cysteine residue of OG1950 was available for thiol conjugation to the OG1802 biopolymer. The thiol reacting chemical group of OG1802 was to react to form stable covalent linkage, which forms the OG1953 bioconjugate.
- OG1950 1 mg was fully reduced with Tris-(2-Carboxyethyl)phosphine, Hydrochloride (TCEP) reducing agent followed by removal of TCEP via buffer exchange using a 30 KDa spin concentrator.
- TCEP Tris-(2-Carboxyethyl)phosphine, Hydrochloride
- the fully reduced OG1950 protein was then allowed to reoxidize to ensure all expected protein disulfide linkage was formed except the engineered cysteine residue (decap OG1950), which remained in reduced form for conjugation to the biopolymer via thiol specific conjugation chemistry.
- Conjugation reaction The conjugation reactions were performed by mixing 100 ug of decap OG1950 with 15 ⁇ molar excess of OG1802 biopolymer with final protein concentration at 2 mg/mL in Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.5). Various additives were evaluated in different conjugation reactions as shown in Table 11.1. in order to compare their impact on the conjugation efficiency. All reactions were setup in a fixed volume and incubated at 4° C. for 20 hours. Table 11.1 and FIG. 19 shows ion Exchanger analysis (A280 absorbance) and fractionation of the conjugation reactions A through G.
- Reactions B-G were started with 100 ug OG1950 protein input with a fixed total reaction volume. Upon reaction completion, equal volumes of B-G reactions were injected for IEX analysis. The conjugation efficiency comparison is shown in FIG. 19 .
- Peak 1(P1) represents the excess biopolymer (OG1802) that was not conjugated to the protein and unable to bind to the ion exchanger column and therefore eluted as unbound fraction in each reaction; Peak 2 (P2) represents the antibody polymer bioconjugate in each reaction; Peak 3 (P3) represents the free antibody that was not conjugated to the polymer in each reaction.
- the final concentration of biotin-VEGF was 4 ng/mL (100 pM).
- FIG. 20 also shows that the other antibody conjugate anti-VEGF Bio Conjugate (anti-VEGF BC) reached a higher maximal inhibition of binding of VEGF to the VEGF receptor when compared to the antibody alone (anti-VEGF).
- anti-VEGF BC anti-VEGF Bio Conjugate
- anti-VEGF antibody conjugates that display a superior (or at least equal) level of blocking ability, as compared to the anti-VEGF antibody alone.
- Example 13 Method of Determining Binding of OG1950 to Fc Gamma Receptor I and IIIa
- Binding kinetics experiments were performed at 25° C. using a BIAcore T200.
- An anti-his antibody was immobilized on a CM5 chip.
- Histidine-tagged Fc ⁇ RI and Fc ⁇ RIIIa at a concentration of 0.5 ⁇ g/mL prepared in HBS-EP buffer (0.01M HEPES pH7.4, 0.15M NaCl, 3 mM EDTA, 0.005% Tween-20) were injected independently for 60-s using a flow rate of 5 ⁇ L/min in the active flow cell only.
- Antibody candidate and Avastin® used as a positive control, were then injected over the reference and active flow cell using 60-s injections at 30 ⁇ L/mL, applying single-cycle kinetics method.
- Antibody concentrations in the range of 0.48 to 300 nM were used for Fc ⁇ RI and 7.8 nM to 2000 nM for Fc ⁇ RIIIa.
- flow cells were regenerated with a 60 s injection of 10 mM glycine pH 1.7 using a flow-rate of 50p/mL. Data was double referenced, using subtraction of both reference flow cell and blank cycles. Analysis was performed using BIA evaluation software. Results are shown in FIGS. 22 and 23 . Results show that OG1950 showed no significant binding to either Fc gamma receptor I and IIIa in this assay.
- Complement engagement liabilities were assessed by C1q ELISA binding.
- the antibody panel was titrated 1:2 from a top concentration of 10 ug/mL in 1 ⁇ PBS for overnight coating at 4 C. Plates were then blocked After a 2 hour blocking step in 1% BSA. Purified human C1q was then applied at 5 ug/mL in 1% BSA for 2 hours at room temperature followed by detection with HRP-conjugated anti-human C1q antibody and TMB development. Results are shown in FIG. 24 . Results show that C1q has more binding affinity for Avastin® (bevacizumab) relative to OG1950 at antibody concentrations between 10 ug/mL and 0.625 ug/mL.
- OG1950 has less than 10% of the binding of that of Avastin. In some embodiments, OG1950 has less binding to C1q than Avastin® (bevacizumab).
- Human retinal microvascular endothelial cell (HuRMVEC) proliferation assays were performed as follows: cells were maintained in CSC complete medium (cell systems, #4Zo-500) supplemented with 2% of CultureBoost (cell systems, #4CB-500) and 0.2% of Bac-off (cell systems, #4ZO-643), seeded in 96-well plates in assay medium (serum free medium (cell systems, #4Z3-500-S) with 5% FBS) at density of 10,000 cells per well.
- VEGF inhibitors were first added at the indicated concentrations to each well. Thirty minutes later, VEGF 165 (R&D systems, #293-VE-500/CF) was added to a final concentration of 1.3 nM. After 3 days, cells were incubated with WST-1 cell proliferation assay reagent and read at OD450 nM.
- Binding kinetics was performed at 25° C. using a BIAcore T200 on Avastin® (bevacizumab), OG1950 and OG1953. Briefly, anti-VEGF agents were captured on a Protein A chip (GE). 1 ug/ml OG1950 and Avastin® (bevacizumab) were flowed at 25 ul/min for 2 mins. 10 ug/ml OG1953 was flowed at 10 uls/min for 10 mins.
- GE Protein A chip
- VEGF (recombinant; R&D systems) was flowed over captured antibodies for 240 seconds contact time each at 0.56 nM, 1.67 nM, 5 nM, 15 nM, and 45 nM for single cycle kinetics, and dissociated for 30 minutes. Analysis was performed using BiaEvaluation software (GE). All sensorgrams were double reference subtracted and fit using a 1:1 Langmuir binding model. Off-rate of these anti-VEGF agents might be under-estimated in this experiment, due to the disassociation between anti-VEGF agents and Protein A capture.
- GE BiaEvaluation software
- Example 17 Excipient Screening Experiment for Prevention of OG1802 Polymer Induced IgG1 Precipitation
- the OG1950 conjugation reaction mixture was found to be cloudy with precipitate immediately present upon mixing. Further investigation revealed the precipitate was the protein itself, which in turn resulted in poor conjugation efficiency observed via either SDS-PAGE or ion exchanger analysis as the protein was lost by precipitation instead of participating in the conjugation reaction.
- Initial troubleshooting experiments performed revealed conditions that did not result in a clear reaction solution included (1) reduction of polymer molar excess ratio from over 10 to less than 5; (2) preadjusting the reaction solution pH to more acidic (e.g. pH 5) or basic (e.g. pH 8.5) from the standard neutral pH range (e.g. pH 6.5-7.5); (3) testing of other IgG1 protein samples with similar or different isoelectric point (pI) as compared to OG1950; (4) buffer exchanged the sample storage buffer into 1 ⁇ PBS pH 7.4 or 20 mM Tris buffer pH 7.4, 100 mM NaCl; and (5) preadjusting the OG1802 solution with 20 mM Tris buffer pH 7.4.
- pI isoelectric point
- Protein is known to carry net surface charge that helps protein solubility in aqueous solution.
- the amino acids are referred to as hydrophilic amino acids which include arginine, lysine, aspartic acid, and glutamic acid. At neutral pH 7 the side chains of these amino acids carry charges—positive for arginine and lysine, negative for aspartic acid, and glutamic acid. Altering the solution pH could modulate the intrinsic protein solubility which is therefore in some of the troubleshoot experiments mentioned above such as (2) this approach was applied.
- proteins solubility in aqueous solution differs depending on the level of hydrophobic or hydrophilic properties of the surface. Proteins with surfaces that have greater hydrophobic properties will readily precipitate.
- the addition of ions e.g.
- NaCl or other salt creates an electron shielding effect that nullifies some activity between water particles and the protein, reducing solubility as the proteins bind with each other and begin to aggregate.
- the biopolymer directly or indirectly modulates the protein surface charge and/or exposed surfaces in a manner that promotes the intermolecular hydrophobic interactions which results in protein precipitation.
- Excipients that were determined to modulate protein solubility include the following categories (i) detergents including neutral detergent (e.g. 0.1-1% polysorbate20 or tween20) or charged detergent (e.g. 0.1-1% Sodium Dodecyl Sulfate (SDS)) (ii) sugars (e.g. 6% Trehalose or 6% sucrose) (iii) negatively charged amino acids (e.g. 0.03-1 mM glutamic acid or 0.03-1 mM aspartic acid) or positively charged amino acids (e.g. 1-100 mM lysine or arginine) (iv) chaotropic agents or denaturants (e.g.
- neutral detergent e.g. 0.1-1% polysorbate20 or tween20
- charged detergent e.g. 0.1-1% Sodium Dodecyl Sulfate (SDS)
- sugars e.g. 6% Trehalose or 6% sucrose
- negatively charged amino acids e.
- polyethylene glycol e.g. 0.03-1 mM PEG8000
- organic solvent e.g. 20% ethanol
Abstract
Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
Description
- Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR § 1.57.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled KDIAK004.txt, created Dec. 28, 2016, which is 18,231 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.
- The present invention relates to antibodies and conjugates thereof and methods of using and manufacturing said antibodies, conjugates thereof, and other protein conjugates.
- Diabetic retinopathy is a leading cause of blindness in people between the ages of about 20 to 64 years of age. Engelgau M, Geiss L, Saaddine J, Boyle J, et al. 2004. The Evolving Diabetes Burden in the United States. Ann of Int Med. 140 (11): 945-951. In the United States, diabetic retinopathy accounts for some 12% of new cases of blindness. Typically, in cases of diabetic retinopathy, retinal blood vessels will swell and leak fluid into the rear of the eye. Hyperglycemia induces intramural and thickening of the basement membrane, resulting in leaky or permeable blood vessels.
- In diabetic retinopathy, changes in blood glucose level cause changes to retinal blood vessels. All people with diabetes mellitus are at risk. The longer a person has diabetes, the higher their risk of developing some ocular problem. Between 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy. Causes and Risk Factors. Diabetic Retinopathy. United States National Library of Medicine. 15 Sep. 2009.
- Diabetic retinopathy is first exhibited in the development of microaneurysms in the retina. Microaneurysms occur when there is a swelling of capillaries (very small blood vessels) that feed the retina. The presence of relatively small numbers of microaneurysms will not usually cause problems with vision. However, if the retinopathy develops to later stages, there are significant chances of vision loss. Such early stage retinopathy are referred to as background diabetic retinopathy or non-proliferative diabetic retinopathy (NPDR). While NPDR patients are generally asymptomatic, early detection of retinopathy is crucial because if the disease proceeds to later stages, significant vision loss is very likely.
- In the next stage of diabetic retinopathy, neovascularization occurs in the back of the eye (proliferative diabetic retinopathy). The neovasculature is leaky and the vessels can burst, followed by bleeding and resulting in blurred or obscured vision. Due to lack of oxygen in the eye, still further neovascularization occurs. Blood vessels grow along the retina and in the vitreous humor. As these vessels burst, there is further bleeding and the retina can be badly damaged or destroyed. The accumulation of fluid in the macula due to leaking blood vessels is called diabetic macular edema. Many patients with diabetic retinopathy will develop diabetic macular edema.
- There are generally three treatment pathways for patients with diabetic retinopathy: laser surgery, injection of corticosteroids and injection of anti-VEGF agents (e.g. AVASTIN® (bevacizumab), LUCENTIS® (ranibizumab) and Eylea® (aflibercept)). While laser surgery is generally effective in treating diabetic retinopathy, retinal damage induced by the laser is a frequent side effect. Steroid preparations such as triamcinolone acetonide have been administered via intravitreal injection to treat diabetic retinopathy. However, to treat diabetic retinopathy, the steroid solutions must be frequently administered. Moreover, intravitreal treatment with steroids has been associated with cataracts, steroid-induced glaucoma and endophthalmitis.
- Another way to treat diabetic retinopathy is the intravitreal injection of anti-VEGF agents. In this regard, LUCENTIS® (ranibizumab) and EYLEA® (aflibercept) have been recently approved for treatment of diabetic retinopathy in patients with diabetic macular edema. VEGF-directed therapies are effective not just for diabetic retinopathy, but also for Age-Related Macular Degeneration (AMD), such as neovascular (wet) AMD.
- Provided herein is an antibody conjugate of an anti-VEGF-A antibody bonded at a cysteine outside a variable region of the antibody to a phosphorylcholine containing polymer, wherein said cysteine has been added via recombinant DNA technology. Optionally the anti-VEGF-A antibody comprises a light chain and a heavy chain and the heavy chain comprises an Fc region. Optionally, the anti-VEGF-A antibody is an immunoglobulin G (IgG). Optionally, the cysteine is in the Fc region of the heavy chain. Optionally, the anti-VEGF-A heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T, and the anti-VEGF-A light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and
Kabat position 4 is L. Optionally, the anti-VEGF-A heavy chain isotype is human IgG1. - Optionally, the heavy chain constant domain of the anti-VEGF-A antibody IgG1 has one or more mutations relative to an IgG1 constant domain to modulate effector function. The mutations are optionally to one or more of the following amino acid positions (EU numbering): E233X, L234X, L235X, G236X, G237X, A327X, A330X, and P331X wherein X is any natural or unnatural amino acid. Optionally, the mutations are selected from the group consisting of (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S. Optionally, the mutations are (EU numbering) L234A, L235A, and G237A. In some embodiments, the effector function is decreased. In some embodiments, CDC, ADCC, and/or ADCP is decreased at least 10, 20, 30, 40, 50, 60, 70, or more percent. In some embodiments, CDC is mediated by Fc binding to C1q, ADCC and ADCP are mediated by Fc binding to various Fc gamma receptors and each of these binding interactions is decreased at least 10, 20, 30, 40, 50, 60, 70, or more percent.
- The cysteine residue is optionally in the anti-VEGF-A heavy chain and is optionally Q347C (EU numbering) or L443C (EU numbering). Optionally, the anti-VEGF-A heavy chain is SEQ ID NO. 1 and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2. Optionally, the cysteine is L443C (EU numbering).
- Optionally, the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- Such that the polymer comprises the following repeating units:
- where n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- The polymer optionally has three or more arms, or is synthesized with an initiator comprising 3 or more polymer initiation sites. Optionally, the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms, or is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites. Optionally, the polymer has 2, 3, 6, or 9 arms, or is synthesized with an initiator comprising 2, 3, 6 or 9 polymer initiation sites. Optionally, the polymer has 9 arms, or is synthesized with an initiator comprising 9 polymer initiation sites.
- Optionally, the polymer has a molecular weight between about 300,000 and about 1,750,000 Da, as measured by size exclusion chromatography—multi angle light scattering (hereinafter “SEC-MALS”). Optionally, the polymer has a molecular weight between about 500,000 and about 1,000,000 Da. Optionally, the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- Optionally, the antibody conjugate is purified and the polymer is polydisperse. Optionally, the polymer has a polydispersity value (PDI) of less than 1.2. In some embodiments, any of the conjugate solutions provided herein can have a PolyDispersity Index (PDI) that is equal to or less than 1.8, for example, less than or equal to: 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.
- Optionally, an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C449 in SEQ ID NO. 1 to the polymer. Optionally, the polymer has 9 arms; and the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- Optionally, an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C443 (EU numbering) to the polymer. Optionally, the polymer has 9 arms; and the polymer has a molecular weight of between about 600,000 to about 800,000 Da.
- Optionally, the antibody conjugate has the following structure:
- wherein: each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L; the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C449 in SEQ ID NO: 1, which bond is depicted on one of the heavy chains; PC is
- where the curvy line indicates the point of attachment to the rest of the polymer; where X=a) OR where R=H, Methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. Optionally, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 3000. Optionally, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 500. In some embodiments, X=OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R7, carbonyl —CCO—R7, —CO—NR8R9, —(CH2)n—COOR7, —CO—(CH)n—COOR7, —(CH2)n—NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each R7, R8 and R9 is separately selected from the group consisting of a hydrogen atom, halogen atom, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, a 5-membered ring, and a 6-membered ring.
- Optionally, the antibody conjugate has the following structure:
- wherein: each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L; the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443 (EU numbering), which bond is depicted on one of the heavy chains; PC is
- where the curvy line indicates the point of attachment to the rest of the polymer; where X=a) OR where R=H, Methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. Optionally, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 3000. Optionally, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are independently integers from 0 to 500. In some embodiments, X=OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R7, carbonyl —CCO—R7, —CO—NR8R9, —(CH2)n—COOR7, —CO—(CH)n—COOR7, —(CH2)n—NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each R7, R8 and R9 is separately selected from the group consisting of a hydrogen atom, halogen atom, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, a 5-membered ring, and a 6-membered ring.
- In some embodiments an antibody conjugate as described above in a liquid solution is provided. Optionally, the liquid solution has a pharmaceutically acceptable carrier.
- In some embodiments an anti-VEGF-A antibody which comprises a heavy chain and a light chain, wherein is provided. The heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T and the light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and
Kabat position 4 is L. Optionally, the heavy chain isotype is IgG1, wherein the IgG1 constant domain comprises one or more of the following mutations to modulate effector function (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S. Optionally, the antibody has (EU numbering) L234A, L235A, and G237A. Optionally, the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1 and sequence of the anti-VEGF-A light chain is SEQ ID NO. 2. - In some embodiments a method for treatment or prophylaxis of an ocular disease is provided. The method comprises administering an antibody conjugate as described above, or the pharmaceutical composition as described above. Optionally, the ocular disease is selected from the group consisting of diabetic retinopathy, choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, and hypertensive retinopathy. Optionally, the disease is diabetic retinopathy.
- In some embodiments a method of making an antibody conjugate comprising an anti-VEGF-A antibody conjugated to a phosphorylcholine containing polymer is provided. The method comprises the step of: conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer; wherein the anti-VEGF-A antibody comprises a cysteine residue added via recombinant DNA technology and wherein the cysteine is outside a variable region of the antibody; wherein the phosphorylcholine containing polymer comprises a sulfhydryl specific reacting group selected from the group consisting of a maleimide, a vinylsulfone, an orthopyridyl-disulfide, and an iodoacetamide; and wherein the sulfhydryl specific reacting group on the phosphorylcholine containing polymer reacts with the cysteine residue on the anti-VEGF-A antibody to make the antibody conjugate.
- Optionally, the anti-VEGF-A antibody is an immunoglobulin G (IgG) and the cysteine is in the Fc region of the antibody. Optionally, the anti-VEGF-A antibody comprises a light chain and a heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T, and the anti-VEGF-A antibody light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and
Kabat position 4 is L. Optionally, the anti-VEGF-A antibody heavy chain isotype is IgG1. - Optionally, the IgG1 constant domain has one or more mutations relative to an IgG1 constant domain to modulate effector function. Optionally, the mutations are to one or more of the following amino acid positions (EU numbering): E233X, L234X, L235X, G236X, G237X, G236X, D270X, K322X, A327X, P329X, A330X, A330X, P331X, and P331X, wherein X is any natural or non-natural amino acid. Optionally, the mutations are selected from the group consisting of (EU numbering) E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S. Optionally, the mutations are (EU numbering) L234A, L235A, and G237A.
- Optionally, the cysteine residue added by recombinant DNA technology is selected from the group consisting of Q347C (EU numbering) and L443C (EU numbering). Optionally, the cysteine residue added by recombinant DNA technology is L443C (EU numbering). Optionally, the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1 and sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- Optionally, the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- Such that the polymer comprises the following repeating units:
- where n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- Optionally, the polymer has three or more arms. Optionally, the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms. Optionally, the polymer has 2, 3, 6, or 9 arms. Optionally, the polymer has 9 arms.
- Optionally, the polymer has a molecular weight between about 300,000 and 1,750,000 Da. Optionally, the polymer has a molecular weight between about 500,000 and 1,000,000 Da. Optionally, the polymer has a molecular weight of between about 600,000 to 800,000 Da.
- Optionally, the method has a further step comprising the step of contacting the anti-VEGF-A antibody with a thiol reductant under conditions that produce a reduced cysteine sulfhydryl group to produce a reduced anti-VEGF-A antibody in which all cysteine residues are reduced. Optionally, the thiol reductant is selected from the group consisting of Tris[2-carboxyethyl]phosphine hydrochloride (TCEP), dithiothreitol (DTT), dithioerythritol (DTE), sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), β-mercaptoethanol (BME), cysteine hydrochloride, and cysteine. Optionally, the thiol reductant is TCEP. Optionally, the thiol reductant is between 1 and 100 fold molar excess relative to the concentration of the anti-VEGF-A antibody. Optionally, the thiol reductant is between 20 to 50 fold molar excess relative to the concentration of the anti-VEGF-A antibody.
- Optionally, the method further comprising the steps of removing the thiol reductant from the reduced anti-VEGF-A antibody, and treating the reduced anti-VEGF-A antibody with an oxidizing agent. Optionally, the oxidizing agent is air, aqueous CuSO4, or dehydroascorbic acid (DHAA). Optionally, the method further comprises the step of purifying the antibody conjugate.
- Optionally, the antibody conjugate is purified using a technique selected from the group consisting of ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, affinity chromatography, and combinations thereof. Optionally, the purified antibody conjugate retains at least 20% biological activity relative to an unconjugated anti-VEGF-A antibody. Optionally, the purified antibody conjugate retains at least 50% biological activity relative to an unconjugated anti-VEGF-A antibody. Optionally, the purified antibody conjugate retains at least 90% biological activity relative to an unconjugated anti-VEGF-A antibody. Optionally, the purified antibody conjugate has an increased half-life relative to an unconjugated anti-VEGF-A antibody. Optionally, the purified antibody conjugate has at least a 1.5 fold increase in half-life relative to an unconjugated anti-VEGF-A antibody.
- Optionally, the method further comprises the step of polymerizing a free radically polymerizable phosphorylcholine containing monomer in a polymerization medium to provide the phosphorylcholine containing polymer, the medium comprising: the radically polymerizable phosphorylcholine containing monomer; a transition metal catalyst Mt (q−1)+ wherein Mt is a transition metal, q is the maximum oxidation state of the metal and q−1 is the oxidation state of the metal, wherein the metal can act as a catalyst, wherein the transition metal catalyst is supplied as a salt of the form Mt (q−1)+X′(q−1), wherein X′ is a counterion or group, or wherein the transition metal catalyst is supplied in situ by providing the inactive metal salt at its highest oxidation state Mt q+X′q together with a reducing agent that is capable of reducing the transition metal from the oxidized inactive state to the reduced active state; a ligand; and an initiator.
- Optionally, the radically polymerizable phosphorylcholine containing monomer is
- wherein R1 is H or C1-6 alkyl; R2, R3, R4 are each methyl; and X and Y are each 2.
- Optionally, Mt is selected from the group consisting of Cu, Fe, Ru, Cr, Mo, W, Mn, Rh, Re, Co, V, Zn, Au, and Ag. Optionally, the metal catalyst is supplied as a salt of the form Mt (q−1)+X′(q−1). Optionally, Mt (q−1)+ is selected from the group consisting of Cu1+, Fe2+, Ru2+, Cr2+, Mo2+, W2+, Mn3+, Rh3+, Re2+, Co+, V2+, Zn+, Au+, and Ag+ and X′ is selected from the group consisting of halogen, C1-6 alkoxy, (SO4)1/2, (PO4)1/3, (R7PO4)1/2, (R72PO4), triflate, hexaluorophosphate, methanesulfonate, arylsulfonate, CN and R7CO2, where R7 is H or a straight or branched C1-6 alkyl group which may be substituted from 1 to 5 times with a halogen. Optionally, Mt (q−1)+ is Cu1+ and X′ is Br. Optionally, Mt (q−1)+ is supplied in situ. Optionally, Mt q+Xq is CuBr2.
- Optionally, the reducing agent is an inorganic compound. Optionally, the inorganic compound is selected from the group consisting of a sulfur compound of a low oxidation level, sodium hydrogen sulfite, sodium sulfite, an inorganic salt comprising a metal ion, a metal, hydrazine hydrate, and derivatives of such compounds.
- Optionally, the reducing agent is a metal. Optionally, the reducing agent is Cu0.
- Optionally, the reducing agent is an organic compound. Optionally, the organic compound is selected from the group consisting of alkylthiols, mercaptoethanol, or carbonyl compounds that can be easily enolized, ascorbic acid, acetyl acetonate, camphorsulfonic acid, hydroxy acetone, reducing sugars, monosaccharides, glucose, aldehydes, and derivatives of such organic compounds.
- Optionally, the ligand is selected from the group consisting of 2,2′-bipyridine, 4,4′-Di-5-nonyl-2,2′-bipyridine, 4,4-dinonyl-2,2′-dipyridyl, 4,4′,4″-tris(5-nonyl)-2,2′:6′,2″-terpyridine, N,N,N′,N′,N″-Pentamethyldiethylenetriamine, 1,1,4,7,10,10-Hexamethyltriethylenetetramine, Tris(2-dimethylaminoethyl)amine, N,N-bis(2-pyridylmethyl)octadecylamine, N,N,N′,N′-tetra[(2-pyridal)methyl]ethylenediamine, tris[(2-pyridyl)methyl]amine, tris(2-aminoethyl)amine, tris(2-bis(3-butoxy-3-oxopropyl)aminoethyl)amine, tris(2-bis(3-(2-ethylhexoxy)-3-oxopropyl)aminoethyl)amine, and Tris(2-bis(3-dodecoxy-3-oxopropyl)aminoethyl)amine. Optionally, the ligand is 2,2′-bipyridine.
- Optionally, the initiator has the structure:
- wherein R1 is a nucleophilic reactive group, R2 comprises a linker, and R3 comprises a polymer synthesis initiator moiety having the structure
- wherein R4 and R5 and are the same or different and are selected from the group consisting of alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido, and any combination thereof; Z is a halogen or CN; and s is an integer between 1 and 20.
- Optionally, Z is Br and R4 and R5 are each methyl. Optionally, R1 is selected from the group consisting of NH2—, OH—, and SH—. Optionally, R1 is NH2—. Optionally, R2 is alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido, and any combination thereof. Optionally, R2 is
- wherein X and Y are the same or different and are integers from 1-20.
- Optionally, X and Y are each 4. Optionally, R3 further comprises
- wherein R6, R7 and R8 are the same or different and are selected from the group consisting of
- wherein Z is NCS, F, Cl, Br or I. Optionally, Z is Br. Optionally, R6, R7 and R8 are each
- Optionally, the initiator has the structure
- wherein A and B are the same or different and are integers from 2 to 12 and Z is any halide, such as Br. Optionally, A and B are each 4.
- Optionally, the method further comprising the step of reacting the polymer with a maleimide reagent to provide a polymer having a terminal maleimide. Optionally, the maleimide compound is
- In some embodiments, the options provided herein avoid one or more issues with other methods or forms of therapy. For example, they can reduce the frequency of administration to less than once a month intravitreal injection, as such intravitreal injections can be painful and require a clinical setting. Furthermore, diabetic retinopathy patients whose vision is relatively unimpaired could be resistant to monthly intravitreal injections and thus may go untreated under other forms of therapy. There is thus a need for diabetic retinopathy treatments with less frequent dosing. In this context, a treatment for diabetic retinopathy could be used early in the disease to prevent progression of the disease and associated vision threatening events.
- In some embodiments, the antibody conjugate comprises (1) an anti-VEGF-A antibody and (2) a phosphorylcholine containing polymer. The polymer is covalently bonded to the antibody at a cysteine outside a variable region of the antibody and said cysteine has been added via recombinant DNA technology.
- In some embodiments, the anti-VEGF-A antibody heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the anti-VEGF-A light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14).
- In some embodiments, the polymer conjugated to the antibody has a molecular weight between about 300,000 and about 1,750,000 Da as measured by size exclusion chromatography—multi angle light scattering (hereinafter “SEC-MALS”).
- In some embodiments, the anti-VEGF-A antibody comprises a heavy chain and a light chain. The heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11) and the light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and the heavy chain isotype is IgG1. The IgG1 constant domain comprises one or more of the following mutations to reduce effector function (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S.
- In some embodiments, any of the methods can employ an anti-VEGF-A antibody that comprises a light chain and a heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the anti-VEGF-A antibody light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14).
- In some embodiments, the antibody comprises a heavy chain amino acid variable region that comprises
SEQ ID NO 1 and a light chain amino acid variable region that comprises SEQ ID NO. 2. - In some embodiments, the antibody is a human IgG1, and the heavy chain constant domain comprises one or more mutations that reduce an immune-mediated effector function.
- In some embodiments, the antibody is further conjugated to a polymer to form a bioconjugate, and wherein the bioconjugate has a molecular weight between about 450,000 and 1,900,000 Daltons.
- In some embodiments, the PolyDispersity Index (PDI) is equal to or less than 1.5.
- In some embodiments, the antibody that binds to VEGF-A comprises a
CDR H1 that is theCDR H1 in SEQ ID NO: 1; aCDR H2 that is theCDR H2 in SEQ ID NO: 1; aCDR H3 that is theCDR H3 in SEQ ID NO: 1; aCDR L1 that is theCDR L1 in SEQ ID NO: 2; aCDR L2 that is theCDR L2 in SEQ ID NO: 2; aCDR L3 that is theCDR L3 in SEQ ID NO: 2; at least one of the following mutations: L234A, L235A, and G237A (EU numbering); and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering). - In some embodiments, the antibody comprises all three of the following mutations (EU numbering) L234A, L235A, and G237A, and wherein the antibody comprises L443C (EU numbering).
- In some embodiments, a process for preparing a conjugated protein comprises reducing one or more cysteines in a protein to form a decapped protein in a solution, reoxidizing the decapped protein to restore at least one disulfide linkage in the reduced protein while ensuring that an engineered cysteine residue in the protein remains in a free thiol form to thereby form a reoxidized decapped protein in the solution, and adding at least one excipient to the solution, wherein the excipient reduces a polymer induced protein precipitation. The process further includes adding a polymer to the solution, and conjugating the polymer to the reoxidized decapped protein at the engineered cysteine residue to form a conjugated protein. In some embodiments, the protein is an antibody, an antibody protein fusion or a binding fragment thereof. In some embodiments, the excipient is an acid or a base. In some embodiments, the excipient is selected from the group consisting of at least one of: a detergent, a sugar, and a charged amino acid. In some embodiments, reaction of a polymer with the reduced protein occurs under aqueous conditions between pH 6.0 to pH 8.5. In some embodiments, an amount of the reduced protein is less than an amount of the polymer. In some embodiments, the polymer is conjugated to the protein at 2-37 degrees Celsius. In some embodiments, the process further comprises the process of contacting a solution comprising the conjugated protein to an ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium. In some embodiments, the ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium separates the conjugated protein from the free polymer and from the reoxidized decapped protein. In some embodiments, the polymer comprises a zwitterion. In some embodiments, the polymer comprises a phosphorylcholine. In some embodiments, the polymer comprises a PEG linker bridging a center of a polymer branching point to the maleimide functional group.
- In some embodiments, an anti-VEGF antibody conjugate is provided that is capable of blocking at least 90% of an interaction between a VEGF ligand and a VEGF-receptor.
- In some embodiments, an anti-VEGF antibody conjugate is provided that blocks at least 95% of an interaction between a VEGF ligand and a VEGF-receptor.
- In some embodiments, an anti-VEGF antibody is provided that blocks at least 90% of an interaction between a VEGF ligand and a VEGF-receptor.
-
FIG. 1 shows Compound L. -
FIG. 2 shows Compound K. -
FIG. 3 shows the synthesis of OG1802 from R3707. -
FIG. 4 shows OG1786. -
FIG. 5 shows the synthesis of OG1546 from OG1550. -
FIG. 6 shows the synthesis of OG1784 from OG1546 and OG1563. -
FIG. 7 shows the synthesis of OG1405 from OG1784. -
FIG. 8 shows the synthesis of OG1785 from OG1405. -
FIG. 9 shows the synthesis of OG1786 from OG1785. -
FIG. 10 shows OG1802. -
FIG. 11 shows Compound E. -
FIG. 12 depicts some embodiments of anti-VEGF-A heavy chain with certain effector function mutations and L443C (EU numbering, which is position 449 in SEQ ID NO. 1). -
FIG. 13 depicts some embodiments of an anti-VEGF-A light chain (SEQ ID NO. 2). -
FIG. 14 depicts some embodiments of a Bevaizumab heavy chain (SEQ ID NO. 3). -
FIG. 15 depicts some embodiments of a Bevaizumab light chain (SEQ ID NO. 4). -
FIG. 16 depicts some embodiments of a Ranibizumab heavy chain (SEQ ID NO. 5). -
FIG. 17 depicts some embodiments of a Ranibizumab light chain (SEQ ID NO. 6). -
FIG. 18 depicts some embodiments of a method for preparing an antibody conjugate. -
FIG. 19 depicts Ion Exchanger analysis (A280 absorbance) of reactions A through G. -
FIG. 20 depicts the effect of various anti-VEGF molecules on binding of biotin-VEGF to plate bound VEGFR ECD-Fc protein, and their IC50 values. -
FIG. 21 depicts the OG1950 binding affinity to VEGF measured by BIAcore single cycle kinetics. -
FIG. 22 depicts binding of the OG1950 to Fc gamma receptor I. -
FIG. 23 depicts binding of the OG1950 to Fc gamma receptor IIIa. -
FIG. 24 depicts binding of QG 1950 to human complement protein C1q. -
FIG. 25 depicts the results of a proliferation assay (including IC50 values). -
FIG. 26 depicts the results of single cycle kinetics of VEGF binding to anti-VEGF agents. -
FIG. 27 depicts some embodiments of nucleic acid sequences encoding heavy and light chain variable regions. -
FIG. 28 depicts the screening results after incubation of various samples (of various excipients) in polymer solution (OG1802) for 20 hours at 2-8 degrees Centigrade. - Provided herein are anti-VEGF-A antibodies. In some embodiments, these antibodies can be conjugated to a half-life extending moiety. In some embodiments, the conjugate can be used for the treatment of certain conditions, such as diabetic retinopathy and/or age-related macular degeneration.
- Further provided herein are methods for preparing conjugate compositions of antibodies (of any type of antibody). In some embodiments, these methods allow for lower aggregate formation or higher efficiency of formation of the desired antibody conjugate.
- These and additional embodiments are provided below, following the definition section.
- A “neovascular disorder” is a disorder or disease state characterized by altered, dysregulated or unregulated angiogenesis. Examples of neovascular disorders include neoplastic transformation (e.g. cancer) and ocular neovascular disorders including diabetic retinopathy and age-related macular degeneration.
- An “ocular neovascular” disorder is a disorder characterized by altered, dysregulated or unregulated angiogenesis in the eye of a patient. Such disorders include optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreal neovascularization, glaucoma, pannus, pterygium, macular edema, diabetic retinopathy, diabetic macular edema, vascular retinopathy, retinal degeneration, uveitis, inflammatory diseases of the retina, and proliferative vitreoretinopathy.
- The term antibody includes intact antibodies and binding fragments thereof. A binding fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of binding fragments include Fv, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. scFv antibodies are described in Houston J S. 1991. Methods in Enzymol. 203:46-96. In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.
- Specific binding of an antibody to its target antigen(s) means an affinity of at least 106, 107, 108, 109, or 1010 M−1. Specific binding is detectably higher in magnitude and distinguishable from non-specific binding occurring to at least one unrelated target. Specific binding can be the result of formation of bonds between particular functional groups or particular spatial fit (e.g., lock and key type) whereas nonspecific binding is usually the result of van der Waals forces. Specific binding does not however necessarily imply that an antibody or fusion protein binds one and only one target.
- A basic antibody structural unit is a tetramer of subunits. Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. This variable region is initially expressed linked to a cleavable signal peptide. The variable region without the signal peptide is sometimes referred to as a mature variable region. Thus, for example, a light chain mature variable region means a light chain variable region without the light chain signal peptide. However, reference to a variable region does not mean that a signal sequence is necessarily present; and in fact signal sequences are cleaved once the antibodies or fusion proteins have been expressed and secreted. A pair of heavy and light chain variable regions defines a binding region of an antibody. The carboxy-terminal portion of the light and heavy chains respectively defines light and heavy chain constant regions. The heavy chain constant region is primarily responsible for effector function. In IgG antibodies, the heavy chain constant region is divided into CH1, hinge, CH2, and CH3 regions. The CH1 region binds to the light chain constant region by disulfide and noncovalent bonding. The hinge region provides flexibility between the binding and effector regions of an antibody and also provides sites for intermolecular disulfide bonding between the two heavy chain constant regions in a tetramer subunit. The CH2 and CH3 regions are the primary site of effector functions and FcR binding.
- Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a “J” segment of about 12 or more amino acids, with the heavy chain also including a “D” segment of about 10 or more amino acids. (See generally, Fundamental Immunology (Paul, W., ed., 2nd ed. Raven Press, N.Y., 1989), Ch. 7) (incorporated by reference in its entirety for all purposes).
- The mature variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites, i.e., is divalent. In natural antibodies, the binding sites are the same. However, bispecific antibodies can be made in which the two binding sites are different (see, e.g., Songsivilai S, Lachmann P C. 1990. Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol. 79:315-321; Kostelny S A, Cole M S, Tso J Y. 1992. Formation of bispecific antibody by the use of leucine zippers. J Immunol. 148: 1547-1553). The variable regions all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FRI, CDR1, FR2, CDR2, FR3, CDR3 and FR4. For convenience, the variable heavy CDRs can be referred to as
CDR H1,CDR H2 andCDR H3; the variable light chain CDRs can be referred to asCDR L1,CDR L2 andCDR L3. The assignment of amino acids to each domain is in accordance with the definitions of Kabat E A, et al. 1987 and 1991. Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md.) or Chothia C, Lesk A M. 1987. Canonical Structures for the Hypervariable Regions of Immunoglobulins. J Mol Biol 196:901-917; Chothia C, et al. 1989. Conformations of Immunoglobulin Hypervariable Regions. Nature 342:877-883. Kabat also provides a widely used numbering convention (Kabat numbering) in which corresponding residues between different heavy chain variable regions or between different light chain variable regions are assigned the same number. Although Kabat numbering can be used for antibody constant regions, EU numbering is more commonly used, as is the case in this application. Although specific sequences are provided for exemplary antibodies disclosed herein, it will be appreciated that after expression of protein chains one to several amino acids at the amino or carboxy terminus of the light and/or heavy chain, particularly a heavy chain C-terminal lysine residue, may be missing or derivatized in a proportion or all of the molecules. - The term “epitope” refers to a site on an antigen to which an antibody or extracellular trap segment binds. An epitope on a protein can be formed from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of one or more proteins. Epitopes formed from contiguous amino acids (also known as linear epitopes) are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding (also known as conformational epitopes) are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996).
- Antibodies that recognize the same or overlapping epitopes can be identified in a simple immunoassay showing the ability of one antibody to compete with the binding of another antibody to a target antigen. The epitope of an antibody can also be defined by X-ray crystallography of the antibody (or Fab fragment) bound to its antigen to identify contact residues.
- Alternatively, two antibodies have the same epitope if all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.
- Competition between antibodies is determined by an assay in which an antibody under test inhibits specific binding of a reference antibody to a common antigen (see, e.g., Junghans et al., Cancer Res. 50: 1495, 1990). A test antibody competes with a reference antibody if an excess of a test antibody (e.g., at least 2×, 5×, 10×, 20× or 100×) inhibits binding of the reference antibody by at least 50%. In some embodiments the test antibody inhibits binding of the reference antibody by 75%, 90%, or 99% as measured in a competitive binding assay. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.
- The term “patient” includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
- For purposes of classifying amino acids substitutions as conservative or nonconservative, amino acids are grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gin, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.
- Percentage sequence identities are determined with antibody sequences maximally aligned by the Kabat numbering convention for a variable region or EU numbering for a constant region. After alignment, if a subject antibody region (e.g., the entire mature variable region of a heavy or light chain) is being compared with the same region of a reference antibody, the percentage sequence identity between the subject and reference antibody regions is the number of positions occupied by the same amino acid in both the subject and reference antibody region divided by the total number of aligned positions of the two regions, with gaps not counted, multiplied by 100 to convert to percentage. Sequence identities of other sequences can be determined by aligning sequences using algorithms, such as BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis., using default gap parameters, or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence similarity over a comparison window). Percentage of sequence identity is calculated by comparing two optimally aligned sequences over a window of comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- Compositions or methods “comprising” one or more recited elements may include other elements not specifically recited. For example, a composition that comprises antibody may contain the antibody alone or in combination with other ingredients.
- The term “antibody-dependent cellular cytotoxicity”, or ADCC, is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells (i.e., cells with bound antibody) with immune cells possessing lytic activity (also referred to as effector cells). Such effector cells include natural killer cells, monocytes/macrophages and neutrophils. ADCC is triggered by interactions between the Fc region of an antibody bound to a cell and Fcy receptors, particularly FcγRI and FcγRIII, on immune effector cells such as neutrophils, macrophages and natural killer cells. The target cell is eliminated by phagocytosis or lysis, depending on the type of mediating effector cell. Death of the antibody-coated target cell occurs as a result of effector cell activity.
- The term opsonization also known as “antibody-dependent cellular phagocytosis”, or ADCP, refers to the process by which antibody-coated cells are internalized, either in whole or in part, by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells) that bind to an immunoglobulin Fc region.
- The term “complement-dependent cytotoxicity” or CDC refers to a mechanism for inducing cell death in which an Fc effector domain(s) of a target-bound antibody activates a series of enzymatic reactions culminating in the formation of holes in the target cell membrane. Typically, antigen-antibody complexes such as those on antibody-coated target cells bind and activate complement component C1q which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes.
- A humanized antibody is a genetically engineered antibody in which the CDRs from a non-human “donor” antibody are grafted into human “acceptor” antibody sequences (see, e.g., Queen, U.S. Pat. Nos. 5,530,101 and 5,585,089; Winter, U.S. Pat. No. 5,225,539, Carter, U.S. Pat. No. 6,407,213, Adair, U.S. Pat. No. 5,859,205 6,881,557, Foote, U.S. Pat. No. 6,881,557). The acceptor antibody sequences can be, for example, a mature human antibody sequence, a composite of such sequences, a consensus sequence of human antibody sequences, or a germline region sequence. Thus, a humanized antibody is an antibody having some or all CDRs entirely or substantially from a donor antibody and variable region framework sequences and constant regions, if present, entirely or substantially from human antibody sequences. Similarly a humanized heavy chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody heavy chain, and a heavy chain variable region framework sequence and heavy chain constant region, if present, substantially from human heavy chain variable region framework and constant region sequences. Similarly a humanized light chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody light chain, and a light chain variable region framework sequence and light chain constant region, if present, substantially from human light chain variable region framework and constant region sequences. Other than nanobodies and dAbs, a humanized antibody comprises a humanized heavy chain and a humanized light chain. A CDR in a humanized antibody is substantially from a corresponding CDR in a non-human antibody when at least 85%, 90%, 95% or 100% of corresponding residues (as defined by Kabat) are identical between the respective CDRs. The variable region framework sequences of an antibody chain or the constant region of an antibody chain are substantially from a human variable region framework sequence or human constant region respectively when at least 85, 90, 95 or 100% of corresponding residues defined by Kabat are identical.
- Although humanized antibodies often incorporate all six CDRs (which can be as defined by Kabat) from a mouse antibody, they can also be made with less than all CDRs (e.g., at least 3, 4, or 5 CDRs from a mouse antibody) (e.g., De Pascalis R, Iwahashi M, Tamura M, et al. 2002. Grafting “Abbreviated” Complementary-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody. J Immunol. 169:3076-3084; Vajdos F F, Adams C W, Breece T N, Presta L G, de Vos A M, Sidhu, S S. 2002. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 320: 415-428; Iwahashi M, Milenic D E, Padlan E A, et al. 1999. CDR substitutions of a humanized monoclonal antibody (CC49): Contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol. 36:1079-1091; Tamura M, Milenic D E, Iwahashi M, et al. 2000. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining regions (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol. 164:1432-1441).
- A chimeric antibody is an antibody in which the mature variable regions of light and heavy chains of a non-human antibody (e.g., a mouse) are combined with human light and heavy chain constant regions. Such antibodies substantially or entirely retain the binding specificity of the mouse antibody, and are about two-thirds human sequence.
- A veneered antibody is a type of humanized antibody that retains some and usually all of the CDRs and some of the non-human variable region framework residues of a non-human antibody but replaces other variable region framework residues that may contribute to B- or T-cell epitopes, for example exposed residues (Padlan E A. 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol. 28:489-98) with residues from the corresponding positions of a human antibody sequence. The result is an antibody in which the CDRs are entirely or substantially from a non-human antibody and the variable region frameworks of the non-human antibody are made more human-like by the substitutions. A human antibody can be isolated from a human, or otherwise result from expression of human immunoglobulin genes (e.g., in a transgenic mouse, in vitro or by phage display). Methods for producing human antibodies include the trioma method of Östberg L, Pursch E. 1983. Human×(mouse×human) hybridomas stably producing human antibodies. Hybridoma 2:361-367; Östberg, U.S. Pat. No. 4,634,664; and Engleman et al., U.S. Pat. No. 4,634,666, use of transgenic mice including human immunoglobulin genes (see, e.g., Lonberg et al., WO93/12227 (1993); U.S. Pat. Nos. 5,877,397, 5,874,299, 5,814,318, 5,789,650, 5,770,429, 5,661,016, 5,633,425, 5,625,126, 5,569,825, 5,545,806, Nature 148, 1547-1553 (1994),
Nature Biotechnology 14, 826 (1996), Kucherlapati, WO 91/10741 (1991) and phage display methods (see, e.g. Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047, U.S. Pat. Nos. 5,877,218, 5,871,907, 5,858,657, 5,837,242, 5,733,743 and 5,565,332. - “Polymer” refers to a series of monomer groups linked together. A polymer is composed of multiple units of a single monomer (a homopolymer) or different monomers (a heteropolymer). High MW polymers are prepared from monomers that include, but are not limited to, acrylates, methacrylates, acrylamides, methacrylamides, styrenes, vinyl-pyridine, vinyl-pyrrolidone and vinyl esters such as vinyl acetate. Additional monomers are useful in high MW polymers. When two different monomers are used, the two monomers are called “comonomers,” meaning that the different monomers are copolymerized to form a single polymer. The polymer can be linear or branched. When the polymer is branched, each polymer chain is referred to as a “polymer arm.” The end of the polymer arm linked to the initiator moiety is the proximal end, and the growing-chain end of the polymer arm is the distal end. On the growing chain-end of the polymer arm, the polymer arm end group can be the radical scavenger, or another group.
- “Initiator” refers to a compound capable of initiating a polymerization using monomers or comonomers. The polymerization can be a conventional free radical polymerization or a controlled/“living” radical polymerization, such as Atom Transfer Radical Polymerization (ATRP), Reversible Addition-Fragmentation-Termination (RAFT) polymerization or nitroxide mediated polymerization (NMP). The polymerization can be a “pseudo” controlled polymerization, such as degenerative transfer. When the initiator is suitable for ATRP, it contains a labile bond which can be homolytically cleaved to form an initiator fragment, I, being a radical capable of initiating a radical polymerization, and a radical scavenger, I′, which reacts with the radical of the growing polymer chain to reversibly terminate the polymerization. The radical scavenger I′ is typically a halogen, but can also be an organic moiety, such as a nitrile. In some embodiments, the initiator contains one of more 2-bromoisobutyrate groups as sites for polymerization via ATRP.
- A “chemical linker” refers to a chemical moiety that links two groups together, such as a half-life extending moiety and a protein. The linker can be cleavable or non-cleavable. Cleavable linkers can be hydrolyzable, enzymatically cleavable, pH sensitive, photolabile, or disulfide linkers, among others. Other linkers include homobifunctional and heterobifunctional linkers. A “linking group” is a functional group capable of forming a covalent linkage consisting of one or more bonds to a bioactive agent. Non-limiting examples include those illustrated in Table 1 of WO2013059137 (incorporated by reference).
- The term “reactive group” refers to a group that is capable of reacting with another chemical group to form a covalent bond, i.e. is covalently reactive under suitable reaction conditions, and generally represents a point of attachment for another substance. The reactive group is a moiety, such as maleimide or succinimidyl ester, is capable of chemically reacting with a functional group on a different moiety to form a covalent linkage. Reactive groups generally include nucleophiles, electrophiles and photoactivatable groups.
- “Phosphorylcholine,” also denoted as “PC,” refers to the following:
- where * denotes the point of attachment. The phosphorylcholine is a zwitterionic group and includes salts (such as inner salts), and protonated and deprotonated forms thereof.
- “Phosphorylcholine containing polymer” is a polymer that contains phosphorylcholine. “Zwitterion containing polymer” refers to a polymer that contains a zwitterion.
- Poly(acryloyloxyethyl phosphorylcholine) containing polymer refers to a polymer containing 2-(acryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEA-PC shown below in Example 6) as monomer.
- Poly(methacryloyloxyethyl phosphorylcholine) containing polymer refers to a polymer containing 2-(methacryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEMA-PC or MPC) as monomer (see below):
- As used herein, “MPC” and “HEMA-PC” are interchangeable.
- Molecular weight” in the context of the polymer can be expressed as either a number average molecular weight, or a weight average molecular weight or a peak molecular weight. Unless otherwise indicated, all references to molecular weight herein refer to the peak molecular weight. These molecular weight determinations, number average (Mn), weight average (Mw) and peak (Mp), can be measured using size exclusion chromatography or other liquid chromatography techniques. Other methods for measuring molecular weight values can also be used, such as the use of end-group analysis or the measurement of colligative properties (e.g., freezing-point depression, boiling-point elevation, or osmotic pressure) to determine number average molecular weight, or the use of light scattering techniques, ultracentrifugation or viscometry to determine weight average molecular weight. In some embodiments, the molecular weight is measured by SEC-MALS (size exclusion chromatography—multi angle light scattering). In some embodiments, the polymeric reagents are typically polydisperse (i.e., number average molecular weight and weight average molecular weight of the polymers are not equal), and can possess low polydispersity values of, for example, less than about 1.5, as judged, for example, by the PDI value derived from the SEC-MALS measurement. In some embodiments, the polydispersities (PDI) are in the range of about 1.4 to about 1.2. In some embodiments the PDI is less than about 1.15, 1.10, 1.05, or 1.03.
- The phrase “a” or “an” entity refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.
- “About” means variation one might see in measurements taken among different instruments, samples, and sample preparations.
- “Protected,” “protected form,” “protecting group” and “protective group” refer to the presence of a group (i.e., the protecting group) that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions. Protecting groups vary depending upon the type of chemically reactive group being protected as well as the reaction conditions to be employed and the presence of additional reactive or protecting groups in the molecule, if any. Suitable protecting groups include those such as found in the treatise by Greene et al., “Protective Groups In Organic Synthesis,” 3rd Edition, John Wiley and Sons, Inc., New York, 1999.
- “Alkyl” refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated. For example, C1-C6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Other alkyl groups include, but are not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl can include any number of carbons, such as 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6 and 5-6. The alkyl group is typically monovalent, but can be divalent, such as when the alkyl group links two moieties together.
- The term “lower” referred to above and hereinafter in connection with organic radicals or compounds respectively defines a compound or radical which can be branched or unbranched with up to and including 7 or up to and including 4 and (as unbranched) one or two carbon atoms.
- “Alkylene” refers to an alkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene. For instance, a straight chain alkylene can be the bivalent radical of —(CH2)n, where n is 1, 2, 3, 4, 5 or 6. Alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.
- Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R″′, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R″′, —NR″C(O)2R′, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR′, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —CN and —NO2 in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″ and R″′ each independently refer to hydrogen, unsubstituted (C1-C8)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C1-C4)alkyl groups. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, —NR′R″ is meant to include 1-pyrrolidinyl and 4-morpholinyl. The term “alkyl” is include groups such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like). In some embodiments, the substituted alkyl and heteroalkyl groups have from 1 to 4 substituents. In some embodiments, the substituted alkyl and heteroalkyl groups have 1, 2 or 3 substituents. Exceptions are those perhalo alkyl groups (e.g., pentafluoroethyl and the like).
- Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R″′, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —O C(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R″′, —NR″C(O)2R′, —NR—C(NR′R″R″′)═NR″″, —NR—C(NR′R″)═NR″′, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —CN and —NO2 in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″, R″′ and R″″ each independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R″′ and R″″ groups when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, —NR′R″ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
- “Alkoxy” refers to alkyl group having an oxygen atom that either connects the alkoxy group to the point of attachment or is linked to two carbons of the alkoxy group. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc. The alkoxy groups can be further substituted with a variety of substituents described within. For example, the alkoxy groups can be substituted with halogens to form a “halo-alkoxy” group.
- “Carboxyalkyl” means an alkyl group (as defined herein) substituted with a carboxy group. The term “carboxycycloalkyl” means a cycloalkyl group (as defined herein) substituted with a carboxy group. The term alkoxyalkyl means an alkyl group (as defined herein) substituted with an alkoxy group. The term “carboxy” employed herein refers to carboxylic acids and their esters.
- “Haloalkyl” refers to alkyl as defined above where some or all of the hydrogen atoms are substituted with halogen atoms. Halogen (halo) represents chloro or fluoro, but may also be bromo or iodo. For example, haloalkyl includes trifluoromethyl, fluoromethyl, 1,2,3,4,5-pentafluoro-phenyl, etc. The term “perfluoro” defines a compound or radical which has all available hydrogens that are replaced with fluorine. For example, perfluorophenyl refers to 1,2,3,4,5-pentafluorophenyl, perfluoromethyl refers to 1,1,1-trifluoromethyl, and perfluoromethoxy refers to 1,1,1-trifluoromethoxy.
- “Fluoro-substituted alkyl” refers to an alkyl group where one, some, or all hydrogen atoms have been replaced by fluorine.
- “Cytokine” is a member of a group of protein signaling molecules that may participate in cell-cell communication in immune and inflammatory responses. Cytokines are typically small, water-soluble glycoproteins that have a mass of about 8-35 kDa.
- “Cycloalkyl” refers to a cyclic hydrocarbon group that contains from about 3 to 12, from 3 to 10, or from 3 to 7 endocyclic carbon atoms. Cycloalkyl groups include fused, bridged and spiro ring structures.
- “Endocyclic” refers to an atom or group of atoms which comprise part of a cyclic ring structure.
- “Exocyclic” refers to an atom or group of atoms which are attached but do not define the cyclic ring structure.
- “Cyclic alkyl ether” refers to a 4 or 5 member cyclic alkyl group having 3 or 4 endocyclic carbon atoms and 1 endocyclic oxygen or sulfur atom (e.g., oxetane, thietane, tetrahydrofuran, tetrahydrothiophene); or a 6 to 7 member cyclic alkyl group having 1 or 2 endocyclic oxygen or sulfur atoms (e.g., tetrahydropyran, 1,3-dioxane, 1,4-dioxane, tetrahydrothiopyran, 1,3-dithiane, 1,4-dithiane, 1,4-oxathiane).
- “Alkenyl” refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one double bond. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. Alkenyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons. The alkenyl group is typically monovalent, but can be divalent, such as when the alkenyl group links two moieties together.
- “Alkenylene” refers to an alkenyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkenylene can be linked to the same atom or different atoms of the alkenylene. Alkenylene groups include, but are not limited to, ethenylene, propenylene, isopropenylene, butenylene, isobutenylene, sec-butenylene, pentenylene and hexenylene.
- “Alkynyl” refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one triple bond. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentenyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatrienyl. Alkynyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons. The alkynyl group is typically monovalent, but can be divalent, such as when the alkynyl group links two moieties together.
- “Alkynylene” refers to an alkynyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkynylene can be linked to the same atom or different atoms of the alkynylene. Alkynylene groups include, but are not limited to, ethynylene, propynylene, butynylene, sec-butynylene, pentenylene and hexynylene.
- “Cycloalkyl” refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Monocyclic rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Bicyclic and polycyclic rings include, for example, norbornane, decahydronaphthalene and adamantane. For example, C3-8cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and norbornane.
- “Cycloalkylene” refers to a cycloalkyl group, as defined above, linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the cycloalkylene can be linked to the same atom or different atoms of the cycloalkylene. Cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cyclooctylene.
- “Heterocycloalkyl” refers to a ring system having from 3 ring members to about 20 ring members and from 1 to about 5 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can also be oxidized, such as, but not limited to, —S(O)— and —S(O)2—. For example, heterocycle includes, but is not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, quinuclidinyl and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl.
- “Heterocycloalkylene” refers to a heterocycloalkyl group, as defined above, linking at least two other groups. The two moieties linked to the heterocycloalkylene can be linked to the same atom or different atoms of the heterocycloalkylene.
- “Aryl” refers to a monocyclic or fused bicyclic, tricyclic or greater, aromatic ring assembly containing 6 to 16 ring carbon atoms. For example, aryl may be phenyl, benzyl or naphthyl. “Arylene” means a divalent radical derived from an aryl group. Aryl groups can be mono-, di- or tri-substituted by one, two or three radicals selected from alkyl, alkoxy, aryl, hydroxy, halogen, cyano, amino, amino-alkyl, trifluoromethyl, alkylenedioxy and oxy-C2-C3-alkylene; all of which are optionally further substituted, for instance as hereinbefore defined; or 1- or 2-naphthyl; or 1- or 2-phenanthrenyl. Alkylenedioxy is a divalent substitute attached to two adjacent carbon atoms of phenyl, e.g. methylenedioxy or ethylenedioxy. Oxy-C2-C3-alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. oxyethylene or oxypropylene. An example for oxy-C2-C3-alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
- In some embodiments the aryl is naphthyl, phenyl or phenyl mono- or disubstituted by alkoxy, phenyl, halogen, alkyl or trifluoromethyl, especially phenyl or phenyl-mono- or disubstituted by alkoxy, halogen or trifluoromethyl, and in particular phenyl.
- Examples of substituted phenyl groups as R are, e.g. 4-chlorophen-1-yl, 3,4-dichlorophen-1-yl, 4-methoxyphen-1-yl, 4-methylphen-1-yl, 4-aminomethylphen-1-yl, 4-methoxyethylaminomethylphen-1-yl, 4-hydroxyethylaminomethylphen-1-yl, 4-hydroxyethyl-(methyl)-aminomethylphen-1-yl, 3-aminomethylphen-1-yl, 4-N-acetylaminomethylphen-1-yl, 4-aminophen-1-yl, 3-aminophen-1-yl, 2-aminophen-1-yl, 4-phenyl-phen-1-yl, 4-(imidazol-1-yl)-phenyl, 4-(imidazol-1-ylmethyl)-phen-1-yl, 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1-yl, 4-(2-methoxyethylaminomethyl)-phen-1-yl and 4-(pyrrolidin-1-ylmethyl)-phen-1-yl, 4-(thiophenyl)-phen-1-yl, 4-(3-thiophenyl)-phen-1-yl, 4-(4-methylpiperazin-1-yl)-phen-1-yl, and 4-(piperidinyl)-phenyl and 4-(pyridinyl)-phenyl optionally substituted in the heterocyclic ring.
- “Arylene” refers to an aryl group, as defined above, linking at least two other groups. The two moieties linked to the arylene are linked to different atoms of the arylene. Arylene groups include, but are not limited to, phenylene.
- “Arylene-oxy” refers to an arylene group, as defined above, where one of the moieties linked to the arylene is linked through an oxygen atom. Arylene-oxy groups include, but are not limited to, phenylene-oxy.
- Similarly, substituents for the aryl and heteroaryl groups are varied and are selected from: -halogen, —OR′, —OC(O)R′, —NR′R″, —SR′, —R′, —CN, —NO2, —CO2R′, —CONR′R″, —C(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″C(O)2R′, —NR′—C(O)NR″R″′, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR′, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —N3, —CH(Ph)2, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″ and R″′ are independently selected from hydrogen, (C1-C8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C1-C4)alkyl, and (unsubstituted aryl)oxy-(C1-C4)alkyl.
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)—(CH2)q—U—, wherein T and U are independently —NH—, —O—, —CH2— or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r—B—, wherein A and B are independently —CH2—, —O—, —NH—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′— or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CH2)r—X—(CH2)r—, where s and t are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituent R′ in —NR′— and —S(O)2NR′— is selected from hydrogen or unsubstituted (C1-C6)alkyl.
- “Heteroaryl” refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, where from 1 to 4 of the ring atoms are a heteroatom each N, O or S. For example, heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any other radicals substituted, especially mono- or di-substituted, by e.g. alkyl, nitro or halogen. Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl represents 2- or 3-thienyl. In some embodiments, quinolinyl represents 2-, 3- or 4-quinolinyl. In some embodiments, isoquinolinyl represents 1-, 3- or 4-isoquinolinyl. In some embodiments, benzopyranyl, benzothiopyranyl can represent 3-benzopyranyl or 3-benzothiopyranyl, respectively. In some embodiments, thiazolyl can represent 2- or 4-thiazolyl. In some embodiments, triazolyl can be 1-, 2- or 5-(1,2,4-triazolyl). In some embodiments, tetrazolyl can be 5-tetrazolyl.
- In some embodiments, heteroaryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl, oxazolyl, indazolyl, or any of the radicals substituted, especially mono- or di-substituted.
- The term “heteroalkyl” refers to an alkyl group having from 1 to 3 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can also be oxidized, such as, but not limited to, —S(O)— and —S(O)2—. For example, heteroalkyl can include ethers, thioethers, alkyl-amines and alkyl-thiols.
- The term “heteroalkylene” refers to a heteroalkyl group, as defined above, linking at least two other groups. The two moieties linked to the heteroalkylene can be linked to the same atom or different atoms of the heteroalkylene.
- “Electrophile” refers to an ion or atom or collection of atoms, which may be ionic, having an electrophilic center, i.e., a center that is electron seeking, capable of reacting with a nucleophile. An electrophile (or electrophilic reagent) is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
- “Nucleophile” refers to an ion or atom or collection of atoms, which may be ionic, having a nucleophilic center, i.e., a center that is seeking an electrophilic center or capable of reacting with an electrophile. A nucleophile (or nucleophilic reagent) is a reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons. A “nucleophilic group” refers to a nucleophile after it has reacted with a reactive group. Non limiting examples include amino, hydroxyl, alkoxy, haloalkoxy and the like.
- “Maleimido” refers to a pyrrole-2,5-dione-1-yl group having the structure:
- which upon reaction with a sulfhydryl (e.g., a thio alkyl) forms an —S-maleimido group having the structure
- For the purpose of this disclosure, “naturally occurring amino acids” found in proteins and polypeptides are L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and or L-valine. “Non-naturally occurring amino acids” found in proteins are any amino acid other than those recited as naturally occurring amino acids. Non-naturally occurring amino acids include, without limitation, the D isomers of the naturally occurring amino acids, and mixtures of D and L isomers of the naturally occurring amino acids. Other amino acids, such as N-alpha-methyl amino acids (e.g. sarcosine), 4-hydroxyproline, desmosine, isodesmosine, 5-hydroxylysine, epsilon-N-methyllysine, 3-methylhistidine, although found in naturally occurring proteins, are considered to be non-naturally occurring amino acids found in proteins for the purpose of this disclosure as they are generally introduced by means other than ribosomal translation of mRNA.
- “Linear” in reference to the geometry, architecture or overall structure of a polymer, refers to polymer having a single polymer arm.
- “Branched,” in reference to the geometry, architecture or overall structure of a polymer, refers to a polymer having 2 or more polymer “arms” extending from a core structure contained within an initiator. The initiator may be employed in an atom transfer radical polymerization (ATRP) reaction. A branched polymer may possess 2 polymer chains (arms), 3 polymer arms, 4 polymer arms, 5 polymer arms, 6 polymer arms, 7 polymer arms, 8 polymer arms, 9 polymer arms or more. Each polymer arm extends from a polymer initiation site. Each polymer initiation site is capable of being a site for the growth of a polymer chain by the addition of monomers. For example and not by way of limitation, using ATRP, the site of polymer initiation on an initiator is typically an organic halide undergoing a reversible redox process catalyzed by a transition metal compound such as cuprous halide. In some embodiments, the halide is a bromine.
- “Pharmaceutically acceptable excipient” refers to an excipient that can be included in compositions and that causes no significant adverse toxicological effect on the patient and is approved or approvable by the FDA for therapeutic use, particularly in humans. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose and the like.
- Therapeutic proteins are administered in an effective regime meaning a dosage, route of administration and frequency of administration that delays the onset, reduces the severity, inhibits further deterioration, and/or ameliorates at least one sign or symptom of a disorder. If a patient is already suffering from a disorder, the regime can be referred to as a therapeutically effective regime. If the patient is at elevated risk of the disorder relative to the general population but is not yet experiencing symptoms, the regime can be referred to as a prophylactically effective regime. In some instances, therapeutic or prophylactic efficacy can be observed in an individual patient relative to historical controls or past experience in the same patient. In other instances, therapeutic or prophylactic efficacy can be demonstrated in a preclinical or clinical trial in a population of treated patients relative to a control population of untreated patients.
- The “biological half-life” of a substance is a pharmacokinetic parameter which specifies the time required for one half of the substance to be removed from a tissue or an organism following introduction of the substance.
- “OG1786” is a 9-arm initiator used for polymer synthesis with the structure shown in
FIG. 30 , which depicts that salt form of OG1786 with trifluoroacetic acid. OG1786 may be used as other salts are used or as the free base. - “OG1801” is an approximately (+/−15%) 750 kDa polymer (either by Mn or Mp) made using OG1786 as an intiator for ATRP synthesis using the monomer HEMA-PC.
- “OG1802” is OG1801 with a maleimide functionality added and is shown in
FIG. 36 wherein each of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is an integer (positive) (from 0 up to about 3000) such that the total molecular weight of the polymer is (Mw) 750,000 t 15% daltons. - Multi-angle light scattering (MALS) is a technique of analyzing macromolecules where the laser light impinges on the molecule, the oscillating electric field of the light induces an oscillating dipole within it. This oscillating dipole will re-radiate light and can be measured using a MALS detector such as Wyatt miniDawn TREOS. The intensity of the radiated light depends on the magnitude of the dipole induced in the macromolecule which in turn is proportional to the polarizability of the macromolecule, the larger the induced dipole, and hence, the greater the intensity of the scattered light. Therefore, in order to analyze the scattering from a solution of such macromolecules, one should know their polarizability relative to the surrounding medium (e.g., the solvent). This may be determined from a measurement of the change, Δn, of the solution's refractive index n with the molecular concentration change, Δc, by measuring the dn/dc (=Δn/Δc) value using a Wyatt Optilab T-rEX differential refractometer. Two molar weight parameters that MALS determination employ are number average molecular weight (Mn) and weight average molecular weight (Mw) where the polydispersity index (PDI) equals Mw divided by Mn. SEC also allows another average molecular weight determination of the peak molecular weight Mp which is defined as the molecular weight of the highest peak at the SEC.
- The PDI is used as a measure of the broadness of a molecular weight distribution of a polymer and bioconjugate which is derived from conjugation of a discrete protein (e.g. OG1950) to a polydisperse biopolymer (e.g., OG1802). For a protein sample, its polydispersity is close to 1.0 due to the fact that it is a product of translation where every protein molecule in a solution is expected to have almost the same length and molar mass. In contrast, due to the polydisperse nature of the biopolymer where the various length of polymer chains are synthesized during the polymerization process, it is very important to determine the PDI of the sample as one of its quality attribute for narrow distribution of molecular weight.
- Size exclusion chromatography (SEC) is a chromatography technique in which molecules in solution are separated by their size. Typically an aqueous solution is applied to transport the sample through the column which is packed with resins of various pore sizes. The resin is expected to be inert to the analyte when passing through the column and the analytes separate from each other based on their unique size and the pore size characteristics of the selected column.
- Coupling the SEC with MALS or SEC/MALS provides accurate distribution of molar mass and size (root mean square radius) as opposed to relying on a set of SEC calibration standards. This type of arrangement has many advantages over traditional column calibration methods. Since the light scattering and concentration are measured for each eluting fraction, the molar mass and size can be determined independently of the elution position. This is particularly relevant for species with non-globular shaped macromolecules such as the biopolymers (OG1802) or bioconjugates (OG1953); such species typically do not elute in a manner that might be described by a set of column calibration standards.
- In some embodiments, a SEC/MALS analysis includes a Waters HPLC system with Alliance 2695 solvent delivery module and Waters 2996 Photodiole Array Detector equipped with a Shodex SEC-HPLC column (7.8×300 mm). This is connected online with a Wyatt miniDawn TREOS and Wyatt Optilab T-rEX differential refractometer. The Empower software from Waters can be used to control the Waters HPLC system and the ASTRA V 6.1.7.16 software from Wyatt can be used to acquire the MALS data from the Wyatt miniDawn TREOS, dn/dc data from the T-rEX detector and the mass recovery data using the A280 absorbance signal from the Waters 2996 Photodiole Array detector. SEC can be carried out at 1 ml/min in 1×PBS pH 7.4, upon sample injection, the MALS and RI signals can be analyzed by the ASTRA software for determination of absolute molar mass (Mp, Mw, Mn) and polydisperse index (PDI). In addition, the calculation also involves the input dn/dc values for polymer and protein as 0.142 and 0.183, respectively. For OG1953 bioconjugates dn/dc value, the dn/dc is calculated based on the weighted MW of the polymer and the protein to be about 0.148 using the formula below:
-
- Where MWpolymer for OG1802 is 800 kDa and the MWprotein for OG1950 is 146 kDa.
- Provided herein are anti-VEGF antibodies and conjugates thereof. In some embodiments, the antibodies themselves are different from other anti-VEGF agents and provide superior results over other anti-VEGF agents. In some embodiments, the anti-VEGF antibody conjugate displays a surprising superiority over other antibodies and/or the expectation of the activity other antibody conjugates.
- Historically, conjugating a molecule to a protein often resulted in a decrease in the protein's binding interaction to its intended target. In some embodiments of the present disclosure, when conjugating to a location that is outside of the active site, the same level of decrease as might have been expected is not necessarily observed. The evidence provided herein shows the opposite effect as to what may have been expected. In some embodiments, and without intending to be limited by theory, the conjugate can be superior to the antibody alone. For example, the interaction of a ligand and its specific receptor is often driven through the stereospecific interaction of the ligand and the receptor, as directed by the interactions of the hydrophilic amino acids on the ligand with the hydrophilic amino acids on the receptor, and water molecules are front and center in those interactions. At the same time, this hydrophilic stereospecificity is further enhanced by de-emphasizing and/or suppressing non-specific hydrophobic interactions that might generally be mediated/created by hydrophobic-to-hydrophobic amino acids.
- In some embodiments, an anti-VEGF antibody conjugate is provided that is capable of blocking at least 90% of an interaction between a VEGF ligand (“VEGFL”) and a VEGF-receptor (“VEGFR”). For example, it can block at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all of the interaction between VEGFR and VEGFL. In some embodiments, the noted blocking occurs at saturating concentrations. In some embodiments, an anti-VEGF antibody conjugate is provided that blocks at least 95% of an interaction between a VEGF ligand and a VEGF-receptor. As an example of such superiority of blocking, see
FIG. 20 , regarding the ability of OG1953 (and antibody conjugate provided herein) to block to a higher degree than Lucentis® (ranibizumab) or Avastin® (bevacizumab) or even the antibody OG1950 (unconjugated). Indeed, this result was unexpected in that while the addition of a polymer to an antibody (to form an antibody conjugate), could be expected to have some or no detrimental impact on binding/activity of the antibody, it was unexpected that it would actually improve the blocking ability of the antibody in this manner. - In some embodiments, the antibodies or conjugates thereof inhibit at least 70, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% of the activity and/or interaction between VEGFR and VEGFL. In some embodiments, the IC50 value can be 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100 nM or less than any one or more of the preceding values. In some embodiments, the KD can be 2*10{circumflex over ( )}-13, 1*10{circumflex over ( )}-13, 1*10{circumflex over ( )}-12, 1*10{circumflex over ( )}-11, 1*10-{circumflex over ( )}10M or less than any one of the preceding values. In some embodiments, the IC50 value can be 1, 5, 10, 20, 30, 40, 50, 60, 70 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, or less than any one of the preceding values.
- In some embodiments, an anti-VEGF antibody is provided that blocks at least 90% of an interaction between a VEGF ligand and a VEGF-receptor. For example, it can block at least 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all of the interaction between VEGFR and VEGFL. As an example of such superiority of blocking, see
FIG. 20 , regarding the ability of OG1950 (and antibody provided herein) to block to a higher degree than Lucentis® (ranibizumab) or Avastin® (bevacizumab). - In some embodiments, other antibodies, such as Lucentis® (ranibizumab) or Avastin® (bevacizumab) can be conjugated to one or more of the polymers as described herein, by one or more of the processes described herein. In some embodiments, any antibody, or fragment thereof, can be conjugated to one or more of the polymers as described herein, by one or more of the processes described herein.
- In some embodiments the antibody comprises a heavy chain amino acid variable region that comprises
SEQ ID NO 1 and a light chain amino acid variable region that comprises SEQ ID NO. 2. In some embodiments, the antibody is conjugated to one or more of the polymers provided herein. In some embodiments, the conjugated antibody is at least 90% identical to SEQ ID NO: 1 and/or 2. In some embodiments, the antibody contains the 6 CDRs within SEQ ID NO:1 and SEQ ID NO: 2, as well as a point mutation of L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the conjugated antibody is at least 90% identical to SEQ ID NO: 1 and/or 2 and includes the following mutations: L234A, L235A, and G237A (EU numbering), and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering). - In some embodiments an antibody that binds to VEGF-A is provided. The antibody comprises: a
CDR H1 that is theCDR H1 in SEQ ID NO: 1, aCDR H2 that is theCDR H2 in SEQ ID NO: 1, aCDR H3 that is theCDR H3 in SEQ ID NO: 1, aCDR L1 that is theCDR L1 in SEQ ID NO: 2, aCDR L2 that is theCDR L2 in SEQ ID NO: 2, aCDR L3 that is theCDR L3 in SEQ ID NO: 2, at least one of the following mutations: L234A, L235A, and G237A (EU numbering), and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering). - As will be appreciated by one of skill in the art, inlight of the present specification, any of the antibodies provided herein can be conjugated to any of the polymers provided herein and/or any antibody provided herein can have a cysteine added such that it allows for site specific conjugation to a polymer.
- “VEGF” or “vascular endothelial growth factor” is a human vascular endothelial growth factor that affects angiogenesis or an angiogenic process. In particular, the term VEGF means any member of the class of growth factors that (i) bind to a VEGF receptor such as VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), or VEGFR-3 (FLT-4); (ii) activates a tyrosine kinase activity associated with the VEGF receptor; and (iii) thereby affects angiogenesis or an angiogenic process.
- The VEGF family of factors is made up of five related glycoproteins: VEGF-A (also known as VPE), -B, -C, -D and PGF (placental growth factor). Of these, VEGF-A is the most well studied and is the target of anti-angiogenic therapy. Ferrara et al, (2003) Nat. Med. 9:669-676. VEGF-A exists as a number of different isotypes which are generated both by alternative splicing and proteolysis: VEGF-A206, VEGF-A189, VEGF-A165, and VEGF-A121. The isoforms differ in their ability to bind heparin and non-signaling binding proteins called neuropilins. The isoforms are all biologically active as dimers.
- The various effects of VEGF are mediated by the binding of a VEGF, e.g., VEGF-A (P15692), -B (P49766), -C(P49767) and -D (Q43915), to receptor tyrosine kinases (RTKs). The VEGF family receptors belong to class V RTKs and each carry seven Ig-like domains in the extracellular domain (ECD). In humans, VEGF binds to three types of RTKs: VEGFR-1 (Flt-1) (P17948), VEGFR-2 (KDR, Flk-1) (P935968) and VEGFR-3 (Flt-4) (P35916). Unless otherwise apparent from the context reference to a VEGF means any of VEGF-A, -B, -C, -D, and PGF, in any of the natural isoforms or natural variants or induced variants having at least 90, 95, 98 or 99% or 100% sequence identity to a natural form. In some embodiments, such VEGFs are human VEGFs. Likewise reference to a VEGFR means any of VEGR-1, R-2 or R-3, including any natural isoform or natural variant, or an induced variant having at least 90, 95, 98 or 99% or 100% sequence identity to a natural sequences.
- VEGF antagonist therapies have been approved for the treatment of certain cancers and wet AMD. Bevacizumab (AVASTIN, Genentech/Roche) is a humanized mouse monoclonal antibody that binds to and neutralizes human VEGF, in particular to all isoforms of VEGF-A and to bioactive proteolytic fragments of VEGF-A. See, e.g., Ferrara N, Hillan K J, Gerber H P, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3(5):391-400. Bevacizumab has been approved for the treatment of certain cancers. The protein sequence of the heavy and light chains of bevacizumab (DrugBank DB00112) are set forth in SEQ ID NO. 3 (heavy) and SEQ ID NO. 4 (light).
- Bevacizumab variable light chain CDRs are CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13) and CDRL3: QQYSTVPWT (SEQ ID NO: 14). Bevacizumab variable heavy chain CDRs are CDRH1: GYTFTNYGMN, CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPHYYGSSHWYFDV. CDRs are defined by Kabat except
CDR H1 uses the composite Kabat/Chothia definition. In some embodiments, a cysteine can be added to the Bevacizumab sequence and the antibody (and/or a variant that includes the 6 CDRs of Bevacizumab) can be conjugated to any one or more of the polymers provided herein. - Another anti-VEGF molecule, derived from the same mouse monoclonal antibody as bevacizumab has been approved as a treatment for wet AMD: ranibizumab (LUCENTIS® (ranibizumab), Genentech/Roche). Ranibizumab is an antibody fragment or Fab. Ranibizumab was produced by affinity maturation of the variable heavy and light chains of bevacizumab. The sequence of the heavy and light chains of ranibizumab (as published by Novartis) is set forth in SEQ ID NO. 5 and 6 respectively. In some embodiments, a cysteine can be added to the ranibizumab sequence and the antibody (and/or a variant that includes the 6 CDRs of ranibizumab) can be conjugated to any one or more of the polymers provided herein.
- The Ranibizumab CDRS are the same as Bevacizumab except where an improvement was added after affinity maturation: Ranibizumab variable light chain CDRs are CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13) and CDRL3: QQYSTVPWT (SEQ ID NO: 14). Ranibizumab variable heavy chain CDRs are CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11).
- In some embodiments, an antibody conjugate is presented having an anti-VEGF-A antibody bonded at a cysteine outside a variable region of the antibody to a phosphorylcholine containing polymer, wherein the cysteine has been added via recombinant DNA technology. In some embodiments, the polymer is bonded to a single cysteine. In some embodiments, “added by recombinant DNA technology” means that the cysteine residue replaces a non-cysteine amino acid that occurs in the same position in a known or existing antibody or in a consensus antibody sequence. Thus, for example where the antibody is an IgG1 and the heavy chain possess a leucine at
EU position 443, the leucine is replaced via recombinant DNA technology with a cysteine (L443C, EU numbering, or 449C in SEQ ID NO: 1). Correspondingly, the native IgG1 sequence at EU position 347 is Q (glutamine) and the Q is replaced with cysteine via recombinant DNA technology to yield Q347C. - In some embodiments, the anti-VEGF-A antibody comprises a light chain and a heavy chain where the heavy chain has an Fc region. In some embodiments, the cysteine is in the Fc region and the anti-VEGF-A antibody is an immunoglobulin G (IgG). In some embodiments, the anti-VEGF-A heavy chain has CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and position 221 (via sequential counting as in SEQ ID NO. 3) is T, and the anti-VEGF-A light chain has CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and
Kabat position 4 is L. - In some embodiments, the anti-VEGF-A heavy chain isotype is IgG1. In some embodiments, the IgG1 constant domain has one or more mutations relative to an IgG1 constant domain (e.g. constant region of SEQ ID NO. 3) to modulate effector function. In some embodiments, the effector function mutations are one or more of the following: (EU numbering) E233X, L234X, L235X, G236X, G237X, A327X, A330X, and P331X wherein X is any natural or unnatural amino acid. In some embodiments, the mutations are selected from the group consisting of (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S. In some embodiments, antibody conjugate has the following mutations (EU numbering): L234A, L235A, and G237A.
- In some embodiments, the cysteine residue is in the anti-VEGF-A heavy chain and is Q347C (EU numbering) or L443C (EU numbering). In some embodiments, the cysteine residue is L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1 and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2.
- In some embodiments, the phosphorylcholine containing polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers as set forth below:
- Such that the polymer comprises the following repeating units:
- where n is an integer from 1 to 3000 and the wavy lines indicate the points of attachment between monomer units in the polymer.
- In some embodiments, the polymer has three or more arms, or is synthesized with an initiator comprising 3 or more polymer initiation sites. In some embodiments, the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms, or is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 polymer initiation sites. More preferably, the polymer has 3, 6, or 9 arms, or is synthesized with an initiator comprising 3, 6, or 9 polymer initiation sites. In some embodiments, the polymer has 9 arms, or is synthesized with an initiator comprising 9 polymer initiation sites.
- In some embodiments, the polymer that is added has a molecular weight between about 300,000 and about 1,750,000 Da (SEC-MALs). In some embodiments, the polymer has a molecular weight between about 500,000 and about 1,000,000 Da. In some embodiments, the polymer has a molecular weight of between about 600,000 to about 900,000 Da. In some embodiments, the polymer has a molecular weight of between about 750,000 to about 850,000 Da. In some embodiments, the polymer has a molecular weight of between about 800,000 to about 850,000 Da. In some embodiments, the polymer has a molecular weight of between about 750,000 to about 800,000 Da.
- In some embodiments, any of the antibodies described herein can be further conjugated to a polymer to form a bioconjugate. The molecular weight of the bioconjugate (in total, SEC-MALs) can be between about 350,000 and 2,000,000 Daltons, for example, between about 450,000 and 1,900,000 Daltons, between about 550,000 and 1,800,000 Daltons, between about 650,000 and 1,700,000 Daltons, between about 750,000 and 1,600,000 Daltons, between about 850,000 and 1,500,000 Daltons, between about 900,000 and 1,400,000 Daltons, between about 950,000 and 1,300,000 Daltons, between about 900,000 and 1,000,000 Daltons, between about 1,000,000 and 1,300,000 Daltons, between about 850,000 and 1,300,000 Daltons, between about 850,000 and 1,000,000 Daltons, and between about 1,000,000 and 1,200,000 Daltons.
- In some embodiments, the antibody conjugate is purified. In some embodiments, the polymer is aspect of the antibody conjugate is polydisperse, i.e. the polymer PDI is not 1.0. In some embodiments, the PDI is less than 1.5. In some embodiments, the PDI is less than 1.4. In some embodiments, the PDI is less than 1.3. In some embodiments the PDI is less than 1.2. In some embodiments the PDI is less than 1.1.
- In some embodiments, the antibody conjugate has an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C449 in SEQ ID NO. 1 to the polymer. In some embodiments, the polymer has 9 arms and has a molecular weight of between about 600,000 to about 1,000,000 Da.
- In some embodiments, the antibody conjugate has an anti-VEGF-A immunoglobulin G (IgG) bonded to a polymer, which polymer comprises MPC monomers, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 1, and the sequence of the anti-VEGF-A light chain is SEQ ID NO. 2, and wherein the antibody is bonded only at C443 (EU numbering, or 449C in SEQ ID NO: 1) to the polymer. In some embodiments, the polymer has 9 arms and has a molecular weight of between about 600,000 to about 1,000,000 Da.
- In some embodiments, the antibody conjugate has the following structure:
- wherein: each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C449 of SEQ ID NO: 1, which bond is depicted on one of the heavy chains; PC is, - where the curvy line indicates the point of attachment to the rest of the polymer; wherein X=a) OR where R=H, Methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n6, n7, n8 and n9 is 2500 plus or minus 10%. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500. In some embodiments, X=OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R7, carbonyl —CCO—R7, —CO—NR8R9, —(CH2)n—COOR7, —CO—(CH)n—COOR7, —(CH2)n—NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each R7, R8 and R9 is separately selected from the group consisting of a hydrogen atom, halogen atom, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, a 5-membered ring, and a 6-membered ring.
- In some embodiments, the antibody conjugate has the following structure:
- wherein: each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443 (EU numbering, or 449C in SEQ ID NO: 1), which bond is depicted on one of the heavy chains; PC is, - here the curvy line indicates the point of attachment to the rest of the polymer; wherein X=a) OR where R=H, Methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n6, n7, n8 and n9 is 2500 plus or minus 10%. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In certain embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500. In some embodiments, X=OR, where R is a sugar, an aminoalkyl, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, —CO—O—R7, carbonyl —CCO—R7, —CO—NR8R9, —(CH2)n—COOR7, —CO—(CH)n—COOR7, —(CH2)n—NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each R7, R8 and R9 is separately selected from the group consisting of a hydrogen atom, halogen atom, mono-substituted, poly-substituted or unsubstituted variants of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl, a 5-membered ring, and a 6-membered ring.
- In some embodiments, the antibody conjugate is present in a liquid formulation. In some embodiments, the antibody conjugate is combined with a pharmaceutically acceptable carrier.
- In some embodiments, an anti-VEGF-A antibody is presented. The anti-VEGF-A antibody heavy chain has at least the following CDR sequences: CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11). In some embodiments, the anti-VEGF-A heavy chain has those CDRs and in addition has threonine (T) at position 221 (via sequential counting as in SEQ ID NO. 3). In some embodiments, the anti-VEGF-A light chain has at least the following CDRs: CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13) and CDRL3: QQYSTVPWT (SEQ ID NO: 14). In some embodiments, the anti-VEGF-A antibody has those CDRs and in addition has leucine (L) at
Kabat position 4. In some embodiments, the isotype of the anti-VEGF-A antibody heavy chain, is IgG1 and has a CH1, hinge, CH2 and CH3 domains. In some embodiments the light chain isotype is kappa. - In some embodiments, the IgG1 domain of the anti-VEGF-A antibody has one or more mutations to modulate effector function, such as ADCC, ADCP, and CDC. In some embodiments, the IgG1 mutations reduce effector function. In some embodiments the amino acids to use for effector function mutations include (EU numbering) E233X, L234X, L235X, G236X, G237X, G236X, D270X, K322X, A327X, P329X, A330X, A330X, P331X, and P331X, in which X is any natural or non-natural amino acid. In some embodiments, the mutations include one or more of the following: E233P, L234V, L234A, L235A, G237A, A327G, A330S and P331S (EU numbering). In some embodiments, the anti-VEGF-A heavy chain has the following mutations (EU numbering): L234A, L235A and G237A. In some embodiments, the number of effector function mutations relative to a natural human IgG1 sequence is no more than 10. In some embodiments the number of effector function mutations reparative to a natural human IgG1 sequence is no more than 5, 4, 3, 2 or 1. In some embodiments, the antibody has decreased Fc gamma binding and/or complement C1q binding, such that the antibody's ability to result in an effector function is decreased. This can be especially advantageous for ophthalmic indications/disorders.
- In some embodiments, the anti-VEGF-A antibody comprises one or more of the following amino acid mutations: L234A, L235A, G237A (EU numbering), and L443C (EU numbering, or 449C in SEQ ID NO: 1).
- In some embodiments, the anti-VEGF-A antibody is or is part of a human immunoglobulin G (IgG1).
- In some embodiments, the VEGF-A antibody comprises a heavy chain constant domain that comprises one or more mutations that reduce an immune-mediated effector function.
- In some embodiments an anti-VEGF-A antibody is provided. The anti-VEGF-antibody comprises a heavy chain that comprises a
CDR H1 comprising the sequence GYDFTHYGMN (SEQ ID NO: 9), aCDR H2 comprising the sequence WINTYTGEPTYAADFKR (SEQ ID NO: 10), aCDR H3 comprising the sequence YPYYYGTSHWYFDV (SEQ ID NO: 11), aCDR L1 comprising the sequence SASQDISNYLN (SEQ ID NO: 12), aCDR L2 comprising the sequence FTSSLHS (SEQ ID NO: 13), and aCDR L3 comprising the sequence QQYSTVPWT (SEQ ID NO: 14). - Alternatively, the IgG domain can be IgG2, IgG3 or IgG4 or a composite in which a constant regions is formed from more than one of these isotypes (e.g., CH1 region from IgG2 or IgG4, hinge, CH2 and CH3 regions from IgG1). Such domains can contain mutations to reduce and/or modulate effector function at one or more of the EU position mentioned for IgG1. Human IgG2 and IgG4 have reduced effector functions relative to human IgG1 and IgG3.
- The anti-VEGF-A heavy chain has a cysteine residue added as a mutation by recombinant DNA technology which can be used to conjugate a half-life extending moiety. In some embodiments, the mutation is (EU numbering) Q347C (EU numbering) and/or L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the mutation is L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the stoichiometry of antibody to polymer is 1:1; in other words, a conjugate has one molecule of antibody conjugated to one molecule of polymer.
- The half-life of the anti-VEGF-A antibodies can be extended by attachment of a “half-life (“half life”) extending moieties” or “half-life (“half life”) extending groups”. Half-life extending moieties include peptides and proteins which can be expressed in frame with the biological drug of issue (or conjugated chemically depending on the situation) and various polymers which can be attached or conjugated to one or more amino acid side chain or end functionalities such as —SH, —OH, —COOH, —CONH2, —NH2, or one or more N- and/or O-glycan structures. Half-life extending moieties generally act to increase the in vivo circulatory half-life of biologic drugs.
- Examples of peptide/protein half-life extending moieties include Fc fusion (Capon D J, Chamow S M, Mordenti J, et al. Designing CD4 immunoadhesions for AIDS therapy. Nature. 1989. 337:525-31), human serum albumin (HAS) fusion (Yeh P, Landais D, Lemaitre M, et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA. 1992. 89:1904-08), carboxy terminal peptide (CTP) fusion (Fares F A, Suganuma N. Nishimori K, et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA. 1992. 89:4304-08), genetic fusion of non-exact repeat peptide sequence (XTEN) fusion (Schellenberger V, Wang C W, Geething N C, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009. 27:1186-90), elastin like peptide (ELPylation) (MCpherson D T, Morrow C, Minehan D S, et al. Production and purification of a recombinant elastomeric polypeptide, G(VPGVG19-VPGV, from Escherichia coli. Biotechnol Prog. 1992. 8:347-52), human transferrin fusion (Prior C P, Lai C-H, Sadehghi H et al. Modified transferrin fusion proteins. Patent WO2004/020405. 2004), proline-alanine-serine (PASylation) (Skerra A, Theobald I, Schlapsky M. Biological active proteins having increased in vivo and/or vitro stability. Patent WO2008/155134 A1. 2008), homo-amino acid polymer (HAPylation) (Schlapschy M, Theobald I, Mack H, et al. Fusion of a recombinant antibody fragment with a homo-amino acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel. 2007. 20:273-84) and gelatin like protein (GLK) fusion (Huang Y-S, Wen X-F, Zaro J L, et al. Engineering a pharmacologically superior form of granulocyte-colony-stimulating-factor by fusion with gelatin-like protein polymer. Eur J. Pharm Biopharm. 2010. 72:435-41).
- Examples of polymer half-life extending moieties include polyethylene glycol (PEG), branched PEG, PolyPEG® (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxylethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrate, polysaccharides, pullulane, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl-dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG), polyoxazoline, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylate, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic acid anyhydride, polystyrene-co-maleic acid anhydride, poly(1-hydroxymethyethylene hydroxymethylformal) (PHF), a zwitterionic polymer, a phosphorylcholine containing polymer and a polymer comprising MPC, Poly (Glyx-Sery), Hyaluronic acid (HA), Heparosan polymers (HEP), Fleximers, Dextran, and Poly-sialic acids (PSA).
- In one embodiment a half-life extending moiety can be conjugated to an antibody via free amino groups of the protein using N-hydroxysuccinimide (NHS) esters. Reagents targeting conjugation to amine groups can randomly react to E-amine group of lysines, α-amine group of N-terminal amino acids, and S-amine group of histidines.
- However, the anti-VEGF-A antibodies disclosed herein have many amine groups available for polymer conjugation. Conjugation of polymers to free amino groups, thus, might negatively impact the ability of the antibody proteins to bind to VEGF.
- In some embodiments, a half-life extending moiety is coupled to one or more free SH groups using any appropriate thiol-reactive chemistry including, without limitation, maleimide chemistry, or the coupling of polymer hydrazides or polymer amines to carbohydrate moieties of the antibody after prior oxidation. In some embodiments maleimide coupling is used In some embodiments, coupling occurs at cysteines naturally present or introduced via genetic engineering.
- In some embodiments, polymers are covalently attached to cysteine residues introduced into anti-VEGF-A antibodies by site directed mutagenesis. In some embodiments, the cysteine residues are employed in the Fc portion of the antibody. In some embodiments, the sites to introduce cysteine residues into an Fc region are provided in WO 2013/093809, U.S. Pat. No. 7,521,541, WO 2008/020827, U.S. Pat. Nos. 8,008,453, 8,455,622 and US2012/0213705, incorporated herein by reference for all purposes. In some embodiments, the cysteine mutations are Q347C (EU numbering) and L443C referring to the human IgG heavy chain by EU numbering.
- In some embodiments, conjugates of antibody and high MW polymers serving as half-life extenders are provided. In some embodiments, a conjugate comprises an antibody that is coupled to a zwitterionic polymer wherein the polymer is formed from one or more monomer units and wherein at least one monomer unit has a zwitterionic group is provided. In some embodiments, the zwitterionic group is phosphorylcholine.
- In some embodiments, one of the monomer units is HEMA-PC. In some embodiments, a polymer is synthesized from a single monomer which is HEMA-PC.
- In some embodiments, some antibody conjugates have 2, 3, or more polymer arms wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 polymer arms wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 3, 6 or 9 arms. In some embodiments, the conjugate has 9 arms.
- In some embodiments, polymer-antibody conjugates have a polymer portion with a molecular weight of between 100,000 and 1,500,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 500,000 and 1,000,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 to 800,000 Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 and 850,000 Da and has 9 arms. When a molecular weight is given for an antibody conjugated to a polymer, the molecular weight will be the addition of the molecular weight of the protein, including any carbohydrate moieties associated therewith, and the molecular weight of the polymer.
- In some embodiments, an anti-VEGF-A antibody has a HEMA-PC polymer which has a molecular weight measured by Mw of between about 100 kDa and 1650 kDa is provided. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 500 kDa and 1000 kDa. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 600 kDa to about 900 kDa. In some embodiments, the polymer molecular weight as measured by Mw is 750 kDa plus or minus 15%.
- In some embodiments, the polymer is made from an initiator suitable for ATRP having one or more polymer initiation sites. In some embodiments, the polymer initiation site has a 2-bromoisobutyrate site. In some embodiments, the initiator has 3 or more polymer initiation sites. In some embodiments, the initiator has 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites. In some embodiments, the initiator has 3, 6 or 9 polymer initiation sites. In some embodiments, the initiator has 9 polymer initiation sites. In some embodiments, the initiator is OG1786.
- The anti-VEGF-A antibodies can be produced by recombinant expression including (i) the production of recombinant DNA by genetic engineering, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by, for example and without limitation, transfection, electroporation or microinjection, (iii) cultivating the transformed cells, (iv) expressing antibody, e.g. constitutively or on induction, and (v) isolating the antibody, e.g. from the culture medium or by harvesting the transformed cells, in order to (vi) obtain purified antibody.
- The anti-VEGF-A antibodies can be produced by expression in a suitable prokaryotic or eukaryotic host system characterized by producing a pharmacologically acceptable antibody molecule. Examples of eukaryotic cells are mammalian cells, such as CHO, COS, HEK 293, BHK, SK-Hip, and HepG2. Other suitable expression systems are prokaryotic (e.g., E. coli with pET/BL21 expression system), yeast (Saccharomyces cerevisiae and/or Pichia pastoris systems), and insect cells.
- A wide variety of vectors can be used for the preparation of the antibodies disclosed herein and are selected from eukaryotic and prokaryotic expression vectors. Examples of vectors for prokaryotic expression include plasmids such as, and without limitation, preset, pet, and pad, wherein the promoters used in prokaryotic expression vectors include one or more of, and without limitation, lac, trc, trp, recA, or araBAD. Examples of vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as, and without limitation, pAO, pPIC, pYES, or pMET, using promoters such as, and without limitation, AOX1, GAP, GAL1, or AUG1; (ii) for expression in insect cells, vectors such as and without limitation, pMT, pAc5, pIB, pMIB, or pBAC, using promoters such as and without limitation PH, p10, MT, Ac5, OpIE2, gp64, or polh, and (iii) for expression in mammalian cells, vectors such as, and without limitation, pSVL, pCMV, pRc/RSV, pcDNA3, or pBPV, and vectors derived from, in one aspect, viral systems such as and without limitation vaccinia virus, adeno-associated viruses, herpes viruses, or retroviruses, using promoters such as and without limitation CMV, SV40, EF-1, UbC, RSV, ADV, BPV, and beta-actin.
- In some embodiments, a method is presented of preparing a therapeutic protein-half life extending moiety conjugate having the step of conjugating a therapeutic protein which has a cysteine residue added via recombinant DNA technology to a half-life extending moiety having a sulfhydryl specific reacting group selected from the group consisting of maleimide, vinylsulfones, orthopyridyl-disulfides, and iodoacetamides to provide the therapeutic protein-half life extending moiety conjugate.
- In some embodiments a method of preparing the OG1953 antibody conjugate from OG1950 is provided. As shown in
FIG. 18 , the method comprises reducing the OG1950 protein with a 50× molar excess of the TCEP reducing agent (FIG. 18 ). After reduction, the antibody is oxidized to produce a decapped OG1950 antibody where the inter- and intra-light and heavy chain disulfide bonds naturally occurring in the antibody are formed, but the engineered Cysteine on the heavy chain position L443C (EU numbering, or 449C in SEQ ID NO: 1) remains to be decapped (FIG. 18 ). The OG1950 is then conjugated by adding an excipient and adding 5-10× molar excess of a maleimide biopolymer. (FIG. 18 ). The biopolymer links to the OG1950 antibody through a covalent thiolether linkage (FIG. 18 ). After conjugation, the OG19503 antibody conjugate is purified with both unconjugated antibody and polymer removed (FIG. 18 ). - The protein and process described above can be varied as well. Thus, in some embodiments, a process for preparing a conjugated protein (which need not be an antibody or an anti-VEGF antibody) is provided. The process includes reducing one or more cysteines in a protein to form a decapped protein in a solution. After reducing the one or more cysteines the decapped protein is reoxidized to restore at least one disulfide linkage in the reduced protein while ensuring that an engineered cysteine residue in the protein remains in a free thiol form to form a reoxidized decapped protein in the solution. At least one excipient is then added to the solution. The excipient reduces a polymer induced protein precipitation. After the excipient is added, a polymer is added to the solution, which is conjugated to the reoxidized decapped protein at the engineered cysteine residue to form a conjugated protein.
- In some embodiments, the molar excess of the reducing agent can be altered to any amount that functions. In some
embodiments - In some embodiments, the purification step is optional.
- In some embodiments, the method of making an antibody conjugate comprises conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer. In some embodiments the method comprises the steps of conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer. The anti-VEGF-A antibody comprises an amino residue added via recombinant DNA technology. In some embodiments, the added amino acid residue is a cysteine residue. In some embodiments, the cysteine residue is added outside a variable region of the antibody. The cysteine residue can be added to either the heavy chain or light chain of the antibody.
- In some embodiments, the polymer comprises or consists of a phosphorylcholine containing polymer. In some embodiments, the phosphorylcholine containing polymer comprises a sulfhydryl specific reacting group selected from the group consisting of a maleimide, a vinylsulfone, an orthopyridyl-disulfide, and an iodoacetamide. In some embodiments, the sulfhydryl specific reacting group on the phosphorylcholine containing polymer reacts with the cysteine residue on the anti-VEGF-A antibody to make the antibody conjugate.
- In some embodiments, the protein to be conjugated can be an antibody, an antibody protein fusion, or a binding fragment thereof. In some embodiments, the protein is not an antibody but is an enzyme, a ligand, a receptor, or other protein or mutants or variants thereof. In some embodiments, the native protein contains at least one disulfide bond and at least one non-native cysteine.
- In some embodiments, the excipient can be an acid or a base. In some embodiments, the excipient is a detergent, a sugar, or a charged amino acid. In some embodiments, the excipient assists in keeping the protein in solution during the conjugation to the polymer. In some embodiments, the excipient is added to the solution containing the protein, prior to the addition of the polymer to the solution that contains the protein.
- In some embodiments, the reaction occurs under aqueous conditions between about
pH 5 to about pH 9. In some embodiments, the reaction occurs between 6.0 and 8.5, between 6.5 and 8.0 or between 7.0 and 7.5. - In some embodiments, the polymer is conjugated to the protein at 2-37 degrees Celsius. In some embodiments, the conjugation occurs at 0-40 degrees Celsius, 5-35 degrees Celsius, 10-30 degrees Celsius, and 15-25 degrees Celsius.
- In some embodiments, the conjugated proteins described herein can be contacted to an ion exchange medium or hydrophobic interaction chromatography or affinity chromatography medium for purification (to remove the conjugated from the unconjugated). In some embodiments, the ion exchange medium, hydrophobic interaction chromatography, and/or affinity chromatography medium separates the conjugated protein from the free polymer and from the reoxidized decapped protein.
- In some embodiments, the processes described herein and outlined in
FIG. 18 involves an excipient that is capable of facilitating and/or maintaining a solubility system. In some embodiments, the process allows the solution to maintain the solubility of the two components meant to interact. This can include the solubility of the protein and the polymer and then the end conjugate as well. In some embodiments, without the excipient approach, the issue can be that while the protein it is soluble, when the biopolymer is added, the solubility of the solution (e.g., protein) drops and it crashes/precipitates out of solution. Of course, when the protein crashes out, it is not available to conjugate efficiently with the biopolymer. Thus, an excipient can be employed to maintain the solubility of the protein in the presence of the biopolymer so the two can couple to form the protein conjugate (or as depicted inFIG. 18 , an antibody conjugate). This also allows for the solubility of the conjugate to be maintained. - In some embodiments, the polymers disclosed herein can comprise one or more of the following: a zwitterion, a phosphorylcholine, or a PEG linker bridging a center of a polymer branching point to the maleimide functional group. In some embodiments, any of the polymers provided herein can be added to a protein via the methods provided herein.
- In some embodiments, any of the proteins provided herein can be conjugated to any of the polymers provided herein via one or more of the methods provided herein.
- In some embodiments, the process(es) provided herein allow(s) for larger scale processing to make and purify protein and/or antibody conjugates. In some embodiments, the volume employed is at least 1 liter, for example 1, 10, 100, 1,000, 5,000, 10,000, liters or more. In some embodiments, the amount of the antibody conjugate produced and/or purified can be 0.1, 1, 10, 100, 1000, or more grams.
- In some embodiments, the therapeutic protein may be any of the anti-VEGF-A antibodies described herein having a cysteine residue added via recombinant DNA technology. In some embodiments, the anti-VEGF antibody heavy chain has the following CDRs: CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11). The heavy chain can also have threonine (T) at position 221 (via sequential counting as in SEQ ID NO. 3). In some embodiments, the anti-VEGF light chain has the following CDRs: CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14). The anti-VEGF-A light chain can also have leucine (L) at
Kabat position 4. - In some embodiments, the anti-VEGF-A antibody is IgG1. In some embodiments, the heavy chain has one or more mutations to modulate effector function. In some embodiments, the mutations are to one or more of the following amino acid positions (EU numbering): E233, L234, L235, G236, G237, A327, A330, and P331. In some embodiments, the mutations are selected from the group consisting of: E233P, L234V, L234A, L235A, G237A, A327G, A330S and P331S (EU numbering). In some embodiments, the mutations are (EU numbering) L234A, L235A and G237A.
- In some embodiments, the cysteine residue added to the therapeutic protein via recombinant DNA technology should not be involved in Cys-Cys disulfide bond pairing. In this regard, therapeutic proteins may be dimeric. So for example, an intact anti-VEGF-A antibody has two light chains and two heavy chains. If a Cys residue is introduced into the heavy chain for instance, the intact antibody will have two such introduced cysteines at identical positions and the possibility exists that these cysteine residues will form intra-chain disulfide bonds. If the introduced cysteine residues form Cys-Cys disulfide bonds or have a propensity to do so, that introduced Cys residue will not be useful for conjugation. It is know in the art how to avoid positions in the heavy and light chains that will give rise to intra-chain disulfide pairing. See, e.g., U.S. Patent Application No. 2015/0158952.
- In some embodiments, the cysteine residue introduced via recombinant DNA technology is selected from the group consisting of (EU numbering) Q347C and L443C. In some embodiments, the cysteine residue is L443C (EU numbering, or 449C in SEQ ID NO: 1). In some embodiments, the heavy chain the antibody has the amino acid sequence set forth in SEQ ID NO. 1 and the light chain has the amino acid sequence of SEQ ID NO. 2.
- In some embodiments, the sulfhydral specific reacting group is maleimide.
- In some embodiments, the half-life extending moiety is selected from the group consisting of polyethylene glycol (PEG), branched PEG, PolyPEG® (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxylethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrate, polysaccharides, pullulane, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl-dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG), polyoxazoline, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylate, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic acid anyhydride, polystyrene-co-maleic acid anhydride, poly(1-hydroxymethyethylene hydroxymethylformal) (PHF), a zwitterionic polymer, a phosphorylcholine containing polymer and a polymer comprising 2-methacryloyloxy-2′-ethyltrimethylammoniumphosphate (MPC).
- In some embodiments, the half-life extending moiety is a zwitterionic polymer. S In some embodiments, the zwitterion is phosphorylcholine, i.e. a phosphorylcholine containing polymer. In some embodiments, the polymer is composed of MPC units.
- In some embodiments, the MPC polymer has three or more arms. In some embodiments, the MPC polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms. In some embodiments, the MPC polymer has 3, 6, or 9 arms. In some embodiments, the MPC polymer has 9 arms. In some embodiments, the polymer is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more polymer initiation sites
- In some embodiments, the MPC polymer has a molecular weight between about 300,000 and 1,750,000 Da. In some embodiments, the MPC polymer has a molecular weight between about 500,000 and 1,000,000 Da or between about 600,000 to 900,000 Da.
- In some embodiments, the method of preparing a therapeutic protein-half life extending moiety conjugate has an additional step of contacting the therapeutic protein with a thiol reductant under conditions that produce a reduced cysteine sulfhydryl group. As discussed above, it is preferable that the cysteine residue added via recombinant DNA technology are unpaired, i.e. are not involved in Cys-Cys intra chain disulfide bonds or are not substantially involved in such bonding. However, Cys residues which are not involved in such Cys-Cys disulfide bonding and are free for conjugation are known to react with free cysteine in the culture media to form disulfide adducts. See, e.g., WO 2009/052249. A cysteine so derivatized will not be available for conjugation. To free the newly added cysteine from the disulfide adduct, the protein after purification is treated with a reducing agent, e.g., dithiothreitol. However, such treatment with a reducing agent will reduce all of the cysteine residues in the therapeutic protein, including native cysteines many of which are involved in inter and intra chain Cys-Cys disulfides bonds. The native Cys-Cys disulfides are generally crucial to protein stability and activity and they should be reformed. In some embodiments, all native (e.g., inter and intra) Cys-Cys disulfides are reformed.
- To reform native inter and intra-chain disulfide residues, after reduction to remove the cysteine disulfide adducts, the therapeutic protein is exposed to oxidizing conditions and/or oxidizing agents for a prescribed period of time, e.g., overnight. In some embodiments, ambient air exposure overnight can be used to achieve reformation of the native disulfide bonds. In some embodiments, an oxidizing agent is employed to restore the native disulfides. In some embodiments, the oxidizing agent is selected from the group consisting of aqueous CuSO4 and dehydroascorbic acid (DHAA). In some embodiments, the oxidizing agent is DHAA. In some embodiments, the range of DHAA used is in the range of 5-30 equivalents. In some embodiments, the range is 10-20 equivalents. In some embodiments, the range is 15 equivalents.
- In some embodiments, the thiol reductant is selected from the group consisting of: Tris[2-carboxyethyl]phosphine hydrochloride (TCEP), dithiothreitol (DTT), dithioerythritol (DTE), sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), β-mercaptoethanol (BME), cysteine hydrochloride and cysteine. In some embodiments, the thiol reductant is TCEP.
- In some embodiments, the thiol reductant concentration is between 1 and 100 fold molar excess relative to the therapeutic protein concentration. In some embodiments, the thiol reductant concentration is between 20 to 50 fold molar excess relative to the therapeutic protein concentration. In some embodiments, the thiol reductant is removed following incubation with the therapeutic protein prior to oxidation of the therapeutic protein.
- In some embodiments, the method for conjugating a therapeutic protein to a half-life extending moiety has a further step of purifying the therapeutic protein conjugate after conjugation. In some embodiments, the therapeutic protein conjugate is purified using a technique selected from the group consisting of ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, and affinity chromatography or combinations thereof.
- In some embodiments, the therapeutic protein conjugate retains at least 20% biological activity relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 50% biological activity relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 90% biological activity relative to native therapeutic protein.
- In some embodiments, the therapeutic protein conjugate has an increased half-life relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate has at least a 1.5 fold increase in half-life relative to unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate has at least a 5 fold increase in half-life relative to unconjugated therapeutic protein.
- In some embodiments, the zwitterionic polymer of the method of conjugating a therapeutic protein to a half-life extending moiety is a radically polymerizable monomer having a zwitterionic group and the method has a further step of polymerizing the free radically polymerizable zwitterionic monomer in a polymerization medium to provide a polymer, the medium comprising: the radically polymerizable zwitterionic monomer; a transition metal catalyst Mt (q−1)+ wherein Mt is a transition metal, q is a higher oxidation state of the metal and q−1 is a lower oxidation state of the metal, wherein the metal catalyst is supplied as a salt of the form Mt (q−1)+X′q−1) wherein X′ is a counterion or group or the transition metal catalyst is supplied in situ by providing the inactive metal salt at its higher oxidation state Mt q+X′q together with a reducing agent that is capable of reducing the transition metal from the oxidized inactive state to the reduced active state; a ligand; and an initiator.
- To function as an ATRP transition metal catalyst, the transition metal should have at least two readily accessible oxidation states separated by one electron, a higher oxidation state and a lower oxidation state. In ATRP, a reversible redox reaction results in the transition metal catalyst cycling between the higher oxidation state and the lower oxidation state while the polymer chains cycle between having propagating chain ends and dormant chain ends. See, e.g., U.S. Pat. No. 7,893,173.
- In some embodiments, the radically polymerizable zwitterionic monomer is selected from the group consisting of
- wherein R1 is H or C1-6 alkyl, ZW is a zwitterion and n is an integer from 1-6.
- In some embodiments, the radically polymerizable monomer is
- wherein R1 is H or C1-6 alkyl, R2, R3, R4 are the same or different and are H or C1-4alkyl and X and Y are the same or different and are integers from 1-6. In some embodiments, R1, R2, R3 and R4 are each methyl and X and Y are each 2.
- In some embodiments, the radically polymerizable monomer is
- wherein R1 is H or C1-6alkyl, R2 and R3 are the same or different and are H or C1-4alkyl, R4 is PO4—, SO3— or CO2— and X and Y are the same or different and are integers from 1-6. In some embodiments, R1, R2 and R3 are methyl, R4 is P04- and X and Y are each 2.
- In some embodiments, the monomer is
- wherein R1 is H or C1-6alkyl, R2, R3 and R4 are the same or different and are H or C1-4alkyl, R5 is PO4—, SO3— or CO2— and X and Y are the same or different and are integers from 1-6. In some embodiments, R1, R2, R3 and R4 are methyl, R5 is P04- and X and Y are 2.
- In some embodiments, the transition metal Mt is selected from the group consisting of Cu, Fe, Ru, Cr, Mo, W, Mn, Rh, Re, Co, V, Zn, Au, and Ag. In some embodiments, the metal catalyst is supplied as a salt of the form Mt (q−1)+X′(q−1). Mt (q−1)+ is selected from the group consisting of Cu1+, Fe2+, Ru2+, Cr2+, Mo2+, W2+, Mn3+, Rh3+, Re2+, Co+, V2+, Zn+, Au+, and Ag+ and X′ is selected from the group consisting of halogen, C1-6 alkoxy, (SO4)1/2, (PO4)1/3, (R7PO4)1/2, (R72PO4), triflate, hexaluorophosphate, methanesulfonate, arylsulfonate, CN and R7CO2, where R7 is H or a straight or branched C1-6 alkyl group which may be substituted from 1 to 5 times with a halogen. In some embodiments, Mt (q−1)+ is Cu1+ and X′ is Br.
- In some embodiments, Mt (q-1)+ is supplied in situ. In some embodiments, Mt q+Xq is CuBr2. In some embodiments, the reducing agent is an inorganic compound. In some embodiments, the reducing agent is selected from the group consisting of a sulfur compound of a low oxidation level, sodium hydrogen sulfite, an inorganic salt comprising a metal ion, a metal, hydrazine hydrate and derivatives of such compounds. In some embodiments, the reducing agent is a metal. In some embodiments, the reducing agent is Cu0.
- In some embodiments, the reducing agent is an organic compound. In some embodiments, the organic compound is selected from the group consisting of alkylthiols, mercaptoethanol, or carbonyl compounds that can be easily enolized, ascorbic acid, acetyl acetonate, camphorsulfonic acid, hydroxy acetone, reducing sugars, monosaccharides, glucose, aldehydes, and derivatives of such organic compounds.
- In some embodiments, the ligand is selected from the group consisting of 2,2′-bipyridine, 4,4′-Di-5-nonyl-2,2′-bipyridine, 4,4-dinonyl-2,2′-dipyridyl, 4,4′,4″-tris(5-nonyl)-2,2′:6′,2″-terpyridine, N,N,N′,N′,N″-Pentamethyldiethylenetriamine, 1,1,4,7,10,10-Hexamethyltriethylenetetramine, Tris(2-dimethylaminoethyl)amine, N,N-bis(2-pyridylmethyl)octadecylamine, N,N,N′,N′-tetra[(2-pyridal)methyl]ethylenediamine, tris[(2-pyridyl)methyl]amine, tris(2-aminoethyl)amine, tris(2-bis(3-butoxy-3-oxopropyl)aminoethyl)amine, tris(2-bis(3-(2-ethylhexoxy)-3-oxopropyl)aminoethyl)amine and Tris(2-bis(3-dodecoxy-3-oxopropyl)aminoethyl)amine. In some embodiments, the ligand is 2,2′-bipyridine.
- In some embodiments the initiator has the structure:
- wherein R1 is a nucleophilic reactive group, R2 comprises a linker, and R3 comprises a polymer synthesis initiator moiety having the structure
- wherein R4 and R5 and are the same or different and are selected from the group consisting of alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido or any combination thereof; Z is a halogen or CN; and s is an integer between 1 and 20.
- In some embodiments, Z is Br and R4 and R5 are each methyl. In some embodiments, R1 is selected from the group consisting of NH2—, OH—, and SH—.
- In some embodiments R2 is alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cyclic alkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, arylene-oxy, heteroaryl, amino, amido or any combination thereof. In some embodiments, R2 is
- wherein X and Y are the same or different and are integers from 1-20. In some embodiments, X and Y are each 4.
- In some embodiments, R3 is
- wherein R6, R7 and R8 are the same or different and are selected from the group consisting of
- wherein Z is NCS, F, Cl, Br or I. In some embodiments, Z is Br and R6, R7 and R8 are each
- In some embodiments, the initiator has the structure:
- wherein A and B are the same or different and are integers from 2 to 12 and Z is any halide, for example Br. In some embodiments, A and B are each 4.
- In some embodiments, the method further has the step of reacting the polymer with a maleimide reagent to provide a polymer having a terminal maleimide. In some embodiments, the maleimide compound is
- In some embodiments, a method is presented for the treatment or prophylaxis of an ocular disease having the step of administering a therapeutic protein selected from the group consisting of an anti-VEGF-A antibody (and conjugates thereof). In some embodiments, any one or more of the antibodies or antibody conjugates provided herein can be used as treatment and/or prophylaxis for an ocular disease. The method includes administering to the subject any one or more of the antibodies or antibody conjugates provided herein.
- In some embodiments a method for treatment or prophylaxis of an ocular disease is provided. The method comprises administering an effective dose of any of the an antibody and/or antibody conjugates described herein to a subject in need thereof. In some embodiments, the disease can be age-related macular degeneration (AMD) or diabetic macular edema (DME). In some embodiments, the disease can be wet AMD.
- In some embodiments, the ocular disease is selected from one or more of the group consisting of diabetic retinopathy, choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, and hypertensive retinopathy. In some embodiments, the ocular disease is diabetic retinopathy.
- In some embodiments, the antibody or antibody conjugate is administered no more frequently than once a month. In some embodiments, the antibody or conjugate thereof is administered two times per month or weekly. In some embodiments, the antibody or conjugate thereof is administered once every two months, once every three months, once every four months, once every five months, once every six months, once every seven months, once every eight months, once every nine months, once every ten months, once every eleven months, or once every twelve months.
- In some embodiments, one or more of the compositions provided herein can allow for a reduction in the consequences of high treatment burdens from the use of intravitreal injection of anti-VEGF agents for the treatment of the wet (proliferative) form of age related macular degeneration (AMD). Real world outcomes for patients with wet AMD lag behind the clinical outcomes demonstrated in the
phase 3 clinical studies such as the MARINA and ANCHOR studies with Lucentis® (ranibizumab) and theVIEW 1 andVIEW 2 studies with Eylea® (aflibercept). An anti-VEGF therapeutic with a longer ocular residence time such that it can be administered less frequently and therefore with a more patient-tolerable profile can bring real world outcomes closer tophase 3 clinical outcomes for more patients. - In some embodiments, compounds, including antibody conjugates and anti-VEGF-A antibodies described herein are used to treat patients who have background or nonproliferative diabetic retinopathy but have little or no vision impairment. In some embodiments, such patients are dosed less than once a month via intravitreal injection. In some embodiments, such patients are dosed six times a year. In some embodiments, such pateints are dosed no more than four times a year. In some embodiments, the patients are dose no more than three times a year. In some embodiments, the patients are dosed no more than twice a year. In some embodiments, the patients are dosed no more than once a year. In some embodiments, the subject receives the antibody or antibody conjugate via intravitreal injection.
- The therapeutic proteins (e.g., both antibodies and antibody conjugates) described herein can be employed by expression of such polypeptides in vivo in a patient, i.e., gene therapy.
- There are two major approaches to getting the nucleic acid (optionally contained in a vector) into the patient's cells: in vivo and ex vivo. For in vivo delivery the nucleic acid is injected directly into the patient, usually at the sites where the therapeutic protein is required, i.e., where biological activity of the therapeutic protein is needed. For ex vivo treatment, the patient's cells are removed, the nucleic acid is introduced into these isolated cells, and the modified cells are administered to the patient either directly or, for example, encapsulated within porous membranes that are implanted into the patient (see, e.g, U.S. Pat. Nos. 4,892,538 and 5,283,187). There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or transferred in vivo in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, transduction, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. Transduction involves the association of a replication-defective, recombinant viral (including retroviral) particle with a cellular receptor, followed by introduction of the nucleic acids contained by the particle into the cell. A commonly used vector for ex vivo delivery of the gene is a retrovirus.
- In some embodiments, the in vivo nucleic acid transfer techniques include transfection with viral or non-viral vectors (such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV)) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol; see, e.g., Tonkinison et al., Cancer Investigation, 14(1): 54-65 (1996)). In some embodiments the vectors for use in gene therapy are viruses, which include adenoviruses, AAV, lentiviruses, or retroviruses. A viral vector such as a retroviral vector includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. In addition, a viral vector such as a retroviral vector includes a nucleic acid molecule that, when transcribed in the presence of a gene encoding the therapeutic protein, is operably linked thereto and acts as a translation initiation sequence. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used (if these are not already present in the viral vector). In addition, such vector typically includes a signal sequence for secretion of the PRO polypeptide from a host cell in which it is placed. In some embodiments, the signal sequence for this purpose is a mammalian signal sequence. In some embodiments, the signal is the native signal sequence for the therapeutic protein. Optionally, the vector construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such vectors will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.
- In some situations, it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell-surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins that bind to a cell-surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g., capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins that undergo internalization in cycling, and proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem., 262: 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA, 87: 3410-3414 (1990). For a review of the currently known gene marking and gene therapy protocols, see, Anderson et al., Science, 256: 808-813 (1992). See also WO 93/25673 and the references cited therein.
- Suitable gene therapy and methods for making retroviral particles and structural proteins can be found in, e.g., U.S. Pat. No. 5,681,746.
- In some embodiments, a method for treatment or prophylaxis of an ocular disease in a mammal is presented in which a nucleic acid molecule that encodes a therapeutic protein selected from the group consisting of an anti-VEGF-A antibody is administered. In some embodiments, the nucleic acid is set forth in
FIG. 27 . - In some embodiments, the heavy chain is that set forth in SEQ ID NO. 1 and the light chain is that set forth in SEQ ID NO. 2. In some embodiments, the nucleic acid molecule is administered via ex vivo gene therapy.
- Therapeutic proteins can be incorporated into a pharmaceutical composition with a pharmaceutically acceptable excipient. Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules, as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. For the preparation of solutions and syrups, excipients which may be used include for example water, polyols and sugars. For the preparation of suspensions oils (e.g. vegetable oils) may be used to provide oil-in-water or water in oil suspensions.
- Pharmaceutical compositions can be adapted for nasal administration wherein the excipient is a solid include a coarse powder having a particle size for example in the
range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable compositions wherein the excipient is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient. Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurized aerosols, nebulizers or insufflators. - Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carried, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets. Pharmaceutical compositions can be substantially isotonic, implying an osmolality of about 250-400 mOsm/kg water.
- The pharmaceutical compositions may contain preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts (substances may themselves be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents or antioxidants. They may also contain therapeutically active agents in addition to the substance. The pharmaceutical compositions may be employed in combination with one or more pharmaceutically acceptable excipients. Such excipients may include, but are not limited to, saline, buffered saline (such as phosphate buffered saline), dextrose, liposomes, water, glycerol, ethanol and combinations thereof.
- The antibodies and pharmaceutical compositions containing them may be administered in an effective regime for treating or prophylaxis of a patient's disease including, for instance, administration by oral, intravitreal, intravenous, subcutaneous, intramuscular, intraosseous, intranasal, topical, intraperitoneal, and intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration or routes among others. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion In some embodiments the agent is isotonic or substantially isotonic.
- For administration to mammals, and particularly humans, it is expected that the dosage of the active agent is from 0.01 mg/kg body weight, typically around 1 mg/kg. The physician can determine the actual dosage most suitable for an individual which depends on factors including the age, weight, sex and response of the individual, the disease or disorder being treated and the age and condition of the individual being treated. The above dosages are exemplary of the average case. There can, of course, be instances where higher or lower dosages are merited. In some embodiments, the dosage can be 0.5 to 20 mg/eye, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 mg.
- This dosage may be repeated as often as appropriate (e.g., weekly, fortnightly, monthly, once every two months, quarterly, twice a year, yearly). If side effects develop the amount and/or frequency of the dosage can be reduced, in accordance with normal clinical practice. In one embodiment, the pharmaceutical composition may be administered once every one to thirty days. In one embodiment, the pharmaceutical composition may be administered twice every thirty days. In one embodiment, the pharmaceutical composition may be administered once a week.
- The antibodies and pharmaceutical compositions can be employed alone or in conjunction with other compounds, such as therapeutic compounds or molecules, e.g. anti-inflammatory drugs, analgesics or antibiotics. Such administration with other compounds may be simultaneous, separate or sequential. The components may be prepared in the form of a kit which may comprise instructions as appropriate.
- The antibodies and pharmaceutical compositions disclosed herein can be used for treatment or prophylaxis of disease, particularly the ocular diseases or conditions described herein.
- So used, the conjugates are typically formulated for and administered by ocular, intraocular, and/or intravitreal injection, and/or juxtascleral injection, and/or subretinal injection and/or subtenon injection, and/or superchoroidal injection and/or subconjunctival and/or topical administration in the form of eye drops and/or ointment. Such antibodies and compositions can be delivered by a variety of methods, e.g. intravitreally as a device and/or a depot that allows for slow release of the compound into the vitreous, including those described in references such as Intraocular Drug Delivery, Jaffe, Ashton, and Pearson, editors, Taylor & Francis (March 2006). In one example, a device may be in the form of a minipump and/or a matrix and/or a passive diffusion system and/or encapsulated cells that release the compound for a prolonged period of time (Intraocular Drug Delivery, Jaffe, Ashton, and Pearson, editors, Taylor & Francis (March 2006).
- Formulations for ocular, intraocular or intravitreal administration can be prepared by methods and using ingredients known in the art. A main requirement for efficient treatment is proper penetration through the eye. Unlike diseases of the front of the eye, where drugs can be delivered topically, retinal diseases require a more site-specific approach. Eye drops and ointments rarely penetrate the back of the eye, and the blood-ocular barrier hinders penetration of systemically administered drugs into ocular tissue. Accordingly, usually the method of choice for drug delivery to treat retinal disease, such as AMD and CNV, is direct intravitreal injection. Intravitrial injections are usually repeated at intervals which depend on the patient's condition, and the properties and half-life of the drug delivered.
- Therapeutic antibodies and related conjugates generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. Such compositions may also be supplied in the form of pre-filled syringes.
- A “stable” formulation is one in which the protein or protein conjugated to a polymer of other half-life extending moiety therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage. By “stable” is also meant a formulation which exhibits little or no signs of instability, including aggregation and/or deamidation. For example, the formulations provided may remain stable for at least two year, when stored as indicated at a temperature of 5-8° C.
- Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301 (Vincent Lee ed., New York, N.Y., 1991) and Jones, 1993 Adv. Drug Delivery Rev. 10: 29-90, for examples. Stability can be measured at a selected temperature for a selected time period. In some embodiments the storage of the formulations is stable for at least 6 months, 12 months, 12-18 months, or for 2 or more years.
- A protein, such as an antibody or fragment thereof, “retains its physical stability” in a pharmaceutical formulation if it shows no signs of aggregation, precipitation, deamidation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography.
- A protein “retains its chemical stability” in a pharmaceutical formulation, if the chemical stability at a given time is such that the protein is considered to still retain its biological activity. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Chemical alteration may involve size modification (e.g., clipping), which can be evaluated using size exclusion chromatography, SDS-PAGE and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS), for examples. Other types of chemical alteration include charge alteration (e.g., occurring as a result of deamidation), which can be evaluated by ion-exchange chromatography, for example. An antibody “retains its biological activity” in a pharmaceutical formulation, if the biological activity of the antibody at a given time is within about 10% (within the errors of the assay) of the biological activity exhibited at the time the pharmaceutical formulation was prepared as determined in an antigen binding assay, for example.
- A protein-polymer conjugate “retains its chemical stability” the chemical bond between the protein and the polymer is maintained intact, e.g., it is not hydrolyzed or otherwise disrupted. The protein part of the conjugate retains its chemical stability as described above.
- By “isotonic” is meant that the formulation of interest has essentially the same osmotic pressure as human blood or the vitreous for intravitreal injections. Isotonic formulations will generally have an osmotic pressure from about 250 to 400 mOsm. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
- As used herein, “buffer” refers to a buffered solution that resists changes in pH by the action of its acid-base conjugate components. In some embodiments, the buffer has a pH from about 3.0 to about 8.0; for example from about 4.5 to 8; or about
pH 6 to about 7.5; or about 6.0 to about 7.0, or about 6.5-7.0, or about pH 7.0 to about 7.5; or about 7.1 to about 7.4. A pH of any point in between the above ranges is also contemplated. - In some embodiments, “PBS” phosphate buffered saline, Tris based buffers and histidine based buffers are used.
- In some embodiments, the PBS buffer is made up of at least Na2HPO4, KH2PO4 and NaCl adjusted so as to provide the appropriate pH. In some embodiments, the buffer may contain other pharmaceutical excipients such as KCl and other salts, detergents and/or preservatives so as to provide a stable storage solution.
- A “preservative” is a compound which can be included in the formulation to essentially reduce bacterial action therein, thus facilitating the production of a multi-use formulation, for example. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
- In some embodiments, formulations, to be safe for human use or for animal testing, should have sufficiently low levels of endotoxin. “Endotoxin” is lipopolysaccharide (LPS) derived from the cell membrane of Gram-negative bacteria. Endotoxin is composed of a hydrophilic polysaccharide moiety covalently linked to a hydrophobic lipid moiety (lipid A). Raetz C R, Ulevitch R J, Wright S D, Sibley C H, Ding A, Nathan C F. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5(12):2652-2660. Lipid A is responsible for most of the biological activities of endotoxin, i.e., its toxicity. Endotoxins are shed in large amount upon bacterial cell death as well as during growth and division. They are highly heat-stable and are not destroyed under regular sterilizing conditions. Extreme treatments with heat or pH, e.g., 180-250° C. and over 0.1 M of acid or base must be used (Petsch D, Anspach F. 2000. Endotoxin removal from protein solutions. J Biotechnol. 76: 97-119). Such conditions of course would be highly detrimental to biological drugs.
- In the biotech and pharmaceutical industries, it is possible to find endotoxin during both production processes and in final products. As bacteria can grow in nutrient poor media, including water, saline and buffers, endotoxins are prevalent unless precautions are taken. Endotoxin injection into an animal or human causes a wide variety of pathophysiological effects, including endotoxin shock, tissue injury and even death. Ogikubo Y, Ogikubo Y, Norimatsu M, Noda K, Takahashi J, Inotsume M, Tsuchiya M, Tamura Y. 2004. Evaluation of the bacterial endotoxin test for quantifications of endotoxin contamination of porcine vaccines. Biologics 32:88-93.
- Pyrogenic reactions and shock are induced in mammals upon intravenous injection of endotoxin at low concentrations (1 ng/mL) (Fiske J M, Ross A, VanDerMeid R K, McMichael J C, Arumugham. 2001. Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations. J Chrom B. 753:269-278). The maximum level of endotoxin for intravenous applications of pharmaceutical and biologic product is set to 5 endotoxin units (EU) per kg of body weight per hour by all pharmacopoeias (Daneshiam M, Guenther A, Wendel A, Hartung T, Von Aulock S. 2006. In vitro pyrogen test for toxic or immunomodulatory drugs. J Immunol Method 313:169-175). EU is a measurement of the biological activity of an endotoxin. For example, 100 pg of the standard endotoxin EC-5 and 120 pg of endotoxin from Escherichia coli O111:B4 have activity of 1 EU (Hirayama C, Sakata M. 2002. Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chrom B 781:419-432). Meeting this threshold level has always been a challenge in biological research and pharmaceutical industry (Berthold W, Walter J. 1994. Protein Purification: Aspects of Processes for Pharmaceutical Products. Biologicals 22:135-150; Petsch D, Anspach F B. 2000. Endotoxin removal from protein solutions. J Biotech 76:97-119).
- The presence of endotoxin in drugs to be delivered via intravitreal injection is of particular concern. Intravitreal injection of drug (penicillin) was first performed in 1945 by Rycroft. Rycroft B W. 1945. Penicillin and the control of deep intra-ocular infection. British J Ophthalmol 29 (2): 57-87. The vitreous is a chamber where high level of drug can be introduced and maintained for relatively long periods of time. The concentration of drug that can be achieved via intravitreal injection far exceeds what can be generated by topical administration or by systemic administration (e.g. intravenous).
- One of the most dangerous complications potentially arising from intravitreal injections is endophthalmitis. Endophthalmitis falls into two classes: infectious and sterile. Infectious endophthalmitis is generally cause by bacteria, fungi or parasites. The symptoms of infectious endophthalmitis include severe pain, loss of vision, and redness of the conjunctiva and the underlying episclera. Infectious endophthalmitis requires urgent diagnosis and treatment. Possible treatments include intravitreal injection of antibiotics and pars plana vitrectomy in some cases. Enucleation may be called for to remove a blind and painful eye. See, e.g., Christy N E, Sommer A. 1979. Antibiotic prophylaxis of postoperative endophthalmitis. Ann Ophthalmol 11 (8): 1261-1265.
- Sterile endophthalmitis in contrast does not involve an infectious agent and can be defined as the acute intraocular inflammation of the vitreous cavity that resolves without the need of intravitreal antibiotics and/or vitreoretinal surgery. If a vitreous microbiological study has been done, it needs to be negative culture proven to sustain a diagnosis of sterile endophthalmitis. Marticorena J, Romano V, Gomez-Ulla F. 2012 “Sterile Endophthalmitis after Intravitreal Injections” Med Inflam. 928123.
- It has been observed that intravitreal injection of biological drugs contaminated with endotoxin can result in sterile endophthalmitis. Marticorena, et al. Bevacizumab (Avastin) is approved by the Food and Drug Administration for the treatment of glioblastoma and of metastatic colorectal cancer, advanced nonsquamous non-small-cell lung cancer and metastatic kidney cancer. Bevacizumab is also widely used off label as a treatment for wet AMD. Bevacizumab comes from the manufacturer as a 100 mg/4 ml. This solution cannot be directly used for intravitreal injection and should be compounded by a pharmacist. Clusters of sterile endophthalmitis have been observed and are theorized to be cause by inadvertent contamination of bevacizumab by endotoxin by the compounding pharmacist.
- Given the dire clinical results of intravitreal injection of endotoxin, the total amount of endotoxin that can be given to a patient via intravitreal dosing is highly limited. In some embodiments, a solution having an antibody or antibody-conjugate is provided having an endotoxin level that does not exceed 5.0 EU/ml. In some embodiments, the endotoxin level does not exceed 1.0 EU/ml. In some embodiments, the endotoxin level does not exceed 0.5 EU/ml. In some embodiments, the endotoxin level does not exceed 0.2 EU/ml. In some embodiments, the endotoxin level does not exceed 2, 1, 0.5, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02 or 0.01 EU/ml.
- Two commonly used FDA-approved tests for the presence of endotoxin are the rabbit pyrogen test and Limulus Amoebodyte Lysate (LAL) assay (Hoffman S, et al. 2005. International validation of novel pyrogen tests based on human monocytoid cells J. Immunol. Methods 298:161-173; Ding J L, Ho B A. 2001. New era in pyrogen testing. Biotech. 19:277-281). The rabbit pyrogen test was developed in the 1920s and involves monitoring the temperature rise in a rabbit injected with a test solution. However, use of the rabbit pyrogen test has greatly diminished over the years due to expense and long turnaround time. Much more common is the LAL test. LAL is derived from the blood of a horseshoe crab and clots upon exposure to endotoxin.
- One of the simplest LAL assays is the LAL gel-clot assay. Essentially, the LAL clotting assay is combined with a serial dilution of the sample in question. Formation of the gel is proportional to the amount of endotoxin in the sample. Serial dilutions are prepared from the sample and each dilution assayed for its ability to form LAL gel. At some point a negative reaction is contained. The amount of endotoxin in the original sample can be estimated from the dilution assay.
- Other LAL tests have also been developed, including the turbidimetric LAL assay (Ong K G, Lelan J M, Zeng K F, Barrett G, Aourob M, Grimes C A. 2006. A rapid highly-sensitive endotoxin detection system. Biosensors and Bioelectronics 21:2270-2274) and the chromogenic LAL assay (Haishima Y, Hasegawa C, Yagami T, Tsuchiya T, Matsuda R, Hayashi Y. 2003. Estimation of uncertainty in kinetic-colorimetric assay of bacterial endotoxins. J Pharm Biomed Analysis. 32:495-503). The turbidimetric and chromogenic assays are much more sensitive and quantitative than the simple gel-clot dilution assay.
- In some embodiments a method of reducing the amount of endotoxin in a composition having an antibody disclosed herein is provided. The method having the steps of contacting the composition with an affinity chromatography resin that binds to the antibody; eluting the antibody from the affinity chromatography resin to form an affinity chromatography eluent having the antagonist; contacting the affinity chromatography eluent with an ion-exchange resin that binds the antibody; and eluting the antibody from the ion-exchange resin, wherein the antibody eluted from the ion-exchange resin is substantially free from endotoxin.
- The above method for reducing the amount of endotoxin, or other method or process recited herein, can be performed in the order described in the steps above or it can optionally be performed by varying the order of the steps or even repeating one or more of the steps. In one embodiment, the method of reducing the amount of endotoxin in a composition is performed in the order of the described steps. In some embodiments, the affinity chromatography resin contacting, washing and eluting steps are repeated in the same order more than one time before contacting the affinity chromatography eluent with the ion exchange resin. The method can also include a filtering step using, for example, a 0.1 micron, 0.22 micron, or 0.44 micron filter, that can be performed on either one or more of the eluents removed after each resin binding step.
- In certain instances, the steps of contacting the composition with affinity chromatography resin, washing and eluting the antibody from the affinity chromatography resin can be repeated more than one time before contacting the first eluent with an ion-exchange resin. In one embodiment, the affinity chromatography resin comprises a recombinant Protein A
- (“rProteinA”) resin. One example of a suitable recombinant Protein A resin is rProteinA Sepharose FF® resin (Amersham, Piscataway, N.J.). In another embodiment, a suitable affinity chromatography resin would comprise a protein G chromatography resin. In other embodiments, a suitable affinity chromatography resin comprises a mixed Protein A/Protein G resin. In other embodiments, a suitable affinity chromatography resin comprises a hydrophobic charge induction resin that comprises a 4-mercaptoethylpyridine ligand such as a MEP HypeiCel® resin (BioSepra, Cergy, Saint Christophe, France).
- In some embodiments, the ion exchange resin comprises an anion-exchange resin. As will be known by the person skilled in the art, ion exchangers may be based on various materials with respect to the matrix as well as to the attached charged groups. For example, the following matrices may be used, in which the materials mentioned may be more or less cross-linked: MacroCap Q (GE Healthcare Biosciences, Piscataway, N.J.), agarose based (such as Sepharose CL-6B®, Sepharose Fast Flow® and Sepharose High Performance®), cellulose based (such as DEAE Sephacel®), dextran based (such as Sephadex®), silica based and synthetic polymer based. For the anion exchange resin, the charged groups, which are covalently attached to the matrix, may, for example, be diethylaminoethyl, quaternary aminoethyl, and/or quaternary ammonium. In some embodiments the anion-exchange resin comprises a quaternary amine group. An exemplarily anion-exchange resin that has a quaternary amine group for binding the anti-M-CSF antibody is a Q Sepharose® resin (Amersham, Piscataway, N.J.).
- In other aspects, if the endotoxin levels are higher than desired after subjecting the composition to the aforementioned anion-exchange chromatography step, the composition may in the alternative be subjected to a cation exchange resin. In some embodiments, any endotoxin in the composition should have a differential binding to the ion-exchange resin than the protein in question to allow purification of the protein from the endotoxin. In this regard, endotoxin is negatively charged and will generally bind to an anion exchange resin. If both the protein and the endotoxin bind to the anion exchange resin, purification of one from the other may be effectuated by using a salt gradient to elute the two into different fractions. The relative binding of the protein to a particular resin may also be effected by changing the pH of the buffer relative to the pI of the protein. In some embodiments, cation-exchange chromatography is the sole ion-exchange chromatography employed.
- In some embodiments, if the endotoxin levels are too high after the anion exchange resin, the composition may be further subjected to a second ion-exchange step, for example, by contacting the compositions with a cation exchange resin and followed by a wash step, then elution from the ion-exchange resin. In some embodiments, the cation exchange resin comprises a sulfonic group for binding. Exemplary cation exchange resins are SP Sepharose® resin FF (Amersham, Piscataway, N.J.) Poros XS (CEX) (Life Technology, Grand Island, N.Y.).
- In some embodiments, after the solution of antibody protein is produced having the specified level of endotoxin, there are a number of steps prior to final formulation of the protein. In some embodiments, a half-life extending moiety is conjugated to the protein. The conjugate is then formulated into a final drug formulation which is injected into the patients. In some embodiments, the conjugate is again purified on an ion-exchange resin which can be a cation-exchange resin. In other embodiments, the protein is formulated. In all cases, normal laboratory procedures should be employed to prevent the introduction of endotoxin contaminants into the protein sample or into the protein-polymer conjugate.
- A first route for the synthesis of OG1802 is as follows. First, TFA/amine salt initiator (Compound L) having the structure shown in
FIG. 1 was synthesized as follows. - First, Compound K, having the structure shown in
FIG. 2 was synthesized as follows. Into a 200 mL round bottom flask under nitrogen was placed Compound J (OG1563) (1.9 g, 2.67 mmol, 3.3 equiv) - and Compound E (0.525 g, 0.81 mmol, 1.0 equiv) (see
FIG. 11 ) followed by dimethylformamide (10 mL) then diisopropylethylamine (2.5 mL, 14.6 mmol, 18 equiv). The flask was cooled to 0° C. using an ice bath. To this was added propylphosphonic anhydride solution (50 wt. % in ethyl acetate, 2.5 mL, 4.04 mmol, 5 equiv) over ˜6 minutes. - The reaction was warmed to room temperature and stirred for 15 minutes. The reaction was quenched by adding water (20 mL), saturated aqueous sodium bicarbonate (20 mL) and ethyl acetate (100 mL). The organic layer was separated and the aqueous layer extracted with ethyl acetate (75 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (30 mL), 0.5 M aqueous citric acid (40 mL), water (25 mL), and saturated aqueous sodium chloride (40 mL), then dried (sodium sulfate), filtered and concentrated under vacuum. The residue which was used without further purification resulted in 2.0 g (0.80 mmol, 99%) of Compound K.
- 1H NMR (400 MHz DMSO-d6): δ=1.36 (s, 9H, OCCH3), 1.90 (s, 54H, CC(CH3)2Br), 2.31 (t, J=7.2 Hz, 6H, CCH2CH2NH), 2.98 (d, J=5.6 Hz, 6H, CCH2NH), 3.04 (q, J=6.0 Hz, 2H, OCH2CH2NH), 3.18 (s, 2H, OCH2C), 3.3-3.37 (m, 8H, CH2), 3.47-3.55 (m, 12H, CH2), 3.58 (s, 6H, OCH2C), 3.87 (s, 6H, O═CCH2O), 4.27 (s, 18H, CCH2OC═O), 6.74 (br t, 1H, CH2NHC═O), 7.69 (t, J=6.8 Hz, 3H, CH2NHC═O), 7.84 (t, J=6.0 Hz, 3H, CH2NHC═O).
- LC-MS (ES, m/z): [(M+2H-boc)/2]+ Calcd for (C84H136Br9N7O33+2H-Boc)/2=1196.6; Found 1196.6.
- Next Compound L (
FIG. 1 ) was synthesized as follows: into a 100 mL round bottom under nitrogen was added Compound K (2.0 g, 0.8 mmol), dichloromethane (10 mL) followed by trifluoroacetic acid (5 mL). The reaction was stirred at room temperature for 30 minutes. The reaction was concentrated under a vacuum. The reaction was diluted using dichloromethane (10 mL) and concentrated under a vacuum. The residue was dissolved using acetonitrile (10 mL), filtered through a syringe filter (Acrodisc CR25, PN 4225T) and loaded onto a preparatory HPLC column and eluted with 60% acetonitrile in water (with 0.1% trifluoroacetic acid) up to 98% acetonitrile (with 0.1% trifluoroacetic acid). The tubes containing product were pooled, concentrated under vacuum, frozen and placed on a lyophilizer. This resulted in 990 mgs (0.4 mmol, 50% over 2 steps) Compound L as a white powder. - 1H NMR (400 MHz DMSO-d6): δ=1.90 (s, 54H, CC(CH3)2Br), 2.31 (t, J=7.2 Hz, 6H, CCH2CH2NH), 2.97-3.0 (m, 8H, CCH2NH and OCH2CH2NH), 3.17 (s, 2H, OCH2C), 3.3 (q, 6H, CH2CH2NHC═O), 3.4-3.59 (m, 20H, CH2), 3.87 (s, 6H, O═CCH2O), 4.27 (s, 18H, CCH2OC═O), 7.69-7.84 (m, 9H, both CH2NHC═O and NH3+).
- LC-MS (ES, m/z): [(M+2H)/2]+ Calcd for (C84H136Br9N7O33+2H)/2=1196.6; Found 1197.4.
- Next, compound L was used as an initiator to synthesize MPC polymer. Initiator is typically prepared as a stock solution in DMF of about 100 mg/mL. The initiator and the ligand (2,2′-bipyridyl) were introduced into a Schlenk tube. The resultant solution was cooled to −78° C. using a dry ice/acetone mixture, and was degassed under vacuum for 10 min. The tube was refilled under Argon and the catalyst (CuBr unless otherwise indicated), kept under Argon, was introduced into the Schlenck tube (the Molar ratio of atom bromine on the initiator/catalyst (CuBr)/ligand was kept at 1/1/2). The solution became dark brown immediately. The Schlenk tube was sealed and immediately purged by applying a short cycle vacuum/Argon. A solution of HEMA-PC was prepared by mixing a defined quantity of monomer, prepared in a glovebox kept under nitrogen, with 200 proof degassed ethanol. The monomer solution was added drop wise into the Schlenk tube (via cannula) (and homogenized by light stirring). The temperature was maintained at −78° C. A thorough vacuum was applied to the reaction mixture for at least 10 to 15 min. until bubbling from the solution ceased. The tube was then refilled with Argon and warmed to room temperature. The solution was stirred, and as the polymerization proceeded, the solution became viscous. After 3 to 8 hours or just left overnight, the reaction was quenched by direct exposure to air in order to oxidize Cu (I) to Cu (II), the mixture became blue-green in color, and was passed through a silica column in order to remove the copper catalyst. The collected solution was concentrated by rotary evaporation and the resulting mixture was either precipitated with tetrahydrofuran or dialyzed against water followed by freeze drying to yield a free-flowing white powder. Table 1.1 below sets forth polymer data for polymer employing compound L as an initiator.
-
TABLE 1.1 Theor. MW Polymer Mn Mp (kDa) ID No. Initiator (kDa) (kDa) PDI 500 130 L 490 530 1.1 750 150 L 645 750 1.1 - Next, the maleimide Mal-PEG4-PFP ester was snapped on (as set forth in
FIG. 29 ) to the 750 kDa polymer referred to above to provide OG1802. Into a 20 mL vial was placed Polymer R3707 (750 kDa polymer made using L as initiator, 515 mg) and dissolved using ethanol (4.0 mL) after stirring for 40 minutes. To this was added a 1% solution of 4-methylmorpholine in acetonitrile (22 uL). In a separate vial was dissolved Mal-PEG4-PFP (1.97 mg) in acetonitrile (1.0 mL) and this solution was added to the polymer solution over ˜2 minute at room temperature and the resulting solution was stirred for overnight. The reaction was diluted with 0.1% aqueous trifluoroacetic acid (2 mL) (pH ˜5) followed by water (˜12 mL), filtered through a syringe filter (Acrodisc Supor, PN 4612) and placed evenly into 3 Amicon centrifuge membrane dialysis tubes (30,000 mwco). The tubes were diluted and mixed with water (˜5 mL each), placed into centrifuge (rpm 3200) for 25 minutes. The filtrate is removed for analysis while the retentate is diluted and mixed with water (˜10 mL/tube). The centrifuge procedure repeated 5 more times, after which the retentate is removed and placed into a vial. The Amicon membrane tubes were rinsed with water (2ט2 mL each tube) and this combined with the retentate. The retentate solution was filtered through a syringe filter (Acrodisc Supor, PN 4612), frozen and placed on a lyophilizer. This resulted in 485 mgs as a white powder. - OG1786 is the nine-arm initiator for polymer synthesis used as a precursor in the synthesis of OG1802. Each arm is terminated with a 2-bromoisobutyrate which is capable of initiating polymerization under ATRP. OG1786 is a salt of trifluoro acetic acid (TFA) as shown in
FIG. 30 . OG1786 is prepared as follows. First, OG1550 is reacted with TFA (trifluoro acetic acid) to produce OG1546 as depicted inFIG. 31 . - In a 1 L round bottom flask equipped with a magnetic stir bar and an addition funnel was added OG1550 (14.8 g), methyl tert-butyl ether (MTBE) (350 ml) and water (30 ml). The mixture was stirred to dissolve the OG1550, then cooled in an ice bath. To this mixture was added a solution of trifluoroacetic acid (4.9 ml) in water (90 ml) dropwise over 90 minutes. After addition is complete the mixture was stirred an additional 15 minutes then removed from the ice bath and allowed to warm to room temperature. The mixture was stirred (after removal from the ice bath) for a further 4-5 hours, until tlc showed ˜5% starting material remaining, and the pH of the aqueous was between 3 and 4 (pH paper).
- The mixture was partitioned. The MTBE layer was washed with water (30 ml). Combine aqueous layers then the aqueous extracted with MTBE (150 ml). This second MTBE phase was washed with water (30 ml). The combined aqueous layers were washed with a third portion of MTBE (100 ml). The third MBTE phase was washed with water (25 ml). The aqueous layers were again combined (˜250 ml, pH ˜4, by pH paper).
- The product was collected by lyophilization. 11.5 g white solid was obtained. This material is extremely hygroscopic, so best handled under nitrogen. The product was confirmed by LCMS.
- The prepared OG1546 was then reacted with OG1563 to yield OG1784 (as depicted in
FIG. 32 ). - In a 250 ml flask under nitrogen equipped with a stir bar was added OG1546 (hygroscopic, 9.0 g), followed by N,N-dimethylformamide (110 ml). The mixture was stirred at room temperature until all OG1546 dissolved (about 15 minutes), then OG1563 (29.9 g) was added, and the mixture stirred a further 3 minutes until the OG1563 had also been dissolved. The resulting solution was cooled in an ice bath, and N,N-diisopropylethylamine (37.6 ml) was added over 3 minutes, followed by propylphosphonic anhydride (T3P), 50% in ethyl acetate (34.5 ml) dropwise over 5 minutes (T3P addition is exothermic). After T3P addition was complete, the flask was removed from the cooling bath and allowed to reach room temperature. Samples were then taken at 5 minute intervals for LCMS analysis. The reaction showed very light yellow/tan color.
- After 20 minutes the reaction was cooled again in an ice bath and 5 ml water added. The mixture was then removed from the cooling bath and a further 50 ml water portion added, followed by 50 ml 0.5 M citric acid then isopropylacetate (300 ml). The mixture was partitioned. The aqueous phase (˜300 ml) was extracted with additional isopropyl acetate (150 ml). The aqueous phase was AQ1 for HPLC test. The combined organics were washed with aqueous citric acid (115 ml, 65 mM, which was the mixture of 15 ml of 0.5 M citric acid plus 100 ml water), and the aqueous phase was AQ2 (pH-3). The organic phase was washed with water/saturated sodium chloride (100 ml/25 ml), and the aqueous phase was AQ3 (pH-3). The organic phase was finally washed with saturated sodium chloride (100 ml), and the aqueous phase was AQ4. None of the AQ fractions contained any significant product (data not provided). The organic phase confirmed the product via LCMS. The product was dried over sodium sulfate (80 g), filtered and rinsed with isopropyl acetate (75 ml), and concentrated on a rotary evaporator to a tan oil (33.2 g). The crude was stored overnight under nitrogen.
- The next day the crude was allowed to come to room temperature, then dissolved in acetonitrile/water (46 ml/12 ml) and filtered using an HPLC filter disk (Cole-Parmer PTFE 0.2 μm, product number 02915-20). The filtrate was split into three equal portions and purified in three runs.
- The filtrate was loaded onto a RediSep Rf Gold C18 column (275 g, SN 69-2203-339, Lot #24126-611Y) equilibrated with 50% acetonitrile/water. The material was eluted at 100 ml/min using the following gradient (solvent A: water, solvent B: acetonitrile). All the relevant fractions were checked by HPLC. The fractions adjudged to be pure enough were pooled (from all three runs) and concentrated (bath temperature kept at about 20° C.) on rotovap, then partitioned between dichloromethane (100 ml) and water (5 ml)/saturated sodium chloride (25 ml). The aqueous was extracted twice more with dichloromethane (2×30 ml). The combined organics were dried over sodium sulfate (35 g), filtered, rinsed with DCM (30 ml), and concentrated. The product and purity were confirmed by LCMS methods. The isolated yield and the purity of the R5172 and R5228 lots are shown in Table 2.1.
-
TABLE 2.1 OG1784 lot R5172 R5228 OG1546 used 5.3 g 9.0 g OG1563 used 17.6 g 29.9 g Isolated yield 53% 58% Purity (a/a 210 nm) 99.3% 100.0% - Next OG1405 was prepared from OG1784 as depicted in
FIG. 33 . In a 500 ml round bottom flask equipped with a magnetic stir bar was added OG1784 (20.9 g), followed by dichloromethane (50 ml) then trifluoroacetic acid (20 ml). The mixture was stirred at room temperature and HPLC analysis showed complete deprotection in 23 minutes. The mixture was concentrated on a rotary evaporator, redissolved in dichloromethane (25 ml) and re-concentrated, then redissolved in acetonitrile (25 ml) and re-concentrated. The product was confirmed by LCMS. The material from above (OG1405, 34.5 g, assume 21.0 g as quantitative yield) was used as a crude oil in the next step. No purification is needed. - Next, OG1405 was reacted with OG1402 to prepare OG1785 as set forth in
FIG. 34 . In a 500 ml flask under nitrogen equipped with a stir bar was placed OG1402 (5.5 g), followed by acetonitrile (70 ml), then N,N-diisopropylethylamine (26.3 ml) and T3P solution (see above) (7.9 ml). The solution was stirred at room temperature for 30 minutes, then cooled in an ice water bath and a solution of OG1405 (crude oil from above, 34.5 g) in acetonitrile (70 ml) added. The mixture was warmed to room temperature. After 20 minutes the reaction was cooled in an ice water bath and quenched with water (5 ml). The mixture was then concentrated under vacuum using a rotary evaporator to half volume. Samples were taken for LCMS. - More water (50 ml), followed by 0.5 M citric acid (75 ml) and isopropyl acetate (175 ml) was added. The mixture was partitioned in 5 minutes. The aqueous was extracted with additional isopropyl acetate (50 mL). The combined organics were washed with aqueous citric acid (0.13 M, 30 ml, consist of 10 ml of 0.5 M citric acid and 20 ml water). The organics were then washed with the mixture of saturated sodium chloride (25 ml) and water (25 ml), then finally washed with the saturated sodium chloride (25 ml). They were then dried over sodium sulfate (124 g), filtered and rinsed with isopropyl acetate (30 ml), and concentrated under rotary evaporator to a tan oil (27.3 g). Samples were taken for LCMS analysis.
- The oil was dissolved in acetonitrile/water (3:1, 15 ml/5 ml), filtered through an HPLC filter disk (Cole-Parmer PTFE membrane 0.2 μm, product number 02915-20) and split into three equal portions, each of which were individually purified as follows.
- Portions were loaded onto Redi-Sep Gold C18 column (275 g, SN-69-2203-339, Lot 241234-611W) equilibrated at 50% solvent B (acetonitrile)/50% solvent A (water). The material was then purified by reverse phase HPLC with a solvent A: water/solvent B: acetonitrile gradient. Appropriate fractions were pooled and partitioned between dichloromethane (150 ml) and water (5 ml)/saturated sodium chloride (25 ml). The aqueous was extracted twice with dichloromethane (2×50 ml). Combined organics were dried over sodium sulfate (60 g), filtered and rinsed with dichloromethane (40 ml) and concentrated. Structure and purity were confirmed by various analytics including LCMS: OG1785 was isolated as a foamy solid (R5329, 19.0 g, 83% yield, 95.1% purity (a/a 210 nm), stored under nitrogen at 4° C.
- Next, the tert-butyloxycarbonyl protecting group on OG1785 was removed using trifluoroacetic acid (TFA) to produce OG1786 as depicted in
FIG. 35 . - Polymer OG1801 is made first from the initiator OG1786. OG1801 has an amine functionality, which is more stable (than maleimide) during polymer synthesis. To synthesize polymer OG1801, a modified version of ATRP is used wherein the copper species (Cu(I)) is generated in situ by adding metallic copper to Cu (II). Starting materials and reagents needed in the reaction are calculated based on batch input of the monomer (HEMA-PC) OG47, as well as the targeted molecular weight (MW).
- Weighed 50 g monomer OG47 in glove box and added 200 mL of degassed EtOH to dissolve the monomer at room temperature; sampled for monomer concentration test. Weighed Cu (II), Bpy, Cu(0) in a 500 mL flask; purged with Argon, while adding monomer solution to the flask; sealed the flask with stopper and vacuumed for 25 min until no bubbles. The reaction changed color gradually from light green to dark green, then to light brown; weighed ˜200 mg of initiator OG1786 in glove box, and dissolved in ˜2000 uL of DMF under room temperature to make 100 mg/mL stock solution; sampled for initiator concentration and purity test; added the initiator solution to the flask under Argon. The reaction solution became dark brown and started thickening over time; sealed the system and let the reaction occur over 2 days.
- OG1801 was then prepared for addition of the maleimide and catalyst (copper) was removed as follows: A prepacked RediSep® Rf normal phase silica column is used to remove the catalyst. The size of the column is chosen based on the copper amount in the reaction mixture. For instance, a 330 g column (Cat. #69-2203-330, Column size 330 g, CV=443 mL) was used for a 50 g batch of OG1801. Teflon tubing is used for all the connection as EtOH is the elute solvent.
- After copper removal, all the fractions were transferred to a round bottom flask in batches, and evaporated the EtOH by rotary evaporator at 45-50° C. at reduced pressure to dryness. In this step, EtOH volume collected from condensation was monitored to make sure EtOH removal was >90%. The polymer was dissolved in 250 mL of WFI and filtered using a 0.2 um filter. It resulted in a clear to light yellow polymer solution at ˜150 mg/mL. The solution could be stored at 2-8° C. up to 3 month before use.
- Starting materials and reagents needed in the reaction are calculated based on batch input of OG1801. The linker is 3-maleimidopropionic acid, NHS ester. Added 30 ml of 0.5 M sodium phosphate (in WFI, pH 8) to 50 g polymer solution (˜150 mg/mL). Let stir for 1 min; pH was 8.0 by pH paper. Weighed 204.8 mg of linker and dissolved in DMF 4.1 mL to make 50 mg/mL stock sln. Added linker solution dropwise 815 uL per minute to the polymer sln with strong stirring. Took 5 min to added 4095 uL of linker solution. Reacted at room temperature for 30 min. Quenched reaction with 20 mL of 5% acetic acid to achieve a final pH of 5. Filtered the solution using 1 L vacuum filter (0.2 um).
- OG1802 (see
FIG. 36 ) is then purified as follows: Milipore cross flow cassettes are used for polymer purification in aqueous system. Started with concentrating the polymer solution to 250 mL (˜200 mg/mL). Added the fresh WFI from reservoir, and adjusted the flow rate of the fresh WFI feed to the same as the permeate (˜2 mL/min). The UFIDF was set up at 2-8° C. overnight. Typically 2.5 L of WFI was used (10× volume ratio to the polymer solution). A sample of retente was collected for purity test. The targeted purity was >98%. Filtered the polymer solution by 0.2 μM 1 L filter bottle. The polymer solution could be stored at 2-8° C. for up to 3 month before conjugation. - A HEA-PC polymer was synthesized as described below. HEA-PC (2-(acryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate), which is an acrylate as opposed to the methacrylate HEMA-PC described above, has the following structure:
- HEA-PC was polymerized to the initiator shown in Example 1 as compound L.
-
TABLE 5.1 Reactant Name Amount MW Initiator Compound L (see above) 1.65 mg 2505.5 Monomer HEA-PC 0.461 g 281.24 Catalyst Cu (I) Bromide 1.2 mg 143.45 Ligand Tris [2-(dimethylamino)ethyl]amine 2.73 mg 230.39 (Me6TREN) Solvent A N,N-Dimethylformamide (DMF) 21.85 μl 73.09 Solvent B Water 0.7 ml 18.02 Solvent C Methanol 0.7 ml 32.04 - Prepared a stock solution of initiator at 200 mg/mL by dissolving 2.2 mg of initiator in 11 μl of dry DMF and a 200 mg/ml solution of ligand by dissolving 4.6 mg of Me6TREN in 23 μL of dry DMF. Dispense 8.25 μl of the stock solution of initiator and 13.6 μl of the ligand into a tube. Degas at −78° C. for 5 mn then refill with Argon and add 1.2 mg of CuBr. Degas and refill with Argon. Add a stock solution of HEA-PC in methanol (weigh out 0.461 g of HEA-PC and dissolve it in 0.5 mL of methanol) to the solution inside the reactor at −78° C. Rinse the vial with 200 μl of methanol and add it inside the reactor at -78° C. and then 0.5 mL of distilled water then another 200 μl of water. Degas thoroughly until no bubbling is seen and all heterogeneity disappears (solid particulates dissolve or disappear). Refill with 4 psi of Argon and let the reaction to proceed at RT for an hour. The reaction was already viscous. The reaction was allowed to proceed for about one hour. A solution of bipyridine in methanol (5 mg in 0.5 uL) was added. Another 2-3 ml of methanol was added and the catalyst was allowed to oxidize overnight at 4° C. Conversion determined by 1H NMR was estimated to be 94%.
- The next day the polymer was dialyzed and subjected to SEC/MALS analysis using Shodex SB806M_HQ column (7.8×300 mm) in 1×PBS pH 7.4 at 1 ml/min, giving a PDI of 1.157, Mn of 723.5 kDa, Mp of 820.4 kDa and Mw of 837.2 kDa (before dialysis PDI is 1.12, Mn=695 kDa, Mp=778 kDa). Next a maleimide functionality was added to the polymer so that it could be conjugate to a protein.
- Next, the maleimide Mal-PEG4-PFP (see Example 1 above) ester was snapped on to the HEA-PC polymer as shown in Example 1. The resulting maleimide functionalized HEA-PC polymer can then be conjugated to sulfhydryl groups as discussed herein for HEMA-PC polymers.
- An acrylamide PC polymer was also made using the monomer 2-(acrylamyl)ethyl-2-(trimethylammonium)ethyl phosphate (Am-PC), having the following structure:
- The Am-PC was used for polymerization employing a 3 arm initiator (a TFA salt) having the structure:
- The synthesis of the Am-PC polymer was conducted as follows:
-
TABLE 5.2 Reactant Name/Identity Amount MW Initiator 3-arm initiator (see above) 2.2 mg 885.35 Monomer Am-PC 0.5 g 280.26 Catalyst (I) Copper (I) Bromide 1 mg 143.45 Catalyst (II) Copper (II) Bromide 0.2 mg 223.35 Ligand Tris[2-(dimethylamino)ethyl]amine 3.94 mg 230.39 (Me6TREN) Solvent A N,N-Dimethylformamide (DMF) 31.7 μl 73.09 Solvent B Water 1 ml 18.02 Solvent C Methanol 1 ml 32.04 - A stock solution of ligand at 200 mg/mL was prepared by dissolving 9 mg of Me6TREN in 45 uL of dry DMF. Add 19.7 uL of the stock solution to a reaction vessel. Prepare a stock solution of initiator at 200 mg/mL by dissolving 6.5 mg of material in 32.5 uL of DMF. Add 11 uL of the initiator stock solution to the ligand from above. Degas for 5 mn. Add 1 mg of CuBr. Prepared a stock solution of CuBr2 at 200 mg/mL by dissolving 4 mg CuBr2 in 20 μL of DMF. Add 0.5 g of monomer (AmPC) to 1 mL of methanol (slow dissolution/viscous solution), followed by 1 uL of the stock solution of CuBr2. Add the monomer solution dropwise to the reaction mixture above. Rinse with 1 mL of water. Degas the reaction mixture thoroughly (freeze-thaw). Let the reaction proceed for 24 hours.
- Afterwards the Am-PC polymer may be dialyzed. The molecular weight of the above polymer was determined by SEC/MALS: Mn is 215 kDa, Mp: 250 kDa, PDI is 1.17. Conversion was estimated by 1H NMR to be 94%. A maleimide functionality can be added to the Am-PC polymer as discussed above for HEMA-PC and HEA-PC. Maleimide functionalized Am-PC polymer can be conjugated to a protein as described above.
- After addition of the maleimide functionality to polymer OG1801 to form OG1802 (see above), an Ellman's assay was used to determine the amount of functional maleimide (i.e. conjugatable) in a sample. Thiol converted Ellman's reagent (DTNB) to TNB- then to TNB2- in water at neutral and alkaline pH, which gave off a yellow color (measured at 412 nm). A standard curve was established with cysteine. Since the maleimide reacts with thiol, this assay actually measured the thiol (cysteine) left. The inhibition was calculated as the (original thiol-thiol left after maleimide polymer addition)/(original thiol) and is expressed as a percentage.
- Reagents Employed in Assay: A standard curve was prepared using the cysteine from 62.5 μM to 2 μM. Polymer stock solutions were prepared by dissolving the powder in 1×PBS pH7.4 (reaction buffer) and mixing thoroughly. An equal molar of polymer and cysteine solutions were mixed and allowed to react at 27° C. for 30 minutes. The 150 μM of DTNB solution was added into the cysteine standards and polymer/cysteine reactions and the color was developed at 27° C. for 5 minutes. OD at 412 nm was read on the Spectramax plate reader and percent inhibition was calculated with the Softmax Pro software and the cysteine standard curve.
- An anti-VEGF-A antibody with an L443C (EU numbering) mutation having the sequence set forth below in SEQ ID NO. 1 (
FIG. 12 ) (heavy chain) was cloned. An anti-VEGF-A antibody light chain having the sequence set forth in SEQ ID NO. 2 (FIG. 13 ) below was cloned. - The OG1950 heavy and light chains may be cloned into expression plasmids and transfected into CHO cells. Cells can be grown up in appropriate media and harvested. OG1950 may be purified using techniques described above. The OG1950 cysteine at position 443 (L443C (EU numbering)) residue is typically “capped” or oxidized by chemicals in the cell culture media and is not available for conjugation. In this regard, purified OG1950 may be subjected to a decapping (i.e. reducing) procedure to remove the cap and enable the free (i.e. those not involved in Cys-Cys disulfide bonds) cysteine residue to be conjugated to the maleimide functionality of a polymer. Decapping may be done by mixing purified OG1950 protein with a 30× molar excess for 1 hour at 25° C. of the reducing agent TCEP (3,3′,3″-Phosphanetriyltripropanoic acid). The reduction reaction with TCEP may be monitored by SDS-PAGE. Following denaturation, the OG1950 protein maybe washed by UFdF using a Pellion XL Ultrafiltration Cassette with 20 mM Tris pH7.5, 150 mM NaCl, 0.5 mM TCEP buffer to remove the cap. The TCEP reagent may then be removed in the same UFdF setup with 20 mM Tris pH7.5, 150 mM NaCl. Reduced OG1950 may then be allowed to refold using air (ambient oxygen) which again is followed by SDS-PAGE as an assay
- The OG1950 heavy and light chains may be cloned into expression plasmids and transfected into CHO cells. Cells can be grown up in appropriate media and harvested. OG1950 may be purified using techniques described above. The OG1950 cysteine at position 443 (L443C (EU numbering)) residue is typically “capped” or oxidized by chemicals in the cell culture media and is not available for conjugation. In this regard, purified OG1950 may be subjected to a decapping (i.e. reducing) procedure to remove the cap and enable the free (i.e. those not involved in Cys-Cys disulfide bonds) cysteine residue to be conjugated to the maleimide functionality of a polymer. Decapping may be done by mixing purified OG1950 protein with a 30× molar excess for 1 hour at 25° C. of the reducing agent TCEP (3,3′,3″-Phosphanetriyltripropanoic acid). The reduction reaction with TCEP may be monitored by SDS-PAGE. Following reduction, the OG1950 protein can be washed by Ultrafiltration/Diafiltration (UF/DF) system using a Pellicon XL Ultrafiltration Cassette with 30 kDa MWCO membrane from Millipore with 20 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM TCEP buffer to remove the cap and the excess TCEP. The residual TCEP reagent may then be removed in the same UF/DF setup with 20 mM Tris pH7.5, 150 mM NaCl. Reduced OG1950 can then be allowed to reoxidize using dHAA at ambient temperature for 1 hour followed by UF/DF for removal of dHAA to form decapped OG1950. The decapping status is monitored by SDS-PAGE assay.
- Decapped OG1950 may be conjugated to polymer OG1802. An excess of OG1802 is used (10-20 fold molar excess). Conjugation can be monitored by SDS-PAGE and driven to near completion. OG1950 conjugate may be purified via cation exchanger chromatography and buffer exchanged into the formulation buffer by UF/DF. Polymer-OG1950 conjugate may be purified chromatographically as described above.
- This Example illustrates binding of OG1950 to VEGF-165 in single cycle kinetics BIAcore™ experiment
- SPR interaction analysis of OG1950 to human VEGF-165 was performed on a BIAcore™ T200 system (GE Healthcare) equipped with a protein A chip (GE Healthcare). A single-cycle kinetics method was implemented. Antibody was captured at 25 pg/mL in HBS-EP+ buffer (0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.15 M sodium chloride, and 0.05% polysorbate 20) with a pulse of 25 s at a flow rate of 10 μl/min. Subsequently, recombinant human VEGF-165 (R&D Systems) was applied at various concentrations with a pulse of 60 s at a flow rate of 30 μl/min and a final dissociation time of 1000 s. The experiment was carried out at 25° C. The surface was regenerated with 10 mM glycine pH 1.7 for 1 min at a flow rate of 50 μL/min. Binding kinetics analysis was performed using the Biacore T200 evaluation software with responses globally fit to a 1:1 interaction. Results are summarized in Table 10.1 and
FIG. 21 . -
TABLE 10.1 BINDING KINETICS OF OG1950 TO VEGF-165 ka (1/Ms) kd (1/s) KD (M) OG1950 3.35E+05 6.77E−08 2.02E−13 OG1950 exhibits < 1 pM KD in a 1:1 binding fit model (beyond instrument sensitivity). - OG1950 protein expression and protein preparation: OG1950 protein was expressed in mammalian GSCHOK1 expression system followed by purification using a Protein A affinity column. The purity of the Protein A column purified OG1950 was over 90% based on size exclusion chromatography and SDS-PAGE. The engineered specific cysteine residue of OG1950 was available for thiol conjugation to the OG1802 biopolymer. The thiol reacting chemical group of OG1802 was to react to form stable covalent linkage, which forms the OG1953 bioconjugate. To accomplish this, 1 mg of OG1950 was fully reduced with Tris-(2-Carboxyethyl)phosphine, Hydrochloride (TCEP) reducing agent followed by removal of TCEP via buffer exchange using a 30 KDa spin concentrator. The fully reduced OG1950 protein was then allowed to reoxidize to ensure all expected protein disulfide linkage was formed except the engineered cysteine residue (decap OG1950), which remained in reduced form for conjugation to the biopolymer via thiol specific conjugation chemistry.
- Conjugation reaction: The conjugation reactions were performed by mixing 100 ug of decap OG1950 with 15× molar excess of OG1802 biopolymer with final protein concentration at 2 mg/mL in Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.5). Various additives were evaluated in different conjugation reactions as shown in Table 11.1. in order to compare their impact on the conjugation efficiency. All reactions were setup in a fixed volume and incubated at 4° C. for 20 hours. Table 11.1 and
FIG. 19 shows ion Exchanger analysis (A280 absorbance) and fractionation of the conjugation reactions A through G. Reaction A contained buffer only; reaction B contained OG1950 antibody only; reaction C contained OG1950 antibody+OG1802 polymer; reaction D contained OG1950 antibody+OG1802 polymer+sucrose; reaction E contained OG1950 antibody+OG1802 polymer+trehalose; reaction F contained OG1950 antibody+OG1802 polymer+glutamic acid; reaction G contained OG1950 antibody+OG1802 polymer+aspartic acid. Reactions B-G were started with 100 ug OG1950 protein input with a fixed total reaction volume. Upon reaction completion, equal volumes of B-G reactions were injected for IEX analysis. The conjugation efficiency comparison is shown inFIG. 19 . Peak 1(P1) represents the excess biopolymer (OG1802) that was not conjugated to the protein and unable to bind to the ion exchanger column and therefore eluted as unbound fraction in each reaction; Peak 2 (P2) represents the antibody polymer bioconjugate in each reaction; Peak 3 (P3) represents the free antibody that was not conjugated to the polymer in each reaction. -
TABLE 11.1 (P2) (P3) Con- OG1953 OG1950 jugation Conjugate Protein efficiency (Au × (AU × P2/ Samples Second) Second) [P3 of B] A Buffer blank injection NA NA NA B OG1950 protein control 0 410129 NA C OG1950 + OG1802 37334 125884 9% biopolymer D C + Sucrose 198064 110356 48% E C + Trehalose 202682 139313 49% F C + Glutamic acid 30401 220577 7% G C + Aspartic acid 29054 175266 7% - As can be seen from the results above, various excipients allowed for significantly higher conjugation efficiency. Without intending to be limited by theory, such excipients which assist in maintaining the solubility of the ingredients help the conjugation efficiency.
- Cation exchanger analysis of the OG1953 conjugation reaction: Upon conjugation reaction completion, 5 ul of each reaction mixture was diluted 3 fold with a column equilibration buffer (20 mM sodium acetate pH 5.5) for cation exchanger chromatography (IEX) analysis and separation using a Shodex SP-825 HPLC column. IEX was performed under bind and elution mode where the reaction mixture was first diluted to lower the salt concentration so both conjugate and unreacted protein would bind to the column, followed by a salt gradient elution where increasing NaCl concentration resulted in elution of the conjugate (OG1953) and unconjugated free protein (OG1950) at different retention times due to the differential charge variation. IEX analysis results, as shown in
FIG. 19 show that the OG1953 conjugate (peak P2) separated very well from the unreacted free polymer (OG1802) as shown in peak P1 and unreacted free protein (OG1950) as shown in P3. - Scale up purification of the OG1953 conjugate for activity analysis: Conjugation reactions D and E were pooled and further separated with the IEX where the conjugate Peak (P2) eluted fractions were collected and concentrated for activity analysis.
- The abilities of OG1950, OG1953 and other anti-VEGF molecules to inhibit binding of Biotin-VEGF-165 to VEGFR were tested on an ELISA assay. 96 well ELISA plates were coated with 1 ug/mL recombinant VEGF R1-Fc protein (R&D systems part #321-FL-050). Plates were Incubated o/n at RT. Plates were then washed and blocked with blocking buffer (1% BSA in 1×PBS, pH7.4) for >=90 min with gentle shaking. 3-fold dilution series of test samples were made. Starting from 400 nM samples were mixed with biotin-VEGF (R&D systems, part #custom06). The final concentration of biotin-VEGF was 4 ng/mL (100 pM). The top concentration of sample dilution series was 85 ug/mL. After dilutions were made, samples were incubated at RT for >=30 min and then washed 3×. After washing, 100 uL of the sample/biotin-VEGF mixture was transferred to each well. Plates were incubated for >=90 min at RT with gentle shaking. After
incubation 100 ul of the 1:1500 diluted SA-HRP (R&D systems, part #A7906) was added to each well. Incubated plates were protected from light for approximately 20 min. Plates were then washed 3×. After washing 100 ul TMB substrate (R&D systems, part #DY998) was added. Plates were incubated and protected from light for approximately 30 min. Color development was monitored. Color development was stopped by adding 50 ul of stop solution. Plates were read at 450 nm. Results are shown inFIG. 20 - These results show that the OG1953 antibody/conjugate reached a higher maximal inhibition of Biotin-VEGF binding to VEGFR when compared to OG1950 (the unconjugated antibody) as well as the commercially available VEGF inhibitors Lucentis® (ranibizumab) and Avastin® (bevacizumab). In a typical VEGF ligand VEGF receptor binding assay, addition of OG1953 results in inhibition 97-98% of VEGF ligand binding to the VEGF receptor. This is compared to adding OG1950, which results in inhibition of 75-87% of VEGF ligand/receptor binding and adding Lucentis® (ranibizumab) or Avastin® (bevacizumab), each of which only results in inhibition of 68-78% of VEGF ligand/receptor binding. Furthermore, previous studies have shown that adding either OG1950, Lucentis® (ranibizumab), or Avastin® (bevacizumab) at concentrations of 400 nM does not result in 100% inhibition of binding of the VEGF ligand to the VEGF receptor.
-
FIG. 20 also shows that the other antibody conjugate anti-VEGF Bio Conjugate (anti-VEGF BC) reached a higher maximal inhibition of binding of VEGF to the VEGF receptor when compared to the antibody alone (anti-VEGF). Together these results show that (i) the OG1953 antibody conjugate is more effective at inhibiting VEGF ligand binding to the VEGF receptor when compared to currently available VEGF inhibitors and (ii) conjugating VEGF antibodies at a site outside of the region of the active site can result increased inhibition of VEGF ligand binding to the VEGF receptor. - In some embodiments, provided herein are anti-VEGF antibody conjugates that display a superior (or at least equal) level of blocking ability, as compared to the anti-VEGF antibody alone.
- Binding kinetics experiments were performed at 25° C. using a BIAcore T200. An anti-his antibody was immobilized on a CM5 chip. Histidine-tagged FcγRI and FcγRIIIa at a concentration of 0.5 μg/mL prepared in HBS-EP buffer (0.01M HEPES pH7.4, 0.15M NaCl, 3 mM EDTA, 0.005% Tween-20) were injected independently for 60-s using a flow rate of 5 μL/min in the active flow cell only. Antibody candidate and Avastin® (bevacizumab), used as a positive control, were then injected over the reference and active flow cell using 60-s injections at 30 μL/mL, applying single-cycle kinetics method. Antibody concentrations in the range of 0.48 to 300 nM were used for FcγRI and 7.8 nM to 2000 nM for FcγRIIIa. Following each run, flow cells were regenerated with a 60 s injection of 10 mM glycine pH 1.7 using a flow-rate of 50p/mL. Data was double referenced, using subtraction of both reference flow cell and blank cycles. Analysis was performed using BIA evaluation software. Results are shown in
FIGS. 22 and 23 . Results show that OG1950 showed no significant binding to either Fc gamma receptor I and IIIa in this assay. - Complement engagement liabilities were assessed by C1q ELISA binding. The antibody panel was titrated 1:2 from a top concentration of 10 ug/mL in 1×PBS for overnight coating at 4 C. Plates were then blocked After a 2 hour blocking step in 1% BSA. Purified human C1q was then applied at 5 ug/mL in 1% BSA for 2 hours at room temperature followed by detection with HRP-conjugated anti-human C1q antibody and TMB development. Results are shown in
FIG. 24 . Results show that C1q has more binding affinity for Avastin® (bevacizumab) relative to OG1950 at antibody concentrations between 10 ug/mL and 0.625 ug/mL. - In some embodiments, OG1950 has less than 10% of the binding of that of Avastin. In some embodiments, OG1950 has less binding to C1q than Avastin® (bevacizumab).
- Human retinal microvascular endothelial cell (HuRMVEC) proliferation assays were performed as follows: cells were maintained in CSC complete medium (cell systems, #4Zo-500) supplemented with 2% of CultureBoost (cell systems, #4CB-500) and 0.2% of Bac-off (cell systems, #4ZO-643), seeded in 96-well plates in assay medium (serum free medium (cell systems, #4Z3-500-S) with 5% FBS) at density of 10,000 cells per well. VEGF inhibitors were first added at the indicated concentrations to each well. Thirty minutes later, VEGF 165 (R&D systems, #293-VE-500/CF) was added to a final concentration of 1.3 nM. After 3 days, cells were incubated with WST-1 cell proliferation assay reagent and read at OD450 nM.
- Results demonstrated that two independent preps of OG1953 (OG1953A and OG1953B) both show potent inhibition to the HuRNVEC proliferation. Both maximal inhibition and IC50 of OG1953 is comparable to that of antibody alone OG1950 in this assay. Maximal inhibition of OG1953 is also significantly better than that of Avastin® (bevacizumab) and Eylea® (aflibercept). The results (including IC50 values and their comparison with Lucentis® (ranibizumab), Eylea® (aflibercept), and Avastin® (bevacizumab)) are shown in
FIG. 25 . - Binding kinetics was performed at 25° C. using a BIAcore T200 on Avastin® (bevacizumab), OG1950 and OG1953. Briefly, anti-VEGF agents were captured on a Protein A chip (GE). 1 ug/ml OG1950 and Avastin® (bevacizumab) were flowed at 25 ul/min for 2 mins. 10 ug/ml OG1953 was flowed at 10 uls/min for 10 mins. VEGF (recombinant; R&D systems) was flowed over captured antibodies for 240 seconds contact time each at 0.56 nM, 1.67 nM, 5 nM, 15 nM, and 45 nM for single cycle kinetics, and dissociated for 30 minutes. Analysis was performed using BiaEvaluation software (GE). All sensorgrams were double reference subtracted and fit using a 1:1 Langmuir binding model. Off-rate of these anti-VEGF agents might be under-estimated in this experiment, due to the disassociation between anti-VEGF agents and Protein A capture.
- The results are presented in
FIG. 26 , including the calculated KD, ka, and kd values - Using the standard conjugation reaction process setup, the OG1950 conjugation reaction mixture was found to be cloudy with precipitate immediately present upon mixing. Further investigation revealed the precipitate was the protein itself, which in turn resulted in poor conjugation efficiency observed via either SDS-PAGE or ion exchanger analysis as the protein was lost by precipitation instead of participating in the conjugation reaction.
- Initial troubleshooting experiments performed revealed conditions that did not result in a clear reaction solution included (1) reduction of polymer molar excess ratio from over 10 to less than 5; (2) preadjusting the reaction solution pH to more acidic (e.g. pH 5) or basic (e.g. pH 8.5) from the standard neutral pH range (e.g. pH 6.5-7.5); (3) testing of other IgG1 protein samples with similar or different isoelectric point (pI) as compared to OG1950; (4) buffer exchanged the sample storage buffer into 1×PBS pH 7.4 or 20 mM Tris buffer pH 7.4, 100 mM NaCl; and (5) preadjusting the OG1802 solution with 20 mM Tris buffer pH 7.4.
- Protein is known to carry net surface charge that helps protein solubility in aqueous solution. The amino acids are referred to as hydrophilic amino acids which include arginine, lysine, aspartic acid, and glutamic acid. At
neutral pH 7 the side chains of these amino acids carry charges—positive for arginine and lysine, negative for aspartic acid, and glutamic acid. Altering the solution pH could modulate the intrinsic protein solubility which is therefore in some of the troubleshoot experiments mentioned above such as (2) this approach was applied. In theory, proteins solubility in aqueous solution differs depending on the level of hydrophobic or hydrophilic properties of the surface. Proteins with surfaces that have greater hydrophobic properties will readily precipitate. The addition of ions (e.g. NaCl or other salt) creates an electron shielding effect that nullifies some activity between water particles and the protein, reducing solubility as the proteins bind with each other and begin to aggregate. In the current situation, it was hypothesized that the biopolymer directly or indirectly modulates the protein surface charge and/or exposed surfaces in a manner that promotes the intermolecular hydrophobic interactions which results in protein precipitation. - Excipients that were determined to modulate protein solubility include the following categories (i) detergents including neutral detergent (e.g. 0.1-1% polysorbate20 or tween20) or charged detergent (e.g. 0.1-1% Sodium Dodecyl Sulfate (SDS)) (ii) sugars (e.g. 6% Trehalose or 6% sucrose) (iii) negatively charged amino acids (e.g. 0.03-1 mM glutamic acid or 0.03-1 mM aspartic acid) or positively charged amino acids (e.g. 1-100 mM lysine or arginine) (iv) chaotropic agents or denaturants (e.g. 1-100 mM urea, guanidine hydrochloride analog or 1-100 mM arginine) (v) polyethylene glycol (e.g. 0.03-1 mM PEG8000); and (vi) organic solvent (e.g. 20% ethanol).
- In a further design of experiment (DOE) study, various excipients from each category mentioned above were selected based on their compatibility to the pharmaceutical manufacturing for human injectable use. In addition, extreme acidic pH at 4 and basic pH at 9 were also included in such evaluation. A standard IgG1 protein sample was selected for such evaluation which did not contain an engineered cysteine to minimize the potential interference of such unpaired cysteine residue complicating the precipitation observation. Table 17.1 depicted such matrix. The asterisk (*) code/rows are conditions that result in clear solution while the non-asterisk rows are the ones that result in various degree of cloudiness or precipitation.
-
TABLE 17.1 code Excipient Reaction buffer 1 OG1898_R5782_5xR7473 (control) 20 mM Tris pH 7.4, 100 mM NaCl 2* 5 mg/mL_R5782_5xR7473_pH4 sodium acetate 3 5 mg/mL_R5782_5xR7473_pH9 sodium carbonate 4* 5 mg/mL_R5782_5xR7473_1% Tween20 Tris 20 mM NaCl 5* 5 mg/mL_R5782_5xR7473_0.1% Tween20 Tris 20 mM NaCl 6* 5 mg/mL_R5782_5xR7473_1% SDS Tris 20 mM NaCl 7 5 mg/mL_R5782_5xR7473_0.1% SDS Tris 20 mM NaCl 8* 5 mg/mL_R5782_5xR7473_6% Sucrose Tris 20 mM NaCl 9* 5 mg/mL_R5782_5xR7473_6% Trehalose Tris 20 mM NaCl 10* 5 mg/mL_R5782_5xR7473_0.03 mM Aspartic Tris 20 mM NaCl acid 11* 5 mg/mL_R5782_5xR7473_1 mM Aspartic Tris 20 mM NaCl acid 12* 5 mg/mL_R5782_5xR7473_0.03 mM Glutamic Tris 20 mM NaCl acid 13* 5 mg/mL_R5782_5xR7473_1 mM Glutamic Tris 20 mM NaCl acid 14 5 mg/mL_R5782_5xR7473_1 mM Arginine Tris 20 mM NaCl 15* 5 mg/mL_R5782_5xR7473_100 mM Arginine Tris 20 mM NaCl 16 5 mg/mL_R5782_5xR7473_1 mM Urea Tris 20 mM NaCl 17* 5 mg/mL_R5782_5xR7473_100 mM Urea Tris 20 mM NaCl 18 5 mg/mL_R5782_5xR7473_0.03 mM PEG8000 Tris 20 mM NaCl 19 5 mg/mL_R5782_5xR7473_1 mM PEG8000 Tris 20 mM NaCl 20 5 mg/mL_R5782_5xR7473_20% EtOH Tris 20 mM NaCl 21 5 mg/mL_OG1931_R8399_5xR7473_CTL Tris 20 mM NaCl 22 5 mg/mL_OG1931_R8399_5xR7473_1 mM Tris 20 mM NaCl Aspartic acid 23* 5 mg/mL_OG1931_R8399_5xR7473_1 mM Tris 20 mM NaCl Arginine 24* 8 mg/mL_OG1321_R7587_5xR7473_CTL Tris 20 mM NaCl 25 5 mg/mL_R5782_5xR7473_1 mM Lysine Tris 20 mM NaCl 26 5 mg/mL_R5782_5xR7473_100 mM Lysine Tris 20 mM NaCl - The resulting precipitated solutions (or non-precipitated solutions) are shown in
FIG. 28 . - All patent filings, websites, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect disclosed herein can be used in combination with any other unless specifically indicated otherwise. Although some embodiments have been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (30)
1.-36. (canceled)
37. A method of making an antibody conjugate comprising an anti-VEGF-A antibody conjugated to a phosphorylcholine containing polymer, the method comprising the step of:
conjugating an anti-VEGF-A antibody to a phosphorylcholine containing polymer;
wherein the anti-VEGF-A antibody comprises a cysteine residue added via recombinant DNA technology and wherein the cysteine is outside a variable region of the antibody;
wherein the phosphorylcholine containing polymer comprises a sulfhydryl specific reacting group selected from the group consisting of a maleimide, a vinylsulfone, an orthopyridyl-disulfide, and an iodoacetamide; and
wherein the sulfhydryl specific reacting group on the phosphorylcholine containing polymer reacts with the cysteine residue on the anti-VEGF-A antibody to make the antibody conjugate.
38. The method according to claim 37 wherein the anti-VEGF-A antibody is an immunoglobulin G (IgG) and the cysteine is in the Fc region of the antibody.
39. The method according to claim 37 , wherein the anti-VEGF-A antibody comprises a light chain and a heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the anti-VEGF-A antibody light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14).
40. The method according to claim 38 , wherein the anti-VEGF-A antibody heavy chain isotype is IgG1, wherein the anti-VEGF-A antibody constant domain has one or more mutations relative to an IgG1 constant domain to modulate effector function.
41.-43. (canceled)
44. The method according to claim 39 , wherein the anti-VEGF-A antibody heavy chain isotype is IgG1 and comprises the mutations (EU numbering) L234A, L235A, and G237A.
45. The method according to claim 44 wherein the cysteine residue added by recombinant DNA technology is selected from the group consisting of Q347C (EU numbering) and L443C (EU numbering).
46. (canceled)
47. The method according to claim 45 , wherein the sequence of the anti-VEGF-A antibody heavy chain is SEQ ID NO: 1 and sequence of the anti-VEGF-A antibody light chain is SEQ ID NO: 2.
48. The method according to claim 39 , wherein the sulfhydryl specific reacting group is maleimide.
50. The method according to claim 49 , wherein the polymer has three or more arms.
51.-53. (canceled)
54. The method according to claim 50 , wherein the polymer has a molecular weight between about 300,000 and 1,750,000 Da.
55. (canceled)
56. (canceled)
57. The method according to claim 39 , further comprising the step of contacting the anti-VEGF-A antibody with a thiol reductant under conditions that produce a reduced cysteine sulfhydryl group to produce a reduced anti-VEGF-A antibody in which all cysteine residues are reduced.
58.-61. (canceled)
62. The method according to claim 57 , further comprising the steps of removing the thiol reductant from the reduced anti-VEGF-A antibody, and treating the reduced anti-VEGF-A antibody with an oxidizing agent.
63.-70. (canceled)
71. The method according to claim 39 , wherein the method further comprises the step of polymerizing a free radically polymerizable phosphorylcholine containing monomer in a polymerization medium to provide the phosphorylcholine containing polymer, the medium comprising:
the radically polymerizable phosphorylcholine containing monomer;
a transition metal catalyst Mt (q−1)+ wherein Mt is a transition metal, q is the maximum oxidation state of the metal and q−1 is the oxidation state of the metal, wherein the metal can act as a catalyst, wherein the transition metal catalyst is supplied as a salt of the form Mt (q−1)+X′(q−1), wherein X′ is a counterion or group, or wherein the transition metal catalyst is supplied in situ by providing the inactive metal salt at its highest oxidation state Mt q+X′q together with a reducing agent that is capable of reducing the transition metal from the oxidized inactive state to the reduced active state;
a ligand; and
an initiator.
73.-106. (canceled)
107. A process for preparing a conjugated protein, the process comprising:
reducing one or more cysteines in a protein to form a decapped protein in a solution;
reoxidizing the decapped protein to restore at least one disulfide linkage in the reduced protein while ensuring that an engineered cysteine residue in the protein remains in a free thiol form to thereby form a reoxidized decapped protein in the solution;
adding at least one excipient to the solution, wherein the excipient reduces a polymer induced protein precipitation;
adding a polymer to the solution; and
conjugating the polymer to the reoxidized decapped protein at the engineered cysteine residue to form a conjugated protein.
108. The process of claim 107 , wherein the protein is an antibody, an antibody protein fusion or a binding fragment thereof.
109. The process of claim 108 , wherein the excipient is an acid or a base.
110. The process of claim 108 , wherein the excipient is selected from the group consisting of at least one of: a detergent, a sugar, and a charged amino acid.
111. The process of claim 107 , wherein reaction of a polymer with the reduced protein occurs under aqueous conditions between pH 6.0 to pH 8.5.
112.-121. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/301,599 US20210324063A1 (en) | 2015-12-30 | 2021-04-08 | Antibodies and conjugates thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562273177P | 2015-12-30 | 2015-12-30 | |
US15/394,500 US11066465B2 (en) | 2015-12-30 | 2016-12-29 | Antibodies and conjugates thereof |
US17/301,599 US20210324063A1 (en) | 2015-12-30 | 2021-04-08 | Antibodies and conjugates thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/394,500 Continuation US11066465B2 (en) | 2015-12-30 | 2016-12-29 | Antibodies and conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210324063A1 true US20210324063A1 (en) | 2021-10-21 |
Family
ID=59225788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/394,500 Active US11066465B2 (en) | 2015-12-30 | 2016-12-29 | Antibodies and conjugates thereof |
US17/301,599 Pending US20210324063A1 (en) | 2015-12-30 | 2021-04-08 | Antibodies and conjugates thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/394,500 Active US11066465B2 (en) | 2015-12-30 | 2016-12-29 | Antibodies and conjugates thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US11066465B2 (en) |
EP (1) | EP3397276A4 (en) |
JP (3) | JP7088454B2 (en) |
KR (1) | KR20180104635A (en) |
CN (1) | CN108712911A (en) |
AU (1) | AU2016381964B2 (en) |
BR (1) | BR112018013407A2 (en) |
CA (1) | CA3010056A1 (en) |
IL (2) | IL260323A (en) |
RU (1) | RU2744860C2 (en) |
SG (1) | SG11201805420SA (en) |
WO (1) | WO2017117464A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11584790B2 (en) | 2017-04-14 | 2023-02-21 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
US11590235B2 (en) | 2013-09-08 | 2023-02-28 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
US11819531B2 (en) | 2009-12-18 | 2023-11-21 | Kodiak Sciences Inc. | Multifunctional zwitterionic polymer conjugates |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
KR102210104B1 (en) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | Butyrylcholinesterase zwitterionic polymer conjugates |
BR112018013407A2 (en) * | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | antibodies and conjugates thereof |
EP3727468A4 (en) * | 2017-12-19 | 2021-09-22 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
CN110003328B (en) * | 2018-01-05 | 2022-04-19 | 百奥泰生物制药股份有限公司 | Long-acting low-toxicity recombinant anti-VEGF humanized monoclonal antibody and production method thereof |
AU2019227997A1 (en) * | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
EP3832292B1 (en) * | 2018-07-31 | 2023-08-30 | Sekisui Chemical Co., Ltd. | Inspecting method, inspecting instrument, and inspecting device |
KR20210125034A (en) | 2019-02-15 | 2021-10-15 | 우시 바이올로직스 아일랜드 리미티드 | Method for preparing antibody-drug conjugates with improved homogeneity |
MX2022013311A (en) * | 2020-04-22 | 2022-11-14 | Akeso Biopharma Inc | Anti-cd73-anti-pd-1 bispecific antibody and use thereof. |
KR20220029524A (en) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | Hexameric anti-VEGF antibody, and compositions comprising the same |
KR20220029343A (en) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | Hexameric anti-VEGF antibody, and compositions comprising the same |
EP4323399A1 (en) * | 2021-04-14 | 2024-02-21 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20230250133A1 (en) * | 2022-02-10 | 2023-08-10 | Kodiak Sciences Inc. | Methods of purifying a product |
CN117257977A (en) * | 2023-11-07 | 2023-12-22 | 正大天晴药业集团南京顺欣制药有限公司 | Methods for preparing antibody drug conjugates |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US20080311134A1 (en) * | 2007-05-08 | 2008-12-18 | Junutula Jagath R | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US20100166700A1 (en) * | 2006-02-28 | 2010-07-01 | Oligasis Corporation | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US20130034517A1 (en) * | 2009-12-18 | 2013-02-07 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
WO2013093809A1 (en) * | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
US20150306234A1 (en) * | 2014-03-05 | 2015-10-29 | Pfizer Inc. | MUTEINS OF CLOTTING FACTOR Vlll |
US11066465B2 (en) * | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
Family Cites Families (675)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE2023169C2 (en) | 1970-05-12 | 1982-07-22 | Hannes 8100 Garmisch-Partenkirchen Marker | Safety ski bindings |
JPS5296363A (en) | 1976-02-06 | 1977-08-12 | Takamatsu Electric Works Ltd | Device for supplementing gas in gas sealed distributing device |
JPS5472168A (en) | 1977-11-18 | 1979-06-09 | Tiger Vacuum Bottle Ind | Electric cooking implement |
JPS5846044B2 (en) | 1979-04-14 | 1983-10-14 | 日本金属株式会社 | powder iron core |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
CH652145A5 (en) | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4609707A (en) | 1983-11-10 | 1986-09-02 | Genetic Systems Corporation | Synthesis of polymers containing integral antibodies |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
SE447704B (en) | 1985-04-16 | 1986-12-08 | Flaekt Ab | CONTACT REACTOR DEVICE INCLUDING MEASURES TO PREVENT RECYCLING OF ABSORPTION MATERIALS TO THE SIZE SURFACE |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
PT88641B (en) | 1987-10-02 | 1993-04-30 | Genentech Inc | METHOD FOR PREPARING A VARIETY OF ADHESION |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5252713A (en) | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
ATE277193T1 (en) | 1989-03-21 | 2004-10-15 | Vical Inc | EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0814159T3 (en) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgenic, non-human animals capable of forming heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH06507543A (en) | 1991-01-31 | 1994-09-01 | コア セラピューティクス,インコーポレイティド | Extracellular domain of human platelet-derived growth factor receptor polypeptide |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
DE4110409C2 (en) | 1991-03-29 | 1999-05-27 | Boehringer Ingelheim Int | New protein-polycation conjugates |
US5325525A (en) | 1991-04-04 | 1994-06-28 | Hewlett-Packard Company | Method of automatically controlling the allocation of resources of a parallel processor computer system by calculating a minimum execution time of a task and scheduling subtasks against resources to execute the task in the minimum time |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
DE122004000008I1 (en) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
ES2197145T3 (en) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL. |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
JPH07503132A (en) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | Transgenic non-human animals capable of producing xenoantibodies |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | Vector particles resistant to inactivation by human serum. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
GB9301702D0 (en) | 1993-01-28 | 1993-03-17 | Biocompatibles Ltd | New materials |
CA2158745C (en) | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
CA2166118C (en) | 1993-06-24 | 2007-04-17 | Frank L. Graham | Adenovirus vectors for gene therapy |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
EP0814154B1 (en) | 1993-09-15 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus vectors |
DE69435223D1 (en) | 1993-10-25 | 2009-09-03 | Canji Inc | Recombinant adenovirus vector and method of use |
GB9324033D0 (en) | 1993-11-23 | 1994-01-12 | Biocompatibles Ltd | Ethylenically unsaturated compounds |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
EP0772689B1 (en) | 1994-05-09 | 2007-12-19 | Oxford Biomedica (UK) Limited | Retroviral vectors having a reduced recombination rate |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US6541580B1 (en) | 1995-03-31 | 2003-04-01 | Carnegie Mellon University | Atom or group transfer radical polymerization |
US5763548A (en) | 1995-03-31 | 1998-06-09 | Carnegie-Mellon University | (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization |
JPH09154588A (en) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf-binding polypeptide |
GB9521234D0 (en) | 1995-10-16 | 1995-12-20 | Biocompatibles Ltd | Synthesis of polymerisable phospho diesters |
CA2233160A1 (en) | 1995-10-16 | 1997-04-24 | Biocompatibles Uk Limited | Oxidation of phosphorus compounds |
US5807937A (en) | 1995-11-15 | 1998-09-15 | Carnegie Mellon University | Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties |
US5663425A (en) | 1996-01-26 | 1997-09-02 | Lignotech Usa, Inc. | Production of acid soluble humates |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
ATE424463T1 (en) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | RECOMBINATION-INCAPABLE RETROVIRAL VECTORS |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5789487A (en) | 1996-07-10 | 1998-08-04 | Carnegie-Mellon University | Preparation of novel homo- and copolymers using atom transfer radical polymerization |
US5863551A (en) | 1996-10-16 | 1999-01-26 | Organogel Canada Ltee | Implantable polymer hydrogel for therapeutic uses |
JPH10139832A (en) | 1996-11-08 | 1998-05-26 | Nof Corp | Copolymer and glucose sensor |
ES2215295T3 (en) | 1997-02-21 | 2004-10-01 | Genentech, Inc. | CONJUGATES OF POLYMERS AND ANTIBODY FRAGMENTS. |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7125938B2 (en) | 1997-03-11 | 2006-10-24 | Carnegie Mellon University | Atom or group transfer radical polymerization |
JP3957765B2 (en) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | Anti-VEGF antibody |
ES2361267T3 (en) | 1997-04-07 | 2011-06-15 | Genentech Inc. | PROCEDURE FOR THE PRODUCTION OF HUMANIZED ANTIBODIES THROUGH RANDOM MUTAGENESIS. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
US20150023951A1 (en) | 1997-04-07 | 2015-01-22 | Genentech, Inc. | Anti-vegf antibodies |
JP3052923B2 (en) | 1997-05-30 | 2000-06-19 | 日本油脂株式会社 | Method for producing (meth) acrylate derivative |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
CN1295680A (en) | 1998-01-30 | 2001-05-16 | 第一化学公司 | Photopolymerization compositions including maleimides and processes for using the same |
JP4162284B2 (en) | 1998-02-04 | 2008-10-08 | 日油株式会社 | Cleaning composition |
CA2321140C (en) | 1998-02-20 | 2015-04-07 | Tanox, Inc. | Inhibitors of complement activation |
US6121371A (en) | 1998-07-31 | 2000-09-19 | Carnegie Mellon University | Application of atom transfer radical polymerization to water-borne polymerization systems |
GB9812550D0 (en) | 1998-06-11 | 1998-08-05 | Aepact Ltd | Tumour therapy and imaging |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6632926B1 (en) | 1998-11-18 | 2003-10-14 | Genentech, Inc. | Antibody variants |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
US6344050B1 (en) | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
EP2016953A3 (en) | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
DE60036082T2 (en) | 1999-02-05 | 2008-06-12 | Samsung Electronics Co., Ltd., Suwon | METHOD AND DEVICE FOR RECONSTRUCTING TEXTURE IMAGES |
AU4195100A (en) | 1999-04-05 | 2000-10-23 | Research Foundation Of State University Of New York, The | Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them |
US6342221B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
GB9914650D0 (en) | 1999-06-24 | 1999-08-25 | Angyogene Pharmaceuticals Ltd | Chimeric proteins mediating targeted apoptosis |
CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
NZ517184A (en) | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
US7049373B2 (en) | 1999-08-06 | 2006-05-23 | Carnegie Mellon University | Process for preparation of graft polymers |
ATE297954T1 (en) | 1999-09-08 | 2005-07-15 | Polytherics Ltd | UNIFORM MOLECULAR WEIGHT POLYMERS |
GB9928956D0 (en) | 1999-12-07 | 2000-02-02 | Malik Navid | Internally supported biomimetic coating systems |
EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20020091082A1 (en) | 2000-09-13 | 2002-07-11 | Aiello Lloyd P. | Methods of modulating symptoms of hypertension |
DE60125409T2 (en) | 2000-10-06 | 2007-09-27 | Carnegie Mellon University | POLYMERIZATION PROCESS FOR ION MONOMERS |
US6627314B2 (en) | 2000-10-06 | 2003-09-30 | Carnegie Mellon University | Preparation of nanocomposite structures by controlled polymerization |
AU2001296670A1 (en) | 2000-10-06 | 2002-04-15 | Carnegie-Mellon University | A catalyst system for controlled polymerization |
EP1325046B1 (en) | 2000-10-06 | 2007-06-27 | Biocompatibles UK Limited | Zwitterionic polymers |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
AU2002307151A1 (en) | 2001-04-06 | 2002-10-21 | Carnegie Mellon University | A process for the preparation of nanostructured materials |
US20040010376A1 (en) | 2001-04-17 | 2004-01-15 | Peizhi Luo | Generation and selection of protein library in silico |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
EP1421376A2 (en) | 2001-08-27 | 2004-05-26 | Zeptosens AG | Bioanalytical recognition surface with optimised recognition element density |
JP2003064132A (en) | 2001-08-28 | 2003-03-05 | Nof Corp | Polymer, method for producing the same and emulsifying/ dispersing agent |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
EP1427829A4 (en) | 2001-08-31 | 2005-10-12 | Abmaxis Inc | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
US6759491B2 (en) | 2001-10-12 | 2004-07-06 | Carnegie Mellon University | Simultaneous reverse and normal initiation of ATRP |
AU2002351471A1 (en) | 2001-10-12 | 2003-04-22 | Carnegie Mellon University | Process for monomer sequence control in polymerizations |
JP4758608B2 (en) | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | Branched polymers and their conjugates |
RS35404A (en) | 2001-11-09 | 2006-10-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
EP2308888B1 (en) | 2001-11-14 | 2017-03-01 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
CU23225A1 (en) | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PEPTIDES FOR THE TREATMENT OF CANCER ASSOCIATED WITH HUMAN PAPILOMA VIRUS (HPV) AND OTHER EPITELIAL TUMORS |
ES2291613T3 (en) | 2002-01-16 | 2008-03-01 | Biocompatibles Uk Limited | CONJUGATES OF POLYMERS. |
GB0202494D0 (en) | 2002-02-02 | 2002-03-20 | Avecia Ltd | Process |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
US20050220880A1 (en) | 2002-03-07 | 2005-10-06 | Lewis Andrew L | Drug carriers comprising amphiphilic block copolymers |
DE60334779D1 (en) | 2002-03-07 | 2010-12-16 | Biocompatibles Uk Ltd | Mit nucleinsäure complexierte block-copolymere |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CN101143221A (en) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | Central airway administration for systemic delivery of therapeutics |
US20060193830A1 (en) | 2002-03-20 | 2006-08-31 | Hauswirth William W | Raav vector compositions and methods for the treatment of choroidal neovascularization |
JP4248189B2 (en) | 2002-04-09 | 2009-04-02 | 株式会社資生堂 | Phosphorylcholine group-containing polysaccharide and method for producing the same |
AU2003241531A1 (en) | 2002-05-21 | 2003-12-12 | Emory University | Multivalent polymers with chain-terminating binding groups |
WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
WO2004014963A2 (en) | 2002-08-09 | 2004-02-19 | Carnegie Mellon University | Polymers, supersoft elastomers and methods for preparing the same |
US20040091490A1 (en) | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
WO2004019860A2 (en) | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
JP2006511475A (en) | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | Method for suppressing choroidal neovascular disease |
WO2004028569A1 (en) | 2002-09-25 | 2004-04-08 | Biocompatibles Uk Limited | Polymer compositions for administration to animals |
JP2006505686A (en) | 2002-11-07 | 2006-02-16 | ロディア・シミ | Copolymers of controlled structure containing amphoteric or zwitterionic moieties |
US20070111279A1 (en) | 2002-11-13 | 2007-05-17 | Procell, Inc. | Production of recombinant therapeutic bioscavengers against chemical and biological agents |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
GB0301014D0 (en) | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
US20060167230A1 (en) | 2003-01-20 | 2006-07-27 | Takaki Koga | Anti-pci neutralizing antibody |
AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
PT3417875T (en) | 2003-02-10 | 2020-08-24 | Biogen Ma Inc | Immunoglobulin formulation and method of preparation thereof |
ATE442861T1 (en) | 2003-03-07 | 2009-10-15 | Univ Texas | PHOTODYNAMIC THERAPY DIRECTED AGAINST ANTIBODIES |
DK1608685T3 (en) | 2003-03-28 | 2007-06-11 | Regeneron Pharma | VEGF antagonists for the treatment of diabetes |
US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20120183593A1 (en) | 2003-04-09 | 2012-07-19 | Directcontact Llc | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
CA2525969A1 (en) | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
EP1626989A2 (en) | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
AR046510A1 (en) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
WO2005014822A2 (en) | 2003-08-04 | 2005-02-17 | Applied Research Systems Ars Holding N.V. | Novel therapeutic fusion proteins |
CA2534197A1 (en) | 2003-08-06 | 2005-02-24 | Thomas Jefferson University | Use of a vegf antagonist in combination with radiation therapy |
AU2004268614C1 (en) | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
KR20120073370A (en) | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | Multi-arm polymer prodrugs |
JP2005141865A (en) | 2003-11-07 | 2005-06-02 | Toyota Motor Corp | High-density recording medium |
US20050100550A1 (en) | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
KR20050047030A (en) | 2003-11-13 | 2005-05-19 | 한미약품 주식회사 | Igg fc fragment for a drug carrier and method for the preparation thereof |
CA2758460C (en) | 2003-12-16 | 2014-09-23 | Nektar Therapeutics | Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US7127655B2 (en) | 2004-01-20 | 2006-10-24 | Qualcomm, Inc. | Methods and apparatus to optimize delivery of multicast content using probabilistic feedback |
CN1925871A (en) | 2004-01-27 | 2007-03-07 | 南加州大学 | Polymer-bound antibody concer therapeutic agent |
KR100593443B1 (en) | 2004-02-11 | 2006-06-28 | 삼성전자주식회사 | Transistors and Manufacturing Methods |
JP4727938B2 (en) | 2004-02-24 | 2011-07-20 | 泰彦 岩崎 | Production method and use of polyphosphoric acid having living radical polymerization initiating group |
ATE507240T1 (en) | 2004-03-05 | 2011-05-15 | Vegenics Pty Ltd | MATERIALS AND METHODS FOR GROWTH FACTOR BINDING CONSTRUCTS |
WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
JP4727941B2 (en) | 2004-03-12 | 2011-07-20 | 泰彦 岩崎 | Production method and use of biodegradable polymer |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
EP1763365B1 (en) | 2004-06-09 | 2016-08-10 | Technion Research And Development Foundation, Ltd. | Antibodies for selective apoptosis of cells |
EP1753442A2 (en) | 2004-06-10 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Method of administering and using vegf inhibitors for the treatment of human cancer |
US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
WO2006009809A2 (en) | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
US20080096923A1 (en) | 2004-07-23 | 2008-04-24 | Aniz Girach | Methods For Diagnosing And Treating Diabetic Microvascular Complications |
JP4807802B2 (en) | 2004-07-30 | 2011-11-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods of treating type I diabetes by blocking VEGF-mediated activity |
CN101123994B (en) | 2004-08-16 | 2012-11-14 | 夸克医药公司 | Therapeutic uses of inhibitors of rtp801 |
US20060067930A1 (en) | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1804835B9 (en) | 2004-09-13 | 2012-05-02 | Genzyme Corporation | Multimeric constructs |
CN101065151B (en) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | Cysteine engineered antibodies and conjugates |
CA2581126A1 (en) | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
MX2007004374A (en) | 2004-10-12 | 2008-01-29 | Amprotein Corp | Chimeric protein. |
ES2390676T3 (en) | 2004-10-21 | 2012-11-15 | Genentech, Inc. | Method for the treatment of intraocular neovascular diseases |
US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
FR2878749B1 (en) | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | ANTITUMOR COMBINATIONS CONTAINING IN VEGT INHIBITOR AGENT AND 5FU OR ONE OF ITS DERIVATIVES |
WO2006063055A2 (en) | 2004-12-06 | 2006-06-15 | Bolder Biotechnology, Inc. | Enzyme conjugates for use as detoxifying agents |
AR051800A1 (en) | 2004-12-15 | 2007-02-07 | Wyeth Corp | BETA ANTIBODIES USED TO IMPROVE COGNITION |
US8211864B2 (en) | 2005-01-26 | 2012-07-03 | Medical College Of Georgia Research Institute | Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors |
WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
AU2006214658A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP2008537538A (en) | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Therapeutic combination of VEGF antagonist and antihypertensive agent |
WO2006091666A2 (en) | 2005-02-23 | 2006-08-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
SI2289533T1 (en) | 2005-02-28 | 2013-11-29 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
CN101171010B (en) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
EP1863931A2 (en) | 2005-03-07 | 2007-12-12 | The Trustees Of Boston University | Diagnostic and therapeutic target for macular degeneration |
TW200714290A (en) | 2005-03-08 | 2007-04-16 | Pharmacia & Upjohn Co Llc | Anti-M-CSF antibody compositions having reduced levels of endotoxin |
CA2598452A1 (en) | 2005-03-11 | 2006-09-21 | Regeneron Pharmaceuticals, Inc. | Treating anemia by inhibition of vegf |
PL1861116T3 (en) | 2005-03-25 | 2016-02-29 | Regeneron Pharma | Vegf antagonist formulations |
US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
WO2006118547A1 (en) | 2005-04-29 | 2006-11-09 | Agency For Science, Technology And Research | Hyperbranched polymers and their applications |
US20070005130A1 (en) | 2005-06-29 | 2007-01-04 | Thierry Glauser | Biodegradable polymer for coating |
WO2007011873A2 (en) | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
WO2008020827A2 (en) | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
WO2007016656A2 (en) | 2005-08-02 | 2007-02-08 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CN101237880B (en) | 2005-08-12 | 2011-09-21 | 瑞泽恩制药公司 | Methods of treating diseases with a VEGF antagonist |
AU2006279541A1 (en) | 2005-08-15 | 2007-02-22 | The Regents Of The University Of California | VEGF-activated FAS ligands |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
DE602006017416D1 (en) | 2005-08-26 | 2010-11-18 | Univ Carnegie Mellon | POLYMERIZATION PROCEDURE WITH CATALYST REACTIVATION |
US20080167600A1 (en) | 2005-09-26 | 2008-07-10 | Peyman Gholam A | Device for delivery of an agent to the eye and other sites |
US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
US8329866B2 (en) | 2005-10-03 | 2012-12-11 | Bolder Biotechnology, Inc. | Long acting VEGF inhibitors and methods of use |
US20070134244A1 (en) | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
KR20080071188A (en) | 2005-11-29 | 2008-08-01 | 스미스클라인 비참 코포레이션 | Treatment method |
WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
JP2009519962A (en) | 2005-12-19 | 2009-05-21 | コメンティス,インコーポレーテッド | Topical mecamylamine formulation for ophthalmic administration and use thereof |
US7906134B2 (en) | 2005-12-21 | 2011-03-15 | Abbott Laboratories | Room temperature-curable polymers |
US20090098139A1 (en) | 2006-01-30 | 2009-04-16 | Barrett Katz | Combination therapy for the treatment of neovascular disorders |
WO2007097839A2 (en) | 2006-02-16 | 2007-08-30 | Massachusetts Eye And Ear Infirmary | Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye |
DE102006009004A1 (en) | 2006-02-23 | 2007-09-06 | Sustech Gmbh & Co. Kg | Multifunctional star-shaped prepolymers, their preparation and use |
RU2477137C2 (en) | 2006-03-08 | 2013-03-10 | АРКЕМИКС Эл Эл Си | Complement-binding aptamers and c5 agents applicable for treating ocular disorders |
US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
CA2645666A1 (en) | 2006-03-15 | 2007-09-20 | Mallinckrodt Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
PL1989231T3 (en) | 2006-03-21 | 2015-10-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
EP2012751A4 (en) | 2006-03-21 | 2010-11-24 | Morehouse School Of Medicine | Novel nanoparticles for delivery of active agents |
JP2007263935A (en) | 2006-03-30 | 2007-10-11 | Canon Inc | Magnetic marker and manufacturing method therefor |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
GB0620255D0 (en) | 2006-10-12 | 2006-11-22 | Fusion Antibodies Ltd | Antibody and uses thereof |
JP2009533519A (en) | 2006-04-14 | 2009-09-17 | インターフェース バイオロジクス,インコーポレーテッド | Graft polymer and use thereof |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
CN101437543A (en) | 2006-05-04 | 2009-05-20 | 佛维雅制药股份有限公司 | Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases |
JP2009540011A (en) | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. | Compositions and methods for siRNA inhibition of angiogenesis |
EP2944306B1 (en) | 2006-06-16 | 2021-01-27 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US9738745B2 (en) | 2006-06-29 | 2017-08-22 | Life Technologies As | Particles containing multi-block polymers |
US20080008736A1 (en) | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
JP5179487B2 (en) | 2006-07-14 | 2013-04-10 | バイオコンパティブルズ ユーケー リミテッド | polymer |
KR100808116B1 (en) | 2006-08-22 | 2008-03-03 | 전남대학교산학협력단 | Anti-fouling copolymers resin coating material |
JP5570809B2 (en) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | Modified protein |
US20080070855A1 (en) | 2006-09-20 | 2008-03-20 | James Pitzer Gills | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes |
MX2009004027A (en) | 2006-10-20 | 2009-09-28 | Schering Corp | Fully human anti-vegf antibodies and methods of using. |
JP5111016B2 (en) | 2006-11-01 | 2012-12-26 | 三井化学株式会社 | Surface hydrophilic polyolefin molded body and method for producing the same |
CU23636A1 (en) | 2006-11-01 | 2011-03-21 | Ct Ingenieria Genetica Biotech | RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTELIUM (VEGF) |
AR063760A1 (en) | 2006-11-02 | 2009-02-18 | Genentech Inc | ANTI-FACTOR D HUMANIZED ANTIBODIES AND USES OF THE SAME |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
CA2666709A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
US20080118500A1 (en) | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
WO2008064058A2 (en) | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings |
EP2091482A2 (en) | 2006-12-01 | 2009-08-26 | Allergan, Inc. | Method for determining optimum intraocular locations for drug delivery systems |
PT2099823E (en) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Variant target binding agents and uses thereof |
CL2008000058A1 (en) | 2007-01-09 | 2008-05-23 | Wyeth Corp | FORMULATION THAT INCLUDES AN ANTI-IL13 ANTIBODY, A CRIPROTECTOR, AND A DAMPING SOLUTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; METHOD TO TREAT AN IL13-RELATED DISORDER; AND PHARMACEUTICAL FORMS THAT UNDERSTAND IT. |
EP2125016A2 (en) | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
AU2008215170A1 (en) | 2007-02-14 | 2008-08-21 | Opto Global Holdings Pty Ltd | Methods and systems of treating age-related macular degeneration |
US8575397B2 (en) | 2007-02-14 | 2013-11-05 | Biocompatibles Uk Limited | Derivatisation of biological molecules |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
CN101631568B (en) | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | Oligomer-protease inhibitor conjugates |
US20100152201A1 (en) | 2007-03-12 | 2010-06-17 | Nektar Therapeutics | Oligomer-Antihistamine Conjugates |
JP2010524851A (en) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | Species-specific binding domains |
EP4059964A1 (en) | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
EP2139921A2 (en) | 2007-04-17 | 2010-01-06 | Imclone LLC | PDGFRbeta-SPECIFIC INHIBITORS |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US20090053217A1 (en) | 2007-05-07 | 2009-02-26 | Miri Blank | Human anti-VEGF polyclonal antibodies and uses thereof |
CA2687269C (en) | 2007-05-11 | 2018-02-20 | The Board Of Regents Of The University Of Nebraska | Compositions for protein delivery and methods of use thereof |
WO2008144248A1 (en) | 2007-05-14 | 2008-11-27 | Tyco Healthcare Group Lp | Furanone copolymers |
AU2008262489B2 (en) | 2007-05-23 | 2013-11-28 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
EA200901494A1 (en) | 2007-06-06 | 2010-06-30 | Домантис Лимитед | METHODS OF SELECTION OF PROTEASO-RESISTANT POLYPEPTIDES |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
KR101631323B1 (en) | 2007-06-21 | 2016-06-17 | 엑스엘-프로테인 게엠베하 | Biological active proteins having increased in vivo and/or vitro stability |
DK3597659T3 (en) | 2007-07-09 | 2023-04-03 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
JP6067207B2 (en) | 2007-07-10 | 2017-01-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Materials and methods for delivering compositions to selected tissues |
JP2009042617A (en) | 2007-08-10 | 2009-02-26 | Canon Inc | Electrostatic charge image developing toner and method for manufacturing the same |
US8529897B2 (en) | 2007-08-16 | 2013-09-10 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
US7943370B2 (en) | 2007-08-23 | 2011-05-17 | Canon Kabushiki Kaisha | Structure, target substance detection element and target substance detection kit |
AU2008304452B2 (en) | 2007-09-26 | 2014-01-16 | Genentech, Inc. | Novel antibodies |
US20090092664A1 (en) | 2007-10-08 | 2009-04-09 | University Of Kentucky Research Foundation | Polymer-metal chelator conjugates and uses thereof |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
RU2505544C2 (en) | 2007-10-19 | 2014-01-27 | Дженентек, Инк. | Antibodies against tenb2 constructed with cysteine, and conjugates, antibody-drug |
CN101918579A (en) | 2007-10-22 | 2010-12-15 | 先灵公司 | Fully human anti-VEGF antibodies and using method |
JP5314033B2 (en) * | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | Single IFN-beta fused to mutant IgG Fc fragment |
EP2217261B1 (en) | 2007-11-09 | 2015-10-07 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist compositions and methods of use |
NZ586053A (en) | 2007-11-09 | 2012-09-28 | Peregrine Pharmaceuticals Inc | Anti-vegf antibody compositions and methods |
GB0722484D0 (en) | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
TWI397589B (en) | 2007-11-28 | 2013-06-01 | Nippon Steel & Sumitomo Metal Corp | Furnace bottom for continuous annealing furnace and method for manufacturing the same |
WO2009092011A1 (en) * | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
IL295449A (en) | 2008-01-31 | 2022-10-01 | Genentech Inc | Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates |
CN101951925A (en) | 2008-02-20 | 2011-01-19 | 建新公司 | Angiogenesis inhibition |
CN101965183A (en) | 2008-02-21 | 2011-02-02 | 伊斯塔药品公司 | Eye NSAID as adjuvant |
US20090220434A1 (en) | 2008-02-29 | 2009-09-03 | Florida State University Research Foundation | Nanoparticles that facilitate imaging of biological tissue and methods of forming the same |
MX2010010025A (en) | 2008-03-14 | 2011-09-01 | Inst Nac Investigacion Inia | Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof. |
CN103992405B (en) | 2008-03-26 | 2016-08-17 | 宜康公司 | Anti-VEGF antibodies |
PT2274008E (en) | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
US7740844B2 (en) | 2008-04-29 | 2010-06-22 | Taiwan Liposome Co. Ltd | Anti-VEGF monoclonal antibody |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2282720B1 (en) | 2008-05-15 | 2013-09-11 | Biocompatibles Uk Ltd. | Intracellular antibody delivery |
WO2009149205A2 (en) | 2008-06-03 | 2009-12-10 | Neurotech Usa, Inc. | Cell lines that secrete soluble vegf receptors and uses thereof |
JP2011523853A (en) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
HUE032894T2 (en) | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | Stable and soluble antibodies inhibiting vegf |
US8187623B2 (en) | 2008-06-25 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical copolymers |
BRPI0913991A2 (en) | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | il6 immunotherapy |
SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
EP2309980A1 (en) | 2008-07-08 | 2011-04-20 | S.I.F.I. Societa' Industria Farmaceutica Italiana | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
EP2303921A2 (en) | 2008-07-18 | 2011-04-06 | Centre National de la Recherche Scientifique | Mutated netrin-4 proteins, fragments thereof and their uses as drugs |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
TW201010829A (en) | 2008-09-08 | 2010-03-16 | Mobiletron Electronics Co Ltd | Automatic screw feeding apparatus for electricity powered screwdriver |
WO2010030813A2 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
JP5913980B2 (en) | 2008-10-14 | 2016-05-11 | ジェネンテック, インコーポレイテッド | Immunoglobulin variants and uses thereof |
DK2540843T3 (en) | 2008-11-05 | 2014-09-01 | Genentech Inc | Genetic polymorphisms in age-related macular degeneration |
JP2010117189A (en) | 2008-11-12 | 2010-05-27 | Sumitomo Bakelite Co Ltd | Substrate for immobilizing physiological active substance |
JP5789192B2 (en) | 2008-11-13 | 2015-10-07 | フェムタ ファーマシューティカルズ インコーポレイテッドFemta Pharmaceuticals,Inc. | Humanized anti-IL-6 antibody |
KR101807319B1 (en) | 2008-11-22 | 2017-12-11 | 제넨테크, 인크. | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
KR101093717B1 (en) | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | VEGF?specific human antibody |
RU2011127198A (en) | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION |
BRPI0923336A2 (en) | 2008-12-12 | 2017-07-11 | Univ Massachusetts | ZWITERIONIC COPOLYMERS |
AU2009327266B2 (en) | 2008-12-16 | 2015-10-29 | Valeant Pharmaceuticals International, Inc. | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature |
US20100158850A1 (en) | 2008-12-23 | 2010-06-24 | The Regents Of The University Of Michigan | Dendrimer based modular platforms |
US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
WO2010085542A2 (en) | 2009-01-23 | 2010-07-29 | Novartis Ag | Biomarkers related to age-related macular degeneration (amd) |
US8883519B1 (en) | 2009-03-17 | 2014-11-11 | University Of Central Florida Research Foundation, Inc. | Oxidase activity of polymeric coated cerium oxide nanoparticles |
CN101838329A (en) | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | Anti-angiogenesis fusion protein |
SG10201609416XA (en) | 2009-03-25 | 2016-12-29 | Genentech Inc | NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF |
WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
GB0907251D0 (en) | 2009-04-28 | 2009-06-10 | Univ Leiden | Coplymers |
WO2010127029A1 (en) | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
TW201042040A (en) | 2009-05-01 | 2010-12-01 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CA2665956A1 (en) | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
PE20120902A1 (en) | 2009-05-08 | 2012-08-08 | Genentech Inc | HUMANIZED ANTI-EGFL7 ANTIBODIES |
AU2010252284A1 (en) | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
JP2012528112A (en) | 2009-05-28 | 2012-11-12 | グラクソ グループ リミテッド | Antigen binding protein |
DK2260873T3 (en) | 2009-06-08 | 2019-09-16 | Biocompatibles Uk Ltd | PCYLING OF PROTEINS |
EP2443150B1 (en) | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
US20190185555A1 (en) | 2017-12-19 | 2019-06-20 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
JP6088246B2 (en) | 2009-08-15 | 2017-03-01 | ジェネンテック, インコーポレイテッド | Anti-angiogenic therapy for the treatment of previously treated breast cancer |
CN102711809B (en) | 2009-08-17 | 2015-09-30 | 特雷康制药公司 | Use anti-endoglin antibody and anti-VEGF agent therapeutic alliance cancer |
US20180057602A1 (en) | 2009-08-17 | 2018-03-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
CN102002104A (en) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | Anti-VEGF monoclonal antibody and medicinal composition containing same |
GB0915515D0 (en) | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
EP2475389A4 (en) | 2009-09-08 | 2013-04-10 | Janssen Biotech Inc | Use of an anti-il6 antibody to decrease hepcidin in cancer patients |
RU2577726C2 (en) | 2009-10-21 | 2016-03-20 | Дженентек, Инк. | Genetic polymorphisms in age-related macular degeneration |
EP2493458A2 (en) | 2009-10-30 | 2012-09-05 | The Ohio State University | Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
US20120282211A1 (en) | 2009-11-24 | 2012-11-08 | Carnegie Mellon University | Antibodies and conjugates for modulators of angiogenesis |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
ES2585350T3 (en) | 2009-12-23 | 2016-10-05 | F. Hoffmann-La Roche Ag | Anti Bv8 antibodies and uses thereof |
US20120301478A1 (en) | 2010-01-14 | 2012-11-29 | Yuichiro Ogura | Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability |
US20110189174A1 (en) | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
US9334324B2 (en) | 2010-02-04 | 2016-05-10 | Agency For Science, Technology And Research | Podocalyxin-like-protein-1 binding antibody molecule |
EP2977055A1 (en) | 2010-02-16 | 2016-01-27 | Novo Nordisk A/S | Factor viii fusion protein |
WO2011101242A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
EP2539367A2 (en) | 2010-02-23 | 2013-01-02 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
AR080794A1 (en) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
WO2011119656A1 (en) | 2010-03-26 | 2011-09-29 | Genentech, Inc. | Anti-angiogenesis therapy for treating abdominal aortic aneurysm |
KR102416359B1 (en) | 2010-04-15 | 2022-07-01 | 코디악 사이언시스 인코포레이티드 | High molecular weight zwitterion-containing polymers |
US8785385B2 (en) | 2010-04-19 | 2014-07-22 | Research Development Foundation | RTEF-1 variants and uses thereof |
CN107648605A (en) | 2010-05-28 | 2018-02-02 | 国家医疗保健研究所 | For treating the anti-CD160 specific antibodies of the eye disease based on new vascular generation |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
JP2013530242A (en) | 2010-07-02 | 2013-07-25 | ジェネンテック, インコーポレイテッド | Treatment of angiogenic pigment epithelial detachment using anti-VEGF therapy |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN102311502B (en) | 2010-07-10 | 2013-12-25 | 成都康弘生物科技有限公司 | Fusion protein used for inhibiting regeneration or growth of blood vessel and medical treatment application thereof |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
JP2012025820A (en) | 2010-07-21 | 2012-02-09 | Kansai Paint Co Ltd | Hydrophilic treatment agent composition |
TWI538918B (en) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | Humanized monoclonal antibody, nucleotide sequence thereof, and use thereof |
KR101773120B1 (en) | 2010-11-01 | 2017-08-30 | 심포젠 에이/에스 | Anti-her3 antibodies and compositions |
BR112013010857A2 (en) | 2010-11-02 | 2016-09-13 | Abbott Laboratoires | double domain variable imonoglubulines and their uses |
UY33707A (en) | 2010-11-04 | 2012-05-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20120156202A1 (en) | 2010-11-05 | 2012-06-21 | Shantha Totada R | Age related macular degeneration treatment |
US8992908B2 (en) | 2010-11-23 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
WO2012075184A2 (en) | 2010-12-02 | 2012-06-07 | Neurotech Usa, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
CU23895B1 (en) | 2010-12-28 | 2013-05-31 | Biorec Sa | RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTHELIUM (VEGF) OBTAINED BY MUTAGENESIS OF VARIABLE REGIONS |
KR20180023015A (en) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | Use of a vegf antagonist to treat angiogenic eye disorders |
CN103391782A (en) | 2011-02-02 | 2013-11-13 | 公立大学法人名古屋市立大学 | Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability |
US9125940B2 (en) | 2011-02-03 | 2015-09-08 | Zhuning Ma | Compositions and methods for treating macular edema |
US20130330341A1 (en) | 2011-02-23 | 2013-12-12 | Sanofi | Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments |
KR20140059168A (en) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions and methods for the treatment of neuromyelitis optica |
JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
ES2704038T3 (en) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Multivalent and monovalent multispecific complexes and their uses |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
KR101397088B1 (en) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same |
CN102250246A (en) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | Bispecific antibody to VEGF/PDGFR beta and application thereof |
CN103764830A (en) | 2011-06-30 | 2014-04-30 | 基因信号国际公司 | Composition comprising inhibitors of IRS-1 and of VEGF |
US9682144B2 (en) | 2011-06-30 | 2017-06-20 | Gene Signal International, Sa | Composition comprising inhibitors of IRS-1 and of VEGF |
US20130004511A1 (en) | 2011-06-30 | 2013-01-03 | Gene Signal International Sa | Composition comprising inhibitors of irs-1 and of vegf |
BR112014001855A2 (en) | 2011-07-27 | 2017-02-21 | Glaxo Group Ltd | antigen-binding construct and protein, dimer, pharmaceutical composition, polynucleotide sequence, host cell and method for construct production |
WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
ES2664224T3 (en) | 2011-08-19 | 2018-04-18 | Children's Medical Center Corporation | VEGF binding protein for angiogenesis blockade |
WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
WO2013059137A1 (en) * | 2011-10-17 | 2013-04-25 | Oligasis | High molecular weight zwitterion-containing polymers |
JO3370B1 (en) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | Methods of inhibiting tumor growth by antagonizing il-6 receptor |
TW202317157A (en) | 2011-11-14 | 2023-05-01 | 安斯泰來再生醫藥協會 | Pharmaceutical preparations of human rpe cells and uses thereof |
AR088694A1 (en) | 2011-11-17 | 2014-06-25 | Pfizer | CYTOTOXIC PEPTIDES AND CONJUGATES OF ANTIBODY-PHARMACY OF THE SAME |
HUE051644T2 (en) | 2011-11-18 | 2021-03-01 | Regeneron Pharma | Micro-particle containing therapeutic protein coated with biodegradable polymer for medical use |
US9988611B2 (en) | 2011-12-01 | 2018-06-05 | Ap Biosciences, Inc. | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
CN103134874B (en) | 2011-12-01 | 2015-05-20 | 成都康弘生物科技有限公司 | Method of measuring glycosyl in protein |
US20130142796A1 (en) | 2011-12-05 | 2013-06-06 | Subhransu Ray | Treatment for angiogenic disorders |
MX2014006500A (en) | 2011-12-05 | 2014-08-21 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer. |
CA2863986A1 (en) | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Emp2 regulates angiogenesis in cancer cells through induction of vegf |
CA2865132A1 (en) | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
WO2013134414A1 (en) | 2012-03-06 | 2013-09-12 | Galaxy Biotech, Llc | Bispecific antibodies with an fgf2 binding domain |
PL2825558T3 (en) | 2012-03-13 | 2019-11-29 | Hoffmann La Roche | Combination therapy for the treatment of ovarian cancer |
AU2013243570B2 (en) | 2012-04-03 | 2017-12-14 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor Bb antibodies and uses thereof |
US20150071941A1 (en) | 2012-04-13 | 2015-03-12 | The Johns Hopkins University | Treatment of ischemic retinopathies |
HUE046134T2 (en) | 2012-05-07 | 2020-02-28 | Allergan Inc | Method of treating amd in patients refractory to anti-vegf therapy |
TWI702955B (en) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | Treatment of amd using aav sflt-1 |
JP5846044B2 (en) | 2012-05-23 | 2016-01-20 | 日油株式会社 | Method for producing (meth) acrylic acid derivative |
JP6234064B2 (en) | 2012-05-23 | 2017-11-22 | キヤノン株式会社 | Polymer, contrast agent or compound for nuclear magnetic resonance analysis or magnetic resonance imaging using the polymer, nuclear magnetic resonance analysis method and magnetic resonance imaging method using the polymer |
WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
PT3536310T (en) | 2012-06-01 | 2021-07-14 | Novartis Ag | Syringe |
EP2861068A4 (en) | 2012-06-01 | 2016-04-13 | Momenta Pharmaceuticals Inc | Methods related to bevacizumab |
AR091237A1 (en) | 2012-06-01 | 2015-01-21 | Ophthotech Corp | COMPOSITIONS THAT INCLUDE AN ANTI FACTOR GROWTH DERIVATIVE APPLICATOR (ANTI-PDGF) AND A VASCULAR ENDOTELIUM GROWTH FACTOR ANTAGONIST (VEGF) |
US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
US9214906B2 (en) | 2012-07-02 | 2015-12-15 | Skyworks Solutions, Inc. | Systems and methods for providing high and low enable modes for controlling radio-frequency amplifiers |
WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
JOP20200175A1 (en) | 2012-07-03 | 2017-06-16 | Novartis Ag | Syringe |
HRP20211641T1 (en) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
EA201590305A1 (en) | 2012-08-02 | 2015-06-30 | Санофи | PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT |
KR20190088571A (en) | 2012-08-07 | 2019-07-26 | 제넨테크, 인크. | Combination therapy for the treatment of glioblastoma |
US11458199B2 (en) | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
JP6280300B2 (en) * | 2012-08-24 | 2018-02-14 | 中外製薬株式会社 | Brain disease treatment |
JP2015528454A (en) | 2012-08-28 | 2015-09-28 | ノバルティス アーゲー | Use of VEGF antagonists in the treatment of ocular proliferative diseases |
US20150210771A1 (en) | 2012-09-13 | 2015-07-30 | Ronald G. Crystal | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
RU2015114331A (en) | 2012-09-17 | 2016-11-10 | Эббви Дойчланд Гмбх Унд Ко. Кг | NEW COMPOUNDS AS PHOSPHODESTERASE TYPE 10A INHIBITORS |
JP6479661B2 (en) | 2012-09-19 | 2019-03-06 | ジェネンテック, インコーポレイテッド | Methods and compositions for preventing norleucine misincorporation into proteins |
MX2015003894A (en) | 2012-09-28 | 2015-07-17 | Boehringer Ingelheim Int | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents. |
WO2014056923A1 (en) | 2012-10-11 | 2014-04-17 | Ascendis Pharma Ophthalmology Division A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
US20150368329A1 (en) | 2012-10-15 | 2015-12-24 | Oncomed Pharmaceuticals, Inc. | Methods of Treating Ocular Diseases |
US20150307865A1 (en) | 2012-10-15 | 2015-10-29 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
JP6469012B2 (en) | 2012-10-22 | 2019-02-13 | ファウンテン バイオファーマ インコーポレーテッドFountain Biopharma Inc. | Antibodies against interleukin-6 and use thereof |
TW202210507A (en) | 2012-11-01 | 2022-03-16 | 美商艾伯維有限公司 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US20140161817A1 (en) | 2012-11-01 | 2014-06-12 | Michael Siedler | Stable dual variable domain immunoglobulin protein formulations |
PL2917195T3 (en) * | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Spliceostatin analogs |
PE20150891A1 (en) * | 2012-11-07 | 2015-06-11 | Pfizer | IL-13 ALPHA 2 ANTI-RECEPTOR ANTIBODIES AND DRUG ANTIBODY CONJUGATES |
JP6487848B2 (en) | 2012-11-08 | 2019-03-20 | クリアサイド バイオメディカル,インコーポレイテッド | Methods and devices for the treatment of ocular disorders in human subjects |
AR093445A1 (en) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | METHODS TO TREAT OVARY CANCER WITH DLL4 ANTAGONISTS |
JP6144771B2 (en) | 2012-11-21 | 2017-06-07 | ファームアブシン インコーポレイテッド | Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition comprising the same |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
CN104968678B (en) | 2012-12-05 | 2018-12-11 | 诺华股份有限公司 | Target the composition and method of the antibody of EPO |
MX2015007931A (en) | 2012-12-18 | 2015-10-05 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan. |
WO2014100913A1 (en) | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
CN103898101B (en) | 2012-12-27 | 2017-08-08 | 上海桀蒙生物技术有限公司 | Utilize the method for the biological platform large-scale production restructuring hBCHE of galactophore of transgenic animal |
WO2014106235A1 (en) | 2012-12-31 | 2014-07-03 | Development Center For Biotechnology | Anti-granulysin antibodies and methods of use thereof |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
US9682154B2 (en) | 2013-02-04 | 2017-06-20 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
PT2968461T (en) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
CN103193819A (en) | 2013-03-13 | 2013-07-10 | 苏州蔻美新材料有限公司 | Method for synthesizing MPC using one-pot method |
US20160015770A1 (en) | 2013-03-13 | 2016-01-21 | The Regents Of The University Of Michigan | Compositions for treatment of retinal detachment |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
RU2015132626A (en) | 2013-03-15 | 2017-04-25 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | MULTIMODAL NANOPARTICLES BASED ON SILICON DIOXIDE |
KR102049990B1 (en) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | Fusion protein comprising anti-c-Met antibody and VEGF binding fragment |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
ES2746136T3 (en) | 2013-04-29 | 2020-03-04 | Hoffmann La Roche | Modified Human FcRn Binding Antibodies and Methods of Use |
RU2019108429A (en) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION |
WO2014178078A2 (en) | 2013-04-30 | 2014-11-06 | Intas Boipharmaceuticals Limited | Novel cloning, expression & purification method for the preparation of ranibizumab |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
JP2016522249A (en) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | Use of VEGF antagonists in the treatment of choroidal neovascularization |
US20160129080A1 (en) | 2013-06-20 | 2016-05-12 | Aaron Osborne | Treatment of polypoidal chroidal vasculopathy |
PL3020731T3 (en) | 2013-07-09 | 2019-11-29 | Ablbio | Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof |
JP2016528202A (en) | 2013-07-11 | 2016-09-15 | ノバルティス アーゲー | Use of VEGF antagonists in the treatment of choroidal retinal neovascularization and permeability disorders in pediatric patients |
CA2917813A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating retinopathy of prematurity |
WO2015006734A1 (en) | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
US9252430B2 (en) | 2013-07-30 | 2016-02-02 | Spectrum Brands, Inc. | Alkaline cell with improved high rate capability |
CN104341504B (en) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
US9962333B2 (en) | 2013-08-16 | 2018-05-08 | Board Of Trustees Of Northern Illinois University | Timed release of substances to treat ocular disorders |
US20180221483A1 (en) | 2013-08-16 | 2018-08-09 | Board Of Trustees Of Northern Illinois University | Timed release of substances to treat ocular disorders |
US20150056195A1 (en) | 2013-08-23 | 2015-02-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
CN103421039B (en) | 2013-09-03 | 2015-12-23 | 重庆工商大学 | The synthetic method of 2-methacryloxyethyl Phosphorylcholine |
JP6463361B2 (en) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugate |
KR20160086819A (en) | 2013-09-11 | 2016-07-20 | 뉴로테크 유에스에이, 인코포레이티드. | Encapsulated cell therapy cartridge |
US9968674B2 (en) | 2013-10-18 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody |
WO2015058369A1 (en) | 2013-10-23 | 2015-04-30 | Sanofi (China) Investment Co., Ltd. | Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma |
WO2015071348A1 (en) | 2013-11-18 | 2015-05-21 | Formycon Ag | Pharmaceutical composition of an anti-vegf antibody |
US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
CA2923591A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
CN105263959A (en) | 2013-12-31 | 2016-01-20 | 财团法人生物技术开发中心 | Anti-vegf antibodies and use thereof |
US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
CN105026433B (en) | 2014-01-24 | 2018-10-19 | 上海恒瑞医药有限公司 | VEGF and PDGFR β bispecific fusion proteins and application thereof |
CA2935610C (en) | 2014-01-25 | 2018-01-02 | Chengdu Kanghong Biotechnologies Co., Ltd. | Fusion protein inhibiting angiogenesis or growth and use thereof |
CA2939556A1 (en) | 2014-02-14 | 2015-08-20 | Andrew S. Chi | Improved methods for the treatment of vascularizing cancers |
WO2015135583A1 (en) | 2014-03-12 | 2015-09-17 | Universität Zu Köln | Method for identifying a candidate subject for anti-vascular endothelial growth factor (vegf) therapy |
KR101844596B1 (en) | 2014-03-18 | 2018-04-05 | 한국과학기술원 | Compositions for Treating Eye Disease comprising Glycosylated VEGF Decoy Receptor Fusion Protein |
LT3122878T (en) | 2014-03-24 | 2019-02-11 | Translate Bio, Inc. | Mrna therapy for the treatment of ocular diseases |
BR112016021383A2 (en) | 2014-03-24 | 2017-10-03 | Genentech Inc | METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD |
JP6588461B2 (en) | 2014-03-31 | 2019-10-09 | ジェネンテック, インコーポレイテッド | Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist |
US20170189546A1 (en) | 2014-04-29 | 2017-07-06 | University Of Mississippi Medical Center | Ocular Compositions and Methods Thereof |
CN106536561A (en) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | Anti-factor D antibody variants and uses thereof |
US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
EP3145532A4 (en) | 2014-05-02 | 2018-02-21 | Mayo Foundation for Medical Education and Research | Individualized treatment of eye disease |
CN106456757A (en) | 2014-05-12 | 2017-02-22 | 福尔密孔股份公司 | Pre-filled plastic syringe containing VEGF antagonist |
HUE049518T2 (en) | 2014-05-15 | 2020-09-28 | Translatum Medicus Inc | Compositions and methods for treating and diagnosing ocular disorders |
KR102511477B1 (en) | 2014-06-17 | 2023-03-16 | 클리어사이드 바이오메디컬, 인코포레이드 | Methods and devices for treating posterior ocular disorders |
EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
MX2016017290A (en) | 2014-06-28 | 2017-08-24 | Kodiak Sciences Inc | Dual pdgf/vegf antagonists. |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
RS58957B1 (en) | 2014-07-18 | 2019-08-30 | Sanofi Sa | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
JP6744292B2 (en) | 2014-07-29 | 2020-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Multispecific antibody |
CA2958017A1 (en) | 2014-08-11 | 2016-02-18 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
MX2017003387A (en) | 2014-09-16 | 2018-01-30 | Regeneron Pharma | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer. |
CN105435222B (en) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | Recombination fusion protein preparation |
KR102210104B1 (en) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | Butyrylcholinesterase zwitterionic polymer conjugates |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
TWI705827B (en) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | Methods for treating ocular diseases |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
KR20170080584A (en) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies and methods of use in ophthalmology |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
US20170326106A1 (en) | 2014-12-11 | 2017-11-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
WO2016109943A1 (en) | 2015-01-06 | 2016-07-14 | 珠海亿胜生物制药有限公司 | Anti-vegf antibody |
MX2017009246A (en) | 2015-01-16 | 2017-10-12 | Chugai Pharmaceutical Co Ltd | Combination drug. |
BR112017015773A2 (en) | 2015-01-28 | 2018-03-27 | Pieris Pharmaceuticals Gmbh | lipocalin mutein, hngal mutein, nucleic acid molecule, host cell, method for producing hngal mutein, pharmaceutical composition, kit, use of hngal mutein, use of hngal mutein, method for binding ang-2 in an individual , method for inhibiting angiogenesis in an individual, method for treating, preventing or ameliorating a disease, and method for inhibiting or reducing angiogenesis in an individual |
RU2699544C2 (en) | 2015-01-28 | 2019-09-06 | Пфайзер Инк. | Stable aqueous anti-vascular endothelial growth factor (vegf) antibody composition |
SG11201705271YA (en) | 2015-03-11 | 2017-07-28 | Allgenesis Biotherapeutics Inc | Fusion protein comprising a ligand binding domain of vegf and pdgf |
WO2016159652A1 (en) | 2015-03-31 | 2016-10-06 | 일동제약주식회사 | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused |
US10421812B2 (en) | 2015-03-31 | 2019-09-24 | University Of Massachusetts | Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof |
WO2016160923A1 (en) | 2015-03-31 | 2016-10-06 | Janssen Biotech, Inc | Antigen binding proteins |
WO2016170040A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1 |
WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
US10202429B2 (en) | 2015-06-08 | 2019-02-12 | Retinal Solutions Llc | Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema |
US20180221339A1 (en) | 2015-06-16 | 2018-08-09 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
JP2018524391A (en) | 2015-07-22 | 2018-08-30 | アイコニック セラピューティクス, インコーポレイテッド | Methods for treating disorders associated with angiogenesis and angiogenesis |
JP2018525389A (en) | 2015-08-12 | 2018-09-06 | ノバルティス アーゲー | How to treat eye disorders |
WO2017032610A1 (en) | 2015-08-21 | 2017-03-02 | F. Hoffmann-La Roche Ag | Affinity chromatography purification with low conductivity wash buffer |
KR102128966B1 (en) | 2015-09-01 | 2020-07-01 | 일동제약(주) | Pharmaceutical compositions for preventing and treating of cancer or angiogenesis related disease comprising fusion protein of tumor penetrating peptide and anti-angiogenesis agent |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
RU2763916C2 (en) | 2015-09-23 | 2022-01-11 | Дженентек, Инк. | Optimized options of anti-vegf antibodies |
JP7239320B2 (en) | 2015-10-02 | 2023-03-14 | エフ. ホフマン-ラ ロシュ アーゲー | Multispecific antibody |
AU2016334051B2 (en) | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
WO2017070460A1 (en) | 2015-10-22 | 2017-04-27 | Massachusetts Institute Of Technology | Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation |
CN108289951A (en) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
EP3165922B1 (en) | 2015-11-06 | 2020-06-17 | Promise Proteomics | A method for quantifying therapeutic antibodies |
US20180355030A1 (en) | 2015-11-13 | 2018-12-13 | Iconic Therapeutics, Inc. | Methods and compositions for treating disorders associated with pathological neovascularization |
AU2016356047B2 (en) | 2015-11-18 | 2021-10-21 | Formycon Ag | Pre-filled plastic syringe containing a VEGF antagonist |
KR102354198B1 (en) | 2015-11-18 | 2022-01-20 | 에스아이오2 메디컬 프로덕츠, 인크. | Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist |
AU2016363668A1 (en) | 2015-11-30 | 2018-05-24 | Pieris Australia Pty Ltd. | Novel anti-angiogenic fusion polypeptides |
HUE063335T2 (en) | 2015-12-03 | 2024-01-28 | Regeneron Pharma | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
US10765759B2 (en) | 2015-12-09 | 2020-09-08 | The Regents Of The University Of California | Methods of treating an ocular disease or disorder |
WO2017117202A1 (en) | 2015-12-29 | 2017-07-06 | Oncobiologics, Inc. | Buffered formulations of bevacizumab |
EP3401331B1 (en) | 2016-01-06 | 2022-04-06 | Order-Made Medical Research Inc. | High-affinity anti-vegf antibody |
US11008387B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | Antibody inhibiting binding of VEGF to NRP1 |
EP3400014A1 (en) | 2016-01-08 | 2018-11-14 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
WO2017120600A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
WO2017129064A1 (en) | 2016-01-28 | 2017-08-03 | 成都康弘生物科技有限公司 | Humanized fab of anti-complement factor d and humanized antibody and use thereof |
CN109195993B (en) | 2016-02-06 | 2022-05-10 | 岸迈生物科技有限公司 | Tandem FAB immunoglobulins and uses thereof |
US20170224815A1 (en) | 2016-02-09 | 2017-08-10 | Nima Tirgan | Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition |
EP3211422A1 (en) | 2016-02-23 | 2017-08-30 | Justus-Liebig-Universität Gießen | Method for measurement and control of intraocular vegf concentration |
US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
EP3424948B1 (en) | 2016-04-07 | 2021-07-28 | Industry-University Cooperation Foundation Hanyang University ERICA Campus | Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis |
JP6938536B2 (en) | 2016-04-14 | 2021-09-22 | アカデミア シニカAcademia Sinica | Suppression of tumor angiogenesis by inhibition of the novel VEGFR2 co-receptor SCUBE2 |
EP3442554A4 (en) | 2016-04-14 | 2019-12-04 | Iconic Therapeutics, Inc. | Compositions and methods for treating disorders associated with neovascularization |
CA3019426A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
KR20240005973A (en) | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
ES2908467T3 (en) | 2016-04-29 | 2022-04-29 | Adverum Biotechnologies Inc | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CN109310756B (en) | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | Novel angiopoietin 2, VEGF bispecific antagonists |
WO2017205559A1 (en) | 2016-05-25 | 2017-11-30 | The Johns Hopkins University | Engineered anucleate cellular and extracellular vesicles as a novel biologics delivery platform |
JP6944958B2 (en) | 2016-05-25 | 2021-10-06 | 参天製薬株式会社 | Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema |
PL3472317T3 (en) | 2016-06-16 | 2022-08-08 | Adverum Biotechnologies, Inc. | Compositions and methods for reducing ocular neovascularization |
AR108800A1 (en) | 2016-06-17 | 2018-09-26 | Genentech Inc | PURIFICATION OF MULTI-SPECIFIC ANTIBODIES |
MX2019001635A (en) | 2016-08-12 | 2019-06-10 | Genentech Inc | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor. |
EP3506945A4 (en) | 2016-08-30 | 2020-07-15 | Board of Regents, The University of Texas System | Production of seleno-biologics in genomically recoded organisms |
JP6644956B2 (en) | 2016-09-07 | 2020-02-12 | サクシン ライフサイエンシス ピーヴィーティー エルティディーSaksin Lifesciences Pvt Ltd | Synthetic antibodies to VEGF and uses thereof |
WO2018051312A1 (en) | 2016-09-19 | 2018-03-22 | Lupin Limited | In-line filter for protein/peptide drug administration |
JPWO2018070390A1 (en) | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | Composition comprising anti-ROBO4 antibody and other agent |
EP3525808A4 (en) | 2016-10-14 | 2020-06-24 | University of Utah Research Foundation | Antibody-polymer-drug conjugates |
US11021530B2 (en) | 2016-10-31 | 2021-06-01 | Hexal Ag | Antibody preparation |
US11123411B2 (en) | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
WO2018122053A1 (en) | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Anti-angiopoietin-2 antibody formulation |
WO2018132696A2 (en) | 2017-01-12 | 2018-07-19 | Russell Alan J | Stomach acid-stable and mucin-binding protein-polymer conjugates |
WO2018139991A1 (en) | 2017-01-24 | 2018-08-02 | Macregen, Inc. | Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics |
WO2018140611A1 (en) | 2017-01-25 | 2018-08-02 | Iconic Therapeutics, Inc. | Methods for treating disorders associated with angiogenesis and neovascularization |
KR102252450B1 (en) | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid |
TW201840584A (en) | 2017-03-20 | 2018-11-16 | 美商歐樂根公司 | Heavy chain only antibodies to vegf |
EP3600441A1 (en) | 2017-03-22 | 2020-02-05 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
AR111249A1 (en) | 2017-03-22 | 2019-06-19 | Genentech Inc | OPTIMIZED ANTIBODY COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS |
WO2018182527A1 (en) | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
WO2018185110A1 (en) | 2017-04-03 | 2018-10-11 | Fit Biotech Oy | Novel expression vectors and uses thereof |
CN106905431B (en) | 2017-04-10 | 2020-01-17 | 旭华(上海)生物研发中心有限公司 | Monoclonal antibody against human complement factor D and use thereof |
EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
US20200237997A1 (en) | 2017-05-24 | 2020-07-30 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
US10460482B2 (en) | 2017-07-26 | 2019-10-29 | Robert Bosch Gmbh | Method and system for automated generation of constrained curves in computer graphics |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | Liquid formulation of a vegf antagonist |
WO2019040397A1 (en) | 2017-08-21 | 2019-02-28 | Ophthotech Corporation | A method for treating or preventing neovascular age-related macular degeneration |
GB201713724D0 (en) | 2017-08-25 | 2017-10-11 | Ucl Business Plc | Formulation |
CN111344002A (en) | 2017-08-31 | 2020-06-26 | 新加坡保健服务集团 | Angio-3 for the treatment of retinal angiogenic diseases |
EP3457139A1 (en) | 2017-09-19 | 2019-03-20 | Promise Advanced Proteomics | Antibody-like peptides for quantifying therapeutic antibodies |
CN107602702A (en) | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | Antibody that is a kind of while targetting people p185 and VEGF and its application |
WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | Multi-cyclic aromatic compounds as factor d inhibitors |
EP3687464A4 (en) | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
WO2019091384A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
CN112040978A (en) | 2017-11-16 | 2020-12-04 | 伊维希比奥公司 | Method of treating or preventing Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) |
ES2946747T3 (en) | 2017-11-27 | 2023-07-25 | 4D Molecular Therapeutics Inc | Adeno-associated virus capsid variants and their use to inhibit angiogenesis |
EP3720460A1 (en) | 2017-12-05 | 2020-10-14 | University of Washington | Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors |
CN110003328B (en) | 2018-01-05 | 2022-04-19 | 百奥泰生物制药股份有限公司 | Long-acting low-toxicity recombinant anti-VEGF humanized monoclonal antibody and production method thereof |
AU2019212622A1 (en) | 2018-01-26 | 2020-08-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
WO2019154776A1 (en) | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
KR20200120927A (en) | 2018-02-11 | 2020-10-22 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
WO2019164219A1 (en) | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
AU2019227997A1 (en) | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
WO2019173482A1 (en) | 2018-03-06 | 2019-09-12 | Sanford Burnham Prebys Medical Discovery Institute | 4-aminoquinoline compounds for the treatment of angiogenesis |
TW202003553A (en) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | ABBV-621 in combination with anti-cancer agents for the treatment of cancer |
CA3091096A1 (en) | 2018-03-16 | 2019-09-19 | Novartis Ag | Methods for treating ocular diseases |
WO2019184909A1 (en) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | Novel antibody molecule, and preparation method and use thereof |
WO2019195313A1 (en) | 2018-04-04 | 2019-10-10 | Pollack Aryeh L | Anti-vegf antagonist and pedf agonist constructs and uses thereof |
WO2019195301A1 (en) | 2018-04-05 | 2019-10-10 | Northern Illinois Research Foundation | Hydrogels with liposomes for controlled release of drugs |
JP2021521173A (en) | 2018-04-11 | 2021-08-26 | オハイオ・ステイト・イノベーション・ファウンデーション | Methods and compositions for sustained release microparticles for intraocular drug delivery |
WO2019201866A1 (en) | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
CN112543645A (en) | 2018-04-17 | 2021-03-23 | 前瞻疗法公司 | Buffered formulations of bevacizumab for treatment of disease |
CN112739323A (en) | 2018-05-10 | 2021-04-30 | 瑞泽恩制药公司 | Formulations containing high concentrations of VEGF receptor fusion proteins |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
WO2019229116A1 (en) | 2018-05-31 | 2019-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation |
EP3813880A4 (en) | 2018-06-29 | 2022-07-13 | Gensun Biopharma Inc. | Antitumor immune checkpoint regulator antagonists |
WO2020006486A1 (en) | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
WO2020023841A1 (en) | 2018-07-27 | 2020-01-30 | Massachusetts Institute Of Technology | Oligomerized protein-polymer conjugates |
US11518819B2 (en) | 2018-08-17 | 2022-12-06 | Trican Biotechnology Co., Ltd | Anti-angiogenesis fusion protein and uses thereof |
US11407825B2 (en) | 2018-08-17 | 2022-08-09 | Mersana Therapeutics, Inc. | NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
CN109053895B (en) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | Bifunctional antibody for resisting PD-1-VEGFA, pharmaceutical composition and application thereof |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
-
2016
- 2016-12-29 BR BR112018013407A patent/BR112018013407A2/en active Search and Examination
- 2016-12-29 AU AU2016381964A patent/AU2016381964B2/en active Active
- 2016-12-29 SG SG11201805420SA patent/SG11201805420SA/en unknown
- 2016-12-29 CA CA3010056A patent/CA3010056A1/en active Pending
- 2016-12-29 KR KR1020187021875A patent/KR20180104635A/en not_active Application Discontinuation
- 2016-12-29 EP EP16882707.9A patent/EP3397276A4/en active Pending
- 2016-12-29 JP JP2018534732A patent/JP7088454B2/en active Active
- 2016-12-29 WO PCT/US2016/069336 patent/WO2017117464A1/en active Application Filing
- 2016-12-29 CN CN201680082940.7A patent/CN108712911A/en active Pending
- 2016-12-29 RU RU2018126519A patent/RU2744860C2/en active
- 2016-12-29 US US15/394,500 patent/US11066465B2/en active Active
-
2018
- 2018-06-28 IL IL260323A patent/IL260323A/en unknown
-
2021
- 2021-04-08 US US17/301,599 patent/US20210324063A1/en active Pending
- 2021-12-09 JP JP2021199881A patent/JP7414371B2/en active Active
-
2022
- 2022-02-08 IL IL290457A patent/IL290457A/en unknown
-
2023
- 2023-12-26 JP JP2023220012A patent/JP2024038137A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US20100166700A1 (en) * | 2006-02-28 | 2010-07-01 | Oligasis Corporation | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US20080311134A1 (en) * | 2007-05-08 | 2008-12-18 | Junutula Jagath R | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US20130034517A1 (en) * | 2009-12-18 | 2013-02-07 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
WO2013093809A1 (en) * | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
US20150306234A1 (en) * | 2014-03-05 | 2015-10-29 | Pfizer Inc. | MUTEINS OF CLOTTING FACTOR Vlll |
US11066465B2 (en) * | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
Non-Patent Citations (4)
Title |
---|
Edwards et al., J Mol Biol. 334(1): 103-118 (Year: 2003) * |
Krinner et al., Protein Engineering, Design & Selection 19(10): 461-470 (Year: 2006) * |
Lloyd et al., Protein Engineering, Design & Selection 22:159-168 (Year: 2009) * |
Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11819531B2 (en) | 2009-12-18 | 2023-11-21 | Kodiak Sciences Inc. | Multifunctional zwitterionic polymer conjugates |
US11590235B2 (en) | 2013-09-08 | 2023-02-28 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
US11584790B2 (en) | 2017-04-14 | 2023-02-21 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Also Published As
Publication number | Publication date |
---|---|
BR112018013407A2 (en) | 2018-12-18 |
KR20180104635A (en) | 2018-09-21 |
JP7414371B2 (en) | 2024-01-16 |
AU2016381964A1 (en) | 2018-08-02 |
AU2016381964B2 (en) | 2024-02-15 |
EP3397276A1 (en) | 2018-11-07 |
JP2022037072A (en) | 2022-03-08 |
JP7088454B2 (en) | 2022-06-21 |
WO2017117464A1 (en) | 2017-07-06 |
CN108712911A (en) | 2018-10-26 |
RU2018126519A (en) | 2020-01-30 |
JP2024038137A (en) | 2024-03-19 |
US11066465B2 (en) | 2021-07-20 |
JP2019510734A (en) | 2019-04-18 |
CA3010056A1 (en) | 2017-07-06 |
SG11201805420SA (en) | 2018-07-30 |
RU2018126519A3 (en) | 2020-09-08 |
IL290457A (en) | 2022-04-01 |
US20170190766A1 (en) | 2017-07-06 |
RU2744860C2 (en) | 2021-03-16 |
IL260323A (en) | 2018-08-30 |
EP3397276A4 (en) | 2019-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210324063A1 (en) | Antibodies and conjugates thereof | |
US11155610B2 (en) | Dual PDGF/VEGF antagonists | |
JP7373514B2 (en) | Dual VEGF/PDGF antagonist | |
US20230382983A1 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
US11912784B2 (en) | Methods of treating an eye disorder | |
US20190270806A1 (en) | Il-6 antibodies and fusion constructs and conjugates thereof | |
US20230250133A1 (en) | Methods of purifying a product | |
EP4323399A1 (en) | Methods of treating an eye disorder | |
PERLROTH et al. | Patent 2953698 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |